<SEC-DOCUMENT>0001213900-24-054877.txt : 20240621
<SEC-HEADER>0001213900-24-054877.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621171747
ACCESSION NUMBER:		0001213900-24-054877
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		241061398

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0207206-10k_modular.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:13 UTC 2024 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:modd="http://www.modularmedicalinc.com/20240331" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-17620">10-K</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-17621">&#9746;</ix:nonNumeric>&#160;<b>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended:&#160; <b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-17622"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-17623">March 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-17624">2024</ix:nonNumeric></ix:nonNumeric></span></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-17625">&#9744;</ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from&#160;</span> <span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 10pt">&#160;
to &#160;</span><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number:&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-88"><b><span style="text-decoration:underline">001-41277</span></b></ix:nonNumeric></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-97"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, INC.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-110"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-116"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>87-0620495</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/> Incorporation or Organization)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/> Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-17626">10470 Thornmint Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-17627">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-17628">California</ix:nonNumeric></b></span></td> <td style="width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-140"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>92127</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s telephone number, including area code:&#160; <b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-17629">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-17630">800-3500</ix:nonNumeric></span></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="white-space: nowrap; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-186"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-191"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MODD</span></ix:nonNumeric></td> <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-17631">Nasdaq</ix:nonNumeric> Stock Market, LLC</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of class)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-17632">No</ix:nonNumeric> &#9746;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160; Yes&#160;&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-17633">No</ix:nonNumeric> &#9746;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 491.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-17634">Yes</ix:nonNumeric> &#9746; No &#9744;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-17635">Yes</ix:nonNumeric> &#9746; No &#9744;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9744;<span style="font-size: 10pt">&#160;</span></span></td> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" name="dei:EntityFilerCategory" id="ixv-280"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated Filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-287"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-293"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td/></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span>&#9744;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-311"><span>&#9744;</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-17636">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160; Yes &#9744;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-17637">&#9746;</ix:nonNumeric></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant, based on the closing price
of the shares of common stock on the Nasdaq Stock Market on September 29, 2023 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-17638">17,971,555</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of the registrant&#8217;s common stock outstanding,
par value $0.001 per share, as of June 17, 2024, was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-17639">32,536,700</ix:nonFraction>.
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
REPORT ON FORM 10-K<br/>
FOR THE YEAR ENDED MARCH 31, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#n_025"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Part
    I</span></b></span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001"><span style="font-size: 10pt">Business</span></a></span></td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_002"><span style="font-size: 10pt">Risk Factors</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004"><span style="font-size: 10pt">Cybersecurity</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005"><span style="font-size: 10pt">Properties</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006"><span style="font-size: 10pt">Legal Proceedings</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_007"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#n_026"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Part
    II</span></b></span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008"><span style="font-size: 10pt">Market for Registrant&#8217;s
    Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_009"><span style="font-size: 10pt">Reserved</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010"><span style="font-size: 10pt">Management&#8217;s Discussion
    and Analysis of Financial Condition and Results of Operations</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011"><span style="font-size: 10pt">Quantitative and Qualitative
    Disclosures about Market Risk</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012"><span style="font-size: 10pt">Financial Statements
    and Supplementary Data</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013"><span style="font-size: 10pt">Changes in and Disagreements
    with Accountants on Accounting and Financial Disclosure</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014"><span style="font-size: 10pt">Controls and Procedures</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Other Information</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_016"><span style="font-size: 10pt">Disclosure Regarding
    Foreign Jurisdictions that Prevent Inspections</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#n_027"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Part
    III</span></b></span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_017"><span style="font-size: 10pt">Directors, Executive
    Officers and Corporate Governance</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_018"><span style="font-size: 10pt">Executive Compensation</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_019"><span style="font-size: 10pt">Security Ownership of
    Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_020"><span style="font-size: 10pt">Certain Relationships
    and Related Transactions, and Director Independence</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_021"><span style="font-size: 10pt">Principal Accountant
    Fees and Services</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#n_028"><span style="font-size: 10pt"><b><span style="text-decoration:underline">Part
    IV</span></b></span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_022"><span style="font-size: 10pt">Exhibits</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_024"><span style="font-size: 10pt">Form 10K Summary</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023"><span style="font-size: 10pt">Signatures</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &#8220;Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of Section
27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934,
as amended (the &#8220;Exchange Act&#8221;), that relate to future events or to our future operations or financial performance. Any forward-looking
statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by
such forward-looking statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Words
such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;targets,&#8221;
&#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;scheduled&#8221;
and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for
each forward- looking statement contained in this report, we caution you that these statements are based on our estimates or projections
of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results,
level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward- looking
statement. Actual results, level of activity, performance, experience or achievements may differ materially from those expressed or implied
by any forward-looking statement as a result of various important factors, including our critical accounting policies and risks and uncertainties
relating to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our strategies, prospects,
    plans, expectations, forecasts or objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve
    a marketable product (i.e., our insulin pump) and the costs and timing thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of our product
    by our target market and our ability to compete in such market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise additional
    financing when needed and the terms and timing thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand,
    protect and maintain our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our future operations,
    financial position, revenues, costs, expenses, uses of cash, capital requirements, our need for additional financing or the period
    for which our existing cash resources will be sufficient to meet our operating requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our analysis of the target
    market for our insulin pump;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain regulatory
    approvals and clearances relating to our insulin pump, including those of the United States Food and Drug Administration, or FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments
    in the United States and other countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and costs of
    our obtaining all regulatory approvals and clearances identified immediately above;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our compliance with all
    applicable laws, rules and regulations, including those of the Securities and Exchange Commission, or SEC, and the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to compete
    in the diabetes marketplace with larger and more substantial medical device companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, business,
    political and social conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on and our
    ability to retain (and if necessary, timely recruit and replace) our officers, directors and key employees and their ability to timely
    and competently perform at levels expected of them;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to generate
    significant revenues and achieve profitability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage the
    growth of our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commercialization,
    marketing and manufacturing capabilities and strategies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand,
    protect and maintain our intellectual property position;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing
    third-party products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    regulatory requirements relating to our business, and the costs of compliance with those requirements, including those on data privacy
    and security;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the specific risk factors
    discussed under the heading &#8220;Risk Factors&#8221; set forth in this report; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">various other matters,
    many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Annual Report on Form 10-K, refers to the
fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2024 refers to the fiscal year ended March 31, 2024).
Unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221;
refer to Modular Medical, Inc. and its consolidated subsidiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="n_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>PART
I</b></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><span style="text-decoration:underline">ITEM
1. BUSINESS</span></b></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical is a pre-revenue, medical device
company focused on the design, development, and commercialization of innovative insulin pumps using modernized technology to increase
pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, we seek to fundamentally alter the
trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available
insulin pumps provide. By simplifying and streamlining the user experience from the initial introduction of the patient to our product,
prescription assistance, establishing insurance reimbursement, streamlined training and day-to-day use with strong clinical support, we
seek to expand the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221; to expand the category
into the mass market. Our product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type
2 diabetes markets for those individuals requiring insulin.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Differentiation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that there are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of
people who require insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe that, by tailoring our
insulin pump to address such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader
market acceptance, an insulin pump must be easier to learn to use, be less time-consuming to operate, more intuitive to both patients
and physicians, and meet the standards for coverage by insurance providers so that co-payments required from patients are affordable
and the hurdles to insurance coverage are significantly reduced.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the more prominent issues are:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><i>Complexity:
                                            </i>Many existing pumps are highly complex and require significant technical expertise to
                                            use effectively. We believe such pumps were designed for &#8220;super users,&#8221; who have
                                            high levels of motivation and technical competence. The complexity of pumps can be daunting
                                            to less technically inclined, less motivated users.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cumbersome</i>:
    We believe that a majority of existing pumps are bulky and difficult to manage, requiring a means of carrying the pump around and
    up to 48 inches of tubing to the injection site to connect the catheter to a pump. The tubing and the cartridge, which holds the
    insulin, must be replaced every few days.&#160;&#160;This requires users to carry spare parts and other equipment adding to the difficulty
    of using the pump. In comparison, our product only requires a cartridge change every few days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost</i>:
    Costs associated with insulin pump therapy can be high and prohibitive, especially for those on fixed or limited incomes. These costs
    vary by pump and insurance coverage, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to
    possible additional co-payments on consumables, can easily place current pumps out of reach for patients. This leads to limited or
    absent reimbursement/coverage and potentially high financial hurdles for patients to gain access.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outdated
    style</i>: Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar progress.
    We believe that consumers will be more receptive of products designed with the user experience in mind and that many have low tolerance
    for complex, difficult procedures for use and maintenance of products.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pump
    mechanism limitations</i>: Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe this
    design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery of the
    full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health events
    due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
team has substantial knowledge of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing
insulin pumps to market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of
pumping insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady
flow) and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not
just care for the super users, but &#8220;diabetes care for the rest of us.&#8221; While our initial target market is people with type
1 diabetes, we believe there is a substantial opportunity to penetrate the type 2 marketplace, whether through our initial MODD1 pump
or further simplification of our pump to address the type 2 marketplace.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MODD1 is a high-precision pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to
learn, easy to use, and has a revolutionary design and internal technology that enable precision with low-cost manufacture and high reproducibility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
features include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two parts - one reusable,
    one disposable - snap together to form the working system;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One button interface, easy
    to learn and use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90-day reusable, 3-day
    disposable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposable portion removable
    at any time from an adhesive-backed retainer, which remains in place;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No external controller
    required, no charging, no battery replacement; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slim profile, lighter weight.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
proprietary survey of American healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives) performed
for us by industry leading survey firm ISA in 2019 has demonstrated that payors are willing to grant equivalent or preferential coverage
for a product with this feature set at launch in exchange for discounts of approximately 20%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diabetes
is typically classified as either type 1 or type 2:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type 1 diabetes, or T1D,
    is an auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently diagnosed
    during childhood or adolescence, although it can sometimes have onset in adulthood. Individuals with T1D require daily insulin therapy
    to survive.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type 2 diabetes, or T2D,
    represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either properly
    utilize insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements
    in diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their
    diabetes advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to
    intensified mealtime rapid-acting insulin therapy. This represents an important portion of the diabetes market with an estimated
    1.6 million individuals with T2D intensively treated with insulin currently in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and
health. The brain works on pure glucose, and, when sufficient glucose is available, the brain allows insulin to be released that allows
the cells to absorb glucose. In people with diabetes, blood glucose levels are not well controlled by the brain due to the shortage of
insulin. Frequently, blood glucose levels become very high, a condition known as hyperglycemia, or very low, a condition called hypoglycemia.
Hyperglycemia can lead to serious long-term complications, including blindness, kidney disease, nervous system disorders, occlusive vascular
diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia can lead to confusion or loss of consciousness,
often requiring a visit to the emergency room or, in certain cases, result in seizures, coma, and/or death.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
people with T1D, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately
18% of people with T2D in the United States, or approximately 4.7 million people, require insulin (basal alone represent 3.1 million
and basal plus mealtime represent 1.6 million) to manage their diabetes. In this Report, we refer to people with T1D and people with
T2D who require mealtime insulin as &#8220;insulin-requiring people with diabetes.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into
the body through syringes or insulin pens (a type of syringe), referred to as Multiple Daily Injection, or MDI therapy, or the use of
an insulin pump to deliver mealtime insulin boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous
insulin infusion, or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy,
primarily an improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure
and more recently Time in Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other clinical
benefits, a study conducted by Tandem Diabetes Care, Inc., or Tandem, in 2021 demonstrated that insulin pump use can decrease glucose
variability, reduce the number of hypoglycemia events, and reduce the fear of hypoglycemia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding these advantages, we believe the
difficulty in use resulting from the complexity and cumbersome design of available insulin pumps, as well as high and often prohibitive
costs for both the patient and insurance provider, has resulted not only in dissatisfaction among many existing pump users. As noted in
a Seagrove Partners 2021 study, fewer than half of first-time pump users purchase a new pump after the warranty expires. We believe the
cost and complexity to the user has severely limited the adoption rate of insulin pumps by a large segment of the diabetes population
using MDI therapy, whom we refer to in this Report as &#8220;Almost Pumpers.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We
define Almost Pumpers as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past
experiences, pump shortcomings, cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps,
continue to receive their daily insulin through MDI therapy. We undertook one-on-one interviews with over 200 of these individuals to
understand their past experiences on or considering pumps, existing pump shortcomings, the cost and insurance challenges, complexity
to learn and time and complexity to operate that drives them to remain on MDI. With this detailed understanding, we brought a series
of prototype models to them to react to, so we could refine the design and include features that would motivate them to be able to use
this technology to better care for their diabetes. Our MODD1 pump has been well received by these individuals and our clinical advisors,
as applicable for this sector of the marketplace.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research, along with marketplace data provided
by Seagrove Partners in 2023, estimates that 33% of Americans with T1D have an insulin pump and 28% of Americans with T1D (44% of those
who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes Association guidelines
of glucose control if their objections to the currently available suite of products can be overcome. They do not want to closely manage
their glucose levels and incur the associated time and effort involved; however, they understand, or are advised by their clinical care
team, that they need to do more to achieve a reasonable level of glucose. They are the Almost Pumpers. We have developed what we believe
to be the most technologically advanced delivery system overcome the objections and provide motivation for this market. We believe that
there are four addressable hurdles to adoption:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usability: the device needs
    to be easy to learn and to operate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affordability: we will
    focus on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance journey&#8221; to the clinician and patient;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accessibility and Education:
    we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training to allow
    people to see first-hand the typical barriers to adoption that have been overcome; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service and Support: where
    we will answer their questions and concerns during this diabetes experience.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe this conversion process, engaging people
to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps among with patients with
T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease that appears randomly throughout the world. Therefore,
we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin pump that appeals to all Almost
Pumpers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The International Diabetes Federation estimated
that, in 2021, approximately 537 million people were living with diabetes worldwide, and by 2045, this number will increase to approximately
783 million people.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
estimated 34 million people in the United States live with diabetes. Within this group, T1D accounts for approximately 1.8 million people
with the remainder being T2D. All people with T1D require daily insulin. However, of the approximately 32.2 million people with T2D,
about 1.6 million of them require MDI therapy to manage their diabetes. This represents a large and growing market with the effects of
diabetes accounting for roughly 25% of all healthcare dollars spent annually in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the National Diabetes Health Care Provider Survey conducted by Seagrove Partners, LLC in 2021, approximately 25% of the 1.6 million
highly insulin intensive individuals with T2D have considered going &#8220;on pump.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insulin
pumps have been shown to provide a higher level of care for insulin-dependent people with diabetes and result in better glycemic control,
fewer comorbidities, fewer trips to the emergency room, and higher overall quality of life. They also result in lower overall costs to
the healthcare system, reducing typical expense per patient year from approximately $27,000 to $17,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
these benefits, only 1 in 3 (33%) of the 1.8 million Americans with T1D and very few of the 1.6 million T2D intensively treated with
insulin currently use an insulin pump, for a total of approximately 670,000 current users, with only a slow increase of insulin pump
use. The remaining 68% of individuals with T1D and virtually all with T2D rely on MDI therapy for glucose control. Decades of advances
in technology advances have left these non-pumpers at a significant disadvantage from a control perspective versus their &#8220;pumping&#8221;
counterparts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified a large segment of the market that we refer to as &#8220;Almost Pumpers.&#8221; Almost Pumpers are those insulin-requiring
people with diabetes (T1D or T2D) who feel that they would adopt the pump if it were less expensive, less time consuming, less technically
intimidating, and if there was no separate controller. We believe that they represent approximately 32% of the T1D market correlating
to a $1.9 billion growth opportunity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insulin
pumps on the market today require a substantial amount of time to manage the therapy, have high out-of-pocket costs that place these
technologies out of reach for a large part of the population, and are feature-heavy with complex systems, which we believe have hampered
adoption and intimidated many users. The most commonly used insulin pumps today require extensive training and hours of daily management.
The average pump user must go through 42 steps of setup and refill process every 72 hours to &#8220;stay on track.&#8221; Our product
only requires nine steps for setup and refill every 72 hours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_001.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current reluctance to adopt the insulin pump has had serious consequences on the healthcare system. In the United States, people living
with T1D have struggled to attain glycemic targets. A 2019 analysis of the large T1D Exchange clinical registry found that only 21% of
U.S. adults with T1D achieved the ADA A1c goal (&lt;7.0%). Further, according to a study published in JAMA Internal Medicine, researchers
found no significant improvements in diabetes care between 2005 and 2016, with persistent gaps in care related to socioeconomic status.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another transition in the care of diabetes is
the measuring of glucose from finger-stick tests to continuous glucose monitoring, or CGM, sensors, which are wearable devices. These
sensors are placed under the skin and give a reading every five minutes of the user&#8217;s glucose level. While Dexcom has been a market
leader in this field, the introduction and rapid adoption of the Freestyle Libre by Abbott Labs has made CGM easier and more affordable,
expanded the product category, and doubled the market size. The Freestyle Libre product is a more affordable, easier to use and smaller
version of the popular Dexcom, Inc. (Dexcom) CGM product. Now, for the first time, there is an easy, less painful, i.e., no more finger
sticks, way for patients to have the data they need to understand more about their glucose levels and their insulin requirements. Access
to such data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made them more comfortable
with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control and better overall care. We
believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. Our MODD1 pump represents
a new and better offering to assist and induce a wide variety of patients to make the transition and overcome the objections to superior
control by becoming a &#8220;pumper.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the present pump marketplace is approximately a $1.9 billion
market, comprising 33% of T1D pumpers and a small group of T2D pumpers. Seagrove Partners surveyed clinicians, and, in its 2021 report,
estimated that 28% of T1D patients and 25% of T2D patients would adopt technology that was easier to use, learn and access and eligible
for insurance reimbursement. We believe this represents a total addressable market of approximately $3 billion for us, assuming cartridge
revenue of approximately $4,100 per patient, per year. We expect to spend approximately 15% of our total revenue on discounts and free
samples to encourage adoption of our pump product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dedicated to helping all people with diabetes gain access to high quality care. We aim to help people with diabetes - especially
Almost Pumpers and the historically underserved communities - gain access to insulin pump technology by making it affordable and easy
to use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Diabetes
Care is at an Inflection Point</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the insulin pump market stands at a crossroads as a confluence of events makes the timing for a new product introduction
ideal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020
was a very difficult year in diabetes. Between COVID-19 and a loss of glycemic control during quarantines and isolation, deaths from
diabetes rose by 17% in 2020 versus the prior year. This was sharpest among the young who saw deaths rise 29% in the 25-44 year old demographic.
This became a pain point and a desire to find new and better solutions and has raised awareness among patients, caregivers, payors, and
policy makers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
also encouraged (and required) trial and adoption of telehealth models and a great many people have found them to their liking with a
high proportion of patients and of health care providers (HCPs) that want to continue to use these technologies. We expect much of this
shift and newfound comfort with distance care models to persist and believes that this can provide a patient acquisition and engagement
model for insulin pumps and diabetes care, especially for pumps optimized for free trial and easy learning.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, reimbursement for patch pumps has been increasingly moving to a pharmacy benefits manager (PBM) model, which simplifies
reimbursement and will further aid in a &#8220;frictionless launch.&#8221; This represents a fundamental shift in the insulin pump market,
making onboarding rapid and simplifying a previously complex and time-consuming &#8220;insurance journey.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe these CGM device users are increasingly interested in adopting technology and wearables to manage their diabetes. We believe
CGM device users are a natural market for a new type of pump, if it can meet their needs and address their objections and that the conjunction
of the above trends represents a unique opportunity in the insulin pump market&#8217;s history. The CGM device provides glucose-level
data, and, as necessary, the user can respond to address any issues with a simple button push on a pump to deliver their insulin versus
taking out a syringe and injecting glucose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diabetes
technology companies understand that we are at a turning point with new markets (T2D, T1D that are currently not using technologies).
This can be seen with increased discussion around this topic during recent national diabetes conferences, as well as an increase in marketing
promotion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
these recent changes support the high proportion of T1D and T2D intensively treated with insulin that we consider to be Almost Pumpers,
and we expect the number of Almost Pumpers to grow in the coming years and be more reachable with appropriate marketing strategies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Insulin Pump</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instead
of building complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and
the user in mind. Using proprietary methods of insulin measurement, we were able to eschew complex mechanisms and instead built a product
candidate using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality curve that has
existed in the insulin pump space and representing the first truly modern insulin pump design. We consider this to be a new kind of product
for a new kind of patient.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2024, we submitted a 510(k) premarket
notification to the United States Food and Drug Administration (&#8220;FDA&#8221;) for our MODD1 insulin pump. In March 2024, we received
comments from the FDA on our submission, and we are in the process of responding to those comments. A good part of our focus has shifted
to managing the process of preparing to move our initial production line to our manufacturing partner, Phillips-Medisize, a large tier-one
medical device manufacturer, which will manage and operate our production to produce products for human use. We believe that Phillips-Medisize
will be able to rapidly scale to higher volumes at lower cost. We continue to devote substantial time and resources, including exhibiting
at major diabetes conferences, to better understand the needs and preferences of Almost Pumpers and the specific patient/provider/payor
requirements to motivate change from MDI therapy. By making the bolus delivery at meals simple, we believe we will drive improved health
outcomes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MODD1
has several distinguishing features:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_002.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
- The pump has a simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor for
rotating a cam to motivate the insulin into the patient along with a low power Bluetooth and near-field communication (NFC) chips to
optionally allow the patient to communicate with their smart phone, tablet, or other mobile computing platform. Our mobile device
application is included in our 510(k) submission and will be a part of our introductory product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
- The pump snaps together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes a simple
coin cell that allows it to run through the 80-hour life of the cartridge.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3 - The infusion set contains a soft 6 mm cannula and an introducer
for insertion into the skin for insulin delivery, and it automatically removes the inserted needle used to transfer insulin to the body.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MODD1 comes with a variety of methods for the
patient to wear the pump. Options include: a base plate with adhesive for attaching to the body that has features for holding the pump
to the patient; overwraps to hold the product to the patient; and a velcro strap with a base plate suitable for wrapping around the arm
or leg of the patient.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The system will deliver a small continuous rate
called a basal that will provide approximately 50% of the total daily dose required, and the user will use the on-pump button to administer
boluses, typically before and after meals. The objective is to make the product simple to acquire and take home, simple to learn and most
importantly, simple to use and live with, to expand the pump market, drive adoption and ultimately better clinical outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technological
Advantages</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of new ultra-high volume technologies
will result in far easier manufacturing scale up, as parts sourcing and assembly processes are far easier. The MODD1 was designed from
the beginning for mass manufacturing, and we have partnered with a manufacturing partner, Phillips-Medisize, a Molex company, to establish
processes and &#8220;lights out&#8221; or near lights out production assembly lines whereby a minimal number of workers will be required
in the production facility. This advantage is compounded by the high availability and already optimized cost reduction in its components.
When we achieve production scale, we believe this should result in a cost of goods for MODD1, estimated on the competitors&#8217; announced
margins and sales, of approximately 50% lower than our closest patch pump competitor.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adoption of modern, miniaturized technologies has led to numerous other advantages, as well. For example, our MODD1 pump is smaller in
overall volume than Insulet&#8217;s popular Omnipod product and has a lower profile to the skin. Despite this, the MODD1 holds a full
3 milliliter, or mL, (300 units) of insulin, in line with full sized pumps such as those offered by Tandem and Medtronic, 50% more than
the 2mL reservoir in the Omnipod. We believe that this volume advantage over other patch pumps will be significant as 24% of type 1 and
over 50% of the rapidly growing type 2 market require more than 2mL of insulin every three days (the expected wear time of patch pumps).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our new pumping modality will provide
what we believe is the most even (and thus closest to the function of a healthy pancreas) delivery of basal insulin in the industry.
We intend to demonstrate the impact of our system on glycemic control in a clinical study specifically focused on improved adherence,
more bolus deliveries per day and providing the clinicians with clear data on patient use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technology allows the patient to simply add insulin and operate. The battery is included in each cartridge, and the device is operated
without a controller. As a result, no charging is required. MODD1 has also been made push-button simple to deliver insulin to appeal
to a wider audience of users.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This new technology has made the MODD1 lighter
than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams (vs. 26 grams) empty and 23 grams (vs. 28 grams) fully
filled (despite carrying 50% more insulin), reductions of 23% and 18%, respectively. Also, unlike existing patch pumps, the MODD1 can
be removed from the needle and taken off and replaced later if the user desires. This avoids loss of insulin in a pump due to accidental
dislodging of the soft canula, an issue for other patch pumps with which users have expressed considerable dissatisfaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our approach to the care of diabetes can be further
enhanced by leveraging the MODD1 single-pumping chamber technology and reusable pump approach to apply to dual (or more) chamber pumping
solutions. We believe that such multi-chamber pumps will be integral to the realization of high time-in-range artificial pancreas solutions
that require no human intervention because of the application of, for instance, drugs to raise glucose levels coupled with drugs to lower
glucose. They will be the next step forward from the cumbersome and awkward solutions today that require the user to announce meals,
count and input carbohydrates, and adjust delivery for exercise and sleep to prevent overdosing of insulin. Instead, if a user overdosed
insulin, the user would simply pump in a drug to release sugar stores to raise it up. We believe that a pre-filled peel and stick patch
pump with the ability to function in a fully autonomous closed loop system with a CGM device, which is measuring and transmitting glucose-level
information, represents the next generation of diabetes care. We believe that we have demonstrated our technology and have secured, and
will continue securing, intellectual property protection on our approach.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe this technology, especially applied in a dual chamber capacity, will open up numerous applications outside of diabetes where
medication compliance of complex therapy regimes is difficult. Example applications would include weight loss, fertility, and simplifying
the delivery of complex multi-drug cocktails, especially those with diverse and challenging dosing schedules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solution</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proposed pump has been designed and developed to address the aforementioned shortcomings of the existing pump market and to appeal to:
(i) the substantial group of Almost-Pumpers, who may be interested in using an insulin pump, but have not done so because of the complexity,
cost or cumbersome nature of existing products and (ii) people who are using one of the currently available insulin pumps but are dissatisfied
with such products. We believe that, owing to our new proprietary technology, our proposed insulin pump will be the simplest and least
expensive product on the market and the easiest for providers to prescribe.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current pump has been built to test what we believe to be our novel approach to insulin pumps. By providing a pump that we believe will
establish industry standards in terms of technology, simplicity to understand, ease of use and price, we believe our MODD 1 pump will
offer the vast majority of benefits afforded by more expensive and complex pumps, but it will remain accessible to a substantially greater
percentage of diabetes sufferers requiring daily insulin therapy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe people generally will not use technology
that intimidates them, especially for a life-sustaining therapy. In addition, we believe that physicians are hesitant to prescribe such
technology due to the level of training and support required with the present pump product offerings. It is our belief that broadly-needed
medical products, such as is intended with our proposed pump, must be user-friendly and affordable. We believe this approach is fundamentally
different from that applied to the existing pump market today, where most pumps are continuously adding complex features appealing to
super users and leaving the other people with diabetes further behind.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current goal is to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter,
commercialize the finished product. Our long-term goal is to become a leading provider of insulin pump therapy by focusing on both consumer
and clinical needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
achieve our above stated immediate and current goals, we intend to pursue the following business strategies:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of innovative
    proprietary technology.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the substantial experience of Paul DiPerna, our President, Chief Financial Officer, Treasurer and Chairman of our board of directors,
in engineering design and innovative technology in the medical device industry and, in particular, with the invention, market vision
and technical development of insulin pumps, we have generated proprietary technology that has been incorporated into our proposed insulin
pump. We believe this technology allowing for a two-part, yet small enough to wear, pump product, along with simplified mechanics for
pumping, has greatly assisted us in creating a simpler, user-friendly pump. We believe the completed design, engineering and technology
being incorporated into our pump will make it substantially simpler and more affordable than those currently available. These features,
together with the safety and reliability of our proposed pump, are designed to create the next generation of insulin pumps that will
feature important and well-differentiated attributes compared to those currently available and make it available to consumers across
mostly all socioeconomic groups in the United States and around the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Keep costs low during
    our design and development process.</i></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
attempt to ensure that we have sufficient funds to design, develop, and obtain all required regulatory approvals for our proposed insulin
pump without having to sacrifice quality and efficiency, we intend to maintain a tight budget and limit expenditures where possible.
We believe this will be possible because of the extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry
and more specifically in the insulin pump device market, but also his experience in designing and developing insulin pumps and other
medical devices and his ability to manage a small, focused development team. We currently expect that various other expenses, such as
sales and marketing costs, will not be incurred until such time as regulatory clearances are obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to establish MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type
2) and newly motivated CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to meet
the needs of both diabetes patients requiring insulin and their clinicians.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that MODD1 is
    approximately 50% less expensive to manufacture than Omnipod. This low cost allows us to spend more on patients and sampling. We
    believe that this will save money for payers because we expect to offer the pump with no upfront cost to patients. Expected benefits
    of MODD1 include:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20% discount vs Insulet
    will drive preferred status;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed to use pharmacy
    benefit manager, or PBM, codes as a disposable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No new code needed to be
    reimbursed at launch because MODD1 will be able to use existing U.S. Center for Medicare and Medicaid Services, or CMS, codes; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saves insurance provider
    an estimated $1,062 per patient per year vs Omnipod, as we will offer providers discounts from the existing reimbursement code.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The MODD1 will be sampled
    and given to patients by a doctor or diabetes nurse educator at the time of the patient visit. When a patient is motivated to make
    change, our starter kit will make it easy for the clinician to initiate the new therapy with training and appropriate supplies that
    same day. We seek to eliminate the currently challenging &#8220;insurance journey&#8221; and product acquisition timeline and significantly
    reduce training time for the busy clinician, which we believe are all major hurdles to pump adoption. We intend to add significant
    telehealth support to help the patient throughout adoption and use and to facilitate greater collaboration between patients and their
    physicians.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Europe
represents another large potential market for MODD1, as approximately 60 million people in Europe live with diabetes. Approximately $161
billion is spent annually on diabetes healthcare costs in Europe based on data from a Seagrove Partners 2023 study. At present, cost
containment is restricting pump uptake across Europe. Current pump usage hovers between 10% and 20% in many markets. Single payor healthcare
systems across Europe traditionally attempt to contain costs in the short term and seek low price technologies with moderate medical
benefits. We anticipate MODD1 will offer a rebalance of this risk/reward strategy in that payors will incur only minor incremental short-term
costs with the benefit of longer -term cost savings associated with reliable pump use. We intend to employ a partnership strategy across
Europe following in-house managed regulatory and pricing activities in the major markets (e.g., UK) and more cost receptive markets (e.g.,
Nordics). We have begun the approval process for Europe and are targeting European and United Kingdom approval towards mid 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MODD1
tackles the most significant barriers to pump use-access and affordability-and makes it easier for clinicians, caregivers and individuals
to manage diabetes care. We believe that MODD1 will be the only insulin pump that patients can take home immediately from the doctor&#8217;s
office. Our commercialization plan will drive adoption and is designed to expand the market and is intended to do the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximize adoption with
    a comprehensive frictionless launch program.&#160;</b>We will seek to decrease the level of reimbursement effort and cost to encourage
    health care providers, or HCPs, to offer our pumps and encourage patient trials. Our product reduces the technical hurdles to widen
    appeal, encourage new starts and increase adherence. We will encourage patients utilizing MDI therapy to make the switch to the pump
    earlier in their treatment, ideally right at diagnosis. For those who want or need more control, a key point is that a simple button
    push to administer insulin is much easier than delivering an injection.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage technology
    to support sales and new patient acquisition</b>. We intend to set up technology-enabled sales teams backed with a full omnichannel
    program to drive awareness and trial with HCPs and patients. We will focus on educating providers that our product candidate is simple
    to teach and easy to support making it an ideal front line offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilitate patient trials.
    To facilitate patient trials, we intend to:</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            a free sample pump, insurance verification, co-pay coupons and telehealth support, as may
                                            be allowed under federal and state law, to patients thereby reducing outlay of time and money;
                                            and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner
                                            with multiple educational and pharmacy channels to support rapid adoption and support of
                                            patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage MODD1 300-unit chamber to increase adoption with Type 2 patients</b>. We believe MODD1 has a major advantage over existing patch pumps in that the chamber carries enough insulin to meet the high doses many Type 2 patients need. We intend to promote this advantage and capture a significant share of the existing Type 2 pump users, as well as new starts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work with key organizations and policy makers to pave the way for greater access to pumps.&#160;</b>We will<b>&#160;</b>promote MODD1 technology among the underserved, who are typically low users of health technology. We will identify individuals, patient organizations, professional societies, and policy and diversity and inclusion organizations that are critically important to the adoption of new technologies in the diabetes space and build relationships with these influential stakeholders.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initiate a clinical
    study program (with key diabetes centers</b>) We intend to provide additional clinical support for MODD1 in special patient types
    and clinical setting. After obtaining 510(k) clearance, we intend to conduct a soft launch and clinical research program in major
    markets to pave the way for the full launch, which is expected to commence in early 2025. We will work with our advisors and key
    diabetes associations to educate the community about the MODD1. In addition, we will conduct clinical studies to develop competitive
    claims and market expansion.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work with major health
    plans to establish MODD1 as the first line pump for Type 2 patients</b>. We believe MODD1 will be payor preferred for both Type 1
    and Type 2 patients. It was designed to attain preferential reimbursement and avoid the coverage pitfalls many other pumps have experienced.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors want an effective
    product whereby the users realize the clinical benefit. We intend to launch with a discount program for payors of 20% to drive uptake.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed to use existing
    PBM codes as a disposable</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No new reimbursement code:
    Reimbursed at launch</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tie-in
with telehealth. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, telehealth has gone mainstream, and patients and providers have become comfortable with it. There are less than 4,000 patient-facing
endocrinologists in the United States. The treatment of diabetes will be significantly enhanced with telehealth to drive more volume
and clinical enhancements through their practices. Telemedicine is a force multiplier for a small group of doctors to better serve a
large market. MODD1 was designed to be affordable enough for free sampling and trial, and simple enough for self-guided user training.
We believe that by combining telehealth support with MODD1, we will decrease the burden of diabetes care and improve the lives of people
with diabetes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_003.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Soft Launch</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to initiate a &#8220;soft launch&#8221; following FDA clearance
of the MODD1 device. Our plan is to select a group of clinicians who are well trained, experienced and have the support infrastructure
to take on initial patients and monitor them carefully to provide clinical feedback on our performance to further refine our product and
the support infrastructure prior to full commercial launch. Many of these clinicians will have been those who assisted in the development
of the MODD1 offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to modify, refine and finalize our system to best meet:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The general needs and preferences
    of our Almost Pumper target market based upon our knowledge of the diabetes industry and information available and/or obtained by
    us from Almost Pumpers and their caregivers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The general guidelines
    of third-party payors, private and public insurance companies, preferred provider organizations and other managed care providers
    with particular focus on the guidelines established by CMS, which administrates the United States Medicare program. To assist us
    in making such modifications and refinements, we have retained independent consultants to focus on ensuring that our product candidate
    satisfies the existing coverage and reimbursement criteria of such third-party payors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to
the user&#8217;s body and the infusion set, which includes a cannula to infuse the insulin into the body. We intend to manufacture the
pump, the cartridge and the baseplate and purchase the infusion set from third parties. Prior to shipment, our pump product will be packaged
with an infusion set. In connection therewith:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have installed automation
    machines in our facility that will be capable of assembling the cartridges at a rate sufficient to supply 6,000 patients (60,000
    cartridges per month), and we are in the process setting up a second line to double this capacity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product packaging will
    initially be performed manually by our personnel, while the cartridge automation is being refined. We expect to purchase and implement
    packaging automation equipment as the second phase of automation of the cartridge.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The infusion sets will
    be purchased from a third-party supplier to cost-effectively introduce our product and focus on our core expertise.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have commenced working with Phillips-Medisize to prepare for the transfer to its facility. We expect to transfer the cartridge automation
equipment to this contract manufacturer in mid 2024 to verify and validate into its manufacturing process. Phillips Medisize would then
perform all manufacturing operations to ensure compliance with FDA regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Clearance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA requires us to meet all applicable regulations for insulin pumps, a subcategory of infusion pumps, which are generally considered
Class II devices by the FDA. In January 2024, we submitted a 510(k) premarket notification to the FDA for our MODD1 insulin pump. In
March 2024, we received comments from the FDA, and we are in the process of responding to those comments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Steps</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To commercialize our product, we must successfully complete a number
of material steps, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue &#160;to ensure it meets:</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA requirements for 510(k) clearance, including taking such actions, if any, as may be required by the FDA as a condition to granting approval and providing 510(k) clearance for our insulin pump;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general needs and preferences of our Almost-Pumper target market
based on our knowledge of the diabetes industry, information gathered from our soft launch and other information available and/or obtained
by us from Almost Pumpers and their caregivers; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            general guidelines of third-party payors, private and public insurance companies, preferred
                                            provider organizations and other managed care providers with particular focus on the guidelines
                                            established by the Center for Medicare and Medicaid Services, or CMS which administers the
                                            United States Medicare program, or Medicare. To assist us in making such modifications and
                                            refinements, we have retained independent consultants to focus on ensuring that our product
                                            candidate satisfies the existing coverage and reimbursement criteria of such third-party
                                            payors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer our manufacturing equipment and process to Phillips-Medisize
prior to product launch; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hire
    and retain appropriate sales and marketing personnel to develop, implement and launch a promotional campaign for our insulin pump
    substantially focused on our target market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with any medical device attempting to enter and successfully compete with existing products in an established and competitive marketplace,
we will face significant hurdles to accomplish the above steps to commercialization including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    FDA 510(k) clearance to market and sell our insulin pump to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    any other FDA-required authorizations with regard to our product, as required by the Federal&#160;Food, Drug, and Cosmetic
    Act, or&#160; FDCA, which is administered by the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Educating endocrinologists, physician&#8217;s assistants, nurse practitioners
and nurse educators, who typically prescribe pump usage, and certified diabetes educators and dieticians, who provide education and guidance
to diabetes patients, as to what we believe to be the superior qualities of our product candidate. We will continue to exhibit at the
Association of Diabetes Care &amp; Education Specialists,&#160;or ADCES, conference annually;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrating
    to select general practitioners, who have historically been skeptical of the heightened support inherent in insulin pumps, our product
    candidate&#8217;s ease of use and convenience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
    that our final product does, in fact, meet the needs of Almost Pumpers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overcoming
    the historic obstacles and reluctance of Almost Pumpers to using insulin pumps to treat their diabetes; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
    that third-party payors agree to cover all or a substantial portion of the purchase price and recurring costs of the use of our insulin
    pump.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Looking
Forward</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going
forward, we expect to continue to evolve the MODD1 pumps and their capabilities and functionality both in response to patient needs and
as part of our current platform roadmap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With our future MODD1+
    product, we intend to seek to add phone-based control and Alternative Controller Enabled (&#8220;ACE&#8221;) and Automated Insulin
    Deliver (&#8220;AID&#8221;) capability to allow integration with popular continuous glucose monitors. We believe this will expand
    our available market to include many existing pumpers. The new model has the same modular design and low-cost components as MODD1
    and provides a much desired breakthrough for patients - two-factor command authentication that allows the wearer to use an application
    on his/her cell phone as the controller.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AID control functionality
    is being developed and will be added via an ACE designation on the pump.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any approved AID controller
    can drive insulin delivery in &#8220;auto&#8221; mode, when appropriate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CGM integration allows
    the controller to potentially adjust basal insulin rate for meals and exercise with an approved algorithm.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With our future MODD2 product,
    we will seek to move to a full-featured, multi-chamber pump optimized for high time-in-range fully autonomous close loop insulin
    delivery utilizing the form factor and cost advantages of its pumping designs to create an affordable, easy to use drug delivery
    system to realize the aspiration of true &#8220;artificial pancreas&#8221; systems. We envision moving to a drug prefill model, such
    that cartridges can be filled with insulin or other drugs and shipped cold chain to patients, further simplifying the use process.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
in the United States, only three companies are commercializing insulin pumps to T1D patients and insulin treated T2D patients and have
significant market share:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medtronic - commercializes
    the durable Minimed 770G and also offers older durable pumps (670G, 630G etc.). In 2020, they held approximately 51% of the US insulin
    pump market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tandem - commercializes
    the durable t:slim X2 pump (with or without algorithms - Basal-IQ and Control-IQ). In 2020, they held approximately 28% of the US
    insulin pump market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insulet - commercializes
    the disposable Omnipod patch pump with approximately 19% of the US market in 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 54%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_004.jpg"/></span></td>
    <td style="width: 46%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_005.jpg"/></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medtronic pump and infusion
    set</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tandem pump and infusion
    set</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
three insulin pump offerings are vying for the attention of the most motivated and well insured in hope of converting them away from
their reliance on MDI. The t:slim X2 and Minimed 770G each have a ~$5,000 list price that is covered through Durable Medical Equipment
(DME) reimbursement and daily consumables, which comprise cartridge, tubing and set for each three-day period, as well. These products
have controllers integrated into the pump, making them cumbersome and bulky, along with long (&gt; 20 inch) tubing between the pump and
the cannular site. The Omnipod is the third offering, a patch pump that attaches to your body for 72 hours and uses a separate controller
to manage the insulin delivery process. Insurance coverage for Omnipod can be provided via DME but also via Pharmacy Benefit (PB). The
Omnipod patch pump is more expensive per day and less accurate than other insulin pumps, according to a Mende 2022 study. Around 33%
of people living with T1D are currently using insulin pumps; of these, the vast majority are using one of these three offerings, a statistic
that has not changed significantly over the last 5+ years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_006.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of these pump products require extensive training to initiate and two to four hours per day to use and manage on an ongoing basis. We
believe this level of sophistication and effort combined with the cost and awkwardness of these products contribute to the limited uptake.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are purely mechanical pumps available to patients with a small percentage of T2D patients using the Mannkind V-Go patch pump, a
fixed basal rate and a button to deliver small boluses. This pump is simple to use, though gives little performance decision to the user
(e.g., no possibility to change the basal rate, no possibility to stop bolus doses, small reservoir, pump that needs to be changed every
day, etc.). The last available patch pump is provided by Cequr, called Simplicity, a bolus only delivery option without basal delivery.
Beta Bionics, Inc. and Deka Research and Development Corp. have received clearance for their tube-based pumps in the last 12 months,
but it is too early to assess their commercial traction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medtronic
has launched a new version of its insulin pump, the Minimed 780G, already available in some European countries with an advanced algorithm,
but no obvious change in hardware. Tandem is now selling a small, no display pump called Mobi. The Mobi has a small 2mL reservoir and
is controlled by a separate unit, similar to the current Omnipod product. Insulet has also launched the Omnipod 5, a similar patch pump
to its current offering, that includes an AID algorithm.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
79% of the people who rely upon MDI therapy choose to not administer a shot outside of their house, which creates a poorly controlled
group. MODD1 is designed to focus upon a segment of these people and mobilize them via a simple, easy to use, affordable product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_007.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary
rights against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and
expense associated with developing new products and bringing them through the regulatory approval process, the health care industry places
considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes,
know-how, and methods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we held four U.S. utility and no foreign patents, and we also held 22 pending applications in the United States and
abroad. The patents and patent applications cover various aspects of our technology, including our proprietary fluid movement technology
and associated features of our insulin delivery methodology. There can be no assurance that the pending patent applications will result
in the issuance of patents, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these
patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our research
and development partners do business. The laws and regulations governing our business and interpretations of those laws and regulations
and are subject to frequent change. Our ability to operate profitably will depend in part upon our ability, and that of our research
and development partners and affiliates, to operate in compliance with applicable laws and regulations. The laws and regulations relating
to medical products and healthcare services that apply to our business and that of our partners and affiliates continue to evolve, and
we must, therefore, devote significant resources to monitoring developments in legislation, enforcement, and regulation in such areas.
As the applicable laws and regulations change, we are likely to make conforming modifications in our business processes from time to
time. We cannot provide assurance that a review of our business by courts or regulatory authorities will not result in determinations
that could adversely affect our operations or that the regulatory environment will not change in a way that restricts our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Regulation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, medical devices are strictly regulated by the FDA. Under the FDCA, a medical device is defined as &#8220;an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part
or accessory which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals; or intended to affect the structure or any function of the body of man
or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; This definition
provides a clear distinction between a medical device and other FDA regulated products such as drugs. If the primary intended use of
a medical product is achieved through chemical action or by being metabolized by the body, the product is usually a drug or biologic.
If not, it is generally a medical device.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed an insulin pump delivery system, which is regulated by the FDA as a medical device under the FDCA, as implemented and
enforced by the FDA. The FDA regulates the development, testing, manufacturing, labeling, packaging, storage, installation, servicing,
advertising, promotion, marketing, distribution, import, export, and market surveillance of medical devices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Device
Premarket Regulatory Requirements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
being introduced into the U.S. market, each medical device must obtain marketing clearance or approval from the FDA through the premarket
notification (or 510(k)) process, the <i>de novo</i> classification process, or the premarket approval, or PMA, process, unless they
are determined to be Class I devices or to otherwise qualify for an exemption from one of these available forms of premarket review and
authorization by the FDA. Under the FDCA, medical devices are classified into one of three classes - Class I, Class II or Class III -
depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance
of safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among
other things, the necessity and type of FDA review required prior to marketing the device. Class I devices are those for which reasonable
assurance of safety and effectiveness can be maintained through adherence to general controls which include compliance with the applicable
portions of the FDA&#8217;s Quality System Regulation (the &#8220;QSR&#8221;), as well as regulations requiring facility registration
and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional
materials. The Class I designation also applies to devices for which there is insufficient information to determine that general controls
are sufficient to provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide
such assurance, but that are not life-supporting or life-sustaining or for a use which is of substantial importance in preventing impairment
of human health, and that do not present a potential, unreasonable risk of illness or injury.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and
there is sufficient information to establish &#8220;special controls.&#8221; These special controls can include performance standards,
post-market surveillance requirements, patient registries and FDA guidance documents describing device-specific special controls. While
most Class I devices are exempt from the premarket notification requirement, most Class II devices require a premarket notification prior
to commercialization in the United States; however, the FDA has the authority to exempt Class II devices from the premarket notification
requirement under certain circumstances. As a result, manufacturers of most Class II devices must submit premarket notifications to the
FDA under Section 510(k) of the FDCA (21 U.S.C. &#167; 360(k)) in order to obtain the necessary clearance to market or commercially distribute
such devices. To obtain 510(k) clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device
is &#8220;substantially equivalent&#8221; to a &#8220;predicate device&#8221; that is already on the market. A predicate device is a
legally marketed device that is not subject to PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (&#8220;pre-amendments
device&#8221;) and for which a PMA is not required, (ii) a device that has been reclassified from Class III to Class II or I or (iii)
a device that was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent
to the predicate device identified by the applicant in a premarket notification submission, the agency will grant 510(k) clearance for
the new device, permitting the applicant to commercialize the device. Premarket notifications are subject to user fees, unless a specific
exemption applies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no adequate predicate to which a manufacturer can compare its proposed device, the proposed device is automatically classified
as a Class III device. In such cases, a device manufacturer must then fulfill the more rigorous PMA requirements or can request a risk-based
classification determination for its device in accordance with the de novo classification process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices
that are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable
risk of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent to
a predicate device and for which safety and effectiveness cannot be assured solely by the general controls and special controls are placed
in Class III. Such devices generally require FDA approval through the PMA process, unless the device is a pre-amendments device not yet
subject to a regulation requiring premarket approval. The PMA process is more demanding than the 510(k) process. For a PMA, the manufacturer
must demonstrate through extensive data, including data from preclinical studies and one or more clinical trials, that the device is
safe and effective for its proposed indication. The PMA must also contain a full description of the device and its components, a full
description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission,
the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application
for review, it has 180 days under the FDCA to complete its review and determine whether the proposed device can be approved for commercialization,
although in practice, PMA reviews often take significantly longer, and it can take up to several years for the FDA to issue a final decision.
Before approving a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;<i>de
novo</i>&#160;classification process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification
of its device to Class I or Class II, on the basis that the device presents low or moderate risk, as an alternative to following the
typical Class III device pathway requiring the submission and approval of a PMA application. With our submission in January 2024, the
FDA has confirmed our MODD 1 qualifies as a 510(k) eligible device and does not require a <i>de novo</i> classification.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are almost always required to support PMAs and are sometimes required to support 510(k) and&#160;<i>de novo</i>&#160;classification
submissions. In our case, usability studies of our intended users are required and have been completed. All clinical investigations of
devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption,
or IDE, regulations that govern investigational device labeling, prohibit promotion of investigational devices, and specify recordkeeping,
reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221;
as defined by the FDA, the agency requires the study sponsor to submit an IDE application to the FDA, which must become effective prior
to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA denies
the application or notifies the sponsor that the investigation is on hold and may not begin until the sponsor provides supplemental information
about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines that there are deficiencies or other concerns
with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval. The
FDA may also notify the sponsor that the study is approved as proposed or approved with specific requested modification. Furthermore,
the agency may withdraw approval of an IDE under certain circumstances. In addition, the study must be approved by, and conducted under
the oversight of, an institutional review board, or IRB, for each clinical site. If the device presents a non-significant risk to the
patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial after obtaining
approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated IDE requirements,
such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Marketing
Restrictions and Enforcement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submitting and updating
    establishment registration and device listings with the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with the QSR,
    which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance
    of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unannounced routine or
    for-cause device facility inspections by the FDA, which may include our suppliers&#8217; facilities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling regulations, which
    prohibit the promotion of products for uncleared or unapproved (or &#8220;off-label&#8221;) uses and impose other restrictions relating
    to promotional activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrections and removal
    reporting regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to reduce a
    risk to health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market surveillance
    regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional
    safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the FDA medical device reporting, or MDR, regulations, medical device manufacturers are required to report to the FDA
information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would
likely cause or contribute to death or serious injury if the malfunction of the device or a similar device of such manufacturer were
to recur. The decision to file an MDR involves a judgment by the manufacturer. If the FDA disagrees with the manufacturer&#8217;s determination,
the FDA can take enforcement action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MDR requirements also extend to health care facilities that use medical devices in providing care to patients, or &#8220;device user
facilities,&#8221; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient
treatment facilities, but not physician offices. A device user facility must report any device-related death to both the FDA and the
device manufacturer, or any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to the FDA) within
10 days of the event. Device user facilities are not required to report device malfunctions that would likely cause or contribute to
death or serious injury if the malfunction were to recur but may voluntarily report such malfunctions through MedWatch, the FDA&#8217;s
Safety Information and Adverse Event Reporting Program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also has the authority to require the recall of commercialized medical device products in the event of material deficiencies or defects
in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that
the device would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product
if any distributed devices fail to meet established specifications, are otherwise misbranded or adulterated under the FDCA, or if any
other material deficiency is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working
days after the recall is initiated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following
sanctions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters, fines,
    injunctions or civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, detentions or
    seizures of products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in the introduction
    of products into the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial suspension
    of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or refusal of the
    FDA or other regulators to grant 510(k) clearance, PMA approvals, or other marketing authorization to new products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals of marketing
    authorizations; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the most serious cases,
    criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled
and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Trade Commission Regulatory Oversight</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
advertising for our products and services will be subject to federal truth-in-advertising laws enforced by the Federal Trade Commission
(the &#8220;FTC&#8221;) as well as comparable state consumer protection laws. Under the Federal Trade Commission Act (the &#8220;FTC
Act&#8221;), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices
in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information
and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC
has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection
laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would
be able to market services or products in the future, or criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Law and Regulation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our MODD1 product or our other future product candidates are approved in the United States, we will have to comply with various U.S.
federal and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral
laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some
instances, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid. These laws include
the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
    directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order
    or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program
    such as Medicare and Medicaid;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal False Claims
    Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly
    presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false
    statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any
    healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the
    Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including
    mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
    information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false statements
    statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement
    in connection with the delivery of or payment for healthcare benefits, items or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal transparency
    requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical
    supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information
    related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care
    practitioners and physician ownership and investment interests; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state and foreign
    laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims
    involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
state laws require pharmaceutical or medical device companies to comply with the relevant industry&#8217;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and device manufacturers to
report information related to payments to physicians and other health care providers or marketing expenditures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other
in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in
the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose,
store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or
reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand
our customer base and thereby decrease our future revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Union approves the use of medical devices in a very different way. They have similar regulations and requirements to adhere
to, however, a Notified Body, in the form of a private company, will represent their interests and is required to have sufficient expertise
to review all applications and the company&#8217;s internal processes to ensure the safety of the product for which approval is being
requested. We are in the process of identifying a Notified Body to represent us, and we will follow our FDA submission process with regard
to preparing the materials and processes required to meet the regulations and gain clearance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">EEA</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Economic Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein),
or EEA, manufacturers of medical devices need to comply with the Essential Requirements laid out in Annex I to the EU Medical Devices
Directive (Council Directive 93/42/EEC) or with the General Safety and Performance Requirements (GSPR) of the new EU Medical Devices
Regulation (EU 2017/745). Compliance with these requirements is a prerequisite to be able to affix the CE mark to medical devices, without
which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements and the GSPR and obtain the
right to affix the CE Mark, manufacturers of medical devices must undergo a conformity assessment procedure, which varies according to
the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which
are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its
products with the Essential Requirements and the GSPR, a conformity assessment procedure requires the intervention of a Notified Body,
which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant
conformity assessment procedure, the Notified Body would audit and examine the Technical File and the quality system for the manufacture,
design and final inspection of the devices. The Notified Body issues a CE Certificate of Conformity following successful completion of
a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential
Requirements and GSPR. This Certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and
signed a related EC Declaration of Conformity. As a general rule, demonstration of conformity of medical devices and their manufacturers
with the Essential Requirements and GSPR must be based, among other things, on the evaluation of clinical data supporting the safety
and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves
its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized
and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety
of the device are supported by suitable evidence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this
system, incidents must be reported to the relevant authorities of the member states of the EEA, and manufacturers are required to take
Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with
the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics
and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly,
might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of
health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated
by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices.
Where appropriate, our products commercialized in Europe are CE marked and classified as either Class I or Class II.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike
directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e.,
without the need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current
differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended
to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro
diagnostic devices and ensure a high level of safety and health while supporting innovation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medical Device Regulation became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to the EU Medical Devices
Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May 26, 2026. The
Medical Devices Regulation, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens the rules on
    placing devices on the market and reinforces surveillance once they are available;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes explicit provisions
    on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improves the traceability
    of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sets up a central database
    to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens rules for the
    assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are
    placed on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished
pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available
free of charge on our website at www.modular-medical.com. as soon as it is reasonably practicable after they are filed or furnished with
the SEC. Our Code of Business Conduct and Ethics and the charters for the Audit Committee, Compensation Committee and Nominating and
Governance Committee are also available on our website. The Code of Business Conduct and charters are also available in print to any
stockholder upon request without charge. Requests for such documents should be directed to Modular Medical, Inc., 10740 Thornmint Road,
San Diego CA 92127, Attn. CFO. Our Internet website and the information contained on it or connected to it are not part of, or incorporated
by, reference into this Report. Our filings with the SEC are also available on the SEC&#8217;s website at http://www.sec.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Nevada corporation, and Quasuras, Inc., a Delaware corporation, is our only subsidiary. Our corporate headquarters and operating
facilities are located at 10740 Thornmint Road, San Diego, CA 92127. Our telephone number is (858) 800-3500. We maintain a website at
www.modular-medical.com.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had 40 employees all of whom are located in the United States and 39 of whom are full-time, consisting of 36 in
research and development and manufacturing operations and 4 in general and administrative functions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><span style="text-decoration:underline">ITEM
1A. RISK FACTORS</span></b></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">This
Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties, such as statements of our objectives,
expectations and intentions. The cautionary statements made in this Annual Report on Form 10-K should be read as applicable to all forward-looking
statements wherever they appear in this report. Our actual results could differ materially from those discussed herein. Factors that
could cause or contribute to such differences include those discussed below, as well as those discussed elsewhere in this Annual Report
on Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might not be able to continue as a going concern.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>
</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements as of
March 31, 2024 have been prepared under the assumption that we will continue as a going concern twelve months from the date of
issuance of this Report. At March 31, 2024, we had cash and cash equivalents of $9.2 million and an accumulated deficit of $65.9
million. In February 2024, we completed a public offering of common stock for net proceeds to us of approximately $10.3 million. In
May 2023, we completed a public offering of common stock and warrants for net proceeds to us of approximately $9.7 million. Even
with these offering proceeds, we do not believe that our cash and cash equivalents would be sufficient to fund our operations for
the period of 12 months from the date of issuance of this report, and we would need to raise additional capital.&#160;As a result of
our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to
raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain
liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going
concern. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to generate sustainable operating profit and sufficient cash flows, then our future success will depend on our ability
to raise capital. We intend to seek additional financing and evaluate financing alternatives in order to meet our cash requirements for
the foreseeable future. We cannot be certain that raising additional capital, whether through selling additional debt or equity securities
or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue
additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock,
and our current stockholders may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be
required to curtail our current product development programs, cut operating costs, forego future development and other opportunities
or even terminate our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a developmental stage medical device company and have a history of significant operating losses; we expect to continue to incur operating
losses, and we may never achieve or maintain profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a development-stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception,
we have incurred operating losses in each year due to costs incurred in connection with research and development activities and general
and administrative expenses associated with our operations. For the years ended March 31, 2024 and, 2023, we incurred net losses of approximately
$17.5 million and $13.9 million, respectively. As a result, we need to raise additional capital in the future, which may or may not be
available to us at all or only on unfavorable terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur losses for the foreseeable future as we continue the development of, and seek regulatory clearance and approvals for,
our insulin pump. As our MODD1 insulin pump is currently our only product, if it fails to gain regulatory approval and market acceptance,
we will not be able to generate any revenue, or explore other opportunities to enhance stockholder value, such as through a sale. If
we fail to generate revenue and eventually become profitable, or if we are unable to fund our continuing losses, our stockholders could
lose all or a substantial part of their investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial additional funding to complete subsequent phases of the development of our insulin pump product candidate and to
operate our business and such funding may not be available or, if it is available, such financing is likely to substantially dilute our
existing stockholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discovery, development, and commercialization
of new medical devices, such as our insulin pump, entails significant costs. We have completed the engineering and mechanical development
of our insulin pump and cartridge, and submitted the product to the FDA for clearance. In addition, we have also implemented a production-level
manufacturing process, including purchasing required equipment for low-level manufacturing. We will continue to refine our insulin pump
to, among other things, meet the general needs and preferences of the Almost Pumper marketplace and the guidelines of third-party payors.
To enable us to accomplish these and other related items and continue to operate our business, we will need to raise substantial additional
capital and/or enter into strategic partnerships or joint ventures to enable us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek European regulatory approvals with appropriate clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand and continue to improve our manufacturing and commercialization capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop, test, and, if
    approved, market our product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire or license additional
    internal systems and other infrastructure; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">hire and support additional management, administrative, sales and marketing,
and technical personnel.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance
our cash needs primarily through public or private equity offerings, debt financings or through the establishment of possible strategic
alliances. We may in the future seek additional capital from public or private offerings of our capital stock or borrow additional amounts
under new credit lines or from other sources. If we issue equity or debt securities to raise additional funds, our existing stockholders
may experience dilution, we may incur significant financing costs, and the new equity or debt securities may have rights, preferences
and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaborations, licensing,
joint ventures, strategic alliances, partnership arrangements or other similar arrangements, it may be necessary to relinquish valuable
rights to the MODD1 pump or our potential future products or proprietary technologies or grant licenses on terms that are not favorable
to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that additional funding will
be available on acceptable terms, or at all. If we are not able to secure additional equity funding when needed, we may have to delay,
reduce the scope of, or eliminate one or more of our post-market clinical studies, development programs or future commercialization initiatives.
In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders. The amount
of this dilution may be substantially increased if the trading price of our common stock is lower at the time of any financing. Regardless,
the economic dilution to stockholders will be significant if our stock price does not increase significantly, or if the effective price
of any sale is below the price paid by a particular stockholder. Any debt financing that we obtain in the future could involve substantial
restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential sources for
such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing. If we
fail to obtain funding as needed, we may be forced to cease or scale back operations, and our business, prospects, results of operations,
financial condition and stock price would be adversely affected.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and historical financial information upon which you may evaluate our performance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that,
like us, are in their early stages of development. We may not successfully address these risks and uncertainties or successfully complete
our studies and/or implement our existing and new products. If we fail to do so, it could materially harm our business and impair the
value of our common stock. Unanticipated problems, expenses and delays are frequently encountered in establishing a new business, conducting
research, and developing new products. These include, but are not limited to, inadequate funding, failure to obtain regulatory approval,
unforeseen research issues, lack of consumer, physician or third-party payor acceptance, competition, sluggish product development, and
inadequate sales and marketing. The failure by us to meet any of these conditions would have a materially adverse effect upon us and
may force us to reduce or curtail operations. No assurance can be given that we can or will ever operate profitably.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial
condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the testing costs for our
    insulin pump product candidate and other development activities conducted by us directly, and our ability to successfully conclude
    the studies and activities and achieve favorable results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract
    future strategic partners to pay for or share costs related to our product development efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of
    seeking and obtaining regulatory clearance and approvals for our product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
    maintaining and enforcing any patents and other intellectual property rights that we may have and defending against potential claims
    of infringement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decisions to hire additional
    scientific, engineering or administrative personnel or consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage administrative
    and other costs of our operations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the presence or absence
    of adverse developments in our research program.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these factors cause our funding needs to be greater than expected, our operations, financial condition, ability to continue operations
and stock price may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future cash requirements may differ significantly from our current estimates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash requirements may differ significantly from our estimates from time to time, depending on a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and results of
    our clinical studies regarding our insulin pump product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved
    in obtaining regulatory clearance and approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we are able to
    obtain funding under future licensing agreements, strategic partnerships, or other collaborative relationships, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of compliance
    with laws, regulations, or judicial decisions applicable to us; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of general and administrative infrastructure required to manage our business and protect corporate assets and stockholder interests.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to raise additional funds on a timely basis, we will need to scale back our business plans, which would adversely affect our
business, prospects, results of operations, financial condition, and stock price, and we may even be forced to discontinue our operations
and liquidate our assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diabetes treatment market is subject to rapid technological change and product innovation. Our insulin pump is based on our proprietary
technology, but a number of companies, medical researchers and existing pharmaceutical companies are pursuing new delivery devices, delivery
technologies, sensing technologies, procedures, drugs and other therapeutics for the monitoring, treatment and/or prevention of insulin-dependent
diabetes. Any technological breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete, which,
since our insulin pump is our only product candidate, would have a material adverse effect on our business, our insulin pump is our only
product candidate, would have a material adverse effect on our business, prospects, results of operations and financial condition and
could result in stockholders losing their entire investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to attract and retain skilled directors, executives, employees and consultants could impair our product development and commercialization
activities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the skills, performance, and dedication of our directors, executive officers and key engineering, scientific and
technical advisors. Many of our current engineering or scientific advisors are independent contractors and are either self-employed or
employed by other organizations. As a result, they may have conflicts of interest or other commitments, such as consulting or advisory
contracts with other organizations, which may affect their ability to provide services to us in a timely manner. We will need to recruit
additional directors, executive management employees, and advisers, particularly engineering, scientific and technical personnel, which
will require additional financial resources. In addition, there is currently intense competition for skilled directors, executives and
employees with relevant engineering, scientific and technical expertise, and this competition is likely to continue. If we are unable
to attract and retain persons with sufficient engineering, scientific, technical and managerial experience, we may be forced to limit
or delay our product development activities or may experience difficulties in successfully conducting our business, which would adversely
affect our business, prospects, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations are substantially dependent upon key personnel.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
performance is substantially dependent on the continued services and performance of our senior management and certain other key personnel.
The loss of services of any of our executive officers or other key employees could have a material adverse effect on our business, financial
condition and results of operations. In addition, any future expansion of our business will depend on our ability to identify, attract,
hire, train, retain and motivate other highly skilled managerial, marketing, customer service and manufacturing personnel, and our inability
to do so could have a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the performance and continued engagement of our Chairman, President and Principal Financial Officer.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on the performance and continued engagement of Paul DiPerna, our chairman, president and principal financial officer. Although
we believe we will be able to engage qualified personnel for such purposes, an inability to do so could materially adversely affect our
ability to market, sell, and enhance our products. While Mr. DiPerna is currently devoting his full-time working efforts to us, other
employees and consultants may only be available to us on a part-time basis. The loss of one or more of our key employees, especially
Mr. DiPerna, or our inability to hire and retain other qualified employees, including but not limited to research and development, sales,
manufacturing, and administrative support staff, could have a material adverse effect on our business, prospects, results of operations
and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited internal research and development personnel, making us dependent on consulting relationships.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider research and development to be an important part of the process of designing, developing, obtaining regulatory required approvals
and the eventual commercialization of our insulin pump. We continue to incur increased research and development expenditures, which are
primarily attributable to effort and expenses incurred in designing and developing our innovative insulin pump. We expect to continue
to incur substantial costs related to research and development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing of
our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future success
will be dependent on the timeliness and effectiveness of the efforts of these third parties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on consultants for important aspects of our product development strategy. We do not have the required financial resources
and personnel to carry out independently the development of our product candidate, and do not have the capability or resources to manufacture,
market or sell our current product candidate. As a result, we contract with and rely on third parties for important functions, including
in connection with the development and finalization of our insulin pump, the preparation and filing of our FDA submission and eventual
manufacturing and commercialization of our product candidate. We have recently entered into several agreements with third parties for
such services. If problems develop in our relationships with third parties, or if such parties fail to perform as expected, it could
lead to delays or lack of progress in obtaining FDA clearance, significant cost increases, changes in our strategies, and even failure
of our product initiatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies,
and we will be dependent on our corporate partners if we do.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to enter into a strategic alliance with a diabetes-related service providing company for the further development and approval
of our insulin pump product candidate. At this time, we have not entered into any such strategic alliance. Strategic alliances, if entered
into, could potentially provide us with additional funds, expertise, access, and other resources in exchange for exclusive or non-exclusive
licenses or other rights to the product that we are currently developing or a product we may explore in the future. We cannot give any
assurance that we will be able to enter into strategic relationships with a diabetes-related service providing company or others in the
near future or at all. In addition, we cannot assure you that any agreements that we do reach will allow us to achieve our goals or that
such grants will be on terms that prove to be economically beneficial to us. When we do enter into strategic or contractual relationships,
we become dependent on the successful performance of our partners or counter-parties. If they fail to perform as expected, such failure
could adversely affect our financial condition, lead to increases in our capital needs, or hinder or delay our development efforts. See
&#8220;<i>Our Business -Employees</i>&#8221; below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can market a new medical device, such as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food,
Drug, and Cosmetic Act, or the &#8220;FDCA.&#8221; In the 510(k) clearance process, before a device may be marketed, the FDA must determine
that such proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes
a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments
device), a device that was originally on the U.S. market pursuant to a premarket approval (PMA) and later down-classified, or a 510(k)-exempt
device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and
either have the same technological characteristics as the predicate device or have different technological characteristics and not raise
different questions of safety or effectiveness than the predicate device. In January 2024, we submitted a 510(k) premarket notification
to the United States Food and Drug Administration (&#8220;FDA&#8221;) for our MODD1 insulin pump.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
future modifications made to our product candidate, which we currently expect to be cleared through 510(k), may require a new 510(k)
clearance. The 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes
less than 12 months, but it can last longer. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any
delay or failure to obtain necessary regulatory authorizations could harm our business, including our ability to commercialize our product
candidate and our stockholders could lose their entire investment. Furthermore, even if we are granted the required regulatory authorizations,
such authorizations may be subject to significant limitations on the indicated uses for the device, which may limit the market for our
product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA requires us to go through a lengthier, more rigorous examination for our product candidate than we had expected, product introductions
or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA can delay, limit or deny clearance or approval for our insulin pump medical device for many reasons, including, for example:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate to the satisfaction of the FDA that our product candidate is substantially
                                            equivalent to the proposed predicate device;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            disagreement of the FDA with the design or implementation of our performance testing protocols
                                            or the interpretation of data from our performance testing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data from performance testing may be insufficient to support a determination of substantial
                                            equivalence or that our device meets required special controls or applicable performance
                                            standards;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate that the benefits of our pump outweigh the risks;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            manufacturing process or facilities we intend to use may not meet applicable requirements;
                                            for example, we experienced issues maintaining insulin stability on an initial version of
                                            our pump product candidate, and we attributed this issue to the materials used in the production
                                            of our product; we believe we have made the necessary changes to our materials and process
                                            to address this issue and will be completing the required testing prior to our FDA submission;
                                            and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential for approval policies or regulations of the FDA to change significantly in a manner
                                            rendering our data or regulatory filings insufficient for clearance or approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our product candidate or impact our ability to modify our product
candidate after clearance on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could
delay our ability to obtain clearance for our pump, increase the costs of compliance or restrict our ability to maintain our current
approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of data supporting the safety and performance of the product candidates during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
marketing authorization in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must
obtain approval from foreign regulatory authorities before we can market and sell any of our product candidates in countries outside
the United States. We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot
be certain that such approvals will be granted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development, manufacture, and marketing of our product candidates outside the United States is subject to government regulation. In most
foreign countries, we must complete rigorous pre-clinical testing and extensive human clinical trials that demonstrate the safety and
efficacy of a product in order to apply for regulatory approval to market the product. If foreign regulatory authorities grant regulatory
approval of a product, the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional
indications for approved devices may not be approved, which could limit our potential revenues. Foreign regulatory authorities may refuse
to grant any approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient to support regulatory approval
for our products, foreign regulatory authorities may not ultimately grant approval for commercial sale in any jurisdiction. If our product
candidates are not approved in such jurisdictions, our ability to generate revenues will be limited and our business will be adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competitors may develop products that are more effective, safer and less expensive than ours.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
insulin pumps are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance
and often require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance
plans, forcing some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any pumps
and places pumps out of reach for many patients who cannot afford such out of pocket expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in the diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products
that are quite effective at addressing the effects of diabetes, and we expect that new developments by other companies and academic institutions
in the areas of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved clinical indication,
our product will be competing with existing and future products related to treatments for diabetes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop product candidates
    and market products that increase the levels of safety or efficacy that our product candidates will need to show in order to obtain
    regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop product candidates
    and market products that are less expensive or more effective than ours;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialize competing
    products before we can launch any products we are working to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hold or obtain proprietary
    rights that could prevent us from commercializing our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduce therapies or
    market medical products that render our potential product candidates obsolete.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to compete against large medical device
companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation, smaller companies that are collaborating with
larger medical device companies, new companies, academic institutions, government agencies and other public and private research organizations.
These competitors, in nearly all cases, produce similar products relative to the treatment of diabetes and have substantially greater
financial resources than we do. Our competitors also have significantly greater experience in:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing medical device
    and other product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking testing and
    clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">building relationships
    with key customers and opinion-leading physicians;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining
    FDA and other regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">formulating and manufacturing
    medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching, marketing and
    selling medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
                                            management oversight for all of the above-listed operational functions; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            insurance coverage and reimbursement for their competitive products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
we fail to achieve acceptance over other existing or newly developed products, we may be unable to obtain regulatory approval or successfully
commercialize our MODD1 insulin pump product candidate or any future products. If our competitors&#8217; market medical devices that
are less expensive, safer or more effective than our insulin pump, or that gain or maintain greater market acceptance, we may not be
able to compete effectively, which would adversely affect our business, prospects, results of operations and financial condition. See
&#8220;<i>Business - Competition</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
insulin pump requires precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including
failure to detect or control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could result
in patient injury or death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product testing or
delivery, cost overruns, product recalls or withdrawals and other problems that could seriously hurt our business. Contract medical device
manufacturers often encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified
personnel. These manufacturers are subject to stringent regulatory requirements, including the FDA&#8217;s current good-manufacturing-practices
regulations. If our contract manufacturers fail to maintain ongoing compliance at any time, the production of our product could be interrupted,
resulting in delays or discontinuance of our clinical studies, additional costs and loss of potential revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay
or prevent us from developing our product candidate and commercializing our product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to conduct larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted,
we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for our product
candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we are
unable to successfully scale up the manufacture of our product candidate in sufficient quality and quantity, the development and testing
of our product candidate and regulatory approval or commercial launch may be delayed, which could significantly harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are dependent upon third-party suppliers to manufacture our product, and this makes us vulnerable to supply shortages and price increases;
we may not be able to obtain an adequate supply of components on a timely basis or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
future manufacture of our product will require the timely delivery of sufficient amounts of components from multiple suppliers in various
countries. We intend to work closely with our suppliers to ensure continuity of supply, but we cannot guarantee these efforts will be
successful. Due to the supply chain issues experienced by the semiconductor industry, at times, we have experienced delays obtaining
integrated circuits from certain suppliers. We may need to enter into &#8220;take or pay&#8221; contracts with suppliers. We have also
seen price increases for various components. We do not have supply agreements with any of our suppliers, and we make purchases based
on individual purchase orders. An interruption, delay, or inability to obtain components from our third-party suppliers at acceptable
prices in a timely manner, could hinder our ability to manufacture our products and have a material adverse effect on our business, prospects,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to potential product liability and other claims that could materially impact our business and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
development and sale of our insulin pump exposes us to the risk of significant damages from product liability and other claims, and the
use of our product in clinical studies may result in adverse effects from liability claims. We cannot predict all the possible harms
or adverse effects that may result. We intend to obtain product liability insurance to provide some protection from claims. Nonetheless,
we may not have sufficient resources to pay for any liabilities resulting from a personal injury or other claim, even if it is partially
covered by insurance. In addition to the possibility of direct claims, we may be required to indemnify third parties against damages
and other liabilities arising out of our development, commercialization and other business activities, which would increase our liability
exposure. If third parties that have agreed to indemnify us fail to do so, we may be held responsible for those damages and other liabilities
as well.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">New
laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the health
care system in the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations in medical
devices, testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject the pricing
of medical devices to government control. In addition, third-party payors in the U.S. are increasingly attempting to contain health care
costs by limiting both coverage and the level of reimbursement of new products. Consequently, significant uncertainty exists as to the
reimbursement status of newly approved health care products. Significant changes in the health care system in the U.S. or elsewhere,
including changes resulting from adverse trends in third-party reimbursement programs, could have a material adverse effect on our projected
future operating results and our ability to raise capital, commercialize products, and remain in business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to extensive regulation by the FDA, which could restrict the sales and marketing of our insulin pump and could cause us to
incur significant costs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
insulin pump is subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution
and shipping. Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States,
it must be cleared or approved by FDA through the applicable premarket review process (510(k), PMA, or de novo classification), unless
an exemption applies. If we receive 510(k) clearance for our insulin pump, we may be required to obtain new 510(k) clearances for significant
post-market modifications to the pump. Each premarket submission and review process can be expensive and lengthy, and entail significant
user fees, unless exempt.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Medical
devices may be marketed only for the indications for which they are approved or cleared. Further, 510(k) clearance can be revoked if
safety or effectiveness problems develop once the device is on the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
current regulatory requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply
with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may
include any of the following sanctions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters, warning
    letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notification,
    or orders for repair, replacement or refunds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary or mandatory
    recall or seizure of our current or future products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative detention
    by the FDA of medical devices believed to be adulterated or misbranded;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing operating restrictions,
    suspension or shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing our requests for
    510(k) clearance, PMA or&#160;<i>de-novo</i>&#160;classification of any new products, new intended uses or modifications to our insulin
    pump;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rescinding 510(k) clearance
    that has already been granted; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in stockholders losing their entire investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Although
our insulin pump product candidate does not presently require clinical trials to apply to the FDA for clearance and even if a clinical
trial is completed, the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal
or otherwise not be sufficient for us to obtain approval of our product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are almost always required to
support a PMA application and may also be required to support 510(k) submissions although at this time ours does not require a PMA. If
the device presents a &#8220;significant risk&#8221; to human health as defined by the FDA, the FDA requires the study sponsor to submit
an investigational device exemption (&#8220;IDE&#8221;) application and obtain IDE approval prior to commencing human clinical trials.
The IDE must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device
in humans and that the testing protocol is scientifically sound. An IDE will automatically become effective 30 days after receipt by the
FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and may not begin until the sponsor
provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. The FDA may also notify the sponsor
that the study is approved as proposed. If the FDA determines that there are deficiencies or other concerns with an IDE that require modification
of the study, the FDA may permit a clinical trial to proceed under conditional approval. Furthermore, the agency may withdraw approval
of an IDE under certain circumstances. Clinical trials for a significant risk device may begin once an IDE is approved by the FDA and
the appropriate Institutional Review Board (&#8220;IRB&#8221;) at each clinical trial site. If the product is deemed a &#8220;non-significant
risk&#8221; device, IDE approval from the FDA would not be required, but the clinical trial would need to meet other requirements including
IRB approval. Our clinical trials must be conducted in accordance with FDA regulations and federal and state regulations concerning human
subject protection, including informed consent and healthcare privacy. A clinical trial may be suspended by the FDA or at a specific site
by the relevant IRB at any time for various reasons, including a determination that the risks to the trial participants outweigh the benefits
of participation in the clinical trial. Even if a clinical trial is completed, the results of our clinical testing may not demonstrate
the safety and efficacy of the device or may be equivocal or otherwise not be sufficient for us to obtain approval of our product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product candidate
and research technologies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to the U.S. Patent and Trademark
Office (the &#8220;USPTO&#8221;) and various foreign patent agencies for patents on our proprietary fluid movement technology and our
insulin delivery methodology. To date, the USPTO has granted four patents to us, and we have additional applications pending and in various
stages of review by the USPTO and foreign patent agencies. There can be no assurance that we will be issued additional patents by the
USPTO or foreign patent agencies and that any of our patents will prevent other companies from competing with us. We will continue to
attempt to patent our innovations, as appropriate, to help ensure a sustainable competitive advantage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due
to evolving legal standards relating to the patentability, validity and enforceability of patents covering health care product inventions,
our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications
is uncertain and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth
of claims allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications
owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable
by a court of law, will provide us with any significant protection against competing products, or will afford us a commercial advantage
over competitive products. If, at some point in the future, one or more products resulting from our product candidates is approved for
sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for
approval and sale in the United States without repeating the extensive testing required of us to obtain FDA approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome
would have a significant adverse effect on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
ability to commercialize our product candidate depends on our ability to use, manufacture and sell our product candidate without infringing
the patents or other proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned
by third parties exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with
our insulin pump candidate could infringe.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
a third party claims that our actions infringe on its patents or other proprietary rights, we could face a number of issues that could
materially harm our competitive position, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement and other
    intellectual property claims that, even if meritless, can be costly and time-consuming, delay the regulatory approval process and
    divert management&#8217;s attention from our core business operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an order that we pay substantial damages for infringement, including consequential damages for lost of profits or market share, if a
    court determines that our products or technologies infringe on a third party&#8217;s patent or other proprietary rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a court prohibiting us
    from selling or licensing our products or technologies unless the holder licenses the patent or other proprietary rights to us, which
    it is not required to do; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if a license is available
    from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or other proprietary rights.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
any of these events occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition to patented technology and technology for which patent protection is being sought, we rely on our unpatented technology, trade
secrets and know-how. We generally seek to protect this information by confidentiality, non-disclosure and assignment of invention agreements
with our officers, employees, contractors and other service providers and with parties with which we do business. These agreements may
be breached, which breach may result in the misappropriation of such information, and we may not have adequate remedies for any such
breach. We cannot be certain that the steps we have taken will prevent unauthorized use or reverse engineering of our technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Moreover,
our trade secrets may be disclosed to or otherwise become known or be independently developed by competitors. To the extent that our
officers, employees, contractors, other service providers, or other third parties with whom we do business use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If, for any
of the above reasons, our intellectual property is disclosed or misappropriated, it would harm our ability to protect our rights and
have a material adverse effect on our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to gain and maintain a competitive advantage. The following examples are illustrative:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may be able to make
    devices that are similar to our insulin pump but that are not covered by the claims of the patents that we own;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we or any collaborators
    might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we might not have been
    the first to file patent applications covering certain of our inventions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may independently
    develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it is possible that our
    pending patent applications will not lead to issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued patents that we
    own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors might conduct
    research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for
    certain research and development activities, as well as in countries where we do not have patent rights, and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not develop additional
    proprietary technologies that are patentable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Healthcare
reform and drug-pricing reform laws could adversely affect our product candidate and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the United States, there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (ACA), was
enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private
insurers. Among other ways in which it may affect our business, the ACA implemented payment system reforms, including a national pilot
program on payment bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency
of certain healthcare services through bundled payment models and expanded the eligibility criteria for Medicaid programs. Since its
enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. It is unclear how the ACA
and its implementation, as well as efforts to repeal or replace, or invalidate, the ACA, or portions thereof, will affect our insulin
pump or our business. Additional legislative changes, regulatory changes, and judicial challenges related to the ACA remain possible.
It is possible that the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may
be adopted in the future, could have an adverse effect on our industry generally and on our ability to commercialize our insulin pump
and achieve profitability. We have assumed in all of our financial projections that there is not an increase in the reimbursement for
our product through the pharmacy or durable medical equipment routes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drug pricing continues to be a subject of debate
at the executive and legislative levels of U.S. government. The American Rescue Plan Act of 2021 eliminated the statutory cap on rebates
that drug manufacturers pay to Medicaid beginning January 1, 2024. With the elimination of the rebate cap, manufacturers may be required
to compensate states in an amount greater than what the state Medicaid programs pay for the drug. Additionally, the Inflation Reduction
Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S.
Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for
certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain
drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide
discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation
Reduction Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement
we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial
condition, results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical
industry in general is not yet known.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect
that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement
and reduced demand for our products, once approved, or additional pricing pressures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any current product or future product candidate. Any reduction in reimbursement from
Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales
and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of any current or future product
candidates, if any, may be. In addition, increased Congressional scrutiny of the FDA&#8217;s approval process may significantly delay
or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing
and distribution of our product candidate could be interrupted, and our product sales and operating results could suffer.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have established initial, low-volume manufacturing capability in our facility, and we have selected an initial, tier one contract manufacturer.
We and the contract manufacturer of our insulin pump will be required to comply with the FDA&#8217;s quality system regulations, which
impose a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control, quality
assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces its quality system regulations
through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing facilities owned by us or any contract
manufacturer will pass any quality system inspection. In the event that our or any contract manufacturer&#8217;s facilities fails a quality
system inspection, the manufacturing or distribution of our product candidate could be interrupted and our operations disrupted. Failure
to take adequate and timely corrective action in response to an adverse quality system inspection could force a suspension or shutdown
of any packaging and labeling operations or then manufacturing operations of any contract manufacturers, or a recall of our insulin pump.
If any of these events were to occur, we at such time would not be able to provide our customers with the quantity of insulin pumps that
they require on a timely basis, our reputation could be harmed and we could lose any customers we then have, any or all of which could
have a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may bring infringement claims or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may come to believe that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized
use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious
counterclaims against us and would distract management&#8217;s attention. Also, in an infringement or misappropriation proceeding, a
court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be able to use our
technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other
party from using the technology at issue on the grounds that the other party&#8217;s activities are not covered by our patents. See &#8220;Business
- Patents,&#8221; below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become involved in disputes with our present or future contract partners over intellectual property ownership or other matters, which
would have a significant effect on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventions discovered in the course of performance
of contracts with third parties or contractors may become jointly owned by such third-party contractors and us, in some cases, and the
exclusive property of one of us, in other cases. Under some circumstances, it may be difficult to determine who owns a particular invention
or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions or jointly developed improvements
thereto. Other disputes may also arise relating to the performance or alleged breach of our agreements with third parties. Any disputes
could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Even
assuming we obtain FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our
pump if we commence manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations
pertaining to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning
the safety or efficacy of the device. A government-mandated recall could occur if the FDA finds that there is a reasonable probability
that our device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of manufacturing
defects, labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall would divert management&#8217;s
attention and financial resources and harm our reputation with customers. A recall involving our insulin pump would be particularly harmful
to our business, financial condition and results of operations because it is currently our only product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets,
and thus adversely affect our business and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Negative
economic conditions and instability or uncertainty in the financial markets could have a negative impact on our ability to access the
capital markets, and thus have a negative impact on our then operations and liquidity. We face certain risks in the event of a sustained
deterioration of financial market liquidity, as well as in the event of sustained deterioration in the liquidity, or failure, of our
banking, cash management and custodial financial institutions. A general shortage of liquidity and credit combined with the substantial
losses in worldwide equity markets could lead to an extended worldwide recession in the future. If such occurred, we would face significant
challenges if conditions in the capital markets did not improve. Our ability to access the capital markets under such circumstances could
be severely restricted at a time when we need to access such markets, which could have a negative impact on our business plans. Even
if we are able to raise capital under such circumstances, it may not be at a price or on terms that are favorable to us. We cannot predict
the occurrence of future disruptions or how long such negative conditions might continue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Because
our current insulin pump is still in the pre-clearance stage with the FDA, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are cleared for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate
reimbursement or insurance coverage for such product candidate from third-party payors, we will be unable to generate significant revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Because
our current insulin pump is still in the pre-clearance stage with the FDA, it is not eligible for reimbursement and is not approved for
insurance coverage. The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain.
In the United States, patients using insulin pumps are generally reimbursed for all or part of the product cost by Medicare or other
third-party payors. Any future commercial success of our insulin pump will be substantially dependent on whether third-party coverage
and reimbursement is available for future customers. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new medical devices,
and, as a result, they may not cover or provide adequate reimbursement for our insulin pump, assuming we are able to fully develop and
obtain all regulatory approval to market it in the United States. In addition, in certain countries, no uniform policy of coverage and
reimbursement for medical device products and services exists among third-party payors. Therefore, coverage and reimbursement for medical
device products and services can differ significantly from payor to payor. In addition, payors continually review new technologies for
possible coverage and can, without notice, deny coverage for these new products and procedures. As a result, the coverage determination
process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our
products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained or maintained, if obtained.
Reimbursement systems in international markets vary significantly by country and by region within some countries, and reimbursement approvals
must be obtained on a country-by-country basis. In many international markets, a product must be approved for reimbursement before it
can be approved for sale in that country. Further, many international markets have government-managed healthcare systems that control
reimbursement for new devices and procedures. Accordingly, unless government and other third-party payors provide coverage and reimbursement
for our insulin pump, patients may not use it, which would cause investors to lose their entire investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Third
parties might attempt to gain unauthorized access to our network or seek to compromise our insulin pump product.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Our
business is dependent on the security and efficacy of our networks and computer and data management systems, and we rely on our internal
computer networks for many of the systems we use to operate our business generally. From time to time, we may face attempts by others
to gain unauthorized access through the Internet or otherwise or to introduce malicious software to our information technology systems.
We or our products may be a target of computer hackers, organizations or malicious attackers who attempt to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gain
                                            access to our network;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">steal
                                            proprietary information related to our business, products and employees; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interrupt
                                            our systems.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may encounter attempts at gaining unauthorized access to our network, and we periodically run security checks. While
we seek to detect and investigate unauthorized attempts and attacks against our network and products of which we become aware, and to
prevent their recurrence where practicable through changes to our internal processes and tools and/or changes to our products, we remain
potentially vulnerable to additional known or unknown threats. In addition to intentional security breaches, the integrity and confidentiality
of Company and customer data and our intellectual property may be compromised as a result of human error, product defects, or technological
failures. Different geographic markets may have different regulations regarding data protection, raising potential compliance risks.
Further, retaliatory acts by foreign governments or terrorist organizations in response to policies of the United States government could
include cyber attacks that could disrupt the economy more generally or that could also impact our operations directly or indirectly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Any
failure or perceived failure by us or our service providers to prevent information security breaches or other incidents or system disruptions,
or any compromise of security that results in or is perceived or reported to result in unauthorized access to, or loss, theft, alteration,
release or transfer of, our information, or any personal information, confidential information, or other data could result in loss or
theft of proprietary or sensitive data and intellectual property, could harm our reputation and competitive position and could expose
us to legal claims, regulatory investigations and proceedings, and fines, penalties, and other liability. Any such actual or perceived
security breach, incident or system disruption could also divert the efforts of our personnel, and could require us to incur significant
costs and operational consequences in connection with investigating, remediating, eliminating and putting in place additional tools,
devices, policies, and other measures designed to prevent actual or perceived security breaches and other incidents and system disruptions,
and in, for example, rebuilding internal systems, reduced inventory value, providing modifications to our products and services, defending
against claims and litigation, responding to regulatory inquiries or actions, paying damages, or taking other remedial steps with respect
to third parties. Moreover, we could be required or otherwise find it appropriate to expend significant capital and other resources to
respond to, notify third parties of, and otherwise address the incident or breach and its root cause, and to notify individuals, regulatory
authorities and others of security breaches involving certain types of data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Further,
we cannot assure that any limitations of liability provisions in our current or future contracts that may be applicable would be enforceable
or adequate or would otherwise protect us from any liabilities or damages with respect to any particular claim relating to a security
breach or other security-related matter. We also cannot be sure that any insurance coverage will continue to be available on acceptable
terms or will be available in sufficient amounts to cover claims related to a security breach or incident, or that the insurer will not
deny coverage as to any future claim. The successful assertion of claims against us that exceed available insurance coverage, or the
occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements,
could have a material adverse effect on our business, including our financial condition, operating results, and reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to oversight by the SEC and other regulatory agencies. Investigations by those agencies could divert management&#8217;s focus
and could have a material adverse effect on our reputation and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are subject to the regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face
legal or administrative proceedings by these agencies. We are unable to predict the effect of any investigations on our business, financial
condition or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could have a
material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to smaller
reporting companies, our common stock may be less attractive to investors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are a &#8220;smaller reporting company,&#8221; and are subject to lesser disclosure obligations in our SEC filings compared to other
issuers. Specifically, &#8220;smaller reporting companies&#8221; are able to provide simplified executive compensation disclosures in
their filings, are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public
accounting firms provide an attestation report on the effectiveness of internal control over financial reporting and have certain other
decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited
financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221;
may make it harder for investors to analyze our operating results and financial prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not expect any cash dividends to be paid on our shares of common stock for the foreseeable future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid a cash dividend and we do not anticipate declaring or paying dividends on our common stock for the foreseeable
future. We expect to use future financing proceeds and earnings, if any, to fund operating expenses. Consequently, stockholders&#8217;
only opportunity to achieve a return on their investment is if the price of our stock appreciates and they sell their shares at a profit.
We cannot assure stockholders of a positive return on their investment when they sell their shares or that stockholders will not lose
the entire amount of their investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
the beneficial ownership of our common stock continues to be highly concentrated, it may prevent our stockholders from influencing significant
corporate decisions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, our executive officers,
directors and certain persons, who may be deemed affiliates, beneficially owned approximately 24% of our issued and outstanding common
stock. Specifically, James Besser, our chief executive officer, and Morgan Frank, a member of our board of directors, were the beneficial
owners of approximately 13% of our outstanding common stock. As a result, such persons may exercise substantial influence over the outcome
of corporate actions requiring stockholder approval including, without limitation, the election of directors, certain mergers, consolidations
and sales of all or substantially all of our assets or any other significant corporate transactions. Such persons may also vote against
a change of control, even if such a change of control would benefit our other stockholders. Thus, investors in our common stock cannot
reasonably expect to have any influence over the election of our directors or other matters submitted to a vote of our stockholders. Instead,
our existing significant stockholders may exert a substantial influence on the election of our directors and any actions requiring or
otherwise put to a stockholder vote, potentially in a manner that you do not support. The concentrated amount of control over our affairs
held by a relatively few significant investors could serve to reduce the attractiveness or liquidity of our common stock, and thereby
depress its trading price. Additionally, conflicts of interest may arise between these executive officers, directors and other affiliates,
on the one hand, and us and our other stockholders, on the other hand. In resolving these conflicts of interests, these investors may
favor their own interests and the interests of their affiliates, over the interests of our other stockholders, which could cause a material
adverse effect on our business, prospects, financial condition and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
sales of our securities could adversely affect the market price of our common stock and our future capital-raising activities could involve
the issuance of equity securities, which would dilute your investment and could result in a decline in the trading price of our common
stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may sell securities in the public or private equity markets at prices per share below the current market price of our common stock, even
if we do not have an immediate need for additional capital at that time. Sales of substantial amounts of shares of our common stock,
or the perception that such sales could occur, could adversely affect the prevailing market price of our shares and our ability to raise
capital. We may issue additional shares of common stock in future financing transactions or as incentive compensation for our executive
management and other key personnel, consultants and advisors. Issuing any equity securities would be dilutive to the equity interests
represented by our then-outstanding shares of common stock. Moreover, sales of substantial amounts of shares in the public market, or
the perception that such sales could occur, may adversely affect the prevailing market price of our common stock and make it more difficult
for us to raise additional capital. Such resulting significant downward pressure on the price of our common stock could also encourage
short sales by third parties. Such an event could place further downward pressure on the price of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
articles of incorporation allow for our board of directors to create new series of preferred stock without further approval by our stockholders,
which could adversely affect the rights of the holders of our common stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Currently, our board
of directors has the authority to designate and issue up to 5,000,000 shares of our preferred stock without further stockholder approval.
In the future, our board of directors could authorize the issuance of one or more series of preferred stock that would grant to holders,
among other rights, the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed
to the holders of common stock and the right to the redemption of our preferred shares acquired by such persons, together with a premium,
prior to the redemption of our common stock. In addition, our board of directors could authorize the issuance of a series of preferred
stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative
voting power of our common stock or result in dilution to our existing stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to establish and maintain an effective system of internal controls, we may not be able to report our financial results accurately
or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely
affect the trading price of our common stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Effective
internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial
reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed,
and our business and reputation with investors may be harmed. If we are unable to maintain effective internal controls, we may not have
adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including
the requirements of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition, we may be unable to accurately report our financial
results in future periods or report them within the timeframes required by the requirements of the SEC or the Sarbanes-Oxley Act. Failure
to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the
SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter
in their implementation, could result in identification of additional material weaknesses or significant deficiencies, cause us to fail
to meet our reporting obligations or result in material misstatements in our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
Section 404 of the Sarbanes-Oxley Act and related regulations require our management to evaluate the effectiveness of our internal control
over financial reporting as of the end of each fiscal year. Based on its evaluation, our management concluded that our internal controls
over financial reporting were effective as of March 31, 2024. We cannot provide assurance that, in the future, a material weakness or
significant deficiency will not exist or otherwise be discovered. If that were to happen, it could harm our operating results and cause
stockholders to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the
trading price of our securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Sustained
inflation could have a material adverse effect on our business, financial condition, results of operations and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Inflation
rates in the United States have remained high and may continue to rise. Inflation over the last several months has led us to experience
higher costs, including, among others, labor and transportation. Some of our suppliers have raised their prices and may continue to raise
prices, and, assuming we achieve FDA clearance and commence commercialization of our product, in the future, we may not be able to make
corresponding price increases to obtain adequate gross margins and achieve profitability. If inflation rates continue to rise or remain
elevated for a sustained period of time, they could have a material adverse effect on our business, financial condition, results of operations
and liquidity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of common stock without
stockholder approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to our amended and restated articles of incorporation, our board of directors has the power, without obtaining stockholder approval,
to effectuate recapitalizations of us through forward or reverse splits of our outstanding common stock. As a result of such provision,
our board of directors can implement recapitalizations of us by effectuating a forward or reverse stock split of our outstanding common
stock, which would increase or decrease each of our stockholder&#8217;s number of shares owned, and our stockholders will have no right
to approve or disapprove any such action even if such actions have a material adverse effect on them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>Item
1C. CYBERSECURITY.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We believe a robust
and proactive approach to cybersecurity risks and threats is essential to achieving our strategic business objectives and protecting
our business. We may face a wide range of cybersecurity threats, such as ransomware and denial-of-service attacks. Our customers, suppliers
and other business partners may also face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these third
parties could have a material adverse effect on our business and results of operations. Due to the risks that cybersecurity threats can
pose to our business, we intend to continually evaluate best practices and methods, including cyber defense systems and training programs,
to protect our business from a wide range of potential threats.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We continue to evaluate
our cybersecurity control processes and procedures to address the evolving cybersecurity risks that we may face in an increasingly technically
capable environment. We are implementing policies to educate and provide guidance to our personnel, including awareness programs and
other related cybersecurity best practices. We plan to conduct technical risk assessments to identify cybersecurity threats, as well
as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to
such cybersecurity threats. We also plan to conduct programmatic risk assessments, including identification of reasonably foreseeable
internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies,
procedures, systems, and safeguards in place to manage such risks. Following these risk assessments, we will evaluate: i) whether and
how to implement, and maintain reasonable safeguards to minimize identified risks, ii) how to reasonably address any identified gaps
in existing safeguards; and how to regularly monitor the effectiveness of our safeguards. As we are a small pre-revenue company, we currently
outsource our information technology (IT) functions to a third party. Working with the outsourced IT firm, our president will manage
the risk assessment and mitigation process. Third parties will play an important role in our cybersecurity program. We intend to engage
third-party service providers to conduct evaluations of our security controls, including penetration testing and consulting on best practices.
The third-party services include testing both the design and operational effectiveness of security controls. This dependence exposes
us, along with others who use such service providers, to the impact of a cyber-attack on their service providers. It is possible for
a cyber-attack at a third-party service provider to have a significant financial, operational, or reputational impact to us. To reduce
the effective impact to us of a cyber-attack on a third-party service provider, we intend to monitor the risks associated with our service
providers through periodic review of these providers&#8217; cybersecurity programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Our
board of directors, through its audit committee, oversees our processes for identifying and mitigating risks, including cybersecurity
risks. Management will periodically brief the audit committee and/or the board of directors on our cybersecurity and information security
policies and plans. Our board of directors will be apprised of cybersecurity incidents deemed to have a moderate or higher business impact,
and we will provide updates on management&#8217;s incident response plan for addressing and mitigating any impacts and risks associated
with such an incident. We intend to develop a formal incident response plan, which sets forth the steps to be followed from incident
detection and assessment to mitigation, recovery and notification and reporting within our organization and to our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">For additional information
regarding whether any risks from cybersecurity threats have materially affected or are reasonably likely to materially affect us, including
our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this Report,
including the risk factor entitled&#160;<i>&#8220;Third parties might attempt to gain unauthorized access to our network or seek to compromise
our insulin pump product.&#8221;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
2. PROPERTIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
principal administrative, operations, and research and development functions are located in a leased facility in San Diego, California.
We currently occupy approximately 24,000 square feet of space in the San Diego facility, and the lease extends through January 2027.
Under the lease, in addition to the minimum lease payments, we are responsible for property taxes, insurance and certain other operating
costs. We believe that our existing facility is adequate to meet our current needs.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
3. LEGAL PROCEEDINGS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are not a party to any material legal proceeding that we believe is likely to have a material adverse effect on our consolidated financial
position or results of operations. From time to time, we may be subject to legal proceedings and claims in the ordinary course of business.
These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management
efforts. to any pending legal proceeding. To the knowledge of our management, no federal, state or local governmental agency is presently
contemplating any proceeding against us. No director, executive officer or affiliate of ours or owner of record or beneficially of more
than five percent of our common stock is a party adverse to us or has a material interest adverse to us in any proceeding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="n_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>Market
Information for Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our common
stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;MODD.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Authorized
Capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company is authorized
by its Certificate of Incorporation to issue an aggregate of up to 5,000,000 shares of preferred stock, $0.001 par value per share, and
100,000,000 shares of common stock, $0.001 par value per share. As of March 31, 2024, zero and 32,463,670 shares of preferred stock and
common stock, respectively, were issued and outstanding.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Holders
of Record</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2024, we had 69 stockholders of record. The actual number of stockholders is greater than this number of stockholders of
record and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This
number of stockholders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
Authorized for Issuance under Equity Compensation Plan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
information regarding securities authorized for issuance under equity compensation plans, please refer to Item 12, <i>Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters</i>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Dividend
Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable
future and we intend to retain all of our earnings, if any, to finance our growth and operations and to fund the expansion of our business.
Payment of any dividends will be made in the discretion of our board of directors, after taking into account various factors, including
our financial condition, operating results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared
or paid on our common stock, must also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock,
if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Sales of Unregistered Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Set
forth below is information regarding securities issued by us within the past two years that were not registered under the Securities
Act. Also included is the consideration, if any, received by us for such issuances, and information relating to the section of the Securities
Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Director
Compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
each of March 31, 2024, December 30, 2023, and June 30, 2023 we issued 6,375 shares of our common stock to four of our non-employee directors
in accordance with our Outside Director Compensation Plan (the &#8220;Director Plan&#8221;). On September 30, 2023, we issued 6,265 shares
of our common stock to four of our non-employee directors in accordance with the Director Plan. On March 31, 2023, December 30, 2022
and September 30, 2022, we issued 6,375 shares of our common stock to four of our non-employee directors in accordance with the Director
Plan. On August 8, 2022, we issued 5,000 shares of our common stock to two of our non-employee directors in accordance with the Director
Plan. On June 30, 2022, we issued 2,664 shares of our common stock to two of our non-employee directors in accordance with the Director
Plan.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><i>Service
Providers</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.95pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
August 2023, we issued 1,429 shares of our common stock to a service provider. In March 2023, we issued 10,000 shares of our common stock
to a service provider. In March 2023, we issued 478 shares of our common stock to a service provider. In February 2023, we issued 438
shares of our common stock to a service provider. In May 2022, we issued 348 shares of our common stock to a service provider.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><i>2022
Placement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">In
May 2022, we issued warrants in a private placement to purchase an aggregate of 1,438,202 shares of common stock at an exercise price
of $6.60 per share. The warrants were exercisable six months from the date of issuance and have a five-year term from the date the warrants
become exercisable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
6. RESERVED</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following discussion of our financial condition and results of operations should be read in conjunction with the financial statements
and related notes included in this Annual Report on Form 10-K, or the Report. <i>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations may contain statements that are forward-looking. These statements are based on current expectations
and assumptions that are subject to risk, uncertainties and other factors. These statements are often identified by the use of words
such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. Actual results could differ
materially because of the factors discussed in Part I, Item 1A, </i>These risks and uncertainties may cause actual results to differ
materially from those discussed in the forward-looking statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March
31 of the calendar year indicated (for example, fiscal 2024 refers to the fiscal year ending March 31, 2024). Unless the context requires
otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical,
Inc. and its consolidated subsidiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized
technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our initial product,
the MODD1, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that
presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement,
training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221;
and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms
of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification to the United States Food
and Drug Administration (&#8220;FDA&#8221;) for our MODD1 insulin pump. In March 2024, we received comments from the FDA, and we are
in the process of responding to those comments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2024, we completed a firm commitment
underwritten offering and issued and sold to the underwriter 9,090,910 shares of our common stock at a price of $1.10 per share (the 2024
Offering). We received aggregate proceeds of approximately $10,000,000 before deducting underwriting discounts and commissions and other
offering expenses. We also granted the underwriter a 30-day option to purchase up to an additional 1,321,989 shares of common stock to
cover over allotments, if any. In March 2024, the underwriter exercised this option in full and purchased the additional securities for
additional aggregate proceeds to us of approximately $1,454,000, before deducting underwriting discounts and commissions and other offering
expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Historically,
we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible
promissory notes. Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period
of at least one year from the date that the financial statements included in Item 8 of this Report are issued exists. Our ability to
continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support
our future operations. If we are unable to secure additional capital, we will be required to curtail our research and development initiatives
and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the consolidated financial statements
in Item 1 of this Report and under <i>Liquidity </i>below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Economic Disruptions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact our operational and financial performance in
the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease
spread are uncertain, out of our control, and cannot be predicted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While we were recently able to access the capital markets, in the future, we may be unable to access
the capital markets, and additional capital may only be available to us on terms that could be significantly detrimental to our existing
stockholders and to our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
additional information on risks that could impact our future results, please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of
this Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following discussion should be read in conjunction with our consolidated financial statements and related notes included elsewhere in
this Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Research
and Development</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year-over-Year Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024 to 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">42.1</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development, or R&amp;D, expenses
include personnel, consulting, testing, materials and supplies, depreciation and amortization and other operational costs associated with
the pre-FDA clearance production of our insulin pump product. We expense R&amp;D costs as they are incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D expenses increased in fiscal 2024 compared
with fiscal 2023 primarily due to increases in engineering and operations personnel costs of $1.6 million, consulting costs of $0.8 million,
stock-based compensation expenses of $0.5 million and materials, supplies expenditures of $0.5 million and depreciation and amortization
of $0.4 million. The increase in personnel costs was attributable to increased average headcount year over year, salary increases effected
during fiscal 2024, payment of a bonus implemented in fiscal 2024 related to our 510(k) submission and higher payroll taxes. Our R&amp;D
employee headcount increased to 36 at March 31, 2024 from 34 at March 31, 2023. The increase in consulting costs was primarily driven
by the utilization of consultants and outside testing and other firms in support of our FDA submission in January 2024. R&amp;D expenses
included stock-based compensation expenses of approximately $1.9 million and $1.4 million for fiscal 2024 and fiscal 2023, respectively.
The increase in stock-based compensation costs was primarily attributable to the granting of stock options under our bonus program for
our FDA submission; these options were granted in October 2023 and expensed over an expected term of four months. We expect R&amp;D expenses
will increase in fiscal 2025, as we continue to engage third parties to support our responses to the FDA on our MODD1 510(k) submission,
hire additional engineering, quality assurance, and operations personnel, bring-up our manufacturing process at our medical device contract
manufacturer and commence the commercialization of our product in late fiscal 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>General
and Administrative</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year-over-Year Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024 to 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">General and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,816</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(167</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3.5</td><td style="width: 1%; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative, or G&amp;A, expenses
consist primarily of personnel and related overhead costs for marketing, finance, human resources, facilities and general management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">G&amp;A expenses decreased in fiscal 2024 compared with fiscal 2023
primarily as a result of reductions in stock-based compensation expense of $0.5 million, consulting fees of $0.4 million and reduced personnel
costs of $0.2 million. The decreases were partially offset by increased professional services expenses of $0.4 million, which was primarily
attributable to higher investor relations and financing-related costs, facilities-related expenses of $0.3 million due to our move to
a larger facility in the fourth quarter of fiscal 2023, marketing expense of $0.2 million for a participant study for our product and
costs incurred for initial trade show activities. G&amp;A expenses included stock-based compensation expenses of approximately $0.8 million
and $1.3 million for fiscal 2024 and fiscal 2023, respectively. We expect G&amp;A expenses to increase in fiscal 2025, as we expect to
increase headcount, as we expand our organization and implement systems to support our anticipated growth and prepare for the commercialization
of our product in late fiscal 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources; Changes in Financial Condition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Going
Concern</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a development-stage enterprise, we do not
currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating losses and
negative cash flows in each year due to costs incurred in connection with R&amp;D activities and G&amp;A expenses associated with our
operations. For the years ended March 31, 2024 and 2023, we incurred net losses of approximately $17.5 million and $13.9 million, respectively.
At March 31, 2024, we had a cash balance of $9.2 million and an accumulated deficit of approximately $66 million. When considered with
our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern for a period of
at least one year from the date that the financial statements included in Item 8 of this Report are issued. Our financial statements
do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue
as a going concern. Our operating needs include the planned costs to operate our business, including amounts required to fund continued
research and development activities, working capital and capital expenditures. Our ability to continue as a going concern depends on
our ability to raise additional capital, through the sale of equity or debt securities to support our future operations. Recently, during
the three months ended March 31 2024, we completed the 2024 Offering for net proceeds of approximately $10.3 million. On November 22,
2023, we entered into a Sales Agreement (the &#8220;ATM Agreement&#8221;) with Leerink Partners LLC (&#8220;Leerink&#8221;) under which
we may offer and sell, from time to time at our sole discretion, shares of our common stock, for aggregate gross proceeds of up to $6.5
million (subject to availability on our shelf registration statement) through an &#8220;at the market offering&#8221; program under which
Leerink will act as sales agent or principal. In January 2024, we sold 153,879 shares of common stock for net proceeds of approximately
$0.3 million under the ATM Agreement. We suspended sales under the ATM Agreement due to the 2024 Offering, and we may resume sales under
the ATM during fiscal 2025. In addition, from December 2023 to April 2024, we received a total of approximately $0.9 million of proceeds
from the exercise of common stock purchase warrants issued in a public offering we completed in May 2023. Our future capital requirements
and the adequacy of our available funds will depend on many factors, including, without limitation, our ability to successfully commercialize
our product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire
other companies or technologies to enhance or complement our product offerings. If we are unable to secure additional capital timely,
we may be required to curtail R&amp;D initiatives, reduce headcount and take additional measures to reduce costs in order to conserve
our cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Purchase
Obligations </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary purchase obligations include purchase
orders for machinery and equipment. At March 31, 2024, we had outstanding purchase orders for machinery and equipment and related expenditures
of approximately $1.1 million. In December 2023, we signed a device integration agreement with a provider of connected-care and remote
monitoring diabetes technology solutions. As of March 31, 2024, we had a remaining obligation under the device integration agreement of
approximately $400,000&#160;over three years for technology license fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Liquidity</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
fiscal 2024, we used approximately $14.0 million in operating activities, which primarily resulted from our net loss of approximately
$17.5 million less changes to operating assets and liabilities of approximately $0.4 million, and as adjusted for non-cash charges and
gains, which included approximately $2.7 million of stock-based compensation expenses, depreciation and amortization expenses of approximately
$0.4 million, and other immaterial adjustments. The changes in operating assets and liabilities primarily related to the timing of payments
to vendors. In fiscal 2023, we used approximately $11.0 million in operating activities, which primarily resulted from our net loss of
approximately $13.9 million plus changes to operating assets and liabilities of approximately $0.2 million, as adjusted for non-cash
charges and gains, which included stock-based compensation expenses of approximately $2.7 million, approximately $0.2 million for issuance
of shares of our common stock in exchange for services, depreciation and amortization expense of approximately $0.2 million and other
immaterial adjustments. The changes in operating assets and liabilities primarily related to the timing of payments to vendors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
fiscal 2024 and fiscal 2023, cash used in investing activities of approximately $1.7 million and $1.6 million, respectively, was for
the purchase of property and equipment.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
provided by financing activities for fiscal 2024 totaled approximately $21.1 million and was primarily attributable to proceeds of approximately
$20.1 million from the sale of shares of common stock in a registered direct offering and issuance of warrants to purchase common stock
in private placements that closed in May 2023 and February 2024, <span>net of underwriter fees and issuance
costs, proceeds of approximately $0.7 million for the exercise of common stock purchase warrants and proceeds of approximately $0.3 from
the sale of shares under the ATM agreement</span>. Cash provided by financing activities for fiscal 2023 totaled approximately $7.4 million
and was attributable to approximately $7.4 million of net proceeds from a registered direct offering of our common stock and common stock
purchase warrants in May 2022, <span>net of placement agent fees and issuance costs</span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America
(GAAP). Note 1 to the consolidated financial statements in Item 8 of this Report describes the significant accounting policies and methods
used in the preparation of our consolidated financial statements. We have identified the accounting policies below as some of the more
critical to our business and the understanding of our results of operations. These policies may involve estimates and judgments that
affect the reported amounts of assets, liabilities, revenues and expenses. Although we believe our judgments and estimates are appropriate,
actual future results may differ from our estimates, and if different assumptions or conditions were to prevail, the results could be
materially different from our reported results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Use
of estimates</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to accruals, stock-based compensation
and income taxes. Actual results could materially differ from those estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Stock-based
compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
periodically issue stock options, restricted stock units and stock awards to employees and non-employees. We account for such awards
based on Financial Accounting Standards Board Accounting Standards Codification (ASC) 718, whereby the value of the award is measured
on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting
period. With respect to performance-based awards, we assess the probability of achieving the requisite performance criteria before recognizing
compensation expense. We estimate the fair value of stock options on the date of grant using the Black-Scholes-Merton Option Pricing
(Black Scholes) model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options,
and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used
in the Black-Scholes model could materially affect compensation expense recorded in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Income
taxes</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
determine deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of our assets
and liabilities using tax rates in effect for the year in which we expect the differences to affect taxable income. A valuation allowance
is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will
not be realized. Based on the available information and other factors, management believes it is more likely than not that our federal
and state net deferred tax assets will not be fully realized, and we have recorded a full valuation allowance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
account for uncertain tax positions in accordance with ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed, it is likely that
some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the
merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized
in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more
likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if
any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Leases</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
account for our leases under ASC 842, <i>Leases</i> (ASC 842), and related ASUs, which provide supplementary guidance and clarifications.
Under ASC 842, all significant lease arrangements are generally recognized at lease commencement. Operating lease right-of-use (ROU)
assets and lease liabilities are recognized at the commencement date. A ROU asset and corresponding lease liability are not recorded
for leases with an initial term of 12 months or less (short-term leases), and we recognize lease expense for these leases as incurred
over the lease term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ROU
assets represent our right to use an underlying asset during the reasonably certain lease terms, and lease liabilities represent our
obligation to make lease payments arising from the lease. Our lease terms may include options to extend or terminate the lease when it
is reasonably certain that we will exercise that option. Operating lease ROU assets and liabilities are recognized at the lease commencement
date based on the present value of lease payments over the lease term. We use our incremental borrowing rate, based on the information
available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease
payments related to initial direct cost and prepayments and excludes lease incentives. Lease expense is recognized on a straight-line
basis over the lease term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect
on our financial condition, results of operations, liquidity or capital resources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Contractual
Obligations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
a &#8220;smaller reporting company,&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide the information requested
by paragraph (a)(5) of this Item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See
Note 1 to the consolidated financial statements in Item 8 of this Report for a full description of relevant recent accounting pronouncements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 91%"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_001"><span style="font-size: 10pt">Report
    of Independent Registered Accounting Firm &#8211; Farber Hass Hurley LLP</span></a></span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance
    Sheets</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#f_003"><span style="font-size: 10pt">Consolidated Statements
    of Operations</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#f_004"><span style="font-size: 10pt">Consolidated Statements
    of Stockholders&#8217; Equity </span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#f_005"><span style="font-size: 10pt">Consolidated Statements
    of Cash Flows</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#f_006"><span style="font-size: 10pt">Notes to Consolidated
    Financial Statements</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - OPEN</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">To the Audit
Committee and<br/>
Stockholders of Modular Medical, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of Modular Medical, Inc. (the &#8220;Company&#8221;) as of March 31, 2024 and
2023, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and
the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2024 and 2023, and
the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying consolidated financial statements have been prepared to assume the Company will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the Company has incurred losses from operations and needs to raise additional funds
to meet its obligations and sustain its future operations until profitability is achieved. These circumstances raise substantial doubt
about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are
material to the consolidated financial statements and (ii) involved especially challenging, subjective, or complex judgments. The communication
of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts
or disclosures to which they relate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Going
Concern</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
described further in Note 1, the Company has incurred losses since inception, and expects to continue to incur operating losses for the
foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization
of its product. The Company expects that its research and development and general and administrative expenses will continue to increase,
and, as a result, the Company will need to generate significant product revenues to achieve profitability. These circumstances raise
substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated
financial statements are issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
identified management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern as a critical audit matter due
to the inherent complexities and uncertainties related to the Company&#8217;s projections of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
primary procedures we performed to address this critical audit matter included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the reasonableness of key assumptions underlying management&#8217;s conclusion.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated that the disclosures included in the Form 10-K were complete and accurate and in
                                            accordance with accounting principles generally accepted in the United States of America.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the impact of the Company&#8217;s existing financing arrangements and future capital
                                            needs over the next 12 months on its ability to continue as a going concern.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><i>Stock-Based
Compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
discussed in Note 5, during the year ended March 31, 2024, the Company granted options to purchase shares of its common stock to employees,
directors and consultants. Management is required to analyze the fair value of each option granted and amortize it over its vesting period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We identified the valuation of stock-based compensation as a critical
audit matter due to the significant judgments made by management when developing underlying assumptions regarding the fair value of the
options.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
primary procedures we performed to address this&#160;critical&#160;audit&#160;matter included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            gained an understanding of Company&#8217;s processes and controls in place for determining
                                            the fair value of each granted option.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We evaluated the option price model management selected to determine
the fair value, and analyzed the underlying data and assumptions used in the calculations.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            also recalculated the fair value of each option granted.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-17640">Farber Hass Hurley LLP</ix:nonNumeric></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">PCAOB
Firm ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-17641">223</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have served as the Company&#8217;s auditor since 2018.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-5949"><span style="font-family: Times New Roman, Times, Serif">Chatsworth,
California</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 21, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Balance Sheets</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands, except par value)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CURRENT ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and
    cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-17642">9,232</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-17643">3,799</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and
    other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-17644">465</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-17645">147</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Security deposit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-0; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-17646">100</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-17647">9,697</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-17648">4,046</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-17649">2,975</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-17650">1,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right of use assets,
    net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-17651">1,135</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-17652">1,478</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    NON-CURRENT ASSETS</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-17653">4,110</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-17654">3,199</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-17655">13,807</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-17656">7,245</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CURRENT LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-17657">802</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-17658">285</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17659">280</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17660">339</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-17661">373</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-17662">355</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17663">1,455</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17664">979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long-term lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-17665">817</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-17666">1,190</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-17667">2,272</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-17668">2,169</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commitments
    and Contingencies (Note 8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17669"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17670">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-17671"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-17672">5,000</ix:nonFraction></ix:nonFraction> shares authorized, <span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6"><span style="-sec-ix-hidden: hidden-fact-7"><span style="-sec-ix-hidden: hidden-fact-8">none</span></span></span></span> issued and&#160;outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common Stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17673"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17674">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-17675">100,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-17676">50,000</ix:nonFraction> shares authorized
as of March 31, 2024 and 2023, respectively; <ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" unitRef="shares" id="ixv-17677"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-17678">32,464</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" unitRef="shares" id="ixv-17679"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-17680">10,949</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-17681">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-17682">11</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-17683">77,432</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-17684">53,524</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-17685">65,929</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-17686">48,459</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17687">11,535</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17688">5,076</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-17689">13,807</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-17690">7,245</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands, except per-share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended<br/> March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-17691">12,880</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-17692">9,062</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-17693">4,649</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-17694">4,816</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-17695">17,529</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-17696">13,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17697">17,529</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17698">13,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-17699">61</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-17700">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before income taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-17701">17,468</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-17702">13,877</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Provision for income taxes</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-17703">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-17704">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17705">17,470</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17706">13,879</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">Basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-17707">0.78</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-17708">1.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares used in computing net loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">Basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-17709">22,377</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-17710">12,103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Stockholders&#8217; Equity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as of March 31, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-17711">10,462</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17712">11</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17713">43,406</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-17714">34,580</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17715">8,837</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock in registered direct offering, net of fees and issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="modd:IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" scale="3" unitRef="shares" id="ixv-17716">449</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" scale="3" unitRef="usd" id="ixv-17717">7,372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" scale="3" unitRef="usd" id="ixv-17718">7,372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" unitRef="shares" id="ixv-17719">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-17720">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-17721">22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuances under equity incentive plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" unitRef="shares" id="ixv-17722">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-17723">86</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-17724">86</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-17725">2,638</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-17726">2,638</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17727">13,879</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17728">13,879</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as of March 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-17729">10,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17730">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17731">53,524</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-17732">48,459</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17733">5,076</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock in public offerings, net of fees and issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" scale="3" unitRef="shares" id="ixv-17734">20,552</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" scale="3" unitRef="usd" id="ixv-17735">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" scale="3" unitRef="usd" id="ixv-17736">20,045</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" scale="3" unitRef="usd" id="ixv-17737">20,065</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">At-the-market sales of stock, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-17738">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="modd:AtthemarketSalesOfStockNet" scale="3" unitRef="usd" id="ixv-17739">278</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="modd:AtthemarketSalesOfStockNet" scale="3" unitRef="usd" id="ixv-17740">278</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" unitRef="shares" id="ixv-17741">719</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-17742">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-17743">883</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-17744">884</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="3" unitRef="shares" id="ixv-17745">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-17746">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-17747">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuances under equity incentive plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" unitRef="shares" id="ixv-17748">88</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-17749">37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-17750">37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-17751">2,664</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-17752">2,664</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17753">17,470</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17754">17,470</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as of March 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-17755">32,464</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17756">32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17757">77,432</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-17758">65,929</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-17759">11,535</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Modular
Medical, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Statements of Cash Flows</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cash Flows from operating activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17760">17,470</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-17761">13,879</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash
    used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-17762">2,701</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-17763">2,724</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on asset disposal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" sign="-" unitRef="usd" id="ixv-17764">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-17765">426</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-17766">152</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-17767">19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-17768">203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and
    other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-17769">94</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-17770">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="modd:IncreaseDecreaseLeaseRightofuseAsset" scale="3" unitRef="usd" id="ixv-17771">342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="modd:IncreaseDecreaseLeaseRightofuseAsset" scale="3" unitRef="usd" id="ixv-17772">203</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-17773">458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-17774">200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-17775">355</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-17776">200</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-17777">13,952</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-17778">11,011</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of property
    and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-17779">1,700</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-17780">1,638</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing
    activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-17781">1,700</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-17782">1,638</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from at-the-market
    sales of common stock, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-17783">278</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from exercise
    of common stock warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-17784">742</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from public
    and registered direct offerings, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd" id="ixv-17785">20,065</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd" id="ixv-17786">7,372</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing
    activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-17787">21,085</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-17788">7,372</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease) in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-17789">5,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-17790">5,277</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents, at beginning of
    year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-17791">3,799</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-17792">9,076</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents,
    at end of year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-17793">9,232</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-17794">3,799</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosure:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Noncash investing and financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right-of-use asset obtained
    in exchange for lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="modd:RightofuseAssetObtainedInExchangeForLeaseLiability" scale="3" unitRef="usd" id="ixv-17795">1,561</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Receivable from transfer
    agent for warrant exercise proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="modd:ReceivableFromTransferAgentForWarrantExerciseProceeds" scale="3" unitRef="usd" id="ixv-17796">142</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" unitRef="usd" id="ixv-17797">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" unitRef="usd" id="ixv-17798">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MODULAR
MEDICAL, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="ixv-8448"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1
&#8211; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin
pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part
patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access
to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and
streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand
the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass
market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the
MODD1. In March 2024, the Company received comments from the FDA on its submission, and the Company is in the process of responding to
those comments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="modd:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-8463"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Going Concern</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and
general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue
to achieve profitability. The Company&#8217;s expected operating losses and cash burn raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company&#8217;s
independent registered public accounting firm, in its report on these consolidated financial statements for the year ended March 31,
2024, expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to
continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital, through the sale of additional
equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form
of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions
acceptable to the Company. In, May 2023 and February 2024, the Company completed public offerings of its common stock and warrants.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="modd_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-8479"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2024 refers to the fiscal year ending March 31, 2024). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-8507"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of
Estimates</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-8519"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reportable
Segment</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
operates in one business segment and uses one measurement of profitability for its business.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-8531"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and Development</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
expenses research and development expenditures as incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-8543"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>General
and Administrative</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily of payroll and
benefit costs, rent, stock-based compensation, legal and accounting fees, and facility and other administrative expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-8554"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration
of Credit Risk</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains its cash
at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" scale="0" unitRef="usd" id="ixv-17799">250,000</ix:nonFraction>. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</p></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_1" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock" id="ixv-8565"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
and Uncertainties</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_2" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_3" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Economic
Disruptions</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_4" id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="modd_RisksAndUncertaintiesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may
be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly
detrimental to its existing stockholders and to its business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-8609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cash and
Cash Equivalents</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash held in
demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of
three months or less.</p></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-8620"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Property
and Equipment</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are recorded at historical
cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <ix:nonNumeric contextRef="c22" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c22_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-17800">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c23" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-17801">five<ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c22_cont_1">
years</ix:continuation></ix:nonNumeric>. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets
acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is
recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment
and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended
use and placed into service.</p></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-8631"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Fair Value
of Financial Instruments</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-8678"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB)
ASC No. 842, <i>Leases</i>, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease
contracts. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liability
represents the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present
value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less
at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the
consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases
where the lease does not provide an implicit interest rate, the Company uses the Company&#8217;s incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments.</span></p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="ixv-8691"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. We account for such
awards based on Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 718, whereby the value of the award
is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually
the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance
criteria before recognizing compensation expense. The fair value of the Company&#8217;s stock options is estimated using the Black-Scholes-Merton
Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected
life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model.
The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-8719"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Per-Share
Amounts</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO)
during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding
for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options
and exercise of warrants.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prior
to April 1, 2023, the Company excluded pre-funded warrants from the computation of WASO. The pre-funded warrants are now included in
the computation of WASO. Prior period amounts have been conformed to the current-period presentation. The impact of the change reduced
the previously reported loss per share by $<ix:nonFraction contextRef="c24" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-17803">0.13</ix:nonFraction> and increased WASO by approximately <ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" unitRef="shares" id="ixv-17804">1,223,000</ix:nonFraction> shares for the year ended March 31, 2023.
The reclassification had no impact on the Company&#8217;s net loss or cash flows for the year ended March 31, 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-8738"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):</span></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17805">3,689</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17806">2,481</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17807">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock purchase warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17808">11,173</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17809">6,217</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17810">15,049</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-17811">8,698</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="ixv-8848"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-8859"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company&#8217;s historical
net operating loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the
year in which such tax attributes are utilized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-8882"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Comprehensive
Loss</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2024 and 2023, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="modd:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="ixv-8910"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements </b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2" id="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective
application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU
will have on the presentation of its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S.
and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently
evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="ixv-8930"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2 &#8211; CONSOLIDATED BALANCE SHEET DETAIL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-8938"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Prepaid and other current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-17812">318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-17813">142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivable from transfer agent for warrant exercise proceeds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-17814">142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-17815">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-17816">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-17817">465</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-17818">147</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-9012"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17819">3,209</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17820">820</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17821">66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17822">66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17823">283</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17824">1,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17825">33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17826">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17827">63</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17828">63</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17829">3,654</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-17830">1,977</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation
    and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-17831">679</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-17832">256</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left"/><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-17833">2,975</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-17834">1,721</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-9209"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-17835">243</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-17836">267</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17837">37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17838">72</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17839">280</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-17840">339</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-9321"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 3
&#8211; LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>W.
Bernardo Drive, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
<ix:nonNumeric contextRef="c41" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-17841">39</ix:nonNumeric>-month lease term expired on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="modd:OperatingLeaseExpiredTerm" id="ixv-17842">June 30, 2023</ix:nonNumeric>, and, subsequent to expiration, the landlord refunded the Company&#8217;s security deposit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Thornmint
Road, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
<ix:nonNumeric contextRef="c42" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-17843">48</ix:nonNumeric>-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-17844">36,000</ix:nonFraction> with annual rent increases
of approximately <ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="modd:PercentageOfAnnualRentIncreases" scale="-2" unitRef="pure" id="ixv-17845">4</ix:nonFraction>%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-17846">8</ix:nonFraction>%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-17847">1,560,000</ix:nonFraction> in exchange for its obligations under the
operating lease.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-9365"><span style="font-family: Times New Roman, Times, Serif">Future minimum
payments under the facility operating lease, as of March 31, 2024, are listed in the table below (in thousands).</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal year
    ending March 31,</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-17848">452</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-17849">470</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-17850">405</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-17851">1,327</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:&#160;Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-17852">137</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-17853">1,190</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
paid for amounts included in the measurement of lease liabilities was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-17854">476,000</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-17855">230,000</ix:nonFraction> for the years ended March 31,
2024 and 2023, respectively. Rent expense was approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-17856">449,000</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-17857">237,000</ix:nonFraction> for the years ended March 31, 2024 and 2023, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-9454"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
4 &#8211; STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Increase
in Authorized Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In
February 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Articles of Incorporation (the Amendment)
to increase the number of authorized shares of common stock from <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-17858">50,000,000</ix:nonFraction> shares, to <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-17859">100,000,000</ix:nonFraction> shares. The Amendment was filed with
the state of Nevada and became effective on February 15, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>February
2024 Public Offering </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, the Company entered into
an underwriting agreement (the 2024 Underwriting Agreement) with Titan Partners Group LLC, a division of American Capital Partners, LLC
(Titan), with respect to the issuance and sale <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17860">9,090,910</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-17861">1.10</ix:nonFraction> per share in a firm commitment
underwritten offering (the 2024 Offering) by the Company. Upon the closing of the 2024 Offering, the Company received aggregate proceeds
of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-17862">10,000,000</ix:nonFraction>, before deducting underwiring discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2024 Underwriting Agreement,
the Company granted Titan a 30-day option to purchase up to an additional <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-17863">1,321,989</ix:nonFraction> shares of common stock to cover over allotments,
if any. On March 13, 2024, Titan exercised this option in full and purchased the additional securities for aggregate proceeds to the
Company of approximately $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-17864">1,454,000</ix:nonFraction> before deducting underwriting discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Titan
was paid a cash fee of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="modd:CashFee" scale="-2" unitRef="pure" id="ixv-17865">7.0</ix:nonFraction>% of the aggregate gross proceeds of the 2024 Offering (including the over-allotment option) and reimbursed
certain out-of-pocket expenses of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd" id="ixv-17866">75,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>ATM Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 22, 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the
Company may offer and sell, from time to time at its sole discretion, shares of its common stock, for aggregate gross proceeds of up
to $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-17867">6,500,000</ix:nonFraction> through an &#8220;at the market offering&#8221; program under which Leerink will act as sales agent or principal. The ATM
Agreement provides that Leerink will be entitled to compensation for its services equal to <ix:nonFraction contextRef="c51" decimals="3" format="ixt:num-dot-decimal" name="modd:compensationServicesEqual" scale="-2" unitRef="pure" id="ixv-17868">3.0</ix:nonFraction>% of the gross proceeds from sales of any
shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at
any time, suspend solicitation and offers under the ATM Agreement. In January 2024, under the ATM Agreement, the Company sold <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17869">153,879</ix:nonFraction>
shares of common stock for net proceeds of approximately $<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="0" unitRef="usd" id="ixv-17870">278,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>May
2023 Public Offering </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2023, the Company entered into an underwriting
agreement (the Underwriting Agreement) with Newbridge Securities Corporation (the Underwriter), with respect to the issuance and sale
in a firm commitment underwritten offering (the 2023 Offering) by the Company of units of its securities. Upon the closing of the 2023
Offering, the Company sold <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17871">8,816,900</ix:nonFraction> shares of its common stock and warrants to purchase <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17872">4,408,450</ix:nonFraction> shares of its common stock for aggregate
proceeds of approximately $<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="0" unitRef="usd" id="ixv-17873">9,390,000</ix:nonFraction>, before deducting underwriting discounts and commissions and other offering expenses. The securities
were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the 2023 Warrants) to purchase
one share of common stock, at a public offering price of $<ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-17874">2.13</ix:nonFraction> per unit. The 2023 Warrants were immediately separable and exercisable,
have a per share exercise price of $<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17875">1.22</ix:nonFraction> and expire <ix:nonNumeric contextRef="c57" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="ixv-17876">five years</ix:nonNumeric> from the date of issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17877">1,322,534</ix:nonFraction> shares of
common stock and an additional <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17878">661,267</ix:nonFraction> of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter exercised
this option in full and purchased the additional securities for aggregate gross proceeds to the Company of approximately $<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-17879">1,408,000</ix:nonFraction>,
before deducting underwriting discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Underwriter was paid a cash fee of <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="modd:PaymentOfUnderwriterPercentage" scale="-2" unitRef="pure" id="ixv-17880">7.0</ix:nonFraction>% of the aggregate gross proceeds of the 2023 Offering (including the over-allotment option) and
reimbursed certain out-of-pocket expenses of approximately $<ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-17881">125,000</ix:nonFraction>. In addition, pursuant to the Underwriting Agreement, the Company
initially issued to the Underwriter common stock purchase warrants (the UW Warrants) for a total of <ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="modd:WarrantsToPurchaseSharesOfCommonStock" scale="0" unitRef="shares" id="ixv-17882">709,760</ix:nonFraction> shares. Subsequently, the
UW Warrants were reissued to the Underwriter and its agents for a total of <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="0" unitRef="shares" id="ixv-17883">604,623</ix:nonFraction> shares. The UW warrants were exercisable six months
from the respective issuance dates and have a four-year term and a per share exercise price of $<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17884">1.32</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>May 2022
Placement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17885">449,438</ix:nonFraction> shares (the Shares)
of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c65" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-17886">0.001</ix:nonFraction> per share, at a purchase price per Share of $<ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="modd:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-17887">4.45</ix:nonFraction> and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of approximately <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-17888">1,348,000</ix:nonFraction> shares of common stock at a purchase price per Pre-Funded Warrant
of $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="modd:PreFundedWarrant" scale="0" unitRef="usdPershares" id="ixv-17889">4.44</ix:nonFraction>. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17890">0.01</ix:nonFraction> per share and
may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the
Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-17891">1,438,202</ix:nonFraction>
shares of common stock at an exercise price of $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-17892">6.60</ix:nonFraction> per share. The Private Placement Warrants were exercisable beginning on the six-month
anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Issuances
of Common Stock and Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the years ended March 31, 2024 and 2023, the Company issued <ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17893">1,429</ix:nonFraction> and <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17894">11,264</ix:nonFraction> shares of common stock to service providers, respectively,
with fair values of approximately $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17895">1,400</ix:nonFraction> and $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-17896">22,000</ix:nonFraction>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-9549"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2" id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Prices</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration<br/> Dates</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2023</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17897">7,565</ix:nonFraction></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="modd:NumberOfSharesIssuanceOfCommonStockWarrants" scale="3" unitRef="shares" id="ixv-17898">605</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" scale="0" unitRef="usdPershares" id="ixv-17899">1.32</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c71" name="modd:ExpirationIssuanceOfCommonStockWarrants" id="ixv-9632"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2027</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="modd:NumberOfSharesIssuanceOfCommonStockWarrants" scale="3" unitRef="shares" id="ixv-17900">5,070</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" scale="0" unitRef="usdPershares" id="ixv-17901">1.22</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c72" name="modd:ExpirationIssuanceOfCommonStockWarrants" id="ixv-9660"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2028</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="modd:NumberOfSharesCommonStockWarrantsExercised" scale="3" sign="-" unitRef="shares" id="ixv-17902">70</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesCommonStockWarrantsExercised" scale="0" unitRef="usdPershares" id="ixv-17903">1.32</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="modd:NumberOfSharesCommonStockWarrantsExercised" scale="3" sign="-" unitRef="shares" id="ixv-17904">649</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="modd:ExercisePricesCommonStockWarrantsExercised" scale="0" unitRef="usdPershares" id="ixv-17905">1.22</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2024</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17906">12,521</ix:nonFraction></span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
March 31, 2024, the Company had a receivable from its transfer agent for approximately $<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-17907">142,000</ix:nonFraction> for the proceeds from warrants exercised
prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_3" id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2023, the Company had the following warrants outstanding (share amounts in thousands):</span></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Exercise Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration <br/> Dates</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17908">1,348</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17909">0.01</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-42">&#8212;</span></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17910">768</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17911">6.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><ix:nonNumeric contextRef="c80" name="modd:ExpirationCommonStock" id="ixv-9824"><span style="font-family: Times New Roman, Times, Serif">January&#160;-&#160;February 2027</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17912">4,011</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17913">6.60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><ix:nonNumeric contextRef="c82" name="modd:ExpirationCommonStock" id="ixv-9848"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17914">1,438</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-17915">6.60</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c84" name="modd:ExpirationCommonStock" id="ixv-9872"><span style="font-family: Times New Roman, Times, Serif">November 2027</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" unitRef="shares" id="ixv-17916">7,565</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-9901"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5
&#8211; STOCK-BASED COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Amended
2017 Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares" id="ixv-17917">1,000,000</ix:nonFraction> shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-17918">333,334</ix:nonFraction> and <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-17919">1,333,334</ix:nonFraction> shares, respectively. In January 2023 and February 2024, the Company&#8217;s stockholders approved increases
in the number of shares reserved for issuance under the Plan by an additional <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-17920">2,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-17921">3,000,000</ix:nonFraction> shares, respectively. Under the
Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation
rights, restricted stock, performance-based awards and restricted stock units (RSUs). The Plan is administered by the Board or, in the
alternative, a committee designated by the Board.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock
options granted by the Company generally vest over 36 months and have a 10-year term. As of March 31, 2024, the unamortized compensation
cost related to stock options was approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableUnamortizedLoanFeeCost" scale="0" unitRef="usd" id="ixv-17922">2,035,000</ix:nonFraction> and is expected to be recognized as expense over a weighted-average period
of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="modd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-17923">1.3</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock
options for&#160;<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-17924">909,533</ix:nonFraction>&#160;shares, which are subject to vesting based upon the achievement of certain performance milestones by the
Company and continued service by the optionees. In January 2024, options to purchase <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-17925">625,326</ix:nonFraction> shares (net of forfeitures), which were
granted under part one of the Bonus Program, vested upon the Company&#8217;s submission to the FDA. As of March 31, 2024, the Company
had not commenced expense recognition of&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares" id="ixv-17926">242,307</ix:nonFraction> (net of forfeitures)&#160;of the options, which were granted under part two of
the Bonus Program, based on its assessment of the probability of achievement of the applicable performance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended March 31, 2024, the Company granted options to purchase <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-17927">127,500</ix:nonFraction> shares that vested immediately when granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAssumptionsUsedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="ixv-9953"><span style="font-family: Times New Roman, Times, Serif">The
weighted-average grant date fair values of stock options granted during the years ended March 31, 2024 and 2023 was $<ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17928">0.99</ix:nonFraction> and $<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17929">2.85</ix:nonFraction>,
respectively. The following assumptions were used in the fair-value method calculations:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAssumptionsUsedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended March 31,</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c98" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-17930">3.51</ix:nonFraction>% - <ix:nonFraction contextRef="c99" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-17931">4.72</ix:nonFraction>%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-17932">2.82</ix:nonFraction>% - <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-17933">4.06</ix:nonFraction>%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-17934">83</ix:nonFraction>% - <ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-17935">152</ix:nonFraction>%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-17936">83</ix:nonFraction>% - <ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-17937">223</ix:nonFraction>%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c98" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-17938">5.0</ix:nonNumeric> - <ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-17939">6.2</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-17940">5.0</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-17941">5.7</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options. The expected volatility is based on the historical volatility of the Company&#8217;s stock price.
The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury
as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has
never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-10076"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the activity in the shares available for grant under the Plan during the year ended March 31, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>for
                                            Grant</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-17942">989,466</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-17943">1,650,705</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17944">6.58</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" unitRef="shares" id="ixv-17945">2,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" scale="0" sign="-" unitRef="shares" id="ixv-17946">1,006,074</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-17947">1,006,074</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17948">3.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" scale="0" sign="-" unitRef="shares" id="ixv-17949">26,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-17950">175,689</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-17951">175,689</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17952">6.48</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-17953">2,132,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-17954">2,481,090</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17955">5.19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" unitRef="shares" id="ixv-17956">3,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" scale="0" sign="-" unitRef="shares" id="ixv-17957">1,448,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-17958">1,448,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17959">0.99</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" scale="0" sign="-" unitRef="shares" id="ixv-17960">25,390</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" scale="0" sign="-" unitRef="shares" id="ixv-17961">250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-17962">240,282</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-17963">240,282</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17964">3.84</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-17965">3,648,651</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-17966">3,689,341</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17967">3.70</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">No
stock options were exercised during the years ended March 31, 2024 and 2023. During the years ended March 31, 2024 and 2023, the Company
issued <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-17968">25,390</ix:nonFraction> and <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-17969">26,789</ix:nonFraction> shares, respectively, to its non-employee directors under the Company&#8217;s outside director compensation
plan. For the years ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-17970">37,000</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-17971">86,000</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-10475"><span style="font-family: Times New Roman, Times, Serif">A
summary of RSU activity under the Plan is presented below.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Grant-</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair Value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares" id="ixv-17972">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-17973">0.91</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-17974">62,501</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-17975">0.91</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at March 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-17976">187,499</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-17977">0.91</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
total intrinsic value of RSUs outstanding as of March 31, 2024 was approximately $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-17978">347,000</ix:nonFraction>. The unamortized compensation cost at March
31, 2024 was approximately $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableUnamortizedLoanFeeCost" scale="0" unitRef="usd" id="ixv-17979">171,000</ix:nonFraction>&#160;related to RSUs and is expected to be recognized as expense over a period of approximately&#160;<ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-17980">2.25</ix:nonNumeric>&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" id="ixv-10554"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the range of outstanding and exercisable options as of March 31, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Range of Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">$<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17981">0.93</ix:nonFraction> - $<ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17982">2.00</ix:nonFraction></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-17983">2,237,066</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c108" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-10825"><span style="font-family: Times New Roman, Times, Serif">8.31</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17984">1.48</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-17985">1,409,750</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17986">1.52</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-17987">538,006</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">$<ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17988">3.95</ix:nonFraction> - $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17989">7.51</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-17990">943,145</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c112" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-10877"><span style="font-family: Times New Roman, Times, Serif">7.20</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17991">5.29</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-17992">771,478</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17993">5.52</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17994">8.61</ix:nonFraction> - $<ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17995">17.70</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-17996">509,130</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c116" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-10929"><span style="font-family: Times New Roman, Times, Serif">7.23</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17997">10.53</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-17998">470,442</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-17999">10.53</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">$<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18000">0.93</ix:nonFraction> - $<ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18001">17.70</ix:nonFraction></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-18002">3,689,341</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-10981"><span style="font-family: Times New Roman, Times, Serif">7.88</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18003">3.70</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-18004">2,651,670</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-18005">4.28</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-18006">538,006</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at March 31, 2024.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-11038"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6
&#8211; INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-11046"><span style="font-family: Times New Roman, Times, Serif">The income
tax provision consisted of the following:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current portion:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18007">2</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18008">2</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18009">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18010">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18011">3,730</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18012">2,933</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18013">657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18014">1,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18015">4,387</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-18016">4,400</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-18017">4,387</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-18018">4,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18019">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-18020">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2024, the Company had net operating
loss carryforwards (NOLs) of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" unitRef="usd" id="ixv-18021">35,000,000</ix:nonFraction> for federal income tax purposes and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-18022">50,400,000</ix:nonFraction> for state income tax purposes.
These NOLs are available to reduce future taxable income and will expire at various times from 2037 through 2045, except federal NOLs
from fiscal 2018 and later, which will never expire.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also had federal research and development
tax credit carryforwards of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" scale="0" unitRef="usd" id="ixv-18023">2,100,000</ix:nonFraction>, which will begin expiring at various times from 2038 through 2044, and state research
and development credits of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd" id="ixv-18024">500,000</ix:nonFraction>, which do not have an expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-11179"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-18025">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-18026">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-18027">6</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-18028">6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" unitRef="pure" id="ixv-18029">7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" unitRef="pure" id="ixv-18030">6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-18031">32</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-18032">29</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-18033">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-18034">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-11262"><span style="font-family: Times New Roman, Times, Serif">The
losses before income tax provision for the years ended March 31, 2024 and 2023 were solely attributable to US operations. Significant
components of the Company&#8217;s deferred tax assets and liabilities were (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-18035">10,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-18036">8,742</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-18037">3,058</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-18038">1,933</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-18039">2,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-18040">2,587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-18041">2,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-18042">1,658</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18043">193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18044">105</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-18045">19,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-18046">15,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" scale="3" unitRef="usd" id="ixv-18047">239</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" scale="3" unitRef="usd" id="ixv-18048">111</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Reserves, accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" sign="-" unitRef="usd" id="ixv-18049">49</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" sign="-" unitRef="usd" id="ixv-18050">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-18051">288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-18052">203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-18053">19,209</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-18054">14,822</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2024 and 2023, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-11421"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7
&#8211; ROYALTY AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of
a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-11434"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 8
&#8211; COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Litigations,
Claims and Assessments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated
financial statements for the years ended March 31, 2024 and 2023 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Purchase
Obligations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2024, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligation" scale="0" unitRef="usd" id="ixv-18055">1,100,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In December 2023, the Company signed a device integration agreement
with a provider of connected-care and remote monitoring diabetes technology solutions. As of March 31, 2024, the Company had a remaining
obligation under the device integration agreement of approximately $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligation" scale="0" unitRef="usd" id="ixv-18056">400,000</ix:nonFraction>&#160;over three years for technology license fees.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-11475"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 9
&#8211; RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Manchester
Management Company, LLC (MMC), as the general partner of Manchester Explorer, LP (Explorer), combined with the holdings of its affiliates,
JEB Partners LP, James Besser and Morgan Frank, owned approximately <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="modd:OutstandingSharesOfCommonStock" scale="-2" unitRef="pure" id="ixv-18057">11</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as
of March 31, 2024. Mr. Besser is the Company&#8217;s chief executive officer and a managing member of MMC. Mr. Frank is one of our directors
and serves as the portfolio manager of Explorer and as a managing member of MMC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
February 2024, Explorer purchased <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-18058">900,000</ix:nonFraction> shares of common stock in the 2024 Offering at the public offering price per share of $<ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-18059">1.10</ix:nonFraction>
for aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="modd:AggregateGrossProceeds" scale="0" unitRef="usd" id="ixv-18060">990,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; ">The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2024 and 2023, the Company paid her approximately
$<ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="0" unitRef="usd" id="ixv-18061">137,000</ix:nonFraction> and $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="0" unitRef="usd" id="ixv-18062">201,000</ix:nonFraction>, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718,
of stock options granted to her during each year.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed with or furnished to the
Securities and Exchange Commission, or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed
under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer,
to allow timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
the supervision and with the participation of our management, including our chief executive officer and our chief financial officer,
we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act). Based on this evaluation, our management
concluded that as of March 31, 2024, our disclosure controls and procedures were effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship
of possible controls. Internal control over financial reporting is the process designed by, or under the supervision of, our chief executive
officer and chief financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance
with generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records
that in reasonable detail accurately and fairly reflect our transactions and dispositions of assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted
accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition
of our assets that could have a material effect on the financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 64; Options: NewSection; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Because
of its inherent limitations, cost-effective internal controls over financial reporting may not prevent or detect misstatements. All internal
control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention
of overriding controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with
respect to consolidated financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted
an assessment of the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual
Report on Form 10-K. In making this assessment, we used the criteria based on the framework in <i>Internal Control&#8212;Integrated Framework
(2013 Framework) </i>issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the assessment, our management
concluded that our internal control over financial reporting was effective as of March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Changes
in Internal Control over Financial Reporting</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">There
were no changes in our internal controls over financial reporting during the fourth fiscal quarter of 2024 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
9B. OTHER INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c127" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-18063"><ix:nonNumeric contextRef="c127" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-18064"><ix:nonNumeric contextRef="c127" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-18065"><ix:nonNumeric contextRef="c127" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-18066">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Not applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 65; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="n_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
names of our directors, executive officers and certain information about each of them at March 31, 2024 are set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 61%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Besser</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul DiPerna</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Financial
    Officer, Treasurer and Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Schmid</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane DeSisto (1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Felsher(2)(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan C. Frank</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Sheibley(2)(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmen Volkart(1)(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen O&#8217;Connor Vos</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
                                            of Compensation Committee</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
                                            of Audit Committee</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
                                            of Nominating and Governance Committee</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">There
are no family relationships among any of our directors or executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
principal occupations and positions for at least the past five years of our directors and executive officers are described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>James
&#8220;Jeb&#8221; Besser</i>. Mr. Besser has served as our chief executive officer since February 2022 and combines over 25 years of
experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a Managing
Member at Manchester Management Company, LLC (&#8220;Manchester&#8221;), an investment management firm. Mr. Besser is also currently
a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University.
We believe that Mr. Besser is qualified to serve as member of our board of directors due to his extensive prior experience conducting
financial analysis of public companies (certain of which were in the development stage), including such public companies&#8217; management
teams, products, including products in the development stage, the potential markets for such products and other factors that could affect
the likelihood and timing of success and market penetration of such entities&#8217; products as well as his capital raising activities.
We believe this provides us with valuable insights into the financial markets and investment criteria of institutional and other investors
as well as capital raising activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paul
DiPerna.</i> Mr. DiPerna has been our chairman, chief financial officer, president and treasurer since we acquired Quasuras, Inc. (&#8220;Quasuras&#8221;)
in July 2017. He also served as our chief executive officer from July 2017 until August 2021, and as our Secretary from July 2017 to
October 2021. In 2015, he founded Quasuras, an early-stage medical device company developing an insulin pump product, and, until its
acquisition by us, he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC
to incubate early stage medical device products and accumulate technical talent. Our current pump product was one of such proposed products
and was spun-out to Quasuras in 2015. From 2012 to 2015, he served as a co-inventor at a private company with property rights in a medical
device used for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded
Tandem Diabetes Care, Inc. (&#8220;Tandem&#8221;) and held various positions, including as director, chief executive officer and chief
technology officer and was primarily responsible for the design concept and development of Tandem&#8217;s initial insulin pump. Prior
to that, he held executive and management positions at Baxter Healthcare Corporation (&#8220;Baxter&#8221;) where he was tasked with
identifying synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge
in the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design
engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents
in medical device and microfluidic technology and has achieved numerous product clearances with the FDA. He has also achieved multiple
successful exits with previous companies. Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a
B.S. in Mechanical Engineering from the University of Massachusetts and has spent over 35 years in the medical-device industry. We believe
that Mr. DiPerna is qualified to serve as the chairman of our board of directors due to his extensive knowledge and experience in the
medical-device industry generally, and, in particular, with regard to insulin pumps and the diabetes industry, as well as his management
and leadership experience from holding director and senior executive positions in other public and private companies and leading project
development teams of medical device companies.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 66; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Kevin
Schmid</i>. Mr. Schmid has served as our chief operating officer since July 21, 2022. He has over 19 years of experience in medical device
senior management and high-volume global manufacturing operations. He served as a consultant to the Company from March 2022 until his
hire date. Mr. Schmid has served as a member of the board of directors of Eitan Medical, an Israel based provider of connected infusion
and wearable drug delivery solutions, since 2018. From 2018 through June 2021, he served as the Chief Executive Officer and a board member
of Common Sensing, Inc., a disposable injector pen dose monitoring and reporting technology company. From 2016 to 2017, Mr. Schmid was
Vice President of Drug Delivery Systems for the Stevanato Group, a provider of innovative packaging and drug delivery solutions for the
pharmaceutical industry. From 2003 to 2015, Mr. Schmid was Vice President of Manufacturing, Operations, and Drug Delivery Systems for
Insulet Corporation. He has a BSME degree from Clarkson University and an MBA from Sacred Heart University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Duane
DeSisto.</i> Mr. DeSisto was appointed to our board of directors in July 2023. He has over 45 years of progressive management experience
and over 25 years of experience in the medical device industry as a member of senior management and as a board member at multiple public
companies. From 2001 to 2014, he served as the chief executive officer of Insulet Corporation, manufacturer of the world&#8217;s first
patch insulin pump. Prior to 2001, he held executive positions with Paper Exchange, an e-business solution for the pulp and paper industry,
AAI-Foster Grant, a sunglass and eyeglass provider to point-of-purchase retail, and Zoll Medical, a defibrillator manufacturer. He has
an undergraduate degree from Providence College and a masters of business administration degree from Bryant University. We believe that
Mr. DeSisto is qualified to serve on our board of directors because of his extensive background in operational leadership and commercialization
of advanced medical devices and therapies, including insulin pumps. In addition, he has served as an executive officer and member of
the board of directors at multiple public companies.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Steven
Felsher. </i>Mr. Felsher was appointed to our board of directors in November 2021. Mr. Felsher is an experienced executive with respect
to finance, administration, governance and other aspects of public and private company management. He served as a member of the board
of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, from March 2021 to February 2023. From August 2018
to July 2020, he served as a member of the board of directors of Sito Mobile, Inc., a publicly-traded company that provided customized,
data-driven solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was a senior advisor at Quadrangle
Group LLC, a private investment firm focused on the information and communications technology sectors. He spent a substantial portion
of his career with Grey Global Group Inc., a global marketing services company, where he served as a senior executive from 1979 until
2007, most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson College and a J.D.
from Yale University School of Law. We believe that Mr. Felsher is qualified to serve on our board of directors because of his extensive
business experience with administration, governance, capital allocation and other aspects of public and private company management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 67; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Morgan
C. Frank. </i>Mr. Frank was appointed to our board of directors in April 2017. In August 2022, he was appointed as chairman of the board
of directors of SANUWAVE Health, Inc., a publicly-traded provider of wound-care products. Mr. Frank has worked with Manchester, LP since
May 2002, and, prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy and principal
investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs. Prior to such
time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco based hedge fund
and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing in primary research to develop
investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at Paine Webber, Mr. Frank was a
currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown University. We believe that
Mr. Frank is qualified to serve as member of our board of directors due to his extensive prior experience conducting financial analysis
of public companies (certain of which were in the development stage), including such public companies&#8217; management teams, products,
including products in the development stage, the potential markets for such products and other factors that could affect the likelihood
and timing of success and market penetration of such entities&#8217; products as well as his capital raising activities. We believe this
provides us with valuable insights into the financial markets and investment criteria of institutional and other investors as well as
capital raising activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Philip
Sheibley.</i> Mr. Sheibley was appointed to our board of directors in November 2021. Mr. Sheibley is an experienced executive and venture
capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private equity firm. From 1981 to 2010, Mr. Sheibley
served as a management and technology consultant with Accenture, where he focused on the life sciences area, holding a variety of leadership
positions, including North American industry director for life sciences and global lead for management consulting. Mr. Sheibley holds
a B.S. in industrial and systems engineering with a business minor from Lehigh University. We believe that Mr. Sheibley is qualified
to serve on our board of directors because of his extensive business experience in the life sciences area and experience with venture
capital investment and consulting, including financing transactions for early- stage and scale-up stage companies, assisting with scale-up
strategy/execution, and participating as a board member in the medical products industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Carmen Volkart.</i> Ms. Volkart was appointed
to our board of directors in December 2019. Since January 2023, she has served as a member of the board of directors of Tactile Systems
Technology, Inc. (Tactile Medical), a Nasdaq-listed, medical technology company developing and marketing at-home therapies for people
suffering from underserved, chronic conditions. Ms. Volkart served as chief financial officer of Natureworks LLC, an advanced materials
company offering a portfolio of renewably-sourced polymers, from October 2018 to September 2023. She served as a member of the board
of directors, including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq-listed, specialty pharmaceutical company,
from October 2021 to May 2022, when it was acquired by another Nasdaq-listed company. From October 2012 to July 2018, Ms. Volkart served
as chief financial officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical
device company pioneering the application of convective radiofrequency thermotherapy to treat endourological conditions. She served as
global chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary,
compliance officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, Ms. Volkart held various executive and financial
positions at American Medical Systems, Inc., Medtronic, Inc. and Honeywell, Inc. She holds a B.S. in accounting from the University of
North Dakota and an MBA with a concentration in strategic management from the University of Minnesota. We believe that Ms. Volkart is
qualified to serve on our board of directors because of her substantial financial and public-company experience, as she has served as
chief financial officer at multiple medical device and other companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Ellen
O&#8217;Connor Vos. </i>Ms. Vos was appointed to our board of directors in May 2021 and served as our chief executive officer from August
2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC since November 2020. Prior to that, she served as the president
and chief executive officer of the Muscular Dystrophy Association from October 2017 to November 2020. Previously, Ms. Vos had been chief
executive officer of ghg | greyhealth group from 1996 to 2017, and she has been a champion of using digital capabilities to improve the
public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a publicly- traded digital health company, and the Jed Foundation,
a leading nonprofit dedicated to protecting the emotional health of college students, and was a founding board member of MMRF, a pioneering
cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred University. We believe that Ms. Vos is qualified to serve on
our board of directors because of her executive experience and extensive executive skills in digital marketing, commercialization and
communications in the healthcare industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>Family
Relationships.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">There
are no family relationships between any of our directors or executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 68; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Involvement
in Legal Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">To
our knowledge, none of our executive officers or our directors has, during the last ten years:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">had
                                            any bankruptcy petition filed by or against the business or property of the person, or of
                                            any partnership, corporation or business association of which he was a general partner or
                                            executive officer, either at the time of the bankruptcy filing or within two years prior
                                            to that time;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction or federal or state authority, permanently or temporarily
                                            enjoining, barring, suspending or otherwise limiting, his involvement in any type of business,
                                            securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
                                            or to be associated with persons engaged in any such activity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
                                            Futures Trading Commission to have violated a federal or state securities or commodities
                                            law, and the judgment has not been reversed, suspended, or vacated;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any federal or state judicial or administrative order, judgment,
                                            decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement
                                            of a civil proceeding among private litigants), relating to an alleged violation of any federal
                                            or state securities or commodities law or regulation, any law or regulation respecting financial
                                            institutions or insurance companies including, but not limited to, a temporary or permanent
                                            injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
                                            cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
                                            mail or wire fraud or fraud in connection with any business entity; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                            or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange
                                            Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act),
                                            or any equivalent exchange, association, entity or organization that has disciplinary authority
                                            over its members or persons associated with a member.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">To
our knowledge, there are no material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially
of more than 5% of any class of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security
holder is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Arrangements
for Appointment of Directors and Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Reorganization and Share Exchange Agreement, hereinafter referred to as the Share Agreement, dated as of July 24, 2017, by and
among us, Quasuras, Mr. DiPerna and the other stockholders of Quasuras, until July 24, 2022, our board of directors was required to consist
of no more than five and no less than two directors of which (i) Manchester Explorer, L.P. has the right to appoint two directors, pursuant
to which Manchester Explorer, L.P. appointed Mr. Frank and Ms. Volkart and (ii) Mr. DiPerna, in addition to being our chairman of the
board, had the right to appoint two additional directors, pursuant to which he appointed Liam Burns, who resigned from our board of directors
in December 2021, and Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester Explorer L.P&#8217;s and Mr.
DiPerna&#8217;s rights to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors
until July 2022; provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr. DiPerna
shall remain as chairman of our board of directors for an additional period of three years. Following such amendment, our board of directors
increased the size of the board to six members and, on May 18, 2021, appointed Ms. Vos as a director to our board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 69; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Communications
with our Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stockholders
who desire to communicate with the board of directors, or a specific director, may do so by sending the communication addressed to either
the board of directors or any individual director, c/o Modular Medical, Inc., 10740 Thornmint Road, San Diego, California 92127. These
communications will be delivered to the board of directors, or any individual director, as specified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>Corporate
Governance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Leadership Structure and Role in Risk Oversight</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to our small size and early stage, we have
not adopted a formal policy on whether the chairman and chief executive officer positions should be separate or combined. Since 2017,
Mr. DiPerna has been serving as our chairman, and, since February 2022, Mr. Besser has been serving as our chief executive officer. Our
board of directors has oversight responsibility for our risk management processes. Our board of directors receives and reviews periodic
reports from management, auditors, legal counsel, and others, as considered appropriate, regarding our assessment of risks. Our board
of directors will focus on the most significant risks facing us and our general risk management strategy, and also ensure that risks
undertaken by us are consistent with our appetite for risk. While our board of directors oversees our risk management processes, management
is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach
for addressing the risks facing us and that the leadership structure of our board of directors supports this approach.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have established an audit committee, a compensation committee, and a nominating and governance committee. Each committee&#8217;s members
and functions are described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Audit
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
board of directors established the audit committee (the Audit Committee) for the purpose of overseeing the accounting and financial reporting
processes and audits of our financial statements. The Audit Committee also is charged with reviewing any internal control violations
under our whistleblower policy. The responsibilities of our audit committee are described in the Audit Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr.
Felsher, Mr. Sheibley and Ms. Volkart are the current members of the Audit Committee. Mr. Felsher serves as the chairperson and has been
designated by the board of directors as the &#8220;audit committee financial expert,&#8221; as defined by Item 407(d)(5) of Regulation
S-K under the Securities Act and the Exchange Act. That status does not impose duties, liabilities or obligations that are greater than
the duties, liabilities or obligations otherwise imposed on Mr. Felsher as a member of the audit committee and the board of directors,
however. Our board of directors has determined that each of our Audit Committee members satisfies the &#8220;independence&#8221; requirements
of the Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
board of directors established the compensation committee (the Compensation Committee) for the purpose of reviewing, recommending and
approving our compensation policies and benefits, including the compensation of all of our executive officers and directors. Mr. DeSisto
and Ms. Volkart are the current members of the compensation committee, and Mr. DeSisto serves as the chairperson. Each of our Compensation
Committee members satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the independence standards
under Rule 10A-3 under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
Compensation Committee is responsible for reviewing, recommending and approving our compensation policies and benefits, including the
compensation of all of our executive officers and directors, and it also has the principal responsibility for the administration of our
equity incentive plan. The responsibilities of our compensation committee are more fully described in the Compensation Committee Charter
adopted by our board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Nominating
and Governance Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
board of directors established the nominating and governance committee (the Nominating and Governance Committee) for the purpose of (i)
carrying out the responsibilities delegated by the board of directors relating to our director nominations process, (ii) developing and
assessing our corporate governance policies, (iii) review our strategies, activities, and policies regarding environmental, social, and
governance, or ESG, matters and (iv) provide oversight for the evaluation of the performance of the board of directors and its committees.
The Nominating and Governance Committee consists of Mr. Sheibley and Mr. Felsher, and Mr. Sheibley serves as the chairperson. Each of
the members of our Nominating and Governance Committee satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules
and meets the independence standards under Rule 10A-3 under the Exchange Act. The responsibilities of our Nominating and Governance committee
are more fully described in the Nominating and Governance Committee Charter adopted by our board of directors, a current copy of which
can be found on the investors section of our website, www.modular-medical.com.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Nominating and Governance Committee will consider persons recommended by stockholders for inclusion as nominees for election to our board
of directors if the information required by our bylaws is submitted in writing in a timely manner addressed and delivered to our secretary
at the address of our executive offices. The Nominating and Governance Committee will identify and evaluate nominees for our board of
directors, including nominees recommended by stockholders, based on numerous factors it considers appropriate, some of which may include
strength of character, mature judgment, career specialization, relevant technical skills, diversity, and the extent to which the nominee
would fill a present need on our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Director
Independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
board of directors has determined that each of the current directors, with the exception of Mr. DiPerna, Mr. Frank and Ms. Vos, is &#8220;independent,&#8221;
as defined by the listing rules of the NASDAQ Stock Market, or Nasdaq, and the rules and regulations of the SEC. Our board of directors
has standing Audit, Compensation and Nominating and Governance Committees, each of which is comprised solely of independent directors
in accordance with the Nasdaq listing rules. No director qualifies as independent unless the board of directors affirmatively determines
that he has no direct or indirect relationship with us that would impair his independence. We independently review the relationship of
the Company to any entity employing a director or on whose board of directors such director is serving currently.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Code of
Business Conduct and Ethics for Employees, Executive Officers and Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We
have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and
members of our board of directors. The Code of Conduct is available on our website at www.modular-medical.com. Our Nominating and Governance
Committee is responsible for overseeing the Code of Conduct, and our board of directors must approve any waivers of the Code of Conduct.
In addition, we intend to post on our website all disclosures that are required by law concerning any amendments to, or waivers from,
any provision of the Code of Conduct.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Diversity</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
seek diversity in experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our board
of directors. We believe directors should have various qualifications, including individual character and integrity; business experience;
leadership ability; strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting,
and legal matters; communications and interpersonal skills; and the ability and willingness to devote time to our company. We also believe
the skill sets, backgrounds, and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in
personal and professional experience, background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated
against on the basis of race, religion, national origin, sex, sexual orientation, disability, or any other basis proscribed by law. The
assessment of prospective directors is made in the context of the perceived needs of our board of directors from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
of our directors have held high-level positions in business or professional service firms and have experience in dealing with complex
issues. We believe that all of our directors are individuals of high character and integrity, are able to work well with others, and
have committed to devote sufficient time to the business and affairs of our company. In addition to these attributes, the description
of each director&#8217;s background set forth above indicates the specific qualifications, skills, perspectives, and experience necessary
to conclude that each individual should continue to serve as a director of ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Delinquent
Section 16(a) Reports</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">Section
16(a) of the Exchange Act requires our directors, executive officers and persons who beneficially own 10% or more of a class of securities
registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the
SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and regulations of the SEC to furnish
us with copies of all reports filed by them in compliance with Section 16(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Based
solely upon a review of Forms 3 and 4 and amendments thereto furnished to us during fiscal 2024,<span>&#160;including
those reports that we filed on behalf of our directors and executive officers, no director, executive officer, beneficial owner of more
than 10% of the outstanding common stock, or any other person subject to Section 16 of the Exchange Act, failed to file with the SEC
on a timely basis during the fiscal year ended March 31, 2024, except </span>that in July 2023 Mr. DeSisto failed to timely file a Form
3 to report his initial beneficial ownership and a Form 4 to report a restricted stock unit award.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 71; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
11. EXECUTIVE COMPENSATION</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.45pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SUMMARY
COMPENSATION TABLE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth compensation information for fiscal 2024 and 2023 for each of our named executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Salary</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock Awards</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option Awards</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-Equity
    Incentive Plan<br/> Compensation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">All Other<br/>
    Compensation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name and
    Principal Position</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)(1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">James E. Besser,</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,480</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,480</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer
    (2)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paul DiPerna,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">182,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">482,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">President, President Chief
    Financial Officer, Treasurer and Chairman</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">189,413</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">489,413</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kevin Schmid,</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160,510</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,510</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Chief Operating Officer
    (4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,121</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">701,945</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">878,066</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
                                            amounts reflect the aggregate grant date fair value with respect to awards granted, as determined
                                            pursuant to Financial Accounting Standards Board (FASB) ASC Topic 718. The assumptions used
                                            to calculate the aggregate grant date fair value of option awards are set forth in the notes
                                            to the consolidated financial statements included in item 8 of this Report. These amounts
                                            do not reflect actual compensation earned or to be earned by our named executive officers.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Besser was appointed our chief executive officer in February 2022, and he is paid <i>de minimis
                                            </i>annual compensation of $1.00.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Schmid was appointed our chief operating officer in July 2022 at an annual base salary of
                                            $250,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 72; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table shows certain information regarding outstanding equity awards held by our named executive officers as of March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options (#) Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options (#) Unexercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Option
    Exercise Price($)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration Date(1)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">James E. Besser</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,136</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif">10/2/2033</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paul DiPerna</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,155</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/1/2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,169</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/1/2030</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,170</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.48</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/1/2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3/2/2030</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,745</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/1/2030</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,727</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">1/1/2030</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/1/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(10)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/1/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(11)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/1/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,662</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(13)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(14)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,650</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(15)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(16)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,624</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(17)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,694</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(18)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,641</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(19)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,603</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(20)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">1/15/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,775</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(21)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/15/2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,775</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(22)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/15/2028</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(23)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/15/2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(24)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">09/15/2028</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(25)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">08/15/2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(26)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/25/2029</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(27)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(27)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/14/2032</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(28)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/3/2033</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,091</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(29)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/2/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,046</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(30)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/2/2033</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kevin Schmid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97,222</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(31)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(31)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/21/2032</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="text-align: left">(32)</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/3/2033</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,538</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(33)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/2/2033</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,769</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(34)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/2/2033</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            standard option term is ten years, but all of the options expire automatically unless exercised
                                            within 90 days after the cessation of service as an employee, director or consultant.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 2, 2023, and the shares subject to this option vested in January
                                            2024 upon the Company&#8217;s 510(k) premarket submission to the FDA for its initial pump
                                            product.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on June 1, 2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on May 1, 2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on April 1, 2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on March 2, 2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on February 1,2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on January 1, 2020, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on December 1, 2019, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on November 1, 2019, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 1, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on September 15, 2019, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on August 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on July 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on June 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on May 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on April 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on March 15, 2019, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on February 15, 2019, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on January 15, 2019, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on December 15, 2018, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on November 15, 2018, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 15, 2018, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on September 15, 2018, and the shares subject to this option were fully
                                            vested on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on August 15, 2018, and the shares subject to this option were fully vested
                                            on the grant date.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on November 25, 2019, and the shares subject to this option vested monthly
                                            over three years commencing January 1, 2020, subject to continued service as an employee,
                                            director or consultant.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on April 14, 2022, and the shares subject to this option vest: i) one-third
                                            on the annual anniversary of the grant date and ii) the remaining two-thirds monthly over
                                            the next two years, subject to continued service as an employee, director or consultant</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on April 3, 2023, and the shares subject to this option vest: i) one-third
                                            on the annual anniversary of the grant date and ii) the remaining two-thirds monthly over
                                            the next two years subject to continued service as an employee, director or consultant.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 2, 2023, and the shares subject to this option vested in January
                                            2024 upon the Company&#8217;s 510(k) premarket submission to the U.S. Food and Drug Administration
                                            (&#8220;FDA&#8221;) for its initial pump product.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 2, 2023, and the shares subject to this option vest if the
                                            Company receives notification of FDA clearance of the 510(k) premarket submission on or before
                                            August 1, 2024, subject to continued service as an employee, director or consultant.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on July 21, 2022, and the shares subject to this option vest: i) one-third
                                            on the annual anniversary of the grant date and ii) the remaining two-thirds monthly over
                                            the next two years subject to continued service as an employee, director or consultant.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on April 3, 2023, and the shares subject to this option vest: i) one-third
                                            on the annual anniversary of the grant date and ii) the remaining two-thirds vest over the
                                            next two years subject to continued service as an employee, director or consultant.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 2, 2023, and the shares subject to this option vested in January
                                            2024 upon the Company&#8217;s 510(k) premarket submission to the FDA for its initial pump
                                            product.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.3in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            option was granted on October 2, 2023, and the shares subject to this option vest if the
                                            Company receives notification of FDA clearance of the 510(k) premarket submission on or before
                                            August 1, 2024, subject to continued service as an employee, director or consultant.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employment
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have entered into our standard form of employment, confidential information and invention assignment agreement with each of our named
executive officers. We also have entered into agreements to indemnify our directors and executive officers, in addition to the indemnification
provided for in our articles of incorporation and bylaws. These agreements, among other things, provide for indemnification of our directors
and certain executive officers for many expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by
any such person in any action or proceeding, including any action by or in the right of the Company, arising out of such person&#8217;s
services as a director or executive officer of ours, any subsidiary of ours or any other company or enterprise to which such person provided
services at our request.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The DiPerna
Employment and Related Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
entered into an employment agreement dated August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna is employed by us as our president.
Mr. DiPerna&#8217;s employment agreement had an initial two-year term and automatically renews for additional one-year terms. Pursuant
to such agreement, we agreed to pay Mr. DiPerna: i) an annual salary of $200,000 in cash, ii) $100,000 per year in fully-vested stock
options granted monthly at an exercise price determined by our board of directors in its sole discretion and iii) an annual bonus of
$300,000, payable at the discretion of our board of directors, either in shares or in cash. If the board chooses to pay the bonus in
shares, such shares will be valued at a price determined by our board of directors. Pursuant to such employment agreement (i) if (a)
we terminate Mr. DiPerna&#8217;s employment without cause or he resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000,
and (b) we terminate Mr. DiPerna&#8217;s employment for cause, we are not obligated to make any severance payment and Mr. DiPerna will
receive only his base compensation through the last day of his employment, (ii) upon Mr. DiPerna&#8217;s death or disability, he will
receive his base compensation through the last day of his employment and will remain eligible for all applicable benefits relative to
death or disability pursuant to any plans that we have in place at such time, and (iii) upon a change of control (as defined in the employment
agreement), Mr. DiPerna will be paid a lump sum of $100,000 within sixty days of the time at which such change of control takes place.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In May 2020,
we amended our employment agreement with Mr. DiPerna to provide that in the event of a change in control:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">within
                                            60 days of the date the change in control occurs, Mr. DiPerna shall be paid by us or our
                                            successor in interest a lump sum cash payment equal to 12 months of Mr. DiPerna&#8217;s then
                                            annual Base Compensation (as defined in the employment agreement); and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
                                            prior to such change of control, any unvested stock options or other unvested securities
                                            of ours issued to Mr. DiPerna shall automatically accelerate and immediately become fully
                                            vested and exercisable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
June 2020, our board of directors approved an amendment to the employment agreement to provide that Mr. DiPerna&#8217;s base salary would
be paid entirely in cash commencing July 1, 2020. The payment of the additional cash component of Mr. DiPerna&#8217;s annual base salary
($8,333.33 per month) was initially be deferred (the Deferred Salary) and accrue for Mr. DiPerna&#8217;s benefit until we have received
$5,000,000 of cumulative gross proceeds of financing, at which time the Deferred Salary shall be paid to Mr. DiPerna and the salary deferrals
will cease. The salary deferrals ceased and the Deferred Salary was paid to Mr. DiPerna in May 2021. In August 2021, Mr. DiPerna resigned
as our chief executive officer, and he continues to serve as our president, chief financial officer, treasurer and chairman of our board
of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
a change of control occurred on March 31, 2024, under his employment agreement, Mr. DiPerna would be entitled to the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of a lump sum of $300,000 within 60 days of the time at which such change of control takes
                                            place.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accelerated
                                            vesting of 111,296 shares of common stock under unvested stock options. The value of the
                                            shares subject to accelerated vesting is calculated as the intrinsic value per share multiplied
                                            by the number of shares that would become fully vested upon a change of control. The intrinsic
                                            value per share would be calculated as the excess of the closing price of the common stock
                                            of $1.85 on the Nasdaq Capital Market on March 28, 2024 over the exercise price of the option.
                                            As of March 31, 2024, the intrinsic value of the shares subject to accelerated vesting was
                                            approximately $67,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
connection with our acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with
Quasuras and Mr. DiPerna, pursuant to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly
by him related to our business. Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services to be performed for
us, pursuant to a royalty agreement, certain fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000
cap on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 75; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>The
Schmid Offer Letter </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to an offer letter with the Company (the &#8220;Offer Letter&#8221;), Mr. Schmid shall receive an annual salary of $250,000 (the &#8220;Schmid
Base Salary&#8221;) for his services as our chief operating officer. Additionally, he is eligible for an annual discretionary target
incentive bonus of up to 50% of his Base Salary. In connection with his appointment, Mr. Schmid was granted a stock option to purchase
175,000 shares of our common stock. The stock option vests over a three-year period with one-third of the shares subject to the stock
option vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly thereafter, subject to Mr. Schmid&#8217;s
continuous service with us. In the event of termination of his employment by us other than for cause or good reason (as defined in the
Offer Letter), Mr. Schmid will receive an amount equal to six months of his then-current base salary as a severance payment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>James
Besser </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
compensation for his services as our chief executive officer, Mr. Besser is paid de minimis compensation of $1.00 per year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Director
Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the first quarter of fiscal 2022, our board of directors approved our outside (non-employee) director compensation plan (the Director
Plan). Pursuant to the Director Plan, outside directors are paid the following annual retainers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25,000
                                            for service as a member of the board of directors; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000
                                            for service as chair of a committee of the board of directors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
annual retainers are paid in quarterly installments in either cash, options to purchase shares of our common stock or in shares of our
common stock, as directed by each director based on an annual election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, under the Director Plan, each director receives an annual service equity award of $100,000 paid in quarterly installments
in either options to purchase shares of our common stock or shares of our common stock, as directed by each director based on an
annual election. In July 2022, the Board amended the Director Plan to provide that a minimum price of $10.00 per share of common
stock would be used to calculate the number of shares subject to options or share awards.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, upon appointment to our board of directors, we award our non-employee directors an equity award under our Amended 2017 Equity
Incentive Plan (the 2017 Plan), and such awards vest over three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table summarizes the compensation earned by our non-employee directors in fiscal 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fee</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Restricted<br/>
                                            Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Awards</b></span></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option<br/>
    Awards</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">All Other<br/>
    Compensation</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">($)(1)(2)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">($)(2)(3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">($)(2)(4)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Duane DeSisto</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,170</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">227,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,103</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">261,773</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">William Febbo(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,328</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,828</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Steven Felsher</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,312</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,377</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,689</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Morgan Frank</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Philip Sheibley</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,550</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,795</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Carmen Volkart</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,312</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,658</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,970</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ellen O&#8217;Connor Vos</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,312</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">42,562</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            DeSisto was appointed to our board of directors in July 2023, and, upon his appointment,
                                            was granted a restricted stock unit (the &#8220;DeSisto RSU&#8221;) for 250,000 shares of
                                            our common stock. As of March 31, 2024, 187,499 shares of our common stock remained unvested
                                            under the DeSisto RSU.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
                                            amounts reflect the aggregate grant date fair value with respect to awards granted, as determined
                                            pursuant to FASB ASC Topic 718. The assumptions used to calculate the aggregate grant date
                                            fair value of option awards are set forth in the notes to the consolidated financial statements
                                            included in Item 8 of this Annual Report on Form 10-K. These amounts do not reflect actual
                                            compensation earned or to be earned by our directors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of March 31, 2024, our non-employee directors each held outstanding options to purchase the
                                            following number of shares of our common stock: Steven Felsher, 98,084; Morgan Frank, 177,458;
                                            Philip Sheibley, 16,667; Carmen Volkart; 150,558, Ellen O&#8217;Connor Vos, 166,020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            stock awards under the Director Plan; we calculated the estimated fair value of the stock
                                            awards issued to Messrs. DeSisto, Felsher and Sheibley and Ms. Volkart using the closing
                                            price per share of our common stock on the day prior to the grant date in accordance with
                                            the Director Plan.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr.
                                            Febbo resigned from our board of directors in July 2023.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth certain information as of May 31, 2024 concerning the ownership of our common stock by:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            stockholder known by us to be the beneficial owner of more than 5% of the outstanding shares
                                            of our common stock (currently our only class of voting securities);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our executive officers; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            directors and executive officers as a group.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.25pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Beneficial
ownership is determined in accordance with Rule 13d-3 of the Exchange Act, and includes all shares over which the beneficial owner exercises
voting or investment power. Shares that are issuable upon the exercise of options, warrants and other rights to acquire common stock
that are presently exercisable or exercisable within 60 days of June 15, 2024 are reflected in a separate column in the table below.
These shares are taken into account in the calculation of the total number of shares beneficially owned by a particular holder and the
total number of shares outstanding for the purpose of calculating percentage ownership of the particular holder. We have relied on information
supplied by our officers, directors and certain stockholders and on information contained in filings with the SEC. Except as otherwise
indicated, and subject to community property laws where applicable, we believe, based on information provided by these persons, that
the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially
owned by them. The percentage of beneficial ownership is based on 32,463,670 shares of common stock outstanding as of May 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unless
otherwise stated, the business address of each of our directors and executive officers listed in the table is 10740 Thornmint Road, San
Diego, California 92127.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name
    and principal position</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares<br/> Beneficially Owned<br/> (Excluding<br/> Outstanding<br/> Equity Awards and<br/> Warrants)(1)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> Shares Issuable &#160;on Exercise&#160;of<br/> Outstanding<br/> Equity Awards and<br/> Warrants(2)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percent
    of<br/> Class</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">JEB Partners, L.P.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">330,473</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Manchester Explorer, L.P.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,118,077</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">653,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Manchester Management Company, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,448,550</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">653,511</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">683 Capital Management, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,570,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sio Capital Management, LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">689,352</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,786,516</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors and Officers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">James Besser</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,593,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">788,647</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paul DiPerna</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,553,586</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">330,436</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kevin Schmid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,871</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Duane DeSisto</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,891</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,833</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Steven Felsher</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">126,177</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,528</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Morgan C. Frank</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,324,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">830,969</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Philip Sheibley</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,139</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,112</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Carmen Volkart</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,558</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Ellen O&#8217;Connor Vos</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,353</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">All current directors and executive officers
    as a group (9 persons)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,153,200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,831,661</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            less than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
                                            shares subject to outstanding options, restricted stock units and warrants to acquire common
                                            stock that are exercisable within 60 days of May 31, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 77; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the number of shares subject to outstanding options, restricted stock units and warrants
                                            to acquire common stock that are exercisable within 60 days of May 31, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            (i) 144,750 shares directly held by Mr. Besser, of which: (a) 60,277 shares were received
                                            in exchange for Mr. Besser&#8217;s shares as a result of our acquisition of Quasuras; (b)
                                            29,630 shares purchased in a private placement in 2018 (the &#8220;2018 Placement&#8221;)
                                            and (c) 34,843 shares were purchased in a private placement in 2020 (the &#8220;2020 Placement&#8221;)
                                            and (d) 20,000 shares were purchased in the open market; (ii) 2,218,077 held by Manchester
                                            Explorer, L.P. of which: (a) 1,515,152 shares were purchased in a private placement in 2017
                                            (the &#8220;2017 Placement&#8221;), (b) 157,037 shares were purchased in the 2018 Placement,
                                            (c) 11,614 were purchased in the 2020 Placement, (d) 300,000 shares were purchased in a public
                                            offering in February 2022, (e) 234,274 shares were acquired upon the conversion of a convertible
                                            note in February 2022 and (f) 900,000 shares were purchased in the Company&#8217;s February
                                            2024 public offering; (iii) 330,473 shares held by JEB Partners, L.P. of which (a) 252,526
                                            shares were purchased in the 2017 Placement, (b) 53,333 shares were purchased in the 2018
                                            Placement and (c) 11,614 shares were purchased in the 2020 Placement; and (iv) 206,226 shares
                                            held by Mr. Frank, which shares were received in our acquisition of Quasuras in exchange
                                            for Mr. Frank&#8217;s shares of Quasuras. Mr. Besser, as the managing member, and Mr. Frank,
                                            as the portfolio manager and consultant of Manchester Management Company, LLC, (&#8220;MMC&#8221;)
                                            the general partner of Manchester Explorer, L.P. and JEB Partners, L. P., have shared voting
                                            and dispositive power over shares held by Manchester Explorer, L.P. and JEB Partners, L.P.
                                            The address for Manchester Explorer, L.P is c/o MMC, 2 Calle Candina, No. 1701, San Juan,
                                            Puerto Rico 00907.</span></td>
</tr></table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on information reported by 683 Capital Management, LLC (&#8220;683 Management&#8221;) on
                                            Schedule 13G filed with the SEC on February 16, 2024. 683 Management, as the investment manager
                                            of 683 Capital Partners, LP (&#8220;683 Capital&#8221;), may be deemed to have beneficially
                                            owned the shares of Common Stock and warrants to purchase&#160;&#160;shares of Common Stock
                                            beneficially owned by 683 Capital. Ari Zweiman as the Managing Member of 683 Management &#160;may
                                            be deemed to have beneficially owned the shares of common stock and warrants to purchase
                                            shares of common stock beneficially owned by 683 Management. The address for 683 Management,
                                            683 Capital and Mr. Zweiman is 1700 Broadway, Suite 4200, New York, NY 10019.</span>

</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on information reported by Sio Capital Management, LLC (&#8220;Sio&#8221;) on Schedule 13G
                                            filed with the SEC on February 6, 2024. Sio and Sio GP, LLC (the &#8220;GP&#8221;) act as
                                            investment advisor and general partner, respectively, to various clients that are the record
                                            owners of the shares of our common stock reported on this Schedule 13G. Because Sio&#8217;s
                                            investment discretion with respect to such clients is subject to oversight by the GP, the
                                            GP may be deemed to be the beneficial owner of the common stock of the Issuer owned by such
                                            clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may
                                            be deemed to control the voting and dispositive decisions with respect to, and therefore
                                            be the beneficial owner of, the shares of our common stock. The address for Sio, the GP and
                                            Mr. Castor is 600 Third Avenue, New York, New York 10016.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            (i) 2,000,000 shares directly held by the Paul DiPerna Irrevocable Trust, (ii) 333,334 shares
                                            directly held by Mr. DiPerna&#8217;s adult daughters, Kelsie DiPerna and Alaria DiPerna,
                                            which shares Mr. DiPerna has sole voting power over; (iii) 207,906 shares directly held by
                                            the Paul DiPerna Trust, of which 101,010 shares were purchased in the 2017 Placement and
                                            23,429 shares were acquired upon the conversion off a convertible note in February 2022 and
                                            (iv) 12,346 shares held by Mr. DiPerna. The 2,000,000 shares held by the Paul DiPerna Irrevocable
                                            Trust, 333,334 shares held by Mr. DiPerna&#8217;s adult daughters and 73,480 shares held
                                            by the Paul DiPerna Trust that were issued in 2017 to Mr. DiPerna in the Control Block Acquisition
                                            and transferred to such persons in December 2020 by Mr. DiPerna. Mr. DiPerna is the chairman
                                            of our board of directors, and also serves as our president, chief financial officer and
                                            treasurer. Mr. DiPerna is the trustee of both the Paul DiPerna Irrevocable Trust and the
                                            Paul DiPerna Trust.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>Changes
in Control</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">We
are not aware of any arrangement that may result in a &#8220;changes in control,&#8221; as that term is defined by the provisions of
Item 403(c) of Regulation S-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Equity
Compensation Plan Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
following table shows the number of securities to be issued upon exercise or vesting of outstanding equity awards under the 2017 Plan
as of March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> securities to be<br/> issued upon<br/> exercise or<br/> vesting of<br/> outstanding<br/> equity awards<br/> (a)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted-<br/>
    average<br/> exercise price<br/> of outstanding<br/> options<br/> (b)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> securities<br/> remaining available<br/> for future issuance<br/> under equity<br/> compensation plans<br/> (excluding securities<br/>
    reflected in<br/> column(a))<br/> (c)</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holders</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689,341</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.70</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,648,651</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 78; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Transactions
with Related Persons</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Below
we describe any transactions to which we have been a participant, in which the amount involved in the transaction exceeds or will exceed
the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal&#160;years and
in which any of our directors, director nominees, executive officers, or holders of more than 5% of our capital stock, or any immediate
family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest
since April&#160;1, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">MMC
as the general partner of Manchester Explorer, L.P. (Explorer), combined with the holdings of its affiliates, JEB Partners LP, Mr. Besser
and Mr. Frank, owned approximately 13% of our outstanding shares of common stock at March 31, 2024. Mr. Besser is our chief executive
officer and a managing member of MMC. Mr. Frank is one of our directors, and he serves as the portfolio manager of Explorer and as a
managing member of MMC. In February 2024, we closed a public offering of our common stock (the 2024 Offering), and Explorer purchased
900,000 shares in the 2024 Offering for aggregate gross proceeds to us of $990,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr.
DiPerna&#8217;s daughter is an employee of ours, and, during fiscal 2024 and fiscal 2023, we paid her approximately $137,000 and $201,000,
respectively, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of stock options granted
to her.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See
&#8220;Management&#8221; above for other related-party transactions involving our executive officers and directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table shows the fees billed to us by Farber Hass Hurley LLP, or Farber, our independent registered public accounting firm,
for the audit of our consolidated financial statements and other services provided (in thousands).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Audit fees(1)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Audit-related fees(2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Total(3)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">101</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                            fees consisted of fees for professional services rendered for the audit of our annual consolidated
                                            financial statements and reviews of our quarterly consolidated financial statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
                                            fees consisted of fees for services related to our issuance of SEC registration statements
                                            and sales of our securities under registration statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Farber
                                            did not provide any non-audit or other services other than those reported under &#8220;Audit
                                            fees&#8221; and &#8220;Audit-related fees.&#8221;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; ">The
Audit Committee meets with our independent registered public accounting firm at least four times a year. At such times, the Audit Committee
reviews and approves both audit and non-audit services performed by the independent registered public accounting firm, as well as the
fees charged for such services. The Audit Committee is responsible for pre-approving all auditing services and non-auditing services
(other than non-audit services falling within the&#160;<i>de minimis</i>&#160;exception set forth in Section 10A(i)(1)(B) of the Exchange
Act and non-audit services that independent auditors are prohibited from providing to us) in accordance with the following guidelines:
(1) pre-approval policies and procedures must be detailed as to the particular services provided; (2) the Audit Committee must be informed
about each service; and (3) the Audit Committee may delegate pre-approval authority to one or more of its members, who shall report to
the full committee, but shall not delegate its pre-approval authority to management. Among other things, the Audit Committee examines
the effect that performance of non-audit services may have upon the independence of the auditors.</span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 79; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="n_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">ITEM
15: EXHIBITS</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>(a)
Financial Statements and Financial Statement Schedules are set forth under Part II, Item 8 of this report.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>(b)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Other
Schedules may omitted because they are not applicable, not required, or because the required information is included in the Consolidated
Financial Statements or notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reference</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    or Furnished</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 56%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing&#160;Date</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023040917/ea178793ex1-1_modular.htm"><span style="font-size: 10pt">Form
    of Underwriting Agreement dated May 15, 2023</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/17/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390024014985/ea193973ex1-1_modular.htm">Underwriting
    Agreement dated as of February 15, 2024 between the Registrant and Titan Partners Group LLC</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/16/2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023089664/ea188824ex1-1_modular.htm">Sales
    Agreement, dated as of November 22, 2023, between Modular Medical, Inc. and Leerink Partners LLC</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm">Reorganization
    and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other stockholders
    of Quasuras, Inc.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm">Addendum
    No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul
    DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm">Third
    Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/29/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000620/ex3_1.htm">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of
    the State of Nevada on November 24, 2021</a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/01/2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390024014542/ea193897ex3-1_modular.htm">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of
    the State of Nevada on February 15, 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; white-space: nowrap; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">8-K</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">3.1</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">02/15/2024</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000102402002000002/bylaws.txt"><span style="font-size: 10pt">Amended
    Bylaws</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-SB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/08/2002</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex4-1_modular.htm"><span style="font-size: 10pt">2017
    Equity Incentive Plan, as amended <span style="text-decoration: none">and restated</span></span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex4_1.htm">Form
    of Warrant to Purchase Common Stock dated February 14, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_1.htm">Form
    of Pre-Funded Warrant to Purchase Common Stock dated May 2, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_2.htm">Form
    of Private Placement Warrant dated May 2, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-5_modular.htm"><span style="font-size: 10pt">Form
    of Warrant</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-6_modular.htm"><span style="font-size: 10pt">Form
    of Underwriter&#8217;s Warrant</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023051688/f10k2023ex4-7_modular.htm"><span style="font-size: 10pt">Description
    of Registrant&#8217;s Securities</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10-K</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;4.7</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;06/26/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm">Employment
    Agreement dated August 1, 2018, by and between the Registrant and Paul DiPerna</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/27/2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm">Intellectual
    Property Assignment Agreement dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm">Technology
    Royalty Agreement dated as of July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878ex10-28_modular.htm">Standard
    Industrial/Commercial Agreement between the Registrant and Michael Summers dated January 5, 2023</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/24/2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm">Form
    of Indemnification Agreement between the Registrant and each of its directors and officers used from January 23, 2020</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm">Form
    of Notice of Stock Option Grant and Stock Option Agreement under the Amended 2017 Equity Incentive Plan</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm">First
    Amendment to the Employment Agreement between the Registrant and Paul DiPerna effective as of May 12, 2020</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/27/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000470/ex10_20.htm">Second
    Amendment to Employment Agreement between the Registrant and Paul DiPerna effective as of July 1, 2020</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/12/2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm"><span style="font-size: 10pt">Form
    of Convertible Promissory Note issued in the 2021 Private Placement</span></a></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 4%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905620000268/ex10_17.htm">Form
    of Common Stock Purchase Agreement dated March 2020 by and between the Registrant and the Investors named therein</a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/09/2020</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_23.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement for the 2021 Private Placement</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm"><span style="font-size: 10pt">Form
    of Registration Rights Agreement for the 2021 Private Placement</span></a></span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm">Form
    of Common Stock Purchase Warrant issued in the 2021 Private Placement</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/12/2021</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm">Promissory
    Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2021</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex10_1.htm">Warrant
    Agency Agreement between the Registrant and Colonial Stock Transfer Company, Inc., dated February 14, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2022</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex10_31.htm">Form
    of Warrant Omnibus Amendment Agreement</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/07/2022</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex10_1.htm">Form
    of Securities Purchase Agreement dated May 2, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2022</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000444/ex10_33.htm">Severance
    and Release Agreement between the Registrant and Ellen O&#8217;Connor Vos dated February 23, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/06/2022</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000518/ex10_1.htm">Offer
    Letter Agreement between the Registrant and Kevin Schmid dated July 13, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/26/2022</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span>*</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023066417/f10q0623ex4-11_modularmedi.htm">Form of Notice of Grant of Restricted Stock Unit Award and Agreement under the Amended and Restated Modular Medical, Inc. 2017 Equity Incentive Plan</a></p></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/14/2023</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex10-29_modular.htm">Form
    of Warrant Agency Agreement</a> </span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/05/2023</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_29.htm">Form
    of Common Stock Purchase Agreement dated October 28, 2021 between the Registrant and the Investors named therein</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/29/2021</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000101376223002171/ea186338ex10-1_modular.htm">Modular
    Medical, Inc. Two-Part FDA Submission and Clearance Milestone Bonus Program</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/05/2023</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24*</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1074871/000121390024031921/ea020366001ex10-1_modular.htm">Third
    Amendment to Employment Agreement between the Company and Paul DiPerna</a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/10/2024</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex21-1_modular.htm"><span style="font-size: 10pt">List
    of Subsidiaries</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex23-1_modular.htm"><span style="font-size: 10pt">Consent
    of Independent Registered Public Accounting Firm</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023"><span style="font-size: 10pt">Power
    of Attorney (see signature page of this Report)</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex31-1_modular.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex31-2_modular.htm"><span style="font-size: 10pt">Certification
    of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea020720601ex32-1_modular.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
    906 of the Sarbanes-Oxley Act of 2002</span></a></span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="ea020720601ex97-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Recovery Policy </span></a></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center">X</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Linkbase Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
                                            a management contract or compensatory plan or arrangement.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
16. Form 10-K Summary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Not applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 81; Value: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized,
on the 21<sup>st</sup> day of June, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR MEDICAL, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160; </span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James E. Besser </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer,</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>POWER
OF ATTORNEY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James E. Besser and Paul DiPerna
as her/his true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for her and him and in her
or his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file
the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorney-in- fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James
    E. Besser</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul DiPerna</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and
    Chief Financial Officer <br/>
    (Principal Financial and Accounting Officer)</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul DiPerna</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Duane
    DeSisto</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane DeSisto</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven
    Felsher</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Felsher</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Morgan
    C. Frank</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan C. Frank</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Philip
    Sheibley</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Sheibley</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Carmen
    Volkart</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmen Volkart</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ellen
    O&#8217;Connor Vos</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center">June 21, 2024</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen O&#8217;Connor Vos</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-9" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.78</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-10" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.15</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="-3" id="hidden-fact-11" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">12103000</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="-3" id="hidden-fact-12" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">22377000</ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-13" name="modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-19" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-24" name="modd:AtthemarketSalesOfStockNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-25" name="modd:AtthemarketSalesOfStockNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-35" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-36" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-37" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="modd:RightofuseAssetObtainedInExchangeForLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-39" name="modd:ReceivableFromTransferAgentForWarrantExerciseProceeds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-40" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-41" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c78" id="hidden-fact-42" name="modd:ExpirationCommonStock" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c103" id="hidden-fact-44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c103" id="hidden-fact-45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c103" id="hidden-fact-46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c103" id="hidden-fact-47" name="modd:ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-51" name="modd:ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-52" name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c97" id="hidden-fact-53" name="modd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-59" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-60" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-61" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-18131">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-18132">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-18133">0001074871</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="modd-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">modd:WBernardoDriveSanDiegoCAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">modd:ThornmintRoadSanDiegoCAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-15</xbrli:startDate>
    <xbrli:endDate>2024-02-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-13</xbrli:startDate>
    <xbrli:endDate>2024-03-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-22</xbrli:startDate>
    <xbrli:endDate>2023-11-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-24</xbrli:startDate>
    <xbrli:endDate>2024-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-15</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-15</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-15</xbrli:startDate>
    <xbrli:endDate>2023-05-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="modd:AgreementAxis">modd:UnderwritingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:UnderwritingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-25</xbrli:startDate>
    <xbrli:endDate>2023-05-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:UnderwriterMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9veu645KQijpYwzxMZ4SFwvd2i08DEcGSCO] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-02</xbrli:startDate>
    <xbrli:endDate>2022-05-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">modd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-02</xbrli:startDate>
    <xbrli:endDate>2022-05-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:IssuanceOfCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:IssuanceOfCommonStockWarrantsOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercisedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercisedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercised1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercised1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-31</xbrli:startDate>
    <xbrli:endDate>2017-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">modd:DeviceIntegrationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:ManchesterManagementCompanyLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-29</xbrli:startDate>
    <xbrli:endDate>2024-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:FounderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:FounderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea020720601ex4-1_modular.htm
<DESCRIPTION>2017 EQUITY INCENTIVE PLAN, AS AMENDED AND RESTATED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MODULAR MEDICAL, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Effective January 23, 2020, August 11, 2021,
January 17, 2023 and February 13, 2024)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Purposes of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The purposes
of this Equity Incentive Plan are to attract and retain the best available personnel, to provide additional incentive to Employees, Directors
and Consultants and to promote the success of the Company&rsquo;s business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Definitions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As used herein,
the following definitions shall apply:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) &ldquo;Administrator&rdquo;
means the Board or any Committee appointed to administer the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) &ldquo;Affiliate&rdquo;
and &ldquo;Associate&rdquo; shall have the respective meanings ascribed to such terms in Rule 12b-2 promulgated under the Exchange Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c) &ldquo;Applicable
Laws&rdquo; means the legal requirements relating to the administration of stock incentive plans, if any, under applicable provisions of
federal securities laws, state corporate and securities laws, the Code, the rules of any applicable stock exchange or national market
system, and the rules of any foreign jurisdiction applicable to Awards granted to residents therein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d) &ldquo;Award&rdquo;
means the grant of an Option, SAR, Dividend Equivalent Right, Restricted Stock, Performance Unit, Performance Share, or other right or
benefit under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e) &ldquo;Award
Agreement&rdquo; means the written agreement evidencing the grant of an Award executed by the Company and the Grantee, including any amendments
thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f) &ldquo;Board&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g) &ldquo;Cause&rdquo;
means, with respect to the termination by the Company or a Related Entity of the Grantee&rsquo;s Continuous Service, that such termination is
for &ldquo;Cause&rdquo; as such term is expressly defined in a then-effective written agreement between the Grantee and the Company or such
Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in the determination of the Administrator,
the Grantee&rsquo;s:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
refusal or failure to act in accordance with any specific, lawful direction or order of the Company or a Related Entity;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
unfitness or unavailability for service or unsatisfactory performance (other than as a result of Disability);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
performance of any act or failure to perform any act, in bad faith and to the detriment of the Company or a Related Entity;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv)
dishonesty, intentional misconduct or material breach of any agreement with the Company or a Related Entity; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(v)
commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h) &ldquo;Code&rdquo;
means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i) &ldquo;Committee&rdquo;
means any committee appointed by the Board to administer the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(j) &ldquo;Common
Stock&rdquo; means the common stock of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(k) &ldquo;Company&rdquo;
means Modular Medical, Inc., a Nevada corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(l) &ldquo;Consultant&rdquo;
means any person (other than an Employee or a Director, solely with respect to rendering services in such person&rsquo;s capacity as a Director)
who is engaged by the Company or any Related Entity to render consulting or advisory services to the Company or such Related Entity.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(m) &ldquo;Continuous
Service&rdquo; means that the provision of services to the Company or a Related Entity in any capacity of Employee, Director or Consultant,
is not interrupted or terminated. Continuous Service shall not be considered interrupted in the case of (i) any leave of absence approved
by the Company or Related Entity, (ii) transfers between locations of the Company or among the Company, any Related Entity, or any successor,
in any capacity of Employee, Director or Consultant, or (iii) any change in status as long as the individual remains in the service of
the Company or a Related Entity in any capacity of Employee, Director or Consultant (except as otherwise provided in the Award Agreement).
For purposes of Incentive Stock Options, no such approved leave of absence may exceed ninety (90) days, unless re-employment upon expiration
of such leave is guaranteed by statute or contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(n) &ldquo;Corporate
Transaction&rdquo; means any of the following transactions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is
to change the state in which the Company is incorporated;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
the sale, transfer or other disposition of all or substantially all of the assets of the Company (including the capital stock of the Company&rsquo;s
subsidiary corporations) in connection with the complete liquidation or dissolution of the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
any reverse merger in which the Company is the surviving entity but in which securities possessing more than eighty percent (80%) of the
total combined voting power of the Company&rsquo;s outstanding securities are transferred to a person or persons different from those who held
such securities immediately prior to such merger; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv) an acquisition by any person or related group
of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule
13d-3 of the Exchange Act) of securities possessing more than eighty percent (80%) of the total combined voting power of the Company&rsquo;s
outstanding securities, but excluding any such transaction that the Administrator determines shall not be a Corporate Transaction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(o) &ldquo;Director&rdquo;
means a member of the Board or the board of directors of any Related Entity.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(p) &ldquo;Disability&rdquo;
means that a Grantee is permanently unable to carry out the responsibilities and functions of the position held by the Grantee by reason
of any medically determinable physical or mental impairment. A Grantee will not be considered to have incurred a Disability unless he
or she furnishes proof of such impairment sufficient to satisfy the Administrator in its discretion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(q) &ldquo;Dividend
Equivalent Right&rdquo; means a right entitling the Grantee to compensation measured by dividends paid with respect to Common Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(r) &ldquo;Employee&rdquo;
means any person, including an Officer or Director, who is an employee of the Company or any Related Entity. The payment of a director&rsquo;s
fee by the Company or a Related Entity shall not be sufficient to constitute &ldquo;employment&rdquo; by the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(s) &ldquo;Exchange Act&rdquo;
means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(t) &ldquo;Fair Market Value&rdquo; means, as of any date, the value of Common Stock determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
Where there exists a public market for the Common Stock, the Fair Market Value shall be (A) the closing price for a Share for the last
market trading day prior to the time of the determination (or, if no closing price was reported on that date, on the last trading date
on which a closing price was reported) on the stock exchange or national market system determined by the Administrator to be the primary
market for the Common Stock, or (B) if the Common Stock is not traded on any such exchange or national market system, the average of the
closing bid and asked prices of a share on the OTC Bulletin Board or other inter-dealer quotation service for the day prior to the time
of the determination (or, if no such prices were reported on that date, on the last date on which such prices were reported), in each
case, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or (ii) in the absence of an established
market for the Common Stock of the type described in subparagraph (i), above, the Fair Market Value shall be determined by the Administrator
in good faith.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(u) &ldquo;Grantee&rdquo;
means an Employee, Director or Consultant who receives an Award pursuant to an Award Agreement under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(v) &ldquo;Incentive
Stock Option&rdquo; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(w) &ldquo;Non-Qualified
Stock Option&rdquo; means an Option not intended to qualify as an Incentive Stock Option.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(x) &ldquo;Officer&rdquo;
means a person who is an officer of the Company or a Related Entity within the meaning of Section 16 of the Exchange Act and the rules
and regulations promulgated thereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(y) &ldquo;Option&rdquo;
means an option to purchase Shares pursuant to an Award Agreement granted under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(z) &ldquo;Parent&rdquo;
means a &ldquo;parent corporation&rdquo;, whether now or hereafter existing, as defined in Section 424(e) of the Code.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(aa) &ldquo;Performance
Shares&rdquo; means Shares or an Award denominated in Shares which may be earned in whole or in part upon attainment of performance criteria
established by the Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(bb) &ldquo;Performance
Units&rdquo; means an Award which may be earned in whole or in part upon attainment of performance criteria established by the Administrator
and which may be settled for cash, Shares or other securities or a combination of cash, Shares or other securities as established by the
Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(cc) &ldquo;Plan&rdquo;
means this 2017 Equity Incentive Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(dd) &ldquo;Related
Entity&rdquo; means any Parent, Subsidiary and any business, corporation, partnership, limited liability company or other entity in which
the Company, a Parent or a Subsidiary holds a substantial ownership interest, directly or indirectly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ee) &ldquo;Restricted
Stock&rdquo; means Shares issued under the Plan to the Grantee for such consideration, if any, and subject to such restrictions on transfer,
rights of first refusal, repurchase provisions, forfeiture provisions, and other terms and conditions as established by the Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ff) &ldquo;Rule
16b-3&rdquo; means Rule 16b-3 promulgated under the Exchange Act or any successor thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(gg) &ldquo;SAR&rdquo;
means a stock appreciation right entitling the Grantee to Shares or cash compensation, as established by the Administrator, measured by
appreciation in the value of Common Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(hh) &ldquo;Share&rdquo;
means a share of the Common Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ii) &ldquo;Subsidiary&rdquo;
means a &ldquo;subsidiary corporation&rdquo;, whether now or hereafter existing, as defined in Section 424(f) of the Code.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(jj) &ldquo;Related
Entity Disposition&rdquo; means the sale, distribution or other disposition by the Company of all or substantially all of the Company&rsquo;s
interests in any Related Entity effected by a sale, merger or consolidation or other transaction involving that Related Entity or the
sale of all or substantially all of the assets of that Related Entity.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Stock Subject to the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Subject
to the provisions of Section 10, below, the maximum aggregate number of Shares which may be issued pursuant to all Awards (including Incentive
Stock Options) is 7,666,667 Shares. The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) Any Shares
covered by an Award (or portion of an Award) which is forfeited or canceled, expires or is settled in cash, shall be deemed not to have
been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the Plan. If any unissued Shares
are retained by the Company upon exercise of an Award in order to satisfy the exercise price for such Award or any withholding taxes due
with respect to such Award, such retained Shares subject to such Award shall become available for future issuance under the Plan (unless
the Plan has terminated). Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan
and shall not become available for future issuance under the Plan, except that if unvested Shares are forfeited, or repurchased by the
Company at their original purchase price, such Shares shall become available for future grant under the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. Administration of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Plan Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
Administration with Respect to Directors and Officers. With respect to grants of Awards to Directors or Employees who are also Officers
or Directors of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which
Committee shall be constituted in such a manner as to satisfy the Applicable Laws and to permit such grants and related transactions under
the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such Committee shall continue
to serve in its designated capacity until otherwise directed by the Board.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
Administration With Respect to Consultants and Other Employees. With respect to grants of Awards to Employees or Consultants who are neither
Directors nor Officers of the Company, the Plan shall be administered by (A) the Board or (B) a Committee designated by the Board, which
Committee shall be constituted in such a manner as to satisfy the Applicable Laws. Once appointed, such Committee shall continue to serve
in its designated capacity until otherwise directed by the Board. The Board may authorize one or more Officers to grant such Awards and
may limit such authority as the Board determines from time to time. Except for the power to amend the Plan as provided in Section 13 and
except for determinations regarding Employees who are subject to Section 16 of the Exchange Act or certain key Employees who are, or may
become, as determined by the Board or the Committee, subject to Section 162(m) of the Code compensation deductibility limit, and except
as may otherwise be required under applicable stock exchange rules, the Board or the Committee may delegate any or all of its duties,
powers and authority under the Plan pursuant to such conditions or limitations as the Board of the Committee may establish to any Officer
or Officers of the Company</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
Administration Errors. In the event an Award is granted in a manner inconsistent with the provisions of this subsection, such Award shall
be presumptively valid as of its grant date to the extent permitted by Applicable Laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) Powers
of the Administrator. Subject to Applicable Laws and the provisions of the Plan (including any other powers given to the Administrator
hereunder), and except as otherwise provided by the Board, the Administrator shall have the authority, in its discretion:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
to select the Employees, Directors and Consultants to whom Awards may be granted from time to time hereunder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii) to determine whether
and to what extent Awards are granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(iii) to determine the number of Shares or the amount of other consideration to be covered by each Award granted hereunder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv)
to approve forms of Award Agreements for use under the Plan;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(v) to determine the terms
and conditions of any Award granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi) to amend the terms of any outstanding Award granted under the Plan, provided that any amendment that would adversely affect the
Grantee&rsquo;s rights under an outstanding Award shall not be made without the Grantee&rsquo;s written consent;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(vii)
to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan, including without limitation, any notice of Award
or Award Agreement, granted pursuant to the Plan;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(viii)
to establish additional terms, conditions, rules or procedures to accommodate the rules or laws of applicable foreign jurisdictions and
to afford Grantees favorable treatment under such laws;&nbsp;provided, however, that no Award shall be granted under any such additional
terms, conditions, rules or procedures with terms or conditions which are inconsistent with the provisions of the Plan; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ix)
to take such other action, not inconsistent with the terms of the Plan, as the Administrator deems appropriate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c) Effect
of Administrator&rsquo;s Decision. All decisions, determinations and interpretations of the Administrator shall be conclusive and binding on
all persons.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. Eligibility. Awards other than Incentive Stock Options may be granted
to Employees, Directors and Consultants. Incentive Stock Options may be granted only to Employees of the Company, a Parent or a Subsidiary.
An Employee, Director or Consultant who has been granted an Award may, if otherwise eligible, be granted additional Awards. Awards may
be granted to Employees, Directors or Consultants who are residing in foreign jurisdictions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. Terms and Conditions of Awards.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Type of
Awards. The Administrator is authorized under the Plan to award any type of arrangement to an Employee, Director or Consultant that is
not inconsistent with the provisions of the Plan and that by its terms involves or might involve the issuance of (i) Shares, (ii) an Option,
a SAR or similar right with a fixed or variable price related to the Fair Market Value of the Shares and with an exercise or conversion
privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions,
or (iii) any other security with the value derived from the value of the Shares. Such awards include, without limitation, Options, SARs,
sales or bonuses of Restricted Stock, Dividend Equivalent Rights, Performance Units or Performance Shares, and an Award may consist of
one such security or benefit, or two (2) or more of them in any combination or alternative.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) Designation
of Award. Each Award shall be designated in the Award Agreement. In the case of an Option, the Option shall be designated as either an
Incentive Stock Option or a Non-Qualified Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair
Market Value of Shares subject to Options designated as Incentive Stock Options which become exercisable for the first time by a Grantee
during any calendar year (under all plans of the Company or any Parent or Subsidiary) exceeds $100,000, such excess Options, to the extent
of the Shares covered thereby in excess of the foregoing limitation, shall be treated as Non-Qualified Stock Options. For this purpose,
Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the Shares shall
be determined as of the date the Option with respect to such Shares is granted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c) Conditions
of Award. Subject to the terms of the Plan, the Administrator shall determine the provisions, terms, and conditions of each Award including,
but not limited to, the Award vesting schedule, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment
(cash, Shares, or other consideration) upon settlement of the Award, payment contingencies, and satisfaction of any performance criteria.
The performance criteria established by the Administrator may be based on any one of, or combination of, increase in share price, earnings
per share, total stockholder return, return on equity, return on assets, return on investment, net operating income, cash flow, revenue,
economic value added, personal management objectives, or other measure of performance selected by the Administrator. Partial achievement
of the specified criteria may result in a partial payment or vesting as specified in the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)
Acquisitions and Other Transactions. The Administrator may issue Awards under the Plan in settlement, assumption or substitution for,
outstanding awards or obligations to grant future awards in connection with the Company or a Related Entity acquiring another entity,
an interest in another entity or an additional interest in a Related Entity whether by merger, stock purchase, asset purchase or other
form of transaction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e) Deferral
of Award Payment. The Administrator may establish one or more programs under the Plan to permit selected Grantees the opportunity to elect
to defer receipt of consideration upon exercise of an Award, satisfaction of performance criteria, or other event that absent the election
would entitle the Grantee to payment or receipt of Shares or other consideration under an Award. The Administrator may establish the election
procedures, the timing of such elections, the mechanisms for payments of, and accrual of interest or other earnings, if any, on amounts,
Shares or other consideration so deferred, and such other terms, conditions, rules and procedures that the Administrator deems advisable
for the administration of any such deferral program.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f) Award
Exchange Programs. The Administrator may establish one or more programs under the Plan to permit selected Grantees to exchange an Award
under the Plan for one or more other types of Awards under the Plan on such terms and conditions as determined by the Administrator from
time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g) Separate Programs.
The Administrator may establish one or more separate programs under the Plan for the purpose of issuing particular forms of Awards to
one or more classes of Grantees on such terms and conditions as determined by the Administrator from time to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h) Early
Exercise. The Award Agreement may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director
or Consultant to exercise any part or all of the Award prior to full vesting of the Award. Any unvested Shares received pursuant to such
exercise may be subject to a repurchase right in favor of the Company or a Related Entity or to any other restriction the Administrator
determines to be appropriate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i) Term of
Award. The term of each Award shall be the term stated in the Award Agreement, provided, however, that the term of an Incentive Stock
Option shall be no more than ten (10) years from the date of grant thereof. However, in the case of an Incentive Stock Option granted
to a Grantee who, at the time the Option is granted, owns stock representing more than ten percent (10%) of the voting power of all classes
of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option shall be five (5) years from the date of grant
thereof or such shorter term as may be provided in the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(j) Transferability
of Awards. Except as otherwise provided in this Section, all Awards under the Plan shall be nontransferable and shall not be assignable,
alienable, saleable or otherwise transferable by the Grantee other than by will or the laws of descent and distribution except pursuant
to a domestic relations order entered by a court of competent jurisdiction. Notwithstanding the preceding sentence, the Board or the Committee
may provide that any Award of Non-Qualified Stock Options may be transferable by the recipient to family members or family trusts established
by the Grantee. The Board or the Committee may also provide that, in the event that a Grantee terminates employment with the Company to
assume a position with a governmental, charitable, educational or similar non-profit institution, a third party, including but not limited
to a &ldquo;blind&rdquo; trust, may be authorized by the Board or the Committee to act on behalf of and for the benefit of the respective
Grantee with respect to any outstanding Awards. Except as otherwise provided in this Section, during the life of the Grantee, Awards under
the Plan shall be exercisable only by him or her except as otherwise determined by the Board or the Committee. In addition, if so permitted
by the Board or the Committee, a Grantee may designate a beneficiary or beneficiaries to exercise the rights of the Grantee and receive
any distributions under the Plan upon the death of the Grantee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(k) Time of
Granting Awards. The date of grant of an Award shall for all purposes be the date on which the Administrator makes the determination to
grant such Award, or such other date as is determined by the Administrator. Notice of the grant determination shall be given to each Employee,
Director or Consultant to whom an Award is so granted within a reasonable time after the date of such grant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. Award Exercise or Purchase Price, Consideration, Taxes and
Reload Options.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Exercise
or Purchase Price. The exercise or purchase price, if any, for an Award shall be as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
In the case of an Incentive Stock Option: (A) granted to an Employee who, at the time of the grant of such Incentive Stock Option owns
stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary,
the per Share exercise price shall be not less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant;
or (B) granted to any Employee other than an Employee described in the preceding clause, the per Share exercise price shall be not less
than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
In the case of a Non-Qualified Stock Option, the per Share exercise price shall be not less than one hundred percent (100%) of the Fair
Market Value per Share on the date of grant unless otherwise determined by the Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
In the case of other Awards, such price as is determined by the Administrator.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv)
Notwithstanding the foregoing provisions of this Section 7(a),in the case of an Award issued pursuant to Section 6(d), above, the exercise
or purchase price for the Award shall be determined in accordance with the principles of Section 424(a) of the Code.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) Consideration.
Subject to Applicable Laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the
method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option, shall be determined at the
time of grant). In addition to any other types of consideration the Administrator may determine, the Administrator is authorized to accept
as consideration for Shares issued under the Plan the following, provided that the portion of the consideration equal to the par value
of the Shares must be paid in cash or other legal consideration permitted by the applicable laws of the jurisdiction in which the Company
is then incorporated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
cash;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
check;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
delivery of Grantee&rsquo;s promissory note with such recourse, interest, security, and redemption provisions as the Administrator determines
is appropriate;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iv)
surrender of Shares or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require including
withholding of Shares otherwise deliverable upon exercise of the Award) which have a Fair Market Value on the date of surrender or attestation
equal to the aggregate exercise price of the Shares as to which said Award shall be exercised (but only to the extent that such exercise
of the Award would not result in an accounting compensation charge with respect to the Shares used to pay the exercise price unless otherwise
determined by the Administrator);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(v)
with respect to options, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (A) shall provide
written instructions to a Company designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit
to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable
for the purchased Shares and (B) shall provide written directives to the Company to deliver the certificates for the purchased Shares
directly to such brokerage firm in order to complete the sale transaction; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(vi)
with respect to options provided there is then an established market for the Common Stock, by a &ldquo;cashless exercise&rdquo; as a result
of which the Grantee shall be entitled to receive that number of shares of Common Stock equal to the quotient of (i) the number of Options
surrendered for exercise and (ii) the difference between the Fair Market Value (determined in accordance with clause (i) of Section 2(t)
hereof) and the exercise price of the Option, in which case the number of Options surrendered for exercise shall be cancelled;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(vii)
any combination of the foregoing methods of payment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c) Taxes.
No Shares shall be delivered under the Plan to any Grantee or other person until such Grantee or other person has made arrangements acceptable
to the Administrator for the satisfaction of any foreign, federal, state, or local income and employment tax withholding obligations,
including, without limitation, obligations incident to the receipt of Shares or the disqualifying disposition of Shares received on exercise
of an Incentive Stock Option. Upon exercise of an Award, the Company shall withhold or collect from Grantee an amount sufficient to satisfy
such tax obligations.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d) Reload
Options. In the event the exercise price or tax withholding of an Option is satisfied by the Company or the Grantee&rsquo;s employer withholding
Shares otherwise deliverable to the Grantee, the Administrator may issue the Grantee an additional Option, with terms identical to the
Award Agreement under which the Option was exercised, but at an exercise price as determined by the Administrator in accordance with the
Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. Exercise of Award.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Procedure
for Exercise; Rights as a Stockholder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
Any Award granted hereunder shall be exercisable at such times and under such conditions as determined by the Administrator under the
terms of the Plan and specified in the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
An Award shall be deemed to be exercised upon the later of (x) receipt by the Company of written notice of such exercise in accordance
with the terms of the Award by the person entitled to exercise the Award and (y) full payment for the Shares with respect to which the
Award is exercised, including, to the extent selected, use of the broker-dealer sale and remittance procedure to pay the purchase price
as provided in Section 7(b)(v).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company)
of the stock certificate evidencing such Shares, no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to Shares subject to an Award, notwithstanding the exercise of an Option or other Award. The Company shall issue (or cause
to be issued) such stock certificate promptly upon exercise of the Award. No adjustment will be made for a dividend or other right for
which the record date is prior to the date the stock certificate is issued, except as provided in the Award Agreement or Section 10, below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) Exercise of Award Following Termination of Continuous Service.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)
An Award may not be exercised after the termination date of such Award set forth in the Award Agreement and may be exercised following
the termination of a Grantee&rsquo;s Continuous Service only to the extent provided in the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)
Where the Award Agreement permits a Grantee to exercise an Award following the termination of the Grantee&rsquo;s Continuous Service for a specified
period, the Award shall terminate to the extent not exercised on the last day of the specified period or the last day of the original
term of the Award, whichever occurs first.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(iii)
Any Award designated as an Incentive Stock Option to the extent not exercised within the time permitted by law for the exercise of Incentive
Stock Options following the termination of a Grantee&rsquo;s Continuous Service shall convert automatically to a Non-Qualified Stock Option
and thereafter shall be exercisable as such to the extent exercisable by its terms for the period specified in the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c) Buyout
Provisions. The Administrator may at any time offer to buy out for a payment in cash or Shares, an Award previously granted, based on
such terms and conditions as the Administrator shall establish and communicate to the Grantee at the time that such offer is made.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. Conditions Upon Issuance of Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) Shares
shall not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares
pursuant thereto shall comply with all Applicable Laws, and shall be further subject to the approval of counsel for the Company with respect
to such compliance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)
As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time
of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such
Shares if, in the opinion of counsel for the Company, such a representation is required by any Applicable Laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. Adjustments Upon Changes in Capitalization. Subject to any required
action by the stockholders of the Company, the Administrator may, in its discretion, proportionately adjust the number of Shares covered
by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have
yet been granted or which have been returned to the Plan, the exercise or purchase price of each such outstanding Award, as well as any
other terms that the Administrator determines require adjustment for (a) any increase or decrease in the number of issued Shares resulting
from a stock split, reverse stock split, stock dividend, combination or reclassification of the Shares, (b) any other increase or decrease
in the number of issued Shares effected without receipt of consideration by the Company, or (c) as the Administrator may determine in
its discretion, any other transaction with respect to Common Stock to which Section 424(a) of the Code applies; provided, however that
conversion of any convertible securities of the Company shall not be deemed to have been &ldquo;effected without receipt of consideration.&rdquo;
Such adjustment shall be made by the Administrator and its determination shall be final, binding and conclusive. Except as the Administrator
determines, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. Corporate Transactions and Related Entity Dispositions. Except
as may be provided in an Award Agreement:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) The Administrator
shall have the authority, exercisable either in advance of any actual or anticipated Corporate Transaction or Related Entity Disposition
or at the time of an actual Corporate Transaction or Related Entity Disposition and exercisable at the time of the grant of an Award under
the Plan or any time while an Award remains outstanding, to provide for the full automatic vesting and exercisability of one or more outstanding
unvested Awards under the Plan and the release from restrictions on transfer and repurchase or forfeiture rights of such Awards
in connection with a Corporate Transaction or Related Entity Disposition, on such terms and conditions as the Administrator may specify.
The Administrator also shall have the authority to condition any such Award vesting and exercisability or release from such limitations
upon the subsequent termination of the Continuous Service of the Grantee within a specified period following the effective date of the
Corporate Transaction or Related Entity Disposition. Effective upon the consummation of a Corporate Transaction or Related Entity Disposition,
all outstanding Awards under the Plan, shall remain fully exercisable until the expiration or sooner termination of the Award.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) The portion
of any Incentive Stock Option accelerated under this Section 11 in connection with a Corporate Transaction or Related Entity Disposition
shall remain exercisable as an Incentive Stock Option under the Code only to the extent the $100,000 dollar limitation of Section 422(d)
of the Code is not exceeded. To the extent such dollar limitation is exceeded, the accelerated excess portion of such Option shall be
exercisable as a Non-Qualified Stock Option.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. Effective Date and Term of Plan. The Plan shall become effective
upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company. It shall continue in effect
for a term of ten (10) years unless sooner terminated. Subject to Section 13 below, and Applicable Laws, Awards may be granted under the
Plan upon its becoming effective.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. Amendment, Suspension or Termination of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) The Board
may at any time amend, suspend or terminate the Plan. To the extent necessary to comply with Applicable Laws, the Company shall obtain
stockholder approval of any Plan amendment in such a manner and to such a degree as required.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) No Award
may be granted during any suspension of the Plan or after termination of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)
Any amendment, suspension or termination of the Plan (including termination of the Plan under Section 12, above) shall not affect Awards
already granted, and such Awards shall remain in full force and effect as if the Plan had not been amended, suspended or terminated, unless
mutually agreed otherwise between the Grantee and the Administrator, which agreement must be in writing and signed by the Grantee and
the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. Reservation of Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a) The Company,
during the term of the Plan, will at all times reserve and keep available such number of Shares as shall be sufficient to satisfy the
requirements of the Plan.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b) The inability
of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&rsquo;s counsel to
be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure
to issue or sell such Shares as to which such requisite authority shall not have been obtained.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. No Effect on Terms of Employment/Consulting Relationship. The Plan
shall not confer upon any Grantee any right with respect to the Grantee&rsquo;s Continuous Service, nor shall it interfere in any way with his
or her right or the Company&rsquo;s right to terminate the Grantee&rsquo;s Continuous Service at any time, with or without cause.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">16. Unfunded Plan. Unless otherwise determined by the Board or the
Committee, the Plan shall be unfunded and shall not create (or construed to create) a trust or a separate fund or funds. The Plan shall
not establish any fiduciary relationship between the Company and any Grantee or other person. To the extent any person holds any rights
by virtue of an Award granted under the Plan, such right (unless otherwise determined by the Board or the Committee) shall be no greater
than the right of an unsecured general creditor of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17. No Effect on Retirement and Other Benefit Plans. Except as specifically
provided in a retirement or other benefit plan of the Company or a Related Entity, Awards shall not be deemed compensation for purposes
of computing benefits or contributions under any retirement plan of the Company or a Related Entity, and shall not affect any benefits
under any other benefit plan of any kind or any benefit plan subsequently instituted under which the availability or amount of benefits
is related to level of compensation. The Plan is not a &ldquo;Retirement Plan&rdquo; or &ldquo;Welfare Plan&rdquo; under the Employee Retirement
Income Security Act of 1974, as amended.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">18. Stockholder Approval. The grant of Incentive Stock Options under
the Plan shall be subject to approval by the stockholders of the Company within twelve (12) months before or after the date the Plan is
adopted by the Board excluding Incentive Stock Options issued in substitution for outstanding Incentive Stock Options pursuant to Section
424(a) of the Code. Such stockholder approval shall be obtained in the degree and manner required under Applicable Laws. The Administrator
may grant Incentive Stock Options under the Plan prior to approval by the stockholders, but until such approval is obtained, no such Incentive
Stock Option shall be exercisable. In the event that stockholder approval is not obtained within the twelve (12) month period provided
above, all Incentive Stock Options previously granted under the Plan shall be exercisable as Non-Qualified Stock Options.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ea020720601ex21-1_modular.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBSIDIARIES OF REGISTRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JURISDICTION OF INCORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quasuras, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020720601ex23-1_modular.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We consent to the incorporation
by reference in the Registration Statements on Form S-3 (No. 333-264193) and Form S-8 (No. 333-278808), as filed with the Securities
and Exchange Commission, of our report dated June 21, 2024, with respect to the consolidated balance sheets of Modular Medical, Inc.
as of March 31, 2024 and 2023 and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for the
years then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">/s/ Farber Hass Hurley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Chatsworth, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">June 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ea020720601ex31-1_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 302 OF THE
SARBANES-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">I, James E. Besser, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1. I have reviewed this Annual Report on Form 10-K of Modular Medical, Inc. for the period ended March 31, 2024;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">3.&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">4.&nbsp;The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal controls over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal controls over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">5.&nbsp;The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</FONT></TD>
    <TD STYLE="text-align: right; width: 60%">Date: June 21, 2024</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ea020720601ex31-2_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 302 OF THE
SARBANES-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">I, Paul M. DiPerna, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 1. I have reviewed this Annual Report on Form 10-K of Modular Medical, Inc. for the period ended March 31, 2024;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">3.&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">4.&nbsp;The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal controls over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal controls over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">5.&nbsp;The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. DiPerna</FONT></TD>
    <TD STYLE="text-align: right; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. DiPerna</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, Chief Financial Officer and Treasurer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ea020720601ex32-1_modular.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION PURSUANT TO 18 U.S.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.05pt">In connection
with the Annual Report on Form 10-K of Modular Medical, Inc. (the &ldquo;Company&rdquo;) for the twelve months ended March 31, 2024, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of James E. Besser, Chief Executive
Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding: 0pt; width: 0.25in; text-align: left">1.</TD><TD STYLE="padding: 0pt; text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding: 0pt; width: 0.25in; text-align: left">2.</TD><TD STYLE="padding: 0pt; text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and the results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James E. Besser</FONT></TD>
    <TD STYLE="text-align: right; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul M.
    DiPerna</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 21, 2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul M. DiPerna</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, Chief Financial Officer
    and Treasurer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This certification accompanies this Report pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required,
be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ea020720601ex97-1_modular.htm
<DESCRIPTION>COMPENSATION RECOVERY POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 97.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Modular Medical, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation Recovery Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Purpose.</B> The purpose of this Compensation
Recovery Policy of the Company (as amended from time to time, the &ldquo;<U>Policy</U>&rdquo;), dated as of November 30, 2023 is to describe
the circumstances in which current and former Executive Officers will be required to repay or return Erroneously Awarded Compensation
to members of the Company Group. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, Exchange Act Rule 10D-1 promulgated thereunder, and the
rules and requirements of Nasdaq (such legal requirements, and rules and requirements, collectively, the &ldquo;<U>Clawback Rules</U>&rdquo;).
Each Executive Officer shall be required to sign and return to the Company the form of acknowledgment to this Policy in the form attached
hereto as <U>Exhibit A</U> pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. Administration.</B> This Policy shall be
administered by the Committee. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary,
appropriate, or advisable for the administration of this Policy, and any such determinations made by the Committee shall be in the Committee&rsquo;s
sole discretion and shall be final and binding on all affected individuals. Except as otherwise required by applicable legal requirements
or the rules and requirements of Nasdaq, any determinations of the Committee hereunder need not be uniform with respect to one or more
Executive Officers (whether current and/or former).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Definitions.</B> For purposes of this Policy,
the following capitalized terms shall have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(a) &ldquo;<U>Accounting Restatement</U>&rdquo;
shall mean an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the
securities laws, including any required accounting restatement (i) to correct an error in previously issued financial statements (a &ldquo;Big
R&rdquo; restatement) that is material to the previously issued financial statements or (ii) that would result in a material misstatement
if the error were corrected in the current period or left uncorrected in the current period (a &ldquo;little r&rdquo; restatement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(b) &ldquo;<U>Board</U>&rdquo; shall mean the
board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(c) &ldquo;<U>Clawback Eligible Incentive Compensation</U>&rdquo;
shall mean all Incentive-Based Compensation Received by any current or former Executive Officer on or after the Nasdaq Effective Date,
provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) such Incentive-Based Compensation is Received
after such individual began serving as an Executive Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) such individual served as an Executive Officer
at any time during the performance period for such Incentive-Based Compensation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) such Incentive-Based Compensation is Received
while the Company has a class of securities listed on Nasdaq; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv) such Incentive-Based Compensation is Received
during the applicable Clawback Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(d) &ldquo;<U>Clawback Period</U>&rdquo; shall
mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement
Date and any transition period (that results from a change in the Company&rsquo;s fiscal year) of less than nine months within or immediately
following those three completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(e) &ldquo;<U>Committee</U>&rdquo; shall mean
the Compensation Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(f) &ldquo;<U>Common Stock</U>&rdquo; shall mean
the common stock, par value $0.001 per share, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(g) &ldquo;<U>Company</U>&rdquo; shall mean Modular
Medical, Inc., a Nevada corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(h) &ldquo;<U>Company Group</U>&rdquo; shall mean
the Company, together with each of its direct and indirect subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(i) &ldquo;<U>Erroneously Awarded Compensation</U>&rdquo;
shall mean, with respect to any current or former Executive Officer in connection with any Accounting Restatement, the amount of Clawback
Eligible Incentive Compensation Received by such current or former Executive Officer that exceeds the amount of Clawback Eligible Incentive
Compensation that otherwise would have been Received by such current or former Executive Officer had such Clawback Eligible Incentive
Compensation been determined based on the restated amounts as reflected in connection with such Accounting Restatement, taking into account
any discretion that the Committee had applied to determine the amount of Clawback Eligible Incentive Compensation originally Received
and computed without regard to any taxes paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(j) &ldquo;<U>Exchange Act</U>&rdquo; means the
Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(k) &ldquo;<U>Executive Officer</U>&rdquo; shall
mean any officer as defined in Rule 10D-1(d) (or any successor provision thereof) under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(l) &ldquo;<U>Financial Reporting Measures</U>&rdquo;
shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s
financial statements, and any other measures that are derived wholly or in part from such measures. For purposes of this Policy, stock
price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return)
shall be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented within
the Company&rsquo;s financial statements or included in a filing with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(m) &ldquo;<U>Incentive-Based Compensation</U>&rdquo;
shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(n) &ldquo;<U>Nasdaq</U>&rdquo; shall mean the
Nasdaq Stock Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(o) &ldquo;<U>Nasdaq Effective Date</U>&rdquo;
shall mean October 2, 2023 (which is the effective date of the final Nasdaq listing standards).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(p) &ldquo;<U>Received</U>&rdquo; shall mean when
Incentive-Based Compensation is received, and Incentive-Based Compensation shall be deemed received in the Company&rsquo;s fiscal period
during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if payment or grant
of the Incentive-Based Compensation occurs after the end of that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(q) &ldquo;<U>Restatement Date</U>&rdquo; shall
mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action
if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting
Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(r) &ldquo;<U>SEC</U>&rdquo; shall mean the U.S.
Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>4.</B> <B>Recovery of Erroneously Awarded Compensation.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(a) In the event that the Company is required
to prepare an Accounting Restatement, (i) the Committee shall determine the amount of any Erroneously Awarded Compensation for each applicable
current or former Executive Officer (whether or not such individual is serving as an Executive Officer at such time) (the &ldquo;<U>Applicable
Executives</U>&rdquo;) in connection with such Accounting Restatement, and (ii) the Company will reasonably promptly require the recovery
of such Erroneously Awarded Compensation from any such Applicable Executive, and any such Applicable Executive shall surrender such Erroneously
Awarded Compensation to the Company, at such time(s), and via such method(s), as determined by the Committee in accordance with the terms
of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(b) For Incentive-Based Compensation based on
(or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical
recalculation directly from the information in the applicable Accounting Restatement, (i) such amount shall be determined by the Committee
based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the
Incentive-Based Compensation was Received, and (ii) the Company will maintain documentation of the determination of that reasonable estimate
and provide such documentation to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(c) The Committee shall determine, in its sole
discretion, the method(s) for recovering any Erroneously Awarded Compensation from any Applicable Executive, which may include one or
more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) requiring one or more cash payments to the
Company Group from such Applicable Executive, including, but not limited to, the repayment of cash Incentive-Based Compensation previously
paid by the Company Group to such Applicable Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) seeking recovery of any gain realized on
the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards previously made by the Company to such
Applicable Executive and/or, subject to applicable legal requirements, otherwise requiring the delivery to the Company of shares of Common
Stock held by such Applicable Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) withholding, reducing or eliminating future
cash compensation (including cash incentive payments), future equity awards and/or other benefits or amounts otherwise to be paid or awarded
by the Company Group to such Applicable Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv) offsetting amounts against compensation or
other amounts otherwise payable by the Company Group to any Applicable Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v) cancelling, adjusting or offsetting against
some or all outstanding vested or unvested equity awards of the Company held by such Applicable Executive; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(vi) taking any other remedial and recovery actions
with respect to such Applicable Executive permitted by applicable legal requirements and the rules and regulations of Nasdaq, as determined
by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(d) Notwithstanding anything herein to the contrary,
the Company shall not be required to recover Erroneously Awarded Compensation from any Applicable Executive pursuant to the terms of this
Policy if both (1) the Committee determines that such recovery would be impracticable and (2) any of the following conditions is met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) the direct expenses paid to a third party
to assist in enforcing the Policy would exceed the amount to be recovered, provided that, before concluding that it would be impracticable
to recover any amount of Erroneously Awarded Compensation based on expense of enforcement pursuant to this clause (i), the Company has
(x) made a reasonable attempt to recover such Erroneously Awarded Compensation, (y) documented such reasonable attempt(s) to recover,
and (z) provided such documentation to Nasdaq;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) recovery would violate home country law where
that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount
of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel,
acceptable to Nasdaq, that recovery would result in such a violation, and has provided a copy of such opinion to Nasdaq; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) recovery would likely cause an otherwise
tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements
of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. No Indemnification, Etc.</B> The Company
Group shall not (a) indemnify any current or former Executive Officer against (i) the loss of any Erroneously Awarded Compensation that
is repaid, returned or recovered pursuant to the terms of this Policy or (ii) any claims relating to the Company Group&rsquo;s enforcement
of its rights under this Policy, or (b) pay or reimburse any current or former Executive Officers for insurance premiums to recover losses
incurred under this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. Supersedure.</B> This Policy will supersede
any provisions in any agreement, plan or other arrangement applicable to any member of the Company Group and any organizational documents
of any entity that is part of Company Group that, in any such case, (a) exempt any Incentive-Based Compensation from the application of
this Policy, (b) waive or otherwise prohibit or restrict the Company Group&rsquo;s right to recover any Erroneously Awarded Compensation,
including, without limitation, in connection with exercising any right of setoff as provided herein, and/or (c) require or provide for
indemnification to the extent that such indemnification is prohibited under Section 5 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. Amendment; Termination; Interpretation.</B>
The Committee may amend or terminate this Policy at any time, subject to compliance with all applicable legal requirements and the rules
and requirements of Nasdaq. It is intended that this Policy be interpreted in a manner that is consistent with the Clawback Rules. This
Policy is separate from, and in addition to, any other compensation recovery or recoupment policy of the Company or any applicable provisions
of plans, agreements, awards or other arrangements of the Company that provide for the recoupment or recovery of compensation from Executive
Officers that is voluntarily adopted by the Company and intended to provide for discretionary recoupment beyond the scope of this Policy
and the Clawback Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8. Other Recoupment Rights; No Additional Payments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(a) Subject to <U>Section 8(b)</U> of this Policy
below, any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that
may be available to the Company Group pursuant to (i) the terms of any recoupment provisions in any employment agreement, incentive or
equity compensation plan or award or other agreement, (ii) any other legal requirements, including, but not limited to, Section 304 of
Sarbanes-Oxley Act of 2002, and (iii) any other legal rights or remedies available to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(b) Notwithstanding anything herein to the contrary,
to prevent duplicative recovery:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) to the extent that the amount of any Erroneously
Awarded Compensation is recovered from any current or former Executive Officers under this Policy, the Company will not be entitled to
recover any such amounts under any other compensation recovery or recoupment policy of the Company or any applicable provisions of plans,
agreements, awards or other arrangements of the Company that provide for the recoupment or recovery of compensation from Executive Officers;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) to the extent that any Erroneously Awarded
Compensation includes any amounts that have been actually reimbursed to the Company Group from any Applicable Executive pursuant to Section
304 of the Sarbanes-Oxley Act (any such amounts that have been reimbursed to the Company Group, the &ldquo;<U>Applicable SOX Recoupment
Amount</U>&rdquo;), the amount of any Erroneously Awarded Compensation to be recovered from any such Applicable Executive shall be reduced
by the Applicable SOX Recoupment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. Successors.</B> This Policy shall be binding
and enforceable against all current and former Executive Officers and their beneficiaries, heirs, executors, administrators or other legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Acknowledgement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By signing below, the undersigned acknowledges and confirms that the
undersigned has received and reviewed a copy of the Modular Medical, Inc. Compensation Recovery Policy (such policy, as amended from time
to time, the &ldquo;Policy&rdquo;). Capitalized terms used but not otherwise defined in this acknowledgement shall have the meanings ascribed
to such terms in the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By signing this acknowledgement, the undersigned
acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during
and after the undersigned&rsquo;s employment with the Company Group. Further, by signing below, the undersigned agrees to abide by the
terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation to the Company group to the extent
required by the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Dated:&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">5</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>modd-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:12 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.modularmedicalinc.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:modd="http://www.modularmedicalinc.com/20240331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="modd-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet" id="modd_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals" id="modd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement" id="modd_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals" id="modd_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>995304 - Statement - Consolidated Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3" id="modd_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow" id="modd_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies" id="modd_r_TheCompanyandSummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail" id="modd_r_ConsolidatedBalanceSheetDetail">
        <link:definition>995308 - Disclosure - Consolidated Balance Sheet Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/Leases" id="modd_r_Leases">
        <link:definition>995309 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity" id="modd_r_StockholdersEquity">
        <link:definition>995310 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation" id="modd_r_StockBasedCompensation">
        <link:definition>995311 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/Incometaxes" id="modd_r_Incometaxes">
        <link:definition>995312 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement" id="modd_r_RoyaltyAgreement">
        <link:definition>995313 - Disclosure - Royalty Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies" id="modd_r_CommitmentsandContingencies">
        <link:definition>995314 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions" id="modd_r_RelatedPartyTransactions">
        <link:definition>995315 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy" id="modd_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables" id="modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables" id="modd_r_ConsolidatedBalanceSheetDetailTables">
        <link:definition>996002 - Disclosure - Consolidated Balance Sheet Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/LeasesTables" id="modd_r_LeasesTables">
        <link:definition>996003 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables" id="modd_r_StockholdersEquityTables">
        <link:definition>996004 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables" id="modd_r_StockBasedCompensationTables">
        <link:definition>996005 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/IncometaxesTables" id="modd_r_IncometaxesTables">
        <link:definition>996006 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails" id="modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable" id="modd_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996008 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable" id="modd_r_ScheduleofPrepaidandOtherCurrentAssetsTable">
        <link:definition>996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable" id="modd_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996010 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable" id="modd_r_ScheduleofAccruedExpensesTable">
        <link:definition>996011 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/LeasesDetails" id="modd_r_LeasesDetails">
        <link:definition>996012 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" id="modd_r_ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable">
        <link:definition>996013 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails" id="modd_r_StockholdersEquityDetails">
        <link:definition>996014 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9veXuFy6FYPiXb74ExmSIVoRU89GPM+zWHd] CSR-->
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable" id="modd_r_ScheduleofWarrantsOutstandingTable">
        <link:definition>996015 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Warrants Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails" id="modd_r_StockBasedCompensationDetails">
        <link:definition>996016 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable" id="modd_r_ScheduleofAssumptionswereusedintheFairValueMethodTable">
        <link:definition>996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable" id="modd_r_ScheduleofSummarizestheActivityintheSharesTable">
        <link:definition>996018 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable" id="modd_r_ScheduleofRSUActivityunderthePlanTable">
        <link:definition>996019 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable" id="modd_r_ScheduleofOutstandingandExercisableOptionsTable">
        <link:definition>996020 - Disclosure - Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/IncometaxesDetails" id="modd_r_IncometaxesDetails">
        <link:definition>996021 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable" id="modd_r_ScheduleofIncomeTaxProvisionTable">
        <link:definition>996022 - Disclosure - Income taxes (Details) - Schedule of Income Tax Provision</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable" id="modd_r_ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable">
        <link:definition>996023 - Disclosure - Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" id="modd_r_ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996024 - Disclosure - Income taxes (Details) - Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails" id="modd_r_CommitmentsandContingenciesDetails">
        <link:definition>996025 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails" id="modd_r_RelatedPartyTransactionsDetails">
        <link:definition>996026 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract"/>
  <xs:element name="ScheduleOfSummarizesTheActivityInTheSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract"/>
  <xs:element name="ScheduleOfOutstandingAndExercisableOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfOutstandingAndExercisableOptionsAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfIncomeTaxProvisionAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
  <xs:element name="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnlabeledAbstract8"/>
  <xs:element name="CashPaidForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CashPaidForAbstract"/>
  <xs:element name="PrepaidAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PrepaidAndOtherCurrentAssetsAbstract"/>
  <xs:element name="PropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PropertyAndEquipmentNetAbstract"/>
  <xs:element name="AccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_AccruedExpensesAbstract"/>
  <xs:element name="CurrentPortionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CurrentPortionAbstract"/>
  <xs:element name="DeferredPortionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DeferredPortionAbstract"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet"/>
  <xs:element name="IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet"/>
  <xs:element name="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts"/>
  <xs:element name="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares"/>
  <xs:element name="AtthemarketSalesOfStockNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_AtthemarketSalesOfStockNet"/>
  <xs:element name="IncreaseDecreaseLeaseRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_IncreaseDecreaseLeaseRightofuseAsset"/>
  <xs:element name="RightofuseAssetObtainedInExchangeForLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_RightofuseAssetObtainedInExchangeForLeaseLiability"/>
  <xs:element name="ReceivableFromTransferAgentForWarrantExerciseProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="RisksAndUncertaintiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RisksAndUncertaintiesPolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="NumberOfSharesIssuanceOfCommonStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_NumberOfSharesIssuanceOfCommonStockWarrants"/>
  <xs:element name="ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare"/>
  <xs:element name="ExpirationIssuanceOfCommonStockWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExpirationIssuanceOfCommonStockWarrants"/>
  <xs:element name="NumberOfSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_NumberOfSharesCommonStockWarrantsExercised"/>
  <xs:element name="ExercisePricesCommonStockWarrantsExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="modd_ExercisePricesCommonStockWarrantsExercised"/>
  <xs:element name="ExpirationCommonStock" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ExpirationCommonStock"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards"/>
  <xs:element name="ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate"/>
  <xs:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense"/>
  <xs:element name="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_LeasesDetailsTable"/>
  <xs:element name="OperatingLeaseExpiredTerm" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OperatingLeaseExpiredTerm"/>
  <xs:element name="PercentageOfAnnualRentIncreases" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="modd_PercentageOfAnnualRentIncreases"/>
  <xs:element name="AgreementDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_AgreementDomainDomain"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockholdersEquityDetailsTable"/>
  <xs:element name="CashFee" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CashFee"/>
  <xs:element name="compensationServicesEqual" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_compensationServicesEqual"/>
  <xs:element name="PaymentOfUnderwriterPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="modd_PaymentOfUnderwriterPercentage"/>
  <xs:element name="WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_WarrantsToPurchaseSharesOfCommonStock"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PurchasePricePerShare"/>
  <xs:element name="PreFundedWarrant" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="modd_PreFundedWarrant"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_StockBasedCompensationDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2"/>
  <xs:element name="IncometaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_IncometaxesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="modd_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="OutstandingSharesOfCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_OutstandingSharesOfCommonStock"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="modd_AggregateGrossProceeds"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="modd_AgreementAxis"/>
  <xs:element name="CommonStockOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockOneMember"/>
  <xs:element name="CommonStockThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockThreeMember"/>
  <xs:element name="CommonStockTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockTwoMember"/>
  <xs:element name="CommonStockWarrantsExercised1Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockWarrantsExercised1Member"/>
  <xs:element name="CommonStockWarrantsExercisedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_CommonStockWarrantsExercisedMember"/>
  <xs:element name="DeviceIntegrationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DeviceIntegrationAgreementMember"/>
  <xs:element name="EightPointSixOneToSeventeenPointSevenZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_EightPointSixOneToSeventeenPointSevenZeroMember"/>
  <xs:element name="FounderMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_FounderMember"/>
  <xs:element name="IssuanceOfCommonStockWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IssuanceOfCommonStockWarrantsMember"/>
  <xs:element name="IssuanceOfCommonStockWarrantsOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_IssuanceOfCommonStockWarrantsOneMember"/>
  <xs:element name="ManchesterManagementCompanyLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ManchesterManagementCompanyLLCMember"/>
  <xs:element name="NonemployeeDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_NonemployeeDirectorsMember"/>
  <xs:element name="PrivatePlacementWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_PrivatePlacementWarrantsMember"/>
  <xs:element name="ThornmintRoadSanDiegoCAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ThornmintRoadSanDiegoCAMember"/>
  <xs:element name="ThreePointNineFiveToSeveenPointFiveOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ThreePointNineFiveToSeveenPointFiveOneMember"/>
  <xs:element name="TwoThousandAndSeventeenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
  <xs:element name="UnderwriterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnderwriterMember"/>
  <xs:element name="UnderwritingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_UnderwritingAgreementMember"/>
  <xs:element name="WBernardoDriveSanDiegoCAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_WBernardoDriveSanDiegoCAMember"/>
  <xs:element name="ZeroPointNineThreeToSeventeenPointSevenZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember"/>
  <xs:element name="ZeroPointNineThreeToTwoPointZeroZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ZeroPointNineThreeToTwoPointZeroZeroMember"/>
  <xs:element name="RoyaltyAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_RoyaltyAgreementAbstract"/>
  <xs:element name="ScheduleOfOutstandingAndExercisableOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems"/>
  <xs:element name="StockholdersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_StockholdersEquityLineItems"/>
  <xs:element name="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="modd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>modd-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofAccruedExpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="4" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9ve3NoogSGO7zoEUfvmlmnXIkdyn8vFaeHa] CSR-->
    <loc xlink:type="locator" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:href="modd-20240331.xsd#modd_IncreaseDecreaseLeaseRightofuseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="modd_IncreaseDecreaseLeaseRightofuseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:href="modd-20240331.xsd#modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>modd-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ShareholdersEquityType2or3" roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPolicies" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheetDetail" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_Leases" roleURI="http://www.modularmedicalinc.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquity" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensation" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_Incometaxes" roleURI="http://www.modularmedicalinc.com/role/Incometaxes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RoyaltyAgreement" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_CommitmentsandContingencies" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RelatedPartyTransactions" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_AccountingPoliciesByPolicy" roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheetDetailTables" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_LeasesTables" roleURI="http://www.modularmedicalinc.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquityTables" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensationTables" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_IncometaxesTables" roleURI="http://www.modularmedicalinc.com/role/IncometaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofAccruedExpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofWarrantsOutstandingTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofAssumptionswereusedintheFairValueMethodTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofSummarizestheActivityintheSharesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofRSUActivityunderthePlanTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofOutstandingandExercisableOptionsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_LeasesDetails" roleURI="http://www.modularmedicalinc.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquityDetails" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensationDetails" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_IncometaxesDetails" roleURI="http://www.modularmedicalinc.com/role/IncometaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_CommitmentsandContingenciesDetails" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RelatedPartyTransactionsDetails" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_AssetsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AtthemarketSalesOfStockNet" xlink:href="modd-20240331.xsd#modd_AtthemarketSalesOfStockNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="modd_AtthemarketSalesOfStockNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:href="modd-20240331.xsd#modd_IncreaseDecreaseLeaseRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="modd_IncreaseDecreaseLeaseRightofuseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:href="modd-20240331.xsd#modd_RightofuseAssetObtainedInExchangeForLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:href="modd-20240331.xsd#modd_ReceivableFromTransferAgentForWarrantExerciseProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CashPaidForAbstract" xlink:href="modd-20240331.xsd#modd_CashPaidForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="modd_CashPaidForAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/Incometaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementAbstract" xlink:href="modd-20240331.xsd#modd_RoyaltyAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_RoyaltyAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/IncometaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:href="modd-20240331.xsd#modd_PrepaidAndOtherCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="modd_PrepaidAndOtherCurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PropertyAndEquipmentNetAbstract" xlink:href="modd-20240331.xsd#modd_PropertyAndEquipmentNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="modd_PropertyAndEquipmentNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockWarrantsMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_IssuanceOfCommonStockWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockWarrantsOneMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_IssuanceOfCommonStockWarrantsOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsExercisedMember" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercisedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_CommonStockWarrantsExercisedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsExercised1Member" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercised1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_CommonStockWarrantsExercised1Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockOneMember" xlink:href="modd-20240331.xsd#modd_CommonStockOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_CommonStockOneMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockTwoMember" xlink:href="modd-20240331.xsd#modd_CommonStockTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_CommonStockTwoMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockThreeMember" xlink:href="modd-20240331.xsd#modd_CommonStockThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="modd_CommonStockThreeMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationCommonStock" xlink:href="modd-20240331.xsd#modd_ExpirationCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExpirationCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfSharesIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_NumberOfSharesIssuanceOfCommonStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_NumberOfSharesIssuanceOfCommonStockWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:href="modd-20240331.xsd#modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_ExpirationIssuanceOfCommonStockWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExpirationIssuanceOfCommonStockWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfSharesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_NumberOfSharesCommonStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_NumberOfSharesCommonStockWarrantsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_ExercisePricesCommonStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="modd_ExercisePricesCommonStockWarrantsExercised" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9vex0B97nt97gtyUwa1rdMEH+IgswDztcGQ] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:href="modd-20240331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ZeroPointNineThreeToTwoPointZeroZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToTwoPointZeroZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_ZeroPointNineThreeToTwoPointZeroZeroMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ThreePointNineFiveToSeveenPointFiveOneMember" xlink:href="modd-20240331.xsd#modd_ThreePointNineFiveToSeveenPointFiveOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_ThreePointNineFiveToSeveenPointFiveOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_EightPointSixOneToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_EightPointSixOneToSeventeenPointSevenZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_EightPointSixOneToSeventeenPointSevenZeroMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfIncomeTaxProvisionAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_CurrentPortionAbstract" xlink:href="modd-20240331.xsd#modd_CurrentPortionAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="modd_CurrentPortionAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_CurrentPortionAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredPortionAbstract" xlink:href="modd-20240331.xsd#modd_DeferredPortionAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="modd_DeferredPortionAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_DeferredPortionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
    <loc xlink:type="locator" xlink:label="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:href="modd-20240331.xsd#modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:href="modd-20240331.xsd#modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="modd-20240331.xsd#modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20240331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RestatementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_LeasesDetailsTable" xlink:href="modd-20240331.xsd#modd_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="modd_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_LeasesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_WBernardoDriveSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_WBernardoDriveSanDiegoCAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="modd_WBernardoDriveSanDiegoCAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ThornmintRoadSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_ThornmintRoadSanDiegoCAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="modd_ThornmintRoadSanDiegoCAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OperatingLeaseExpiredTerm" xlink:href="modd-20240331.xsd#modd_OperatingLeaseExpiredTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="modd_OperatingLeaseExpiredTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfAnnualRentIncreases" xlink:href="modd-20240331.xsd#modd_PercentageOfAnnualRentIncreases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="modd_PercentageOfAnnualRentIncreases" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="modd_StockholdersEquityLineItems" xlink:href="modd-20240331.xsd#modd_StockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockholdersEquityDetailsTable" xlink:href="modd-20240331.xsd#modd_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AgreementAxis" xlink:href="modd-20240331.xsd#modd_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="modd_AgreementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AgreementDomainDomain" xlink:href="modd-20240331.xsd#modd_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="modd_AgreementAxis" xlink:to="modd_AgreementDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AgreementDomainDomain_0" xlink:href="modd-20240331.xsd#modd_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="modd_AgreementAxis" xlink:to="modd_AgreementDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwritingAgreementMember" xlink:href="modd-20240331.xsd#modd_UnderwritingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="modd_UnderwritingAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwriterMember" xlink:href="modd-20240331.xsd#modd_UnderwriterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="modd_UnderwriterMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PrivatePlacementWarrantsMember" xlink:href="modd-20240331.xsd#modd_PrivatePlacementWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="modd_PrivatePlacementWarrantsMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_AgreementDomainDomain" xlink:to="modd_UnderwritingAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_CashFee" xlink:href="modd-20240331.xsd#modd_CashFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_CashFee" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_OtherExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_compensationServicesEqual" xlink:href="modd-20240331.xsd#modd_compensationServicesEqual"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_compensationServicesEqual" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PaymentOfUnderwriterPercentage" xlink:href="modd-20240331.xsd#modd_PaymentOfUnderwriterPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_PaymentOfUnderwriterPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_WarrantsToPurchaseSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_WarrantsToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_WarrantsToPurchaseSharesOfCommonStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PurchasePricePerShare" xlink:href="modd-20240331.xsd#modd_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_PurchasePricePerShare" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_PreFundedWarrant" xlink:href="modd-20240331.xsd#modd_PreFundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_PreFundedWarrant" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="modd_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:href="modd-20240331.xsd#modd_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="modd_TwoThousandAndSeventeenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_NonemployeeDirectorsMember" xlink:href="modd-20240331.xsd#modd_NonemployeeDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="modd_NonemployeeDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="modd-20240331.xsd#modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/IncometaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_IncometaxesDetailsTable" xlink:href="modd-20240331.xsd#modd_IncometaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="modd_IncometaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_CommitmentsandContingenciesDetailsTable" xlink:href="modd-20240331.xsd#modd_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="modd_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_DeviceIntegrationAgreementMember" xlink:href="modd-20240331.xsd#modd_DeviceIntegrationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="modd_DeviceIntegrationAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsTable" xlink:href="modd-20240331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="modd_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_FounderMember" xlink:href="modd-20240331.xsd#modd_FounderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="modd_FounderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_ManchesterManagementCompanyLLCMember" xlink:href="modd-20240331.xsd#modd_ManchesterManagementCompanyLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="modd_ManchesterManagementCompanyLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_OutstandingSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_OutstandingSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="modd_OutstandingSharesOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateGrossProceeds" xlink:href="modd-20240331.xsd#modd_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="modd_AggregateGrossProceeds" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesAndWages" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.modularmedicalinc.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>modd-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheet Detail [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Schedule of Prepaid and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Shares, balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Number of Shares, balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Number of Shares, Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, Begining Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Shares Available for Grant, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Begining Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Begining Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule of RSU Activity Under the Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Balance Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Balance Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant- Date Fair Value, Balance Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant- Date Fair Value, Balance Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes - Open [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfIncomeTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfIncomeTaxProvisionAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="modd_ScheduleOfIncomeTaxProvisionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RoyaltyAgreementAbstract" xlink:href="modd-20240331.xsd#modd_RoyaltyAgreementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementAbstract_lbl" xml:lang="en-US">Royalty Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementAbstract" xlink:to="modd_RoyaltyAgreementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract" xlink:to="modd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract0" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract0" xlink:to="modd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract1" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract1" xlink:to="modd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract2" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract2" xlink:to="modd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, 100,000 and 50,000 shares authorized as of March 31, 2024 and 2023, respectively; 32,464 and 10,949 shares issued and outstanding as of March 31, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract3" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract3" xlink:to="modd_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract4" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract4" xlink:to="modd_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Shares used in computing net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic shares used in computing net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted shares used in computing net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl" xml:lang="en-US">Issuance of common stock in registered direct offering, net of fees and issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:to="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl" xml:lang="en-US">Issuance of common stock in registered direct offering, net of fees and issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:to="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuances under equity incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuances under equity incentive plan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US">Issuance of common stock in public offerings, net of fees and issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl" xml:lang="en-US">Issuance of common stock in public offerings, net of fees and issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AtthemarketSalesOfStockNet" xlink:href="modd-20240331.xsd#modd_AtthemarketSalesOfStockNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AtthemarketSalesOfStockNet_lbl" xml:lang="en-US">At-the-market sales of stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AtthemarketSalesOfStockNet" xlink:to="modd_AtthemarketSalesOfStockNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">At-the-market sales of stock, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Stock options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:href="modd-20240331.xsd#modd_IncreaseDecreaseLeaseRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl" xml:lang="en-US">Lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:to="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Change in lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract5" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract5" xlink:to="modd_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract6" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract6" xlink:to="modd_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from at-the-market sales of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from public and registered direct offerings, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract7" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract7" xlink:to="modd_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnlabeledAbstract8" xlink:href="modd-20240331.xsd#modd_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract8" xlink:to="modd_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:href="modd-20240331.xsd#modd_RightofuseAssetObtainedInExchangeForLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:to="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:href="modd-20240331.xsd#modd_ReceivableFromTransferAgentForWarrantExerciseProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl" xml:lang="en-US">Receivable from transfer agent for warrant exercise proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:to="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CashPaidForAbstract" xlink:href="modd-20240331.xsd#modd_CashPaidForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidForAbstract" xlink:to="modd_CashPaidForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on asset disposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:href="modd-20240331.xsd#modd_PrepaidAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PrepaidAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid and other current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="modd_PrepaidAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivable from transfer agent for warrant exercise proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PropertyAndEquipmentNetAbstract" xlink:href="modd-20240331.xsd#modd_PropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and equipment, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PropertyAndEquipmentNetAbstract" xlink:to="modd_PropertyAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AccruedExpensesAbstract" xlink:href="modd-20240331.xsd#modd_AccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AccruedExpensesAbstract_lbl" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedExpensesAbstract" xlink:to="modd_AccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under the Facility Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfSharesIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_NumberOfSharesIssuanceOfCommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl" xml:lang="en-US">Number of Shares, Issuance of common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesIssuanceOfCommonStockWarrants" xlink:to="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:href="modd-20240331.xsd#modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl" xml:lang="en-US">Exercise Prices, Issuance of common stock warrants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:to="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_ExpirationIssuanceOfCommonStockWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExpirationIssuanceOfCommonStockWarrants_lbl" xml:lang="en-US">Expiration Dates, Issuance of common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationIssuanceOfCommonStockWarrants" xlink:to="modd_ExpirationIssuanceOfCommonStockWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_NumberOfSharesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_NumberOfSharesCommonStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_NumberOfSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US">Number of Shares, Common stock warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesCommonStockWarrantsExercised" xlink:to="modd_NumberOfSharesCommonStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ExercisePricesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_ExercisePricesCommonStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExercisePricesCommonStockWarrantsExercised_lbl" xml:lang="en-US">Exercise Prices, Common stock warrants exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesCommonStockWarrantsExercised" xlink:to="modd_ExercisePricesCommonStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Prices, Common stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ExpirationCommonStock" xlink:href="modd-20240331.xsd#modd_ExpirationCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ExpirationCommonStock_lbl" xml:lang="en-US">Expiration Dates, Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationCommonStock" xlink:to="modd_ExpirationCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions were used in the Fair-Value Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Summarizes the Activity in the Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl" xml:lang="en-US">Shares Available for Grant, Additional shares authorized under the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Number of Shares, Additional shares authorized under the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Additional shares authorized under the Plan (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Fair value of stock options granted price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl" xml:lang="en-US">Shares Available for Grant, Share awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of Shares, Share awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Share awards (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, Options cancelled and returned to the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, RSUs granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU Activity under the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant- Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant- Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining	Contractual Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CurrentPortionAbstract" xlink:href="modd-20240331.xsd#modd_CurrentPortionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CurrentPortionAbstract_lbl" xml:lang="en-US">Current portion:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CurrentPortionAbstract" xlink:to="modd_CurrentPortionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredPortionAbstract" xlink:href="modd-20240331.xsd#modd_DeferredPortionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_DeferredPortionAbstract_lbl" xml:lang="en-US">Deferred portion:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredPortionAbstract" xlink:to="modd_DeferredPortionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:href="modd-20240331.xsd#modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Capitalized research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:to="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Reserves, accruals and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Options cancelled and returned to the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:href="modd-20240331.xsd#modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:to="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl" xml:lang="en-US">Section 179 assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Options to purchase common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested restricted stock units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Common stock purchase warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment and software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction-in-process [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockWarrantsMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IssuanceOfCommonStockWarrantsMember_lbl" xml:lang="en-US">Issuance of Common Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockWarrantsMember" xlink:to="modd_IssuanceOfCommonStockWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_IssuanceOfCommonStockWarrantsOneMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_IssuanceOfCommonStockWarrantsOneMember_lbl" xml:lang="en-US">Issuance of Common Stock Warrants One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockWarrantsOneMember" xlink:to="modd_IssuanceOfCommonStockWarrantsOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsExercisedMember" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercisedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockWarrantsExercisedMember_lbl" xml:lang="en-US">Common Stock Warrants Exercised [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsExercisedMember" xlink:to="modd_CommonStockWarrantsExercisedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockWarrantsExercised1Member" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercised1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockWarrantsExercised1Member_lbl" xml:lang="en-US">Common Stock Warrants Exercised 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsExercised1Member" xlink:to="modd_CommonStockWarrantsExercised1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockOneMember" xlink:href="modd-20240331.xsd#modd_CommonStockOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockOneMember_lbl" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockOneMember" xlink:to="modd_CommonStockOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockTwoMember" xlink:href="modd-20240331.xsd#modd_CommonStockTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockTwoMember_lbl" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockTwoMember" xlink:to="modd_CommonStockTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommonStockThreeMember" xlink:href="modd-20240331.xsd#modd_CommonStockThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CommonStockThreeMember_lbl" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockThreeMember" xlink:to="modd_CommonStockThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ZeroPointNineThreeToTwoPointZeroZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToTwoPointZeroZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ZeroPointNineThreeToTwoPointZeroZeroMember_lbl" xml:lang="en-US">$0.93 - $2.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ZeroPointNineThreeToTwoPointZeroZeroMember" xlink:to="modd_ZeroPointNineThreeToTwoPointZeroZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ThreePointNineFiveToSeveenPointFiveOneMember" xlink:href="modd-20240331.xsd#modd_ThreePointNineFiveToSeveenPointFiveOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ThreePointNineFiveToSeveenPointFiveOneMember_lbl" xml:lang="en-US">$3.95 - $7.51 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ThreePointNineFiveToSeveenPointFiveOneMember" xlink:to="modd_ThreePointNineFiveToSeveenPointFiveOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_EightPointSixOneToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_EightPointSixOneToSeventeenPointSevenZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_EightPointSixOneToSeventeenPointSevenZeroMember_lbl" xml:lang="en-US">8.61 - $17.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EightPointSixOneToSeventeenPointSevenZeroMember" xlink:to="modd_EightPointSixOneToSeventeenPointSevenZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember_lbl" xml:lang="en-US">0.93 - $17.70 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember" xlink:to="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AgreementAxis" xlink:href="modd-20240331.xsd#modd_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AgreementAxis" xlink:to="modd_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US">Measurement Basis [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xml:lang="en-US">Federal deposit insurance corporation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Weighted average share outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OperatingLeaseExpiredTerm" xlink:href="modd-20240331.xsd#modd_OperatingLeaseExpiredTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OperatingLeaseExpiredTerm_lbl" xml:lang="en-US">Operating lease expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseExpiredTerm" xlink:to="modd_OperatingLeaseExpiredTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PercentageOfAnnualRentIncreases" xlink:href="modd-20240331.xsd#modd_PercentageOfAnnualRentIncreases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PercentageOfAnnualRentIncreases_lbl" xml:lang="en-US">Annual rent increases percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRentIncreases" xlink:to="modd_PercentageOfAnnualRentIncreases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Obtained a right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Purchase up additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Public offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CashFee" xlink:href="modd-20240331.xsd#modd_CashFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_CashFee_lbl" xml:lang="en-US">Cash fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashFee" xlink:to="modd_CashFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Pocket expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_compensationServicesEqual" xlink:href="modd-20240331.xsd#modd_compensationServicesEqual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_compensationServicesEqual_lbl" xml:lang="en-US">Compensation services equal percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_compensationServicesEqual" xlink:to="modd_compensationServicesEqual_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PaymentOfUnderwriterPercentage" xlink:href="modd-20240331.xsd#modd_PaymentOfUnderwriterPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PaymentOfUnderwriterPercentage_lbl" xml:lang="en-US">Paid cash fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PaymentOfUnderwriterPercentage" xlink:to="modd_PaymentOfUnderwriterPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_WarrantsToPurchaseSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_WarrantsToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_WarrantsToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Underwriter common stock purchase warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsToPurchaseSharesOfCommonStock" xlink:to="modd_WarrantsToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl" xml:lang="en-US">Underwriter agents shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PurchasePricePerShare" xlink:href="modd-20240331.xsd#modd_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PreFundedWarrant" xlink:href="modd-20240331.xsd#modd_PreFundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PreFundedWarrant_lbl" xml:lang="en-US">Pre funded warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PreFundedWarrant" xlink:to="modd_PreFundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Shares approved under equity incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl" xml:lang="en-US">Unamortized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="modd-20240331.xsd#modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Expense recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted options to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Total intrinsic value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Net operating loss carryforwards federal income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards state income tax</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9veFRR1+siMy//jgFOpMy7dmZvNVjXezwE4] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xml:lang="en-US">Federal research and development tax credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">State research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_OutstandingSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_OutstandingSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_OutstandingSharesOfCommonStock_lbl" xml:lang="en-US">Company&#8217;s outstanding shares of common stock percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OutstandingSharesOfCommonStock" xlink:to="modd_OutstandingSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AggregateGrossProceeds" xlink:href="modd-20240331.xsd#modd_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Company paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per-Share Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_WBernardoDriveSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_WBernardoDriveSanDiegoCAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_WBernardoDriveSanDiegoCAMember_lbl" xml:lang="en-US">W. Bernardo Drive, San Diego, CA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WBernardoDriveSanDiegoCAMember" xlink:to="modd_WBernardoDriveSanDiegoCAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ThornmintRoadSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_ThornmintRoadSanDiegoCAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ThornmintRoadSanDiegoCAMember_lbl" xml:lang="en-US">Thornmint Road, San Diego, CA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ThornmintRoadSanDiegoCAMember" xlink:to="modd_ThornmintRoadSanDiegoCAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwritingAgreementMember" xlink:href="modd-20240331.xsd#modd_UnderwritingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwritingAgreementMember" xlink:to="modd_UnderwritingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_UnderwriterMember" xlink:href="modd-20240331.xsd#modd_UnderwriterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwriterMember" xlink:to="modd_UnderwriterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_PrivatePlacementWarrantsMember" xlink:href="modd-20240331.xsd#modd_PrivatePlacementWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PrivatePlacementWarrantsMember" xlink:to="modd_PrivatePlacementWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:href="modd-20240331.xsd#modd_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="modd_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl0" xml:lang="en-US">Stock-Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_NonemployeeDirectorsMember" xlink:href="modd-20240331.xsd#modd_NonemployeeDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_NonemployeeDirectorsMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NonemployeeDirectorsMember" xlink:to="modd_NonemployeeDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_DeviceIntegrationAgreementMember" xlink:href="modd-20240331.xsd#modd_DeviceIntegrationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_DeviceIntegrationAgreementMember_lbl" xml:lang="en-US">Device Integration Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeviceIntegrationAgreementMember" xlink:to="modd_DeviceIntegrationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ManchesterManagementCompanyLLCMember" xlink:href="modd-20240331.xsd#modd_ManchesterManagementCompanyLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_ManchesterManagementCompanyLLCMember_lbl" xml:lang="en-US">Manchester Management Company LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ManchesterManagementCompanyLLCMember" xlink:to="modd_ManchesterManagementCompanyLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_FounderMember" xlink:href="modd-20240331.xsd#modd_FounderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="modd_FounderMember_lbl" xml:lang="en-US">Founder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FounderMember" xlink:to="modd_FounderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrants Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:to="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems_lbl" xml:lang="en-US">Schedule of Assumptions were used in the Fair-Value Method [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:to="modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Summarizes the Activity in the Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:href="modd-20240331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="modd_ScheduleOfOutstandingAndExercisableOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20240331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="modd-20240331.xsd#modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_LeasesDetailsTable" xlink:href="modd-20240331.xsd#modd_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LeasesDetailsTable" xlink:to="modd_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_AgreementDomainDomain" xlink:href="modd-20240331.xsd#modd_AgreementDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AgreementDomainDomain_lbl" xml:lang="en-US">AgreementDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AgreementDomainDomain" xlink:to="modd_AgreementDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US">Fair Value Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockholdersEquityDetailsTable" xlink:href="modd-20240331.xsd#modd_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockholdersEquityDetailsTable" xlink:to="modd_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockholdersEquityLineItems" xlink:href="modd-20240331.xsd#modd_StockholdersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockholdersEquityLineItems" xlink:to="modd_StockholdersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_StockBasedCompensationDetailsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockBasedCompensationDetailsTable" xlink:to="modd_StockBasedCompensationDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl0" xml:lang="en-US">Stock-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_IncometaxesDetailsTable" xlink:href="modd-20240331.xsd#modd_IncometaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncometaxesDetailsTable_lbl" xml:lang="en-US">Income taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncometaxesDetailsTable" xlink:to="modd_IncometaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeLineItems_lbl" xml:lang="en-US">Income taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_DeferredIncomeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_CommitmentsandContingenciesDetailsTable" xlink:href="modd-20240331.xsd#modd_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommitmentsandContingenciesDetailsTable" xlink:to="modd_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="modd_RelatedPartyTransactionsDetailsTable" xlink:href="modd-20240331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RelatedPartyTransactionsDetailsTable" xlink:to="modd_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AggregateGrossProceeds_lbl0" xml:lang="en-US">The amount of aggregate gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_AtthemarketSalesOfStockNet_lbl0" xml:lang="en-US">At-the-market sales of stock, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AtthemarketSalesOfStockNet" xlink:to="modd_AtthemarketSalesOfStockNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_CashFee_lbl0" xml:lang="en-US">Percentage of cash fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashFee" xlink:to="modd_CashFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Capitalized research and development expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:to="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:to="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExercisePricesCommonStockWarrantsExercised_lbl0" xml:lang="en-US">Exercise Prices, Common stock warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesCommonStockWarrantsExercised" xlink:to="modd_ExercisePricesCommonStockWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl0" xml:lang="en-US">Number of exercise prices, issuance of common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:to="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExpirationCommonStock_lbl0" xml:lang="en-US">Expiration common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationCommonStock" xlink:to="modd_ExpirationCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ExpirationIssuanceOfCommonStockWarrants_lbl0" xml:lang="en-US">Expiration, Issuance of common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationIssuanceOfCommonStockWarrants" xlink:to="modd_ExpirationIssuanceOfCommonStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl0" xml:lang="en-US">Lease right-of-use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:to="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl0" xml:lang="en-US">Represent the share of issuance of common stock and warrants in equity offering net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:to="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl0" xml:lang="en-US">Amount of issuance of common stock in public offerings, net of fees and issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl0" xml:lang="en-US">Number of issuance of common stock in public offerings, net of fees and issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_NumberOfSharesCommonStockWarrantsExercised_lbl0" xml:lang="en-US">Number of shares, common stock warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesCommonStockWarrantsExercised" xlink:to="modd_NumberOfSharesCommonStockWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl0" xml:lang="en-US">Represent the share issuance of common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesIssuanceOfCommonStockWarrants" xlink:to="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OperatingLeaseExpiredTerm_lbl0" xml:lang="en-US">Operating lease expired term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseExpiredTerm" xlink:to="modd_OperatingLeaseExpiredTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_OutstandingSharesOfCommonStock_lbl0" xml:lang="en-US">Company&#8217;s outstanding shares of common stock percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OutstandingSharesOfCommonStock" xlink:to="modd_OutstandingSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PaymentOfUnderwriterPercentage_lbl0" xml:lang="en-US">Payment of Underwriter Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PaymentOfUnderwriterPercentage" xlink:to="modd_PaymentOfUnderwriterPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PercentageOfAnnualRentIncreases_lbl0" xml:lang="en-US">Represent the percentage of annual rent increases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRentIncreases" xlink:to="modd_PercentageOfAnnualRentIncreases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PreFundedWarrant_lbl0" xml:lang="en-US">Per share of pre funded warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PreFundedWarrant" xlink:to="modd_PreFundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_PurchasePricePerShare_lbl0" xml:lang="en-US">Purchase price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl0" xml:lang="en-US">The amount of receivable from transfer agent for warrant exercise proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:to="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for recently issued accounting pronouncements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl0" xml:lang="en-US">The amount of right-of-use asset obtained in exchange for lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:to="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for risks and uncertainties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl0" xml:lang="en-US">Shares available for grant, options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl0" xml:lang="en-US">Options cancelled and returned to the plan, shares available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl0" xml:lang="en-US">RSUs granted, number of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl0" xml:lang="en-US">RSUs granted, shares available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl0" xml:lang="en-US">Represent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">RSUs granted, weighted average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share awards, weighted average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl0" xml:lang="en-US">The amount of issuance of common stock and warrants in equity offering, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:to="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_WarrantsToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">Number of warrants to purchase shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsToPurchaseSharesOfCommonStock" xlink:to="modd_WarrantsToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_compensationServicesEqual_lbl0" xml:lang="en-US">Compensation services equal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_compensationServicesEqual" xlink:to="modd_compensationServicesEqual_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_WBernardoDriveSanDiegoCAMember_lbl0" xml:lang="en-US">WBernardo Drive San Diego CAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WBernardoDriveSanDiegoCAMember" xlink:to="modd_WBernardoDriveSanDiegoCAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract_lbl" xml:lang="en-US">Schedule Of Summarizes The Activity In The Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract" xlink:to="modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl1" xml:lang="en-US">Receivable From Transfer Agent For Warrant Exercise Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:to="modd_ReceivableFromTransferAgentForWarrantExerciseProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IssuanceOfCommonStockWarrantsMember_lbl0" xml:lang="en-US">Issuance Of Common Stock Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockWarrantsMember" xlink:to="modd_IssuanceOfCommonStockWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DeferredPortionAbstract_lbl0" xml:lang="en-US">Deferred Portion Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredPortionAbstract" xlink:to="modd_DeferredPortionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnderwriterMember_lbl0" xml:lang="en-US">Underwriter Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwriterMember" xlink:to="modd_UnderwriterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ZeroPointNineThreeToTwoPointZeroZeroMember_lbl0" xml:lang="en-US">Zero Point Nine Three To Two Point Zero Zero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ZeroPointNineThreeToTwoPointZeroZeroMember" xlink:to="modd_ZeroPointNineThreeToTwoPointZeroZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeaseExpiredTerm_lbl1" xml:lang="en-US">Operating Lease Expired Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeaseExpiredTerm" xlink:to="modd_OperatingLeaseExpiredTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NumberOfSharesCommonStockWarrantsExercised_lbl1" xml:lang="en-US">Number Of Shares Common Stock Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesCommonStockWarrantsExercised" xlink:to="modd_NumberOfSharesCommonStockWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl0" xml:lang="en-US">Long-Term Debt, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ThreePointNineFiveToSeveenPointFiveOneMember_lbl0" xml:lang="en-US">Three Point Nine Five To Seveen Point Five One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ThreePointNineFiveToSeveenPointFiveOneMember" xlink:to="modd_ThreePointNineFiveToSeveenPointFiveOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Common Stock And Warrants In Equity Offering Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:to="modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl1" xml:lang="en-US">Issuance Of Common Stock In Public Offerings Net Of Fees And Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExpirationIssuanceOfCommonStockWarrants_lbl1" xml:lang="en-US">Expiration Issuance Of Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationIssuanceOfCommonStockWarrants" xlink:to="modd_ExpirationIssuanceOfCommonStockWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExercisePricesCommonStockWarrantsExercised_lbl1" xml:lang="en-US">Exercise Prices Common Stock Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesCommonStockWarrantsExercised" xlink:to="modd_ExercisePricesCommonStockWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award RSUs Granted Shares Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl1" xml:lang="en-US">Share-Based Payment Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="modd_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract3" xlink:to="modd_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract2" xlink:to="modd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract5" xlink:to="modd_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0" xml:lang="en-US">Research and Development Arrangement with Federal Government, Costs Incurred, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract4" xlink:to="modd_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract1" xlink:to="modd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract0" xlink:to="modd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl1" xml:lang="en-US">Exercise Prices Issuance Of Common Stock Warrantsin Dollars Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:to="modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract7" xlink:to="modd_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract6" xlink:to="modd_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract8" xlink:to="modd_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AggregateGrossProceeds" xlink:to="modd_AggregateGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Obtained In Exchange For Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:to="modd_RightofuseAssetObtainedInExchangeForLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PropertyAndEquipmentNetAbstract_lbl0" xml:lang="en-US">Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PropertyAndEquipmentNetAbstract" xlink:to="modd_PropertyAndEquipmentNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl0" xml:lang="en-US">Financing Receivable, Unamortized Loan Cost (Fee)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PaymentOfUnderwriterPercentage_lbl1" xml:lang="en-US">Payment Of Underwriter Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PaymentOfUnderwriterPercentage" xlink:to="modd_PaymentOfUnderwriterPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockWarrantsExercisedMember_lbl0" xml:lang="en-US">Common Stock Warrants Exercised Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsExercisedMember" xlink:to="modd_CommonStockWarrantsExercisedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OutstandingSharesOfCommonStock_lbl1" xml:lang="en-US">Outstanding Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OutstandingSharesOfCommonStock" xlink:to="modd_OutstandingSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockTwoMember_lbl0" xml:lang="en-US">Common Stock Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockTwoMember" xlink:to="modd_CommonStockTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnlabeledAbstract" xlink:to="modd_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ThornmintRoadSanDiegoCAMember_lbl0" xml:lang="en-US">Thornmint Road San Diego CAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ThornmintRoadSanDiegoCAMember" xlink:to="modd_ThornmintRoadSanDiegoCAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl1" xml:lang="en-US">Number Of Shares Issuance Of Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NumberOfSharesIssuanceOfCommonStockWarrants" xlink:to="modd_NumberOfSharesIssuanceOfCommonStockWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options RSUs Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AgreementAxis_lbl0" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AgreementAxis" xlink:to="modd_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="modd_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockThreeMember_lbl0" xml:lang="en-US">Common Stock Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockThreeMember" xlink:to="modd_CommonStockThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl1" xml:lang="en-US">Risks And Uncertainties Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="modd_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockOneMember_lbl0" xml:lang="en-US">Common Stock One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockOneMember" xlink:to="modd_CommonStockOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember_lbl0" xml:lang="en-US">Zero Point Nine Three To Seventeen Point Seven Zero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember" xlink:to="modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PercentageOfAnnualRentIncreases_lbl1" xml:lang="en-US">Percentage Of Annual Rent Increases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PercentageOfAnnualRentIncreases" xlink:to="modd_PercentageOfAnnualRentIncreases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IssuanceOfCommonStockWarrantsOneMember_lbl0" xml:lang="en-US">Issuance Of Common Stock Warrants One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockWarrantsOneMember" xlink:to="modd_IssuanceOfCommonStockWarrantsOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockWarrantsExercised1Member_lbl0" xml:lang="en-US">Common Stock Warrants Exercised1 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockWarrantsExercised1Member" xlink:to="modd_CommonStockWarrantsExercised1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_compensationServicesEqual_lbl1" xml:lang="en-US">compensation Services Equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_compensationServicesEqual" xlink:to="modd_compensationServicesEqual_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ExpirationCommonStock_lbl1" xml:lang="en-US">Expiration Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ExpirationCommonStock" xlink:to="modd_ExpirationCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled And Returned To The Plan Shares Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PrepaidAndOtherCurrentAssetsAbstract_lbl0" xml:lang="en-US">Prepaid And Other Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PrepaidAndOtherCurrentAssetsAbstract" xlink:to="modd_PrepaidAndOtherCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_WarrantsToPurchaseSharesOfCommonStock_lbl1" xml:lang="en-US">Warrants To Purchase Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WarrantsToPurchaseSharesOfCommonStock" xlink:to="modd_WarrantsToPurchaseSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl0" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CurrentPortionAbstract_lbl0" xml:lang="en-US">Current Portion Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CurrentPortionAbstract" xlink:to="modd_CurrentPortionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EightPointSixOneToSeventeenPointSevenZeroMember_lbl0" xml:lang="en-US">Eight Point Six One To Seventeen Point Seven Zero Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EightPointSixOneToSeventeenPointSevenZeroMember" xlink:to="modd_EightPointSixOneToSeventeenPointSevenZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl1" xml:lang="en-US">Issuance Of Common Stock In Public Offerings Net Of Fees And Issuance Costsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedExpensesAbstract_lbl0" xml:lang="en-US">Accrued Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedExpensesAbstract" xlink:to="modd_AccruedExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NonemployeeDirectorsMember_lbl0" xml:lang="en-US">Nonemployee Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NonemployeeDirectorsMember" xlink:to="modd_NonemployeeDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl1" xml:lang="en-US">Issuance Of Common Stock And Warrants Shares In Equity Offering Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:to="modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DeviceIntegrationAgreementMember_lbl0" xml:lang="en-US">Device Integration Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeviceIntegrationAgreementMember" xlink:to="modd_DeviceIntegrationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:to="modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PrivatePlacementWarrantsMember_lbl0" xml:lang="en-US">Private Placement Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PrivatePlacementWarrantsMember" xlink:to="modd_PrivatePlacementWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionsAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfOutstandingAndExercisableOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding And Exercisable Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfOutstandingAndExercisableOptionsAbstract" xlink:to="modd_ScheduleOfOutstandingAndExercisableOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_UnderwritingAgreementMember_lbl0" xml:lang="en-US">Underwriting Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_UnderwritingAgreementMember" xlink:to="modd_UnderwritingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AtthemarketSalesOfStockNet_lbl1" xml:lang="en-US">Atthemarket Sales Of Stock Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AtthemarketSalesOfStockNet" xlink:to="modd_AtthemarketSalesOfStockNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ManchesterManagementCompanyLLCMember_lbl0" xml:lang="en-US">Manchester Management Company LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ManchesterManagementCompanyLLCMember" xlink:to="modd_ManchesterManagementCompanyLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl1" xml:lang="en-US">Increase Decrease Lease Rightofuse Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseLeaseRightofuseAsset" xlink:to="modd_IncreaseDecreaseLeaseRightofuseAsset_lbl1"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfWarrantsOutstandingAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfWarrantsOutstandingAbstract" xlink:to="modd_ScheduleOfWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashPaidForAbstract_lbl0" xml:lang="en-US">Cash Paid For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidForAbstract" xlink:to="modd_CashPaidForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PreFundedWarrant_lbl1" xml:lang="en-US">Pre Funded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PreFundedWarrant" xlink:to="modd_PreFundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashFee_lbl1" xml:lang="en-US">Cash Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashFee" xlink:to="modd_CashFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Regulatory Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FounderMember_lbl0" xml:lang="en-US">Founder Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FounderMember" xlink:to="modd_FounderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Grant In Share Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award RSUs Granted Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl0" xml:lang="en-US">Purchase Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensations Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Share Awards Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:to="modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0" xml:lang="en-US">Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract_lbl" xml:lang="en-US">Schedule Of Assumptions Were Used In The Fair Value Method Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract" xlink:to="modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="modd_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="modd_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PurchasePricePerShare" xlink:to="modd_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:to="modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>modd-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 21 20:10:12 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheet" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedIncomeStatement" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ShareholdersEquityType2or3" roleURI="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedCashFlow" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPolicies" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheetDetail" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_Leases" roleURI="http://www.modularmedicalinc.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquity" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensation" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_Incometaxes" roleURI="http://www.modularmedicalinc.com/role/Incometaxes"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RoyaltyAgreement" roleURI="http://www.modularmedicalinc.com/role/RoyaltyAgreement"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_CommitmentsandContingencies" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RelatedPartyTransactions" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_AccountingPoliciesByPolicy" roleURI="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ConsolidatedBalanceSheetDetailTables" roleURI="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_LeasesTables" roleURI="http://www.modularmedicalinc.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquityTables" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensationTables" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_IncometaxesTables" roleURI="http://www.modularmedicalinc.com/role/IncometaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofAccruedExpensesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofWarrantsOutstandingTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofAssumptionswereusedintheFairValueMethodTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofSummarizestheActivityintheSharesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofRSUActivityunderthePlanTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofOutstandingandExercisableOptionsTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_TheCompanyandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_LeasesDetails" roleURI="http://www.modularmedicalinc.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockholdersEquityDetails" roleURI="http://www.modularmedicalinc.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_StockBasedCompensationDetails" roleURI="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_IncometaxesDetails" roleURI="http://www.modularmedicalinc.com/role/IncometaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_CommitmentsandContingenciesDetails" roleURI="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="modd-20240331.xsd#modd_r_RelatedPartyTransactionsDetails" roleURI="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_AssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AtthemarketSalesOfStockNet" xlink:href="modd-20240331.xsd#modd_AtthemarketSalesOfStockNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="AtthemarketSalesOfStockNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseLeaseRightofuseAsset" xlink:href="modd-20240331.xsd#modd_IncreaseDecreaseLeaseRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="IncreaseDecreaseLeaseRightofuseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetObtainedInExchangeForLeaseLiability" xlink:href="modd-20240331.xsd#modd_RightofuseAssetObtainedInExchangeForLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="RightofuseAssetObtainedInExchangeForLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableFromTransferAgentForWarrantExerciseProceeds" xlink:href="modd-20240331.xsd#modd_ReceivableFromTransferAgentForWarrantExerciseProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ReceivableFromTransferAgentForWarrantExerciseProceeds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAbstract" xlink:href="modd-20240331.xsd#modd_CashPaidForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="CashPaidForAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/Incometaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/RoyaltyAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="RoyaltyAgreementAbstract" xlink:href="modd-20240331.xsd#modd_RoyaltyAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RisksAndUncertaintiesPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RisksAndUncertaintiesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="modd-20240331.xsd#modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/IncometaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidAndOtherCurrentAssetsAbstract" xlink:href="modd-20240331.xsd#modd_PrepaidAndOtherCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidAndOtherCurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentNetAbstract" xlink:href="modd-20240331.xsd#modd_PropertyAndEquipmentNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="PropertyAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsOutstandingAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockWarrantsMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="IssuanceOfCommonStockWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockWarrantsOneMember" xlink:href="modd-20240331.xsd#modd_IssuanceOfCommonStockWarrantsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="IssuanceOfCommonStockWarrantsOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercisedMember" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercisedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockWarrantsExercisedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsExercised1Member" xlink:href="modd-20240331.xsd#modd_CommonStockWarrantsExercised1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockWarrantsExercised1Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOneMember" xlink:href="modd-20240331.xsd#modd_CommonStockOneMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrak83t5PZiFfgwtJOF/yP9Tgfcm0JqcWtjlgEeYLSw7LM+9TqQnpiyhCalo136o2+7dvcVg1iZ7x9aSosykf0X+gFWr4a3tGWT2u2vS0ebAoE4BpQDVJEn3te2sWKbmVlOW82IGzy+FGkS1n0bL+6nnA1e+2624IKdru76cDIIlLikOiz9Ca9ve6jgwocxKxlTDWfOfr0BpVQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockOneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockTwoMember" xlink:href="modd-20240331.xsd#modd_CommonStockTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockTwoMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockThreeMember" xlink:href="modd-20240331.xsd#modd_CommonStockThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockThreeMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationCommonStock" xlink:href="modd-20240331.xsd#modd_ExpirationCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExpirationCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_NumberOfSharesIssuanceOfCommonStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesIssuanceOfCommonStockWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" xlink:href="modd-20240331.xsd#modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationIssuanceOfCommonStockWarrants" xlink:href="modd-20240331.xsd#modd_ExpirationIssuanceOfCommonStockWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExpirationIssuanceOfCommonStockWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_NumberOfSharesCommonStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesCommonStockWarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesCommonStockWarrantsExercised" xlink:href="modd-20240331.xsd#modd_ExercisePricesCommonStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExercisePricesCommonStockWarrantsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract" xlink:to="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable" xlink:to="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesTheActivityInTheSharesAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummarizesTheActivityInTheSharesAbstract" xlink:to="StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" xlink:href="modd-20240331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="19.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingAndExercisableOptionsAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:href="modd-20240331.xsd#modd_ScheduleOfOutstandingAndExercisableOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsAbstract" xlink:to="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ZeroPointNineThreeToTwoPointZeroZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToTwoPointZeroZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ZeroPointNineThreeToTwoPointZeroZeroMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThreePointNineFiveToSeveenPointFiveOneMember" xlink:href="modd-20240331.xsd#modd_ThreePointNineFiveToSeveenPointFiveOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ThreePointNineFiveToSeveenPointFiveOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EightPointSixOneToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_EightPointSixOneToSeventeenPointSevenZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="EightPointSixOneToSeventeenPointSevenZeroMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZeroPointNineThreeToSeventeenPointSevenZeroMember" xlink:href="modd-20240331.xsd#modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ZeroPointNineThreeToSeventeenPointSevenZeroMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable" xlink:to="ScheduleOfOutstandingAndExercisableOptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxProvisionAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfIncomeTaxProvisionAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentPortionAbstract" xlink:href="modd-20240331.xsd#modd_CurrentPortionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="CurrentPortionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentPortionAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredPortionAbstract" xlink:href="modd-20240331.xsd#modd_DeferredPortionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="DeferredPortionAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredPortionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" xlink:href="modd-20240331.xsd#modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="modd-20240331.xsd#modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" xlink:href="modd-20240331.xsd#modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="modd-20240331.xsd#modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="modd-20240331.xsd#modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RestatementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="modd-20240331.xsd#modd_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WBernardoDriveSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_WBernardoDriveSanDiegoCAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="WBernardoDriveSanDiegoCAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThornmintRoadSanDiegoCAMember" xlink:href="modd-20240331.xsd#modd_ThornmintRoadSanDiegoCAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="ThornmintRoadSanDiegoCAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseExpiredTerm" xlink:href="modd-20240331.xsd#modd_OperatingLeaseExpiredTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="OperatingLeaseExpiredTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAnnualRentIncreases" xlink:href="modd-20240331.xsd#modd_PercentageOfAnnualRentIncreases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="PercentageOfAnnualRentIncreases" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="modd-20240331.xsd#modd_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityLineItems" xlink:href="modd-20240331.xsd#modd_StockholdersEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwritingAgreementMember" xlink:href="modd-20240331.xsd#modd_UnderwritingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwritingAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterMember" xlink:href="modd-20240331.xsd#modd_UnderwriterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwriterMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="modd-20240331.xsd#modd_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="AgreementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomainDomain" xlink:href="modd-20240331.xsd#modd_AgreementDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnderwritingAgreementMember_0" xlink:href="modd-20240331.xsd#modd_UnderwritingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="UnderwritingAgreementMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementWarrantsMember" xlink:href="modd-20240331.xsd#modd_PrivatePlacementWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivatePlacementWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFee" xlink:href="modd-20240331.xsd#modd_CashFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="CashFee" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_OtherExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="compensationServicesEqual" xlink:href="modd-20240331.xsd#modd_compensationServicesEqual"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="compensationServicesEqual" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_LongTermDebtTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUnderwriterPercentage" xlink:href="modd-20240331.xsd#modd_PaymentOfUnderwriterPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="PaymentOfUnderwriterPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_WarrantsToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="WarrantsToPurchaseSharesOfCommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="modd-20240331.xsd#modd_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="PurchasePricePerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrant" xlink:href="modd-20240331.xsd#modd_PreFundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="PreFundedWarrant" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="modd-20240331.xsd#modd_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:href="modd-20240331.xsd#modd_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndSeventeenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonemployeeDirectorsMember" xlink:href="modd-20240331.xsd#modd_NonemployeeDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="NonemployeeDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockCompensationPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableUnamortizedLoanFeeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanFeeCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="modd-20240331.xsd#modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/IncometaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncometaxesDetailsTable" xlink:href="modd-20240331.xsd#modd_IncometaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncometaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncometaxesDetailsTable" xlink:to="us-gaap_DeferredIncomeLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="modd-20240331.xsd#modd_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DeviceIntegrationAgreementMember" xlink:href="modd-20240331.xsd#modd_DeviceIntegrationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="DeviceIntegrationAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="modd-20240331.xsd#modd_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ManchesterManagementCompanyLLCMember" xlink:href="modd-20240331.xsd#modd_ManchesterManagementCompanyLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ManchesterManagementCompanyLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FounderMember" xlink:href="modd-20240331.xsd#modd_FounderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FounderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesOfCommonStock" xlink:href="modd-20240331.xsd#modd_OutstandingSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="OutstandingSharesOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="modd-20240331.xsd#modd_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="AggregateGrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesAndWages" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 5 # 2(  A$! Q$!_\0
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M?]$=\!?^""T_^)KW>B@#PC_AF#]GK_HCO@+_ ,$%I_\ $T?\,P?L]?\ 1'?
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MS17%K=VEQ''/!/#(CQR(K XR#]L5X1^T_P#\F]?&+_L0M?\ _21J (?V4?\
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M?3=+TC5]%^+5WIZ6>O>,O!%IK.F>(/B#_;>B:9X+OM,L_%<6AS:.-.TN_O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM2UWPO\ %[QM\#?$GA#X0^(=%L8Y9K/5-*\;:G,+:XLO$,,8E\-S&V0:O'-
M\(594) /MJBOG/\ :A_:=^'W[)7PYT/XG?$NR\2W_A_Q!\6_@Q\&K*#PKI]I
MJ6I)XI^.7Q.\,?"GPE=7%O>ZAID*:/9^(/%>GW6MW*7$ES;:7#=2VEG?72Q6
MDWT90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5X1^T__P F]?&+_L0M?_\ 21J]WKPC]I__ )-Z^,7_ &(6O_\
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MRC)^ ?\ V%/BQ_ZMGQI7Z\5YF0?\B/)_^Q9@?_4>!\_P7_R2'"__ &(,I_\
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MPZA6=7^%5_Z]5/\ TW4,<1_N^(_Z\5__ $Q6/R__ ."%7_*,GX!_]A3XL?\
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M*_&+QGX2\#^+IO#W]L>+/ 7AR3P UM=Z%HVIV?AV_LO$&C'3)@#Z%_X+@?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A'[3_\ R;U\8O\
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MRI3@O@D\3AY5U&R2AB8\MXJ+91117SY]8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>$?M/_ /)O7QB_[$+7_P#TD:O=Z\(_:?\ ^3>O
MC%_V(6O_ /I(U $/[*/_ ":Y^S9_V0+X._\ JN_#E>^UX%^RC_R:Y^S9_P!D
M"^#O_JN_#E>^T %</\3O^2;?$+_L1_%G_IAU"NXKA_B=_P DV^(7_8C^+/\
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MD^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"/VG_\
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M_P#@JO\ LE?$/2?&GP]_X*M_L+7#3?$CP-9:'XK^(FG^&;9KU_%WA6RTV/\
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ME;33=)TJPB,MQ=7$K9+' $<%O"LES=W,D-K:0S7,T43_ ,IWAFR^(G_!>/\
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M %R,8QBHQ2C&*48QBE&,8Q2C&,8I)1C&,8QC%))12222211112&%>$?M/_\
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MI]6II'B'PLSK'X>IAI/3VN(X6XHQ.9Y5CZ47[TZ.'S# U6DXTYIM'M.B>(=
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MV(6O_P#I(U>[UX1^T_\ \F]?&+_L0M?_ /21J (?V4?^37/V;/\ L@7P=_\
M5=^'*]]KP+]E'_DUS]FS_L@7P=_]5WX<KWV@ KYP_:V_9J\%?M=?L^?$CX">
M.HHTT[QMHDL6D:P8$GN?"WBRP/VWPMXJL0REA<Z)K,-K=21(T?VZQ%YIDS_9
MKZ=6_F"_9G^+OBG3K#]D?QOH_P &O^"@/PA\?ZY^V?IGAOXO?MU?$_XH:[K/
M[&'Q,^'WB']H3QKX5U7PIKWAF7X\_$.34]'^*-K<Z'\)_AJ-5^!_P\T[P_\
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MOPK_ &U?V?\ ]H_X#?$#2_A*=)^&&B_"'5_#=I\'?A!#\1?!'Q&T+7_#6O\
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M>^.+=M)^(MEXEU.VT3Q$VF6NLQ-ING75OV7A3]AS_A7OQ'U'Q#\.?VE?V@O
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M&=I\1O"T^A>&]7UKRO[&T37;R/4V72=>U<W%NNEZ%?"#5]0>XMX[2RF>>%7
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MT#_A9MUK-K?-X)ALI8WO=433/&&H6$UEI%_9:5?W-^EO?3Z/8:JUA<0#TSX
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M1Z/XLTD+J6D75EJ-M]FUW0=+O";:YB\T6Y@EWP2R1M[&B*BJB#:B*J*HZ!5
M"CGG@ "G44 %%%% !7A'[3__ ";U\8O^Q"U__P!)&KW>O"/VG_\ DWKXQ?\
M8A:__P"DC4 0_LH_\FN?LV?]D"^#O_JN_#E>^UX%^RC_ ,FN?LV?]D"^#O\
MZKOPY7OM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q
M]^W;\+_B_P#'3]FOQE\"?@QJ?_",ZY\;=1\,?"SQGX]6?1A=?#GX.^+]?L=/
M^,GC'3-+US_1/$6M6WPV/B32=!T!,37NM:Q82EH[:VN)4^P:* /P"^//[(_Q
MS^!=G^T5XP\0_$_P/\8/@9XOMOV3?CWKDGQ57X8_ CP7I_Q1_9'^,?PYM8?A
M+KMEX9T6R\(V7A'XV_!K1_#WABV\::[HO]@^$_$'PR\.Q>,[^'PQ>1R6/SKX
M;^$OQ?\ VP/CM^U+^U/\*?"?BS2M"\,?MS_L_>.8_A[\)OC9\&+7Q+XLA\"_
ML0ZE\%/%FO> ?C#I_P#PFOP*U3XI>#M:^)6B^)-3T:;Q1>:'_P 4_?\ A*X\
M?Z)XP@@DTC^H"ZM;:^MKBRO;>"[L[N":UN[2ZACN+:ZMKB-HI[>X@E5XIX)X
MG>*:&5&CDC9D=65B#1T30M$\-:79Z'X<T?2O#^B:?&T5AH^B:?::5I=C$TCR
MM'9Z?80P6EM&TLDDK)#"BF1W<@LS$@'Y">-/@'XC^$__  3<\5V.E_#;XCZ1
MXD\*_'#P]^UKXN^&GC+XB:%\8O'^N1>#_P!JCPK^T5\2+?5-9\%Z;:>$[[6_
M%.@>'-?UX>#/ \%WH=CKM^NA:-J&KM_IUWPWBWP9X?\ CA_P4Y^&FG?!KQQX
M'\<? 7XD^ /A3^VI^T[I7AK7UU:YL?B#^SJR:/\ LH>(;J/3VN-,@LOC*OCG
MP?XBBM]2D@O]9TO]F?1]2L(+BPANKB+]R:Y_0_"?A7PP]Y)X;\,^'_#TFH)8
M1W[Z'HVG:2]]'I=J++3$O&L+:W-RFG60%I8+,76SM0+>W$<0V4 ?SR>#?^">
MO[3?A+P?JGP\N_ ?C;XD?$/X1Z1^U]JGP8^)GQ<^.'PF\3?LJ>*?%OQHTGXB
MV6@ZG?\ P6A\,/\ $G6[WXG6?Q%OK+XF^#?B=I[>!=+\00W.MZAJ_CVTM])\
M[?T+]B?]J?XCZY^T'<_$KX3^,I/!7Q+3_@FI8Z3HO[17Q?\ @3\1_%_B2']F
MO]K#4?BG\9TU[1_A%I=E\-_#OAC2/ ]_#<>"_#-G+K2ZL;:]M+8Z/)?VOAG3
M?Z'** /QF_:;^"_QET7]I/QI\7_ /PJT[P]X+\0^-OV<?&GQ3^)_BOXF_"/Q
M#^S)XQ^&7P:N_#]_XT\5_M"_"#XJ:8OQ \"_%7X1>'?#^JO\(?&_P#FG>:\L
M/A_KNNZ]HT^A:Q!#]??\$]]+U6']FK3O%NJ:7J>@Q_&#XI?'GX[^']!UFWDL
M]5TGP5\:_C5X[^)7@2'4;*54FL;^\\&^(]#U:_L)T2XL;W4;BTN$6>&05]GZ
MAI]AJUC=Z9JMC9ZGIM_;RVM]I^H6T-[8WMK,I2:VN[2Y22"XMYD)26&:-XY%
M)5U()%7       , #@ #H .P% !1110 4444 %%%% !1110 4444 %>$?M/_
M /)O7QB_[$+7_P#TD:O=Z\(_:?\ ^3>OC%_V(6O_ /I(U $/[*/_ ":Y^S9_
MV0+X._\ JN_#E>^UX%^RC_R:Y^S9_P!D"^#O_JN_#E>^T %%%% !1110 444
M4 %%%% !1110 45R?CWQ/<^"? WC+QE9>&/$7C:]\*>%M?\ $=GX,\(6D5_X
MK\6W>B:5=:E;>&?#-E/-;07>OZ[-;)I>D6\]S;P2ZA=6Z33PQ%Y%_-_5?^"@
M'Q9^%W_"TO#/QU_9KTO1/BOX8^%OP:^*7P^\"_#3XN0^-].\3S_'SXM/\#/
M'PP\8^*M9\%>$(O _C6W^)DECINL:O%I/B#PM>:#)J_B+0;N_3PYJ6GD _4R
MBOSLL/VP/CQ9>'/VB?#6N_LQZ7XD_:*_9TD\%ZCK/P_^'_QDT:+X;^+/!'Q$
M\+:MXK\,>/=,^)GC_P .>$=0T;2+1?#GBKP]XETFZ\$ZGXBLM:\//+H^EZ[I
MVJ6D\>CK'[9/C;7?AO\ L<77P@^%&A^(OC)^V=X)L_'OA/PCXV\<W7A?P)X
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M>+M!U:UN(SI^J6-Q/=:9K&CZ?=VF)@#Z2HHHH **** "O"/VG_\ DWKXQ?\
M8A:__P"DC5[O7A'[3_\ R;U\8O\ L0M?_P#21J (?V4?^37/V;/^R!?!W_U7
M?ARO?:\"_91_Y-<_9L_[(%\'?_5=^'*]]H **** "BBB@ KS[XI^(O&WA3P)
MKVO_  [\#GXC^,-/BM7TCP<-9M- _M9Y;VV@NO\ B:7J200_8[.6XOO+*F2Y
M^S?9HL2RH1Z#17/BJ-3$87$X>EBJV"JUZ%6E3QF&C0EB,)4J4Y0AB:$<32KX
M>5:A*2J4XUZ-:BYQBJE.<+Q?5@J]+"XS"8FO@\/F-'#XFA7K8#%RQ$,+C:5*
MK"I/"8F>$K8;%QH8B,71JRPV(H5U3G)TJU.:C-?G./VD?VY,#_C!AO\ P[GA
MO^L%'_#2/[<G_1C#?^'<\-__ !BOT8HKX?\ U-XB_P"CH<:?^$/!7_T,'Z1_
MK_PK_P!&:\/?_#CXA_\ T9'YS_\ #2/[<G_1C#?^'<\-_P#QB@_M(_MR?]&,
M,/?_ (6YX<./7@6Y)_ 5^C%%'^IO$7_1T.-/_"'@K_Z& _U_X5_Z,UX>_P#A
MQ\0__HR//4UCXC:C\*Y-=T_PCHFC?%B\\"W&IZ9X'\3^(9?^$;L/'LNAR7&G
M>&_$/BG0M-U.XCT2/7C!I^K:UI.D:C<P6'VB\LM.O)DCMI/R8\(_L??M>>)?
M@C\7/#7Q5\+_  4T?]I;XD>*_AA\??$/[1,7QG\6_$;3?B!\=?@O\1_!OC_X
M>> +WP/)\%O =[\/OV?/#]GX7/@/PCHNA^(->U#P=X5FN=4.E^(/&>M^(=<U
M3]J:*^\HPE3I4J<ZLZ\Z=*G3G7JJFJM:<*<(2K5%2A3I*I6E"56HJ5.G34ZD
MU3A"FH0C^95ZD*M>M5IT:>&IU:U:K##475E1P\*E6I4AAZ4JU2K6E2H0G&C2
M=:K5K.G2INK4J5'4G/X+^$/P/^-VHZS^UM\7?C-I_P /O!7Q"_:3\->#/ GA
MOX=^"/%NL^//#W@3PA\-/!'BCP_X<DU[Q[J7A#P5<Z_K_B#Q+XX\5ZYJO]F>
M#[#3]&T:71-+MGU6^M;Z\G\\F_9>^//PX^'_ /P3[\2?#2W^&WCKXN?L9_"]
M?A9XP\">)?%^N^"O!OQ$\/>*OA!X9^'OC5_#'C^V\%^*M1T'5=&\3>$/#?B7
MP]<:OX(N;36='M-5TF_AT>\O[6\M/TWHK0R/SS^!_P"QS?\ PB^&UK\0M9T7
MP+XV_;*TY?CQ\0;/78O%?Q"\.?"<?%'XV>._B)\5+CPFD-O)<R'P!I7B3QZ_
MA1?$VH>"]1\3R>'K+^VUT>/4FBTN'YD\'_L??M<^(/@C\3_#OQ/\+?!32?VF
M/'/C;X5?M$Z_^T/_ ,+G\6?$?3_B=\>_@O\ $CP7X]\#^!=7\&M\%/ 5[\._
M@#HVF>%3\/?!FB^'];U^[\"^$9&OTT?Q!XMU3Q!K6K?M/10!\"?"OX#_ !LU
M6Z_;!^*GQAL?A_X+^)'[3WAWPSX)\.?#WP7XLUGQUX;\ ^$?AY\/-?\ "?A;
M^WO'FH^$/!MWXAU_7/$7BWQ3X@UJ33/!UAI^D:5=:/I-F-4N[*\OKKP#XK_L
MO_M;:I\'/V-_V<-'\*_!?XF? +X3_"#X?Z+^TMX&U7XS>+_A;J'QG\>?#3PS
MX5T7PKX%;5;7X,?$"*^^ LFKZ1J'B7QMI-S;Z1K7C\VGA[PIJUG;>$KCQ3IN
ML_KU10!S_A2?Q!=>&= N/%>AZ3X9\33:182:]X=T'6YO$NBZ)JK6T9OM+TKQ
M!/HGAJ;6=/LI]]O::E+X?T5[N&-)FTRS+^0G0444 <!\5/AOX?\ C!\.?&?P
MO\57&N6GASQUH%_X<UFY\-:S=^']>AL-1B,4\FEZS8LMS872J?DE3>C#=%/%
M-!)+$_Y6_P##C?\ 8\[^,_VF2>Y/QKO,GW.-" Y]@!Z"OV1HKU<OSS.,JIU*
M66YCBL%2JS56I"A.$8SJ*'(IR4J%5N2A[MTTK=.IX>:\,\/Y[5I5\XR? YE6
MH4Y4:-3%4ZDYTZ4I^TE3@X8J@E%U/?:<9/FUOT/QN_X<;_L>?]#G^TS_ .'K
MO?\ Y1T?\.-_V//^AS_:9_\ #UWO_P HZ_9&BN__ %PXH_Z'V8_^#:7_ ,QG
ME?\ $/>!_P#HELG_ /!%?_YXGXW?\.-_V//^AS_:9_\ #UWO_P HJ_3[X*?"
M#PM\!?A=X0^$?@J[\27WA?P58W&GZ3=^+M?O?$_B&:&YU"\U.5M1UJ_/GW+"
MYO9DMXE2&UL[58+*SM[>TMX84]3HKAQ^>YSFE*%#,<RQ>-HTZGM84Z\X2A&I
MRN'.E&A2?-R2E&[DU9O3JO3RKA?AW(Z]3$Y/DV!R[$5:7L*M;"TZD)SH\\:G
MLY.>*KIP]I&,[**?-%>];1_E?X^TC]J+X@?MHZ5XE^)'[+GC'QC^SE\"O%&@
M3_LYV_A'XL? ^'PMK'C?5M'%EXH_:3^*WA_Q/X]\/^+KG7? -KK6K>&?A5X%
MM="U"/P[;KXD\<%M4\6:WX7B\*<'\$OV;OVEM#U?]E/X"^,?ACI>@?"?]C_X
M^?%[XN_\+Z7Q]X7U.P^+7AN]TGXP:'\(-#\)^ M-N)_&NB>*+VT^,D=S\11X
MPT[1-#T&X\%ZE%X=U3Q6FOZ;+:?L917DGO'YC?%C]COXA_&7PG_P59^&][>6
M'A/2OVSO#^D^%?A?XG76I@?L\O[*O@CX2:C?:R-%#ZUX>M[;Q?H^IV,[P1OJ
M9TN,ZIIT<C26ZMY+^SO^Q9XGU;XB>,/$&K_ ?4/V!OAE=? ;X0_"W4/AY\ O
MC+I/A[Q!\1OB;X!\1ZWKL_Q%/B'X':E9VT/ASPWHVI-X+T'6O$$UA\0/'FF:
MI?MXRT'1[31]%LV_9.B@#\I/$?AS]I_Q;^V)H&L_$G]F/QYXV_9T_9^U[P[8
M_LU-H/QB^"UUH.J^*K_0$T;Q3^U!\8=*\6?$#0_&VL>,?"6GZQK/AKX:^$5T
M/4F\.63>*/&Q;5O&7B70AX6X[X$?LW_M,:#K'[)'P+\;_#'2O#OPJ_8S^,OQ
M?^)?_"]H_'WAC5;#XP:%>>'OBQX1^$&D^#_ NF7-SXTT+Q!?:7\7_P"TOB-_
MPFNG:%I&@WO@^_L_#FH>+(M<T^[M/V,HH _(']I/]D#XT_$[PO\ MZZ#8>$=
M'\7>$/VA/V@/V</&LOPY;QK9>%;[XX_ KX?_  S^!GAGXP_#&W\8 ";X8^(_
M%X\#>*?#^A:_-<:5=0RQ6=Q;Z_X;BU*/Q%I?K7_!.+]FKQ!^S1X>^.>@V7PH
MG_9[^"OC#XJVOBSX*_ /6OB!:?%;QEX$L6\&^'])\=:[XL\>VGB+QJEY=_$'
MQCIMYXDL/#O_  GOC9/#%@8[:#6K:"ZCT'1OTDHH **** "BBB@ KPC]I_\
DY-Z^,7_8A:__ .DC5[O7A'[3_P#R;U\8O^Q"U_\ ])&H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '4 JT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_CEC_JX/_F8#_AN[X1?]"Y\1_P#P4>&?_FOH_P"&[OA%_P!"Y\1__!1X9_\
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M_P!"Y\1__!1X9_\ FOH_X81^$7_0Q_$?_P &_AG_ .9"C_AA'X1?]#'\1_\
MP;^&?_F0H_X[,_ZM?_Y@0_XY8_ZN#_YF _X;N^$7_0N?$?\ \%'AG_YKZ/\
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MA?\ Y:<Y_P -P?!C_GU\:_\ @CL/_EU1_P -P?!C_GU\:_\ @CL/_EU71_\
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MT%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M70R(M(-VK'3)HM6OX[RXBMYY(+41(]ZP_!?7?VF?AW\-$U?0=/TW1- TG6-
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M:6<_AS5M/EU&RUV&20[H[%EM-2MIX[U+2^MKG2[PW%G':M97-W!KGC.S\/\
MA:R\57VD^('AOKKPG8Q:-;::)?$$=]XQUS1_#VF6=SIS7$:03VVI:W:+JN^Y
M$=A#%=SR2,ENV?(8/#$FG:?\'OAF-8TN\\2:5X/T3PI\1;*RO;JZBG\!:3H=
MG/J^HS:=.ZWUS::SXC\-:;X0TN_UQT>#1_&/B9X$N+Z:X0>R^,=#N_$.DVEA
M926\4UOXI\#:X[73RI$;3PSXV\/^)+^-6BAG8W$UCI-S%:(46*2[>".::WA:
M2>, YX_$E(XM0N[CP=XMMM.T))6\5:G(_A&2T\+R6MM'J.H0:@MMXMGO-5DT
M[2)[;5+M_"EKXBM_+G.F6\]QX@M-0T>SV;_QOI.G:9\0-5GM]1:W^''VW^W$
MBBMFFNOL/A'2?&<W]E*]VB3[M+UFU@C^V26.;^.XB;9;K'=2\'K7PIT;4]:U
MA]4^&/PG\=:1XCU![G4;[Q=I]A'K=K87]M#;ZII=Q!-X*\21^)XO.2[N[674
M-6TM6L]1306MX;328;R]9X]\&^/+[0OBQH?@F'PC-+\3]+UKR]8\5:UK-C'X
M=UK4? 6E^![0OH6D>&]2;7=+M?[$LM6N0OB#0[NZ^U76GQ&T\F&_F .XOO&Z
MVFI:G96_AGQ-JMEH5U!9Z[K>EQ:)-8:3<36&FZLZ2V-QKMMXCOS;:5JUEJ$_
M]BZ%JA>*1X+47-]%):K8D\7/;Z@+>[\,>);/2FU*'25\2W2:'%I+7USJ1T:S
M1;+^W3XH,-[JK6UG:7@\._8YDO;741.-):34(N=\1^&O$FJZM/-9Z5X5MI#<
MP/I?C2SUW7-!\5:/%#'9- +O3M/T2[A\4V]I?1W%U<:#J/B+3_#WB&U@L])U
M?3Q;27,HY#6OAOXRUR\TY[F> /IWC?P?XC?6)?B=\19K;4M-\.>/=,\3WD#_
M  ]M[/3_  CI]S<:7IYM["U:?5;&TNF@AD>:.!+Z@#7\&>.KJ#3;\ZOHWBNY
MTZ+XD?$;0I/%ES_9TVE6:I\5/$6AZ/;O%=:TOB0Z5:"6QTJ"\M="GTC3+*U,
MLES:Z-9-=Q6?#'C*YM=+:R.G^(?%^O7?C3XLF'3]-GTM[VUT'0_BAXDTB*ZN
M+WQ)K6BZ;;Z=ID<FE:386 U(W\D&R/2=-N+'2]1DT^31_#7CFST_4_"UU%X7
MBT/5?%7CC5KG7[/6=3GU<:'XI\=:[XH338_#ESX:BLA?SZ-JPT*ZOO\ A)O+
ML+QY=8M;>]6"+3I<6X^%<ACCNK[PO\/O'%TNL_$.Y.D^+X4-E':>*_'VM^+]
M$O;'6KCPOXCNM.O+"SU.2PUC3+?1C;:E/>K.=3*:#9KJ0![%HNL6VNZ='J-J
MD\*M/?65Q;72QK<V6HZ5?W.E:KI]QY,L]L\^GZG97=C--9W-W83R6[3V%Y=V
M<D%S+JU@>%]"TWPWH5CI&D^'?#_A2TA-W=/H/A>"WM]"LK_5+VYU357L4MM,
MT>*4WVJWMYJ%W=G3+.:^O;JYO;F+[3<2LV_0 5^8?Q]\>6]\OC'XHZC?1P:#
MIAU3P=X'DNY3%;:7IOAN2Y7QEXLCR519[_4$;38+@YE$%L88SEPI_1WQ7?R:
M7X7\1ZE$=LNGZ%JU[&W99+:PN)D=CV5&0,Q[*">U?SX?ME^+;C4-"^!WP=CC
MN%TRZ\ P_$;QH$E"+=SZAK.F:C9:#<>5GS8-6UJ_U/5;U&8,UKIR1RJ4D4GY
M_.<51HUJ#Q.N%P6%Q.;5:;VK5:%2EA,%3?1J.(Q$ZR337M(TY<K=.-LZV#QF
M8QP^5X"ZQ6<8[#Y:JB5_8X><:F)QM5ZIJ*PU"2EJKJ\'*,9R9\.>,9M7^-.N
MQ:AJAU'1_ \!G6R\-L?LU[XDD:5F.JZ_+"QN$T^6/:+/0DDCW*6GU)I#(UK7
MI?A[PK8Z;;06MC90V=M"@2"*WB2..-!C"QHBA8U[D*,9Y))J_I6E%@LK+EC@
MG V<_+D*"!A>.<<\Y[UZ+8V0&T%!@ <?+GM^6!C\N,Y)/XYFV>8S,Z]24IN%
M-RDH0C=6C=I**O:*Y59V]Y[RF[V7]$<,\(Y7PY@:&&PU&,ZD81=2K)*4JM1)
M-U*LK)U)<W,TFU3AM3I12N\NTTA(QD!0<C&5YZX[C  [8.>2<Y(-;A6VL+=[
MN[GMK.TA4%[FZFCMX(QWW2RLD:X +?>Z9.,#-?*G[4?[6/A+]E[3X)?$UA>F
M?4K.*ZT>6VTZ\UNXU.629K46VF:18*&EDM[LI!<76J7=AI=K)/:B:9VNK>&;
M\M/#'[8OQH_:B^+7AWPO:Z+-X"^'>M:A+IC^(];O+>[UN*YDB>33\L GA/PQ
M!++&(&MK5=:U/=,C2W1N7AMHN*A@Z$J^!I8W,,/@GF-2C'"TDIXK&5XUJOL8
M5(X>@ING2]HG'V^)G3IIWYE9,_3,IX3XPXARG/<YX:X;QV;97PYA,?B\WS6<
MJ&!RK"K+,&\;BL-#%XRI3^MXV&%3JK!8&C7K.*7O1YHJ?ZO_ !E_;%^#7P6T
MR6\UOQ%IAE)\NU%S.\7V^?'RPZ1I4*R:YKLYR&6/3[%867][)<PP+YI_,+XW
M_MY_$KQMX>\&WG@S1=7T?3?B1\3+?X5>'&U_3K6VU&VU75EM(M*UFT\!&[5[
MBTN&U""YMYO$,\N^UM;^:XM8XK">U/P=_P % _B[\,O@]\4+6S\#6$6H^.H=
M(O\ 1_$6K/<S:_K37^FWKB"<:_JQECTZTEAG*8L(#=7,4-O,9$65B_YP^"/V
MVOB5X&\16>L2,MS8IXMTSQ'J4<,@-Z+:QMY;6XM[&^N8Y;B&_N;::6(:D9D:
M!7=(U2$^4/L<KRFOA,_KX/\ LNF\#A(UJ<\TKWJUZU5T*=2C4P\ZB5*DW*HX
MJ%##M4Y/FG6ER14O)XDI^'^#\*\KXCGQM5QG'N>5,MQ6%X6H>PI8/+<)#-,5
MALRP^/P6&=?%5X*CA56CB\RQF&C6IM1P^!:KRY?K[XA^$5M_%6HZG^T/\2=:
M^(?Q"TK4+VUFT2/4O[4NK*]L;B2WF@M@$CTGP]:K-!L:#0],M(U51"+A88(H
MCY%XC^-GAG1_BE\-M:\"20Z9JT7BGP_XBT^QMIDOKC1KNQNK6]A6YF5W5XH]
M4B8RI*[?Z(PLY"51V/Q7\5/C?XS^-/C77[W1=-GT>#Q5JTVH0^&O#$%Y>ZE=
MBZ90INKV))=0OW8[,NGEVQ9B?F+!J^K/V7?V+_&FI^(M'O/%>D7FG^(=1N;.
M\L_#\UN[7&F>&8;B.;4KV]D8"*+49XE(2V\S=9JZ"<B=F5>G+<MJ9(\=B,RQ
ME*3Q;G2P]&-6IB,563JU84JV(Q5>7-)*C-.<80I4:5WHGRQ,_$WQ+X>\1L+P
MMD_!/#E; QR"G2Q>89@\'A\JRFA5J9=@GC<OR[+\+3YY06/H35"OB*OM:_)%
MPIN+G5?ZV_\ !8#XP_&CXP_LZ6LOAT^(;^_C^('AN6]T[1+>:_U)-(U6POXK
M](H;5";9(;I[229X%+D0RH<&4 _SY?"7]A[XR?$[5HM8\9>&M=\'>$8F6[U"
MYUN%H/%&M(H\P66F:5<LM[ UX1M>]U);588FDDCCED,*2?UF:=\,M<\2'&N2
MO:V9*.]E:'=-L4JP,EP=L5NX9<[D4D'<3(WW*T[7X%PV=Q?7ME/;W%I<-';0
MVQN!/>3.V9(S:1H"]U' I9+BX0FV *[)W+1L<\;Q&L)A\1# 1I3Q-*D^?$NF
M[*$Y*U.G7DN5U+N4XQYJC5^?DE*UOS["\-U,QQ&#IYIB,8LKEB/:4<ICB9K"
M_65!>TQ=;!QJ?#-4Z5.K55.FY*"IRQ$(Z2_-#X*_LZP^#_  BTZ\_<:WY$D.
MC:+&Q>UL=-CELK"RU&]E39!/"K3F:&"*YG5Y29'1B(WR]0_9\\3Z?JU_XCTN
M.U1;VSCTR6S\^6&2/=,9_M9N9VF9S$8Q'+")'N9'8F* *DGE?I]JNB_#KX1Z
M5,WBO7[/11<237[Z==21WFI7%U<\SO::%9?-&MPZY47LC6[3-)(419)XS\C_
M !&^+GB_6;6[A^$_A"/PS83QRQ/X[\:1"ZU6>%U*LNB:<Z-!:F2(J5:UM[AX
MU*8FM_EE?R*.,S&JH8GF=."49^TQ25##Q;2=I>T_?XB=];TXQC*45RRL]?:Q
M.!RVE[7"J$9U&YQ]GA+U\1))M6@J?+0PE.VD5.;<8-*4;V:^8=(^&OAJT\8^
M&- \7:];'5O$6KP6%GI22&/?PTT\C0+)]MN1'#'(W[V6V1CA5BVL'D]]_9F^
M-EYK'C9YO GQ"T3X0>%?[8O]!U71Y('U%[&3PS>W&AR:OI<B6$K0ZIJ!T\O<
MFU%NJW!CW>6,-7YI>)=$U[P/\2?"OQ)U/7=7UGQ/HFO)J,-]<"66WMI(=\QC
M-L1(5AGB$D3+(89&0LL4<+J#7USX#\&?LW>*_$,/B^YN/BM\,;76;Z[U?QCX
M*^'4VFGP_P"(K_4E:6ZN+&]O%;5-!^VW,DDEU'8.GG&9FEDC ;S/9P6(B\;0
MQ.,KU<PPSIPC%1HJ5"GBH8CFJQ>']I%J%6BJ<*6(DG*E*$I2Y(S4G\7F6(GE
MCKPP^$^IU(T:D'3I5N;$2HUJ:]E5G5BE>I&I"HIT8MTYPG&-I.+:_0'6[3PY
M\<H=*^-":AXPU[0/$FM>*M!M-)\3>([C4;2[U+P/KEUX;O\ Q(SQ%;EX=;O-
M-NKC^SC< 1-&Q$P25TKL[31;:RTX+Y5IINEV,+SM%##%9V-M##&6:3R(EC0E
M4R#)("[?*NXY"U5^'UQX)_X1KP]X+^&7A1/!'P[\$6MY#X1\*FZEU"\M;74[
M^>[OM2U;4)Y[F2ZU35=0GN;R[9KFYV2SRQK/< -*WS_^V]\69?AI\,K+PWI%
MR(/$_CBX>SM2KXEM],@,<EW=J@PQ";2H/W=VP$'I7S.;8^NL97P]:K.-*G4K
M8B<Y3514,-.=;$1C&,>6%6K3H3ITU*5U.JX1C+E]Y^E@\RR_(N"<5Q5F-E2P
M=#$25-)PK8JM3JO"87#\\G*4'B,0HTXQ@[QI\S>L7;\X_P!L']H/Q)XO^(6C
MZ3\.M8O-,\._#O78-2BDL7-N-1UW3I<0RSRIDW,C2AU*',5I&%$8\\%A\<+I
M$E]>7FKZY.]_J^IW$M]?W$ISYMQ.[2-NYY4,S;%)*HK' R23TR6XPQ+L[,6:
M1Y#NEDD=MSR/(3EI'<EV+'=(Q8^F)&B11O9D50H&3\HXR.2V,8[D^N<9Z_&8
M_/:^,E%4Z<</1I1=.E&$5[3V7-SI5*O*I3G*;=2<F[.I*4HQBE%+^,>).,,Z
MXIQ=:MFN,J5<-+%3Q-'+U-QP>&J<CHP<*2DU*5/#*%",IW:A&327/(R[73KJ
MZF2STZRN;VYDSY-EI]K)=7$JHI9C';V\<DCB-5+,0F%5"[;0I:J$L><AE*$
M[E*D,IX!W(1\K<\YZ=#DU]*?!.]^+7PNU6?XT^'?AUK?B'X>VME'X>\1:U=P
M3Z9X<$>L7UO!9^9?S*GVF)[MH5BN[!)X+&[>TEOI5TZXG2X]R^%?@'X6>/\
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M_!'I?_R+1_PAOA#_ *%7PW_X(]+_ /D6NDHH^LXC_H(Q'_A17_\ EX_8T?\
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MS1ZG@7]FKXRZ=/;6*6.@SVZM&BZD^K-;Q&)3M662T%K-.F%P3'&7D+'"(Q
M_8C_ (1.TN(98Y[<D$%U*CD-&-P*DCOC'3G)!XY&?HEI8B6WMK>-OM$DBH\2
MHN^/EO,=R5^54 +9[]^M>G@,^Q7))<N']RSGRX>G33DH**JOV;BYU'&G:7-:
M.GN0C'1_+YUPIE<J[<8XIO$2E)3GC*U2=Y5)N5%.KSJ%",JUJ48ZP3=YR:NN
M"^$_POF\$^'UMK^\.JZS>.LEY>QPF"WC$:X2TLX69G2V@+2MNE9Y997>1]O"
MKXQ^TE^S]%\=O#OC#2(_)A\5:$;:Y\ WLNU8X-8L+'>VGSS'!CL]?CD^Q7(R
M(TE>VN6P\ (^^EL(X$5!R%8@Y'!&#Z#(&,'CKC\:Y$Z.L>J:E*JL//NA<9SG
M)>"( CT V[!D#(4,">!7A8[,9UZF,JMJ4L5!TGS)-\CE3Z*T8V5&"48JT$DE
M9W9Z=;A;*<QR'_5O&X6-7+*N&J8:OAXR:3]I"LN>,VI35:E5K/$4JM^:.)I0
MJZM6E_._\*/V+/CW\4Y5F?PN_P /O#Z7$D%SXA\<I+IZA[>1HKD:9HRJVKZN
M\3JP65+>VLS@;KI2R1R?IS\)?V#/@O\ #0VVI>(;2?XG^*K<I*=3\60Q#0;:
MX7:X.F>%8V>Q1%;/ER:I)J4\AP\FWY(8/ODVKXRX)^8*<G)4#H#SR![\ $X!
M!J*6UZ@@=N>H(/0J,9SCG'(ZG /->"HI?\'7\SY;@_P2X%X3E3Q,\#+B'-*;
M4HYAGBHXF-&:=U+"Y=&G_9U!P]UJI.CC*UTIJI!OW?/=9\.Z1K>BWGAO5]+L
MM1T#4=/N-*OM%N+=!IEUI=W&8;BP:VC\J-+:2)F5EB\HYP5(?:U8.A>#_#W@
M[1+?PYX3T+2_#>@V:".#2]$LH+&S &?WDBPH&NKAV8R2W5T]Q<SRN\TLTDTC
MR-Z5J#VEA:7-W=S0VT%I;3W5S--(J)#;6\9EGF8,<F.*-&=W ;:O)[5\Q7O[
M2'@_4?$_PLT3P-I.O_$?P[\5)O$%O9^/_!MBVJ^"O#D_APC[?%XDUV$-8:5\
MQ40-<S)Y[L(H]TC!*Z(4,37I3C1A4G3CS5):N-&,J=&51N3G.%%5/8PFXIOV
MTHJ2I1G\+_5ZE7 8>O2K5GAZ>(Y(8:C-TX2Q*I5J].DJ=-QI3KPP\J[I0DH*
M&'A-P=5TURM>DWML%SC(VDMG!S@].G4#G)ZG/?C/"ZI&%)Y)Y8K][G/4=!C
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M)W=M.9RMI8****],Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4=6DF8Y;"CE4'"+Z[5R>P'S-S[]!7YS*<YN[=WW?:^T5HM.GV5YGT:22LO\
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M1."<'D'^1#]NWX?>'X/VH]0^)/C75+RZT7XRZ1X5\9^#-/FN98-#O[Z_TO\
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M"3+(1+$<\?-GYU&/NM]W. P%?77A[XN6M_;Q)<R1RY.#<(0DF#@ S1]<D]6
MY]:]&ABHM6DXJ3=M=G_EZ=3Q<1@)TY-Q3E'>W;OZ[>I]!7%Z.2S#MR3D#^H]
M1CCU%<Y>ZM#&K?-DCKSUZ]?QQP#WZFN+N_$+R1&<S)%; ;C/*ZI$%([,V >,
M$ <MZ9XKS36_B!:6N^.PS=SC*BYF7]PI_P"F4/#RX)X:3:F>QSBNJ=56LM7U
M\NYSPHMZ6:7EN_G_ ,.>F:CK$<,;7%U.EI;YX>0[6?!Z11Y+2''0*,<C/I7E
M^M?$ @/;Z2'@1LHURV#=S \?+C_CW!]%R_(PP.*\SU'7+W46EO-0O&2-$:22
M:XDVB.)1DD#(2*-1T"A5)XY.,^;7?Q*T2P6:6U'FI &Q<2C=+<R X"VEMD'9
MT)GN'AC5>[.RH>:=7E4GJ[:66]WLDW9-MZ:O[CMIX9MQ5M7TUT75NUVTE=OR
M6EW:WL,]O*]C)KOB+5+;P_H*M(3J6HEFDO7CP98-+L@ZW>KW@R T=LODQN5^
MU7-N"&/DOB3XIK)9WND^#K$Z3I[%5DU:\V2>(KZ!$W%)'C+6^FP3D>8;:S!9
M5(CDN;H L?+]3U_4_$-R+O4KJ:X!51!%+-)+'! "3'"@?"+$F?D@ACAMXV)*
M0AB7;*8_OYU&1OCB;K@DD/'^/;Z=/K@Y.=N=:-KW;Z+9M/OV=]--CNA3C!2Y
M7>2B[2M;K;2^J=GNG?S1F^(U&+.0$D,KDDDG+MM8L23\SGD%B,G'7%5M$L[F
M]OK:SM(9+BYN)5ABAB4L\CR?NU5>@&YV5<L0H) R,UZGX-^%?C3XLWNF:+X0
MTBXU&X,D0N+D*J6=A;,?+EO+VYD9(8+:#!+RNZ@LH@CWW,L$,OZZ? /]E3P9
M\&[>WU;4%M_$_C?Y97UJX@!L])E*;3'HD$J!E= 63^U+A1>2;I&MHM-AN)K0
M]E"G*HK)6BG).3VW>W=^GS9SU&EOJVEI\E]VVVGEN?-W[-O['&H1367C;XHQ
MR6$!S-8>$6#1W]RNY7@GU9PROIT) #BU 74W+!91I;0_Z5^F=I9VFGVMO96-
MM!9V=K$D%M:6L,<%O;PQJ%CBAAB58XHT4 *B*JJ!@"K%%>A"G&FK16KM>3W=
MMKO\ELC ****L HHHH *\V\'_$1/%7@&+QC+I#Z5J2>';77=1\.R7HNC9O>Z
M';^(+*&#55M(([^QOM/N[:>SU**SC)25[>]LK'5K/4=+LO2:\1LO"'B32_AE
MX/MK.R*^*M'^'&D>$M?T%+FP0:Q$GAR'3I]-?43<C3C>Z#JCRZCH]Y)<S69_
MXFVF07%G;^(KK5+< ]'U#QAX?TR\N;.\NKM6L!&=3NX-(UF\TG1Q)"EU_P 3
MO7+/3[C1M%,-E)#J-VNJW]FUCI=S:ZI>"#3[JVN9=35=8T_1H([B_EE43SK:
MVL%K:7FHW][<M%+.;>PTW3H+K4+^=+6WN;R:&SM9Y(;&TN[V94M+2XFB\\U:
MQ\10:9XK\(V?ABXUJ/Q,/$TFG>(I+K0FT.W/B=;EU@\66]]K%AKQBTR]O9[-
MXM%T;7$;PQ::;]GEEU!IM+M=+QUX6;7+O0-5\GQ#J$6B'5(;C2?#GBO5?"6H
MW$6K0VJK?V=[IFM^'5NKVPGL88/L>HZQ9V!TK4=8G4W&HP:?:7 !OV7B_P .
MWZP/#?M"+C3]8U1?[0LM0TEH[+P_?Q:7KDETFJ6MFUE)I%_-#;:C;7@@NK1Y
M$::%(V#US]G\4O"MYXBO?#@7Q#:2V'A+0?&USK&I^%/$>E^&8="\0QZ]/:2W
M7B'4-,MM+TVYM;?P[?2ZC:ZK<6$MHSQ6C;K^*^M+/C=6^&[ZYI=CHVDZ9JWA
MRW_MB3QQJ.H^+M?G\7:G?>(M.LUT'3/#NJR7'B/Q#?WWA_7]*@2Q\8Q0Z]#!
M>^!C<^#8%W>)]3N-!N>(/#&O>([W5)Y='U.R;QIX)\$65REKKEG86WAW5_!F
ML^)_$\VBZ[K>F:K!KJV>NSZ_!X?;4_".G:I/##'J%V)+56M96 .Z_P"$]\,I
M;ZA<W%SJ5BFF2:-%=0ZGX=\1Z5>M+XBOSI.A1V>G:CI-K?ZE)J^J Z9IZ:=;
M7;76H V40:Y_=4Z;QUX=AG@LV?69+^?3;;5_[,MO"WBF[U:WTV\GNK6UN]0T
MJUT:;4=,CGN+&\@C&HVMJ[2V\J;=RD5R&E^#K(3'4K?P[XXL=4M+K0X()O&G
MCJ^\6@Z8WB;0]8U9=-BOO'?BZVLC'_8-E<W;B.QN;@V]I';M=,KQIZ+!921^
M(-3U PJL5UHVA627 ,>^62PO?$4\L+ 'S0L"ZC"Z%U$9-P_E%F$P4 HZCXR\
M/Z7Y9N+J[GBDT^'5C<Z7H^LZW90Z7<2-';ZA=WVC:??V=E93^7-+%<WD\$4E
MM;7=VKFUL[J:%OA_7+O5M6\<V%S';I#X9\4VFAV#0)*LLUI<>"?!_B1Y+QI)
MI%DN!?>(;V)7A2WB%I%:QF%IDEGG\R\3:+X]G\,1>'-);Q=I[GPG9Z1:'PH_
MPR33H;M]%:QGC\077C6WU6^18;[(F;P]I=U'%IR6\UH=0NY;BUAZ'P7X4U:R
MTOQUIVK0MII\07VE?8IDFMKE_L\?PK\!>&+JY46UQ)L:VUC1]4MECE:&20V@
MGC!M9[>>4 ZFT\<>%[W<T>I/!;#3+C6H]0U'3]3TG2;K2+4![G4[#6-4LK/2
M]1L((7CNY;NPO+F!+&:"_+BSN(9Y"/QOX<:WO[JXNKW2H=-TN\UN[_M_1-=\
M.2KI&G(DFI:C#;Z]INFW%W:Z:LL']I2V<4ZZ>UU9I>>2][:+-R]S'XC\3Z1;
M:1>^!1H>IZ0VG:E!>ZCJ7A^7PN^JZ.(IA9Z)+I-[K&O_ -DZK.LFB32ZAX>T
M2Z/A:_U1Y[>.Y*:-?/U"WUWQ6]_<3>$+W0XHO!GC+P^MOXAG\-3ZCJ-YX@?0
MVLHM.?0=?UZRCTUTT>Y&JC4[FQ=I9=(,44R)>&U +VN?$_PQH/ACQ+XLN8O$
M<^G^%] O_$MW:6OA+Q)_:^HZ7IL!N+F70-,N]+M;C7=BF%9)-.$]K:&ZM);^
MXM+>YBG;8L_&N@7U]9:9;MK!U&]L[;4!83>&/$]I>6%C>W&IVEC=ZY;76CPS
M>'8+ZXT;5(K&77TTU;QK&X^S&4)DY?CWPS>^*=*US2K/RXFU?P!X[\,QW<A0
MK;7OB*VTFVL]Z%TE:-C;S2R%,(!;@2.C-%NG6POO$<.ORWFG:KX6/B+PK::+
MLNY](DUC3IDN/%,$K&31-4U>P\^WAU&UOK9[?4)XL7$:^8EPES#" 8_BCXF:
M5IWA+Q3K6B3-/?Z9X7\2ZUH$NJ:+KMIH&NW>BZ)J&L6T>FZK<6NG:?K]M=06
M$M_$-#U29]0T:"ZU33YGL(9+V/4L_&<4=_XUM]8,<,&@>,++PUHT6GV.H7VI
MZFMSX$\*>+)(X].LEO[[4[^.76=6G=--L@(-'L&NIX%BL;Z];A/'>F>,?&?@
M_4O#=OX(;3=1LM \5VRSW%]X;;1-2OK_ .'OBGPQ:6W@^:VUN74K<76K:W:)
M9W/B32?#J)H(OS?K87;16<BZGX!U&[\2^)?$-Y9>(;JR;QG/?V.F^'/&%_X5
MU'4M+U#X<_#O06U:SN]'U_0"][IVM^&;S3O[.UK5M-MWTJXUB^CCN;@:1%>
M'LFDZM8ZY81:EITDTEI-)<PJ;BSO-/N8Y[*ZGL;NWN;'4+>UOK2XMKNVGMY[
M>ZMX9HI8G1T!%:59.A6$.F:18V<$>K0QI#YOD:[K-]X@U>W>Z=[J6WOM7U'5
M-:NKR:WEF>'<=5OK>%$2WLIVLXK<#6H **** .<\5:%'X@T:ZL2%%P%\ZSE(
MR8KJ/)C.1SM?)C?'!1VR".#\2_$C7].\'^#/$VL>(+*2ZL=.LY;6_P!.V+FY
M:>061M9B_P"[@@:27_2+B4B.VB#3,0$R/OVOFGX\?#;1?%>@>(-*UBR>[\+^
M.-&U'PSXILX9'@<V^JVDEI+/#/$1)!,T;^;#,#^[NX8G(=69#\]GV"]K2>+I
MQ4ITX2A6CHN>FTU%NZ:M!RY9732A.[346GY^-HING75UR2@JKC?F]FIQ?.K-
M/FIZM6:=K)-.S7\6_P#P4M_93^%_[?'PYU3]H3X&ZW:ZQXM^%]Q=?##XK0Z8
M)I)[_P .:/-]DT'Q*K%5FO+SP'+=P:-J.I)$9[GPS+IMZK?9=%DDM>]^$EGK
M>H_#7X2:KXX@-M\1=-\!>'O#'CR-XU8WVL^%+1=$@UM+A&,<IUJPM+>]EP3M
MED;:%0*#^N'P)_8P/[-X\2>#/ WA5=0T#[9JMQK7B?4A@^/C+:-$ME>Q,["2
M/5=/GGTV>"RB-O9.VYWDE\MG^+/BK\.!\,?%K6&F"XE\):S&VK^#[V="LATM
MYFCN-%O^JIK'AN[$NDZC'N^<06]VNU+H1Q_EN/S#,L)ED\NJPM2J1HV=::Q%
M6%.C*U*5.I2Y*:E2=2IA*TG!IP]A+E2E&;_7N!,1E&/S"I1CB/:5L*ZT\)*-
M.6'CB*=1QGB*$Z=1SG)4Y6QF'7.I*G/$4U)NC*$<:Q=0% SA1@ XX(&,D >A
M(Q]..IKH[<@+\ORD8(&"3CV'TZCD]:Y"QN" N[ [#KNS@@\>^>N "3[UOI/C
M&=QP-W3NWN"#GUYQC/7BO@ZFDY*W7OY7OT6O_ >J/W*FU&7:]FG;?3I;OO\
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M3T7M4M3\+/#O@WX[?M!W$6D_!GX9:EINBZBPMX/B'\2]/U31;*Z60;5G\,>
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M[MI^;L=4:5.C&324%:TIR>K7G)VT\E9=$F['):4'GM[01HTDDD48544LQ(0
MX49R05.<9.!DU]N_!']CSQ5X^GL_$GC0S^%_";QY2.2,#6=50,KQMI]K*NV.
MVD!8IJ%TOV5AY<UK!JL$CJGUY\!/V0/"/PLLK#5/%8M/%WC")$<R21-)H>ES
M"3SE%E;3HIOYX'V;+V]A2-7BBGMK"UN$,\GV/7N4<'M*MZJFG_Z4U_Z2GZOH
M>).O:ZI[--.3ZJ_1?):OY(Y#P5X#\*?#S18= \(Z/;:3I\03S/*!>YO)40(+
MB^NGW3W4^T;5:1RD*8AMTA@1(EZ^BBO0225DDDMDM$<P4444P"BBB@ HHHH
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MCI=C:*XM=2OM8M@RV\$886VKZGJ6JP @B'4M0OKZ/;=7<\LCM5\/:!KWV?\
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MU6#PU-X0\/#Q1JOB70]-^'>[7?"VEWM@%TX![O\ LO4M1NHUFT87$<.H6O\
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MQ*^'VA:3KVN:KXT\,VNE^&-)O-<\077]LV,_]E:38*ANKV[@MIIKA8HS)%$
ML+22SS06\*23SPQOYSX8\*7T$^B:-KGC+XDMJFD:Y+K,]DOA;PY;>&KS5H;^
M\U2\U&#Q5I?P\5[?3_%"S7ES=6__  F*ZM<6&MW?AS6[F2_NM2L9+GBCPA=7
MGPCTKPGHFE&WNAX-U?1[.P6"2WCL;N^^&7BC1H([I%0M; WU]%;2M,F[[1.
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M8_\ P5M5 ?\ BP!)!P1_PM0#T_ZIP?7T_6I>.PJWJO\ \%U/_D2UAJSVA?\
M[>C_ /)'[)45^-$G_!7$1Q+(/@ CMOV2PK\6XO-@)0LADC'PY,@5]K ,8P.,
M@D5[S^SA^W[??M">(O$ND1?!AO"NF>&-'L]1O-9_X6"-=\R^U.]-KINE1V7_
M  A.C@27,4-]=O-]L8PQVFT6\GFADTHXFC7G&G2FYSDVHKDFKV5WK**222O=
MM(BM2G0IRJU4H4X).4N:+M=J*TBVVVVDDDWY'Z/45^,_Q'_X*W7/A/XF^+OA
MGX+_ &<;KXD7^@^);WPKH5QIGQ0FL;OQ9JEB5MY8K+2+3X8Z]/;EM1$]DJQ7
M&H + ;EF6-F6/[^^%'QU\:^,/"OA&_\ B5\*K+X6^./$D<L^H^!+7X@P^-SX
M;C!DG2VO?$$/A3PY;7NI6VFHMWK%M96#V6F7#FQCU*^9#.=:$XXFI5I4.:I.
MC)PJI1DHQE%M-<\DH-^[)^[)Z1<OA5SGK5:="G"K5G&$*D5*#;NW%I-2Y%>:
M5FKMQ23:6[L?35%?F?\ M'_\%&+?]F?Q5\+T\9_!Z]U'X6_$5[ZRNOB/I/C3
M?>>%]8TZ2)[JPO/"3^#RE_'_ &=<V^J6]Q;^)8IKFT2_$=EYMCLG^M_#/QZ\
M/>,=$TGQ+X:@L]:\/ZY9Q:AI&L:;K,=W8W]E.H:.:"5+$ GDI+$P66"57AF1
M)49![F+X=SG Y5EN>8C SCE&;NO# 9A3J4:^&JUL-4G3KX:I.A4J?5<73E"4
MGA<4J%>5-.K3A4IWE'S<)GN58W'8S+,/C(2S# *E/%82<*M&O"G7C&=*M"%:
M$/;X>:E&/M\.ZM*,VJ<Y4YM*7O-%><6_Q#AN,8TQES_T^*<?^2RUKP>+HIL9
MLG0$\D3JV!W(_=*#[#(R>_>O&<6MT>ISQ[_@SL**QX=<L9NIEBXX,D>0?8>4
M9#Q[@=?7.-".ZMI=OESQ,6Z+O <]\;&PX..Q4&D--/9HL4444#"BBB@ HHHH
M **** .(U#</B-X3<LBQ'P9X_APT9WO.^M?#B6)(YL;5/DP7+M!G?,J&55*V
MTA7B?#_Q*^'?Q"\1Z5>Z;X[\$ZE8:=>W7_"%V&G^*M$O-1\0:O+9WVE3^)+2
M&SU!Y[K3&TN\U.Q\/Q1)-:ZK97USX@V7,$F@75OZOJVBVFL'39+AIH;G1]3B
MU?3+RV9%N+*]CM[JQDDB,L<T++=Z;?ZAIETDL,BR65_=(NR1HY8]"XB>:WGA
MCN)K226&6*.[MUMVN+5Y$9$N(%NX+JU::%B)(EN;:XMRZJ)H)HRT; '+^&I(
MA!XEN;"VG>Q/B;7FL;5'C5YKFSD2SUM;5+BX2*W^U^*;37)0)Y;6*:XFDO&,
M<-R)6\ZN-;TKQ%XK\.7>E^/7U"ZENH9F^&=U#H8UCPM=7FBS6#ZN;*RT^'Q#
MH6J^'H)=5NM4L?'C:YHZWTMSIJV.GZS'H;V?LFF:98Z-86VF:; +:SM$*11^
M9+-(S.[2S3W%Q</+<W=W<SO)<WE[=337=[=RS7=W/-<S2RO?H \6\0:7X<TG
M4- MOB;XB/B;P\]IXDGCO_B1!X+M_#<.MM=>$(](LY4M="\/:"==CMH]:F\.
M-)92ZP;2X\4B&Z>U5HH/*O#VI^ H?!^G:>FC> -5T@^.?C?)X>3XC^)CX<\(
MM&/C?XHM_LWAU-4T+Q):ZDUO-#$=$^P:4;+2M$;3H= N8-%U>TCF^OJ* /F3
MPOXHGT7P9I/Q'ETNV$<6O?$#P'?:-HEY?26DFGP_$CQ1H?PVTK1!=Z5IMWJI
M@\06VB^"_"5I_8MA!:VOC.ZNK2"RTV%X9/5+_1]2T'X9WNEP7&I7NK0Z-=3:
MO?Z&+U=:U'4+Z22_\5ZGH<=HS7\.LZE<7.K7VD6^GE9K?4;BV@TZ.(QV\:=/
MJ_A^/6KW2+B[U+4EL=)NX]0;0X?[/72M4O[2:*ZTN[U-I-/EU1WTB^AAU"PA
ML]3LK4WL,,U[;WGD0JG04 ?/FI7_ ,(]/2YD\*6G@^\L9XFMO$:>'M3T'1?
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M+SQ+\'=:NTDUSPTLIFN?#\\Q59/$?A0R,5M[I%(DOM-!6TU6)2&6.Y$5PO\
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M?*EPP'/]D7Q6^"?PX^-&C-H_CWP_;:B5B,5GJT*10:UIR^8)MEI?-%+NMVE
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M]>@!F#Z'\C3U4$<CG/N/2I , #T&** "BBB@ HHHH Q_$*[] UQ?[VCZFO\
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M8'4"XL]#M+.VM=+\,:7.PS-IN@65C%>%8Y=4DU&\0W;^V          8  X
M '  '  Z4M>A3I0I*T5=VUG+6<O65MO)67J<<I.3N[)+:*5HQ7:*V7KN^K84
M445H2%%%% !1110 4444 %%%% !1110 4444 %(0#UI:* &[%]/U/^-&Q?3]
M3_C3J* &[5';]3_C3J** "BBB@ HHHH **** ,;Q'))%X>UV6)BDL>C:I)&Z
MG#)(EC.R,I[%6 (/J*_+Q_,=W=V=V9V9W<EG=B>69CEF))R3UK]0?$W'AOQ
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M%O!PDC;S8+:\=%\2>)@!&\VC0:5IRF>SUO48EJ,7)I?UJTOQ;27FQI7:7?\
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MT>6=++Z=1.5/1N%3%U/]KK*Z4L/2E[*3_AOX!M-'AM8;:V2.--H 10!Q@<G
M)Z=N_P"OUGX>TX6ZJ H&U=[=%5(T4L[NQ(5$1 7>1B%159V(4$U\U_$3XT?"
MSX":1IM[X^UITU;7)X['PAX)T*RFUWQ[XWU>5MEMI/A'PGIZRZIJ]U<RXB65
M(4M58E6GWXC;\5?VTOV]]7\37>H?#?QK/K$,,S&WM_V//@QXNEL?$VK;<E8_
MVM?CGX:=Y/!NE#,;ZI\&?AA<OXTGCWV'BW6?A_(7DE_+9SITH\U67*K7459S
MDN\8MI*.CO4J.%-:ZS:Y3]$A&4Y<L%=]9/2,?)R2=Y?W(\TGUY%J?K=\5_\
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MJTBVXIN[;2;;W;:NV_,VBK1BET27X!1113&%%%% !1110 C,J*S,0JJ"S$]
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ME<8Z')"L<'OC)'8<5='Q)O+Y C:@\<><"+888B >/EC_ '8!)[\'J0!T\O\
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MUJY+L0"0$\K<2 2 ,@$U_#_KOQ1G\9?$RWUB2^?[+96\*V<B2%D2*SBCMH9
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MRQV%D)$C2!0N%GNF::8.SHJ)Q7J/[??['=E\/?#>G_M"? ;2Y;WX0O;6UO\
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M(;.-&"H"VS+$@#! P2,#CGD8[=NS^'7P[M=-MX(;>U2!8PN%1!NP !R0!SC
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M[3X6D1+B/1].ETZ"PTJ[D\/6QD:'4=(T+0=-U&T41QZ;-+#'>W?Z33X&H4^
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M0-<UBTC>TU7Q)H=O<C4+NQ!34!<V[7%M:7\MI=G\9PV=E?7%_H6MV-_93:)
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M&CM&\3.BLT4AC,D3,H)C<Q/+$70G:QCDDC+ ['=<,7T %%%% !1110 4444
M%%%% 'FOQGA%Q\'OBO;D9$_PU\=0D>HE\+ZJA'X[L5_)9XX^"'A#XD^&+[PA
MXRT6'4M%NY5N(6>)!>:5J5ON-AK&DW+(S6>IV+L3%,GRRQF6VN%EMIIHG_K-
M^-^OV?A3X+?%[Q1J%G-J-AX;^%_C_7[[3[<QB>^L]'\*:MJ-S9P&8B$374-L
M\$9E(C#NN\A<U^"7@*^^&'Q.\)V?C;X?SZ?KOA_4E91(RO\ :].NT4-<Z1JV
MGSN\VE:M9DA;FSF57'RS022VTD4TG-C:&(AAUC_JU>>"IUHX6IBH0;H4L34@
MZ].A5J*ZIU*M*,ITU/E510FH.<XR@LUB*/UB.$=:G'$SI2Q$*#DE5G1A-4IU
M81;3G"%2483<>;D<HN2C&2D_P%\4?!76_A5XE_X1?48 ^FNK3Z)KD$.RTUC3
M4DV^;&H^6'4(LK'?6#'S+68[AOMWBF?1U/X=>'O%?AV[\.Z]9?:=*OTC,B0R
MO;W<%S"XEM=0M+V+$UIJ5E.JW%G=0,&@E7/*%T;]Q/B7\+?"7Q \):CX.US3
ME@L+H&:SO=/CB@U+1]2166WU73+C&Z.Z@W%71RT-W;-+:7"M#*PK\AOB+H.M
M_!_Q!-X0\0B*6:.!9]*U6WA6*RUO36S'!J%I$"1#(^W9>VLO[VUNA(LF\,DT
MO+AL72JMQMRR2=XR:]Z'=6T_Q+=;ZIW53I3C[ZNU?XET?];/Y;GYU^,/@-\0
M_"EYJ%KHEMX5\=>&=1\G;<^(]633-5MHX XC&JVUS;S12O$)'#7&DE_M 8*;
M6%253CH/"$FD36UQ=W,$^JV(!L['0%N++0-,G52B2ASY5WJL\8)VF9;:S5OG
M%FS[9*^R_$-Y<ZP)$\W"/SLW'GCG<PY.?0<<@<=^&B\,0JYD:)6?&<8S@#IN
M/;DY ')Y]*[(U*:M%+F2ORJ;O&-[MJ*^;:5VE?2VC)Y9-N5^63U;BDG)JUFW
MM?1*Z2>FK[^$>$[GQOH.O:[>W%@UQINIRPZC'?6\L)>%XK>&S:Q>PWK/(ABC
M$J>3&^P^8NY@P4_07@_Q[<17EMJ&@7LEEJT4B,EM!*R&:7> !;@$,LCO\GE'
M@N=C!&.T4YM/CB!.T!4R1QA01T &.@]3ST/>MGX7^$M,U;Q_%KLBXD\-PIJD
MT,;QK'=7=QYMMI1N[<<$1.D]W%+A6F>S".\BAE$5:5.--UH3E"=).2:;YD[W
MBDUJUS.,;2VO=33TETT:TZE14*L%.-2T5HK+37F3VT3=X[_ROI]]^#98K.\_
MX2F]T;2+'QEK.GVD'B+4=/MDM[F\9"9 MRZ$1M=!BBWT\"1F\EB4SM,8T<?4
M_A#XMOX;A:\O;PQ6=JI>4.2[>9CY5A7<':29E$?EC(=QO^1ANKXVM+UMP"MU
M(^H;J&)XYP,DG@@$\=*76-;@,2K>7(@M8<DG:"-Q4DRH@RTDF/DC7 )+"/@D
MD\-'$UZE:56I4ESWO4J2?1*R7;962LU;6S;=]\3A</3HPI0II1?NTX1^]WWN
MKN]][NR:2T]O^+W[2WB[QI'+I5I<'POX8D5E^PV,Y2^U4,I\R75;V,K(\3X#
M-86X^SJK[)#.1FOE2+Q/I<>HVD!MH[R>25?(LYLI8R/$^V6XN67839Q$*/)B
MXN&81$J"]?=?[-S> M1D,6MZ+IJ0WJF-Q?00ZAJ,T3$H3>W-TLQ@,BD,MK8)
M''  JM*S Y[7]H']A/3K/3+CXH?"J*:_\/W<<<NK:8)Y;R[T*3;\DD#8,BZ<
M&W!53Y+:4D-^[8&O8E1Q-?"RQ.'FJTHZU()MU84UNX1V:_F44G%:I/=>)'$X
M;#XJ.&Q$)4(STIU&DJ<JCVC*2UBWT<G[S5KK1/O/V=M<^'GC#05\&^,=-TW5
MM-OX4M39W*1VUHD9!3RK6RM_*AM6C#%HVC#2@$,T@+5Y7^T=^P]_PKU!XM\
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M<=?3/ORGIJTD?E2BWLK+^OZN,MD<8!SS_P#6_7J.?QZ\[$43. ,=<=1^A^G
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MZGP;X6\ Z+X16Y;25O'GO$BCGGOKV2<M%#O>.*.W016D,:.Q.Y(#.P)\R>4
M&NR1(U_UC L20_("YQDC!Z#&#D=<9..<_9J?#'P-&P9= MFQVDENY!CJ,;[@
M]#W.23AFRP!&Q:^#/"ED0UMX?TJ-@00QM(I&RO3F57)P0#R?O?,<MS64Z=6I
M)SJ574G*SE.I*4YOIK*3<G9:+6R6B2220DDDDDDE9**44EV2222^7S>M_BVP
MT:_U5Q%I>EWE\[,,?9[>5D!(P"96 B4$="9%!YVDFNW;X+^+KVV3SK*QB69
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M#GUX6J$U<^6(+48!Q[_YZ 8[9[D'OBM>&WQC _\ U_3'?\^F>IKZ5  Z #Z
M#^5+5*5OZ_KIH1R>?X&!X67;H.G+Z)-_Z4S&M^BBI+2LDNP4444#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S G # 2(  A$! Q$!_\0
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M:1'))/4^U)<T535->Z]P;C*4W4WZ!J5A%!K$28"PRL"1V'/-:NIS7EC%&;"
M,G\7RYQ^%9^LNMYJL-J'"!>"WH34LIU;2PB1G[5&1UVYQ[4H\L)3Y5I?== :
M<E'F>MMF5]0U.UO;+RY8G2Y !'RX ;_"M31;V6\M':15!0[1M],5#J,23Z,9
MKF(13A<@>A]*9X:P;.<$\[_Z5=-RC72O>Z[?F*:BZ+:6S_JQC:AJ$M[./-"C
M9D#:/>HK?_C[A_WQ_.EN[66WN'\V-D!8[>>M,M_^/J#_ *Z+_.O'FY.O>?<]
M6"BJ/N[6.KU:]_L^VC>*)7=CM!(Z<5'872:S8RK/&H8?*P'3ZBC7[26ZM(Q
MFXJV2*;H5K)96<LER-A8YP>P%>X^?V_*_AL>,E#V/,OBN5_#<6RYO(V'W"%_
M4UDW_P#R%Y?^NG]:UO#TZR7]Z1QO.X#\356[TN]DU9V2(E&?<&XQBN6I3YZ,
M5!7L_P!3IA/EK2<W;0T?$8 TN+C^,?R-3F9;?04F:,,$C4[3Z\5#XDXTN/\
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ME7(G)7%69M0NY;?R6E+)Q\N.*ZZ&+<%+G;;:M<Y*V%YG%1LDF6)M;O9XC&9
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M !1110 4444 %+24M 'HM%)GCFEK[T^."BDI,&@!U%-P:,&@!U%%% !1110
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M".&''7G-&X8Z@<=<]J ,3_A#M$_Y]G_[_/\ XT?\(=HG_/L__?Y_\:WJ* ,
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M'+H=I)[CM6QGO7LTJJJ04UU/+J0]G)Q?0P?^$0T0'_CVD_[_ #_XU2GT?PS
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M8444<_\ UZXTKG7=(**3IC]..M+Z_KQTHY6',@HI-W%+AMNXJ=I. >V:+-[
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M>PQ7B9DZ4IWB_>ZGKX!5(PU6A-86C7EVD: E006.. *[D?*N/05Q=EJMQ9L
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M_P"/>;_>'\JS_$>/[4'^X/ZU]!7D_J2/#HQ7UM_,RJ***^?/;")VBE1U."C
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M4 %%%% !1110 4444 &*,444 &*,444 %%%% !BBBB@ HHHH **** "C%%%
M!1110 48HHH **** "BBB@ Q1BBB@ IK=*=2-TJ9; CS^Y_X^YO^NC?SJ'^*
MIKG_ (^YO^NC?SJ'^*OB:WQOU9]92^!>@M%%%9&H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2TE+0!Z(3BH_-3O(F1_M5+C-9QT/32<FSCR?K_C7WI\<7/.C_
M .>B?]]"CSH_^>B?]]"J7]@Z9_SYQ_K_ (T?V#IG_/G'^O\ C1H+4N^='_ST
M3_OH4>='_P ]$_[Z%4O[!TS_ )\X_P!?\:/[!TS_ )\X_P!?\:- U+OG1_\
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M]"E\Z/\ YZ)_WT*H_P!@Z9_SYQ_K_C36T/2E7<UG$ !G//'ZUKH9ZE_SH_\
MGHG_ 'T*#-'_ 'U_[Z%<S--H$,A1;)9-IY*YP/UJW9VNB7ZDQ6L>X=5.<C]:
MPCB*4I<L9:FKHU%'F<=#;\Z/_GHG_?0H\Z/_ )Z)_P!]"J7]@Z9_SYQ_K_C2
M?V#I?_/G'^O^-;Z&6I>\Z/\ OK_WT*/.C_YZ)_WT*Q[JPT:QCWS6L8]!SD_K
M6>ESH#-AK *O]X@X_G6$\12@^64K,UC2J27-&.AU'G1_WU_[Z%'G1_WU_P"^
MA6;%I&D3QJ\=I$RGH1G_ !J0:#IG_/G'^O\ C6R::NF9M-.S+WG1_P#/1/\
MOH4>='_?7_OH51.AZ8!_QZ1?K_C65=/H5HYC^QI(XZA,]?SJ*E6%-7D[%0IR
MF[15SH_.C_YZ+_WT*0RQD??7_OH5@62Z%>OM2T19.FQLY/ZUHG0],"Y^QQ_K
M_C4QJ0J*\7=!*$HNTE9G(7)_TJ;#+_K&_B'K4.\9ZK_WT*9<V%G]KF_T6/\
MUC>OK]:2/2K:601I9JSGH #7R<U"51I7O<^EA*48)NUK$N\>H_[Z%&\>J_\
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MSDBHVFC$3Q;P[+"$W#^(YJEBC _&F\0WT$L,A:*,T5RG8%%&:,T %%&:0'-
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M*S.7%8R%6'*D<QX@ ;57_P!U?Y5FXKLKK1[2\G,LJL6(QP:B_P"$=L?[C_\
M?595\NJU*DIJVK+H8ZG"FHN^AR/X49Y%==_PCMA_<?\ [ZH_X1VP_N/_ -]5
ME'*ZR=]#668TFMF7SQ8D_P#3/^E<#GYB.U>A^6OE;/X<8_"LO_A'+#_GF_\
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M,'BEKC/[>U#_ )ZK_P!\T?V]J'_/4?\ ?->@LTH^9Q_V?6\CLJY[Q1_J+?\
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M^M1S3AX8H8^(XASGNQHJU:<XM+L%*C4A)-]R*BBBO./3"BBB@ HHHH ****
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MO-,$LT$(222.4M]T 1GYESR?G[>U '?T5PL_Q$@5=T=K*BI)^\:3G=&"P9E
M/7*]#CK5FX\83W/AZVU'3[4P/<7:6P%\-H /\7':@#L:*X(?$6WE6*%872[>
M)92/O*OS %?7^+(]:OZ'XS75;B.PEMW2_9'D8+]P(,X?/H2,?6@#KJ*X.V^(
M?G:>&>R=)S$S>8.8PX4L%QG/058M?B!:74ACBL;QW,H@C8@*DK<Y().!C!ZT
M =I17"VOCYW*FXLBC/N6.!'#,[>:8Q\V< <=_2IX_B#:39>.QO&782"%'S,%
MW% ,YSCO0!V=%<9J7BVZ6&TFTJ".8SV;7(C=NN"H501WRU9@^(-Y?76S3H;4
M6\K1)!/,QP2Q(<GV!!'X4 >BYI:X+3/&UWJ.I6T?V:..%I8X9,,226#?,#Z
MKQZ@UWM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4C=*6D;I2>P'G]S_Q]S?\ 71OYU#_%4US_ ,?<W_71OYU#_%7Q%;XWZL^L
MI? O06BBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/I0!<HJF+^V9RHN8R0GF$;QD+US]*GCD$J*Z,&1N05.01V- $M%%% !1110
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M2.TV]4D4, S'&<#<.!UJG%X.UK["$DU:X:9;9D0FZ;_6E@=V0.0![5Z  !T
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MPDM;<B0K\S_>W#'([#T KK/#]G<:?H-C970036\*Q-Y9)4X&.X%:V*0 #H*
M%HHHH **** "BBB@ HHHH **** "D;I2TUNE)[ <!<_\?<W_ %T;^=0_Q5-<
M_P#'W-_UT;^=0_Q5\16^-^K/K*7P+T%HHHK(U"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-_J9/\
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M_C[F_P"NC?SJ'^*BBOB*WQOU9]92^!>@M%%%9&H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)O]3)_
MNG^59VB_\>+?[]%%=M/_ '>7J<E3^-'T&7_RZU:%>"<=/K6I*2(G(X.TT45K
M4VIDT_ME#1?^/'/<L23ZU'=?\ARV^@_K116B_CR]/T,I?PH^IK4M%%>2STC_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "; (L# 2(  A$! Q$!_\0
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M#O3)+VH:BE]XGO\ 4K.,0VLUR\L,>/NYS_2JEP#) R@X;[R^QJ,LF[$08(.
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'<!C^= C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- )<# 2(  A$! Q$!_\0
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MD'\&[&,_6L8''->76OB:>#Q7=ZE<,6CO'+2A1SC)Y_ 8KT2TU&WO(E>*0,K
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M>E&#WZT=1W%/4&Q*6D%'>@D,44M% 'T5?/)-,8F.Z29B,]R35^",16X1!A5
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6=$NEZ%6_"BNO,:9^Z**?.Q>S\S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D *D# 2(  A$! Q$!_\0
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MU*BAB6) H%2TA%>ZM(KR Q3*"I_2N*U'PO=Z>9)-.<&-B28VY%=[2$ C!'%
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BBBB@ HHHH 0@&F[5ST%%% QP %+110(**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+B+($L8ZHW^T/UH Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ08X)]ZY2Z^$NB3S7*PWNIVMA=2>9<6$%P5A=B<GCM7;65G;Z=8P6=K$L5O
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MC><0SNS?-D=#GU'K6A10!E-HEJ_F,\MPSR+M=_-.YE]/IQ4R:9;Q+$(C*GE
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M-J1 &['2-:WKK3K.\ DN[6)C&."X!X^OI5)VW)91TIQ-J-_/"08'* LOW7D
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MN43V'J?:N_L;&'3[58(1P.K'JQ]33K.SM["U2VM8DBA085%& *L4[""BBBF
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M>3Z5[W??"3P;>$L-+,#'G]Q*R_XUM:1X<LM"M1;:;806\0&#Y8&6]R>I/UH
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M._X2"^_Z!C_K_A6R]U&&(*M^5'VR+^Z?RKSYTIMMJ5CU8U(**3C<QO[?O?\
MH&/^O^%']OWO_0,?]?\ "MC[9'_</Z4?;(_[A_2I]E4_F*]I3_D,?_A(+W_H
M&/\ K_A1_P )!>_] Q_U_P *V?MD?]PT?;(_[AI^RJ?S#]I3_D,;_A(+W_H&
M/^O^%'_"07O_ $#'_7_"MG[9'_<-'VR/^X:/95/Y@]I3_D,;^W[W_H&/^O\
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M/[K50HH O_;4_NM0MXC, %;FJ%/C_P!8OUH N?;4_NM1]M3^ZU43U-)0!?\
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M-1]AC_O-5JB@"LUG&S9+-2?88_[S5:HH J_88_[S4?88_P"\U6J* *OV&/\
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MD'L< UB:;I_BBUU)/M-SYD)N2[,D@V,G0EE/.2 , =#F@#O/MT?]UJ/MT?\
M=:O/Y]!U.::0*LL4_P!H,C7J71!D7?E0%YQ@<=/SS2QVOBV2X FNC%&$!8I,
M#N8(<<8Z%MN0* ._^W1_W6H^W1]P17FM@OBR_MGDAN;J) 65/M) ?=M&2>.5
M+;L>E:5]HVH3QI(%>>X1@J^=,""H4 %QWR=QR,$<8H [C[='_=:D^W1^AKSB
M>V\3V%FTYO)C&K$/%!(&.S<#\@P?G^]S4NC6/BC?!<RSM''/()9%E.6[??'N
M!C Z&@#T/[='_=:C[='_ '6K@[^V\6-(XMIFVK,64I*JAU+Y YY  P.OYUKZ
M'#JT7VDZM,)&9QL"G*CKDCT!XX]J .E^W1_W6H^W1_W6JA2CJ* +S7B*Q!5N
M*/MT?]UJIR?ZQOK3* +_ -NC_NM1]NC_ +K50HH O_;H_P"ZU'VZ/^ZU4,44
M 7_MT?\ =:C[='_=:J%!!'44 7_MT?\ =:C[='_=:J%% %_[='_=:C[='_=:
MJ%% %_[='_=:A;Q&8 *W-4*?'_K%^M %S[='_=:C[='_ '6JB>II* +_ -NC
M_NM1]NC_ +K50HH O_;H_P"ZU'VZ/^ZU4,44 7_MT?\ =:C[='_=:J&,T4 7
M_MT?]UJ/MT?]UJH44 7_ +='_=:C[='_ '6JA10!?^W1_P!UJ5;Q&. K=,UG
MT^+[Q^AH N?;H_[K4?;H_P"ZU4** +_VZ/\ NM1]NC_NM5"B@"_]NC_NM1]N
MC_NM5"EP?2@"]]NC_NM1]NC_ +K50HH O_;H_P"ZU'VZ/^ZU4 ,T4 7_ +='
M_=:C[='_ '6JA10!?^W1_P!UJ='=)(P4 Y-9U3VG_'POT- &E1110(**** "
MBBB@ HHHH R[X,9) APY7"GT..*\WCT/Q3"EK-9I/;WD",97EO5D6YEPN6VG
M(53@^_L*]*N_]>WTJ"@9P,@\=QQWL\LWD01^9)&-\<C$?)@?^AD=.V:@L_\
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M[9+_ +/Y56HH L_;)?\ 9_*D^VR^B_E5>B@"U)=R*Y VXI/MDO\ L_E4,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742179965872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR
MEDICAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,971,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10470 Thornmint Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,536,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742296272368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Farber Hass Hurley LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Chatsworth,
California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742284388688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,232<span></span>
</td>
<td class="nump">$ 3,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">9,697<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">4,110<span></span>
</td>
<td class="nump">3,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">13,807<span></span>
</td>
<td class="nump">7,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">2,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, 100,000 and 50,000 shares authorized as of March 31, 2024 and 2023, respectively; 32,464 and 10,949 shares issued and outstanding as of March 31, 2024 and 2023, respectively</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">77,432<span></span>
</td>
<td class="nump">53,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(65,929)<span></span>
</td>
<td class="num">(48,459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">11,535<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 13,807<span></span>
</td>
<td class="nump">$ 7,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170640688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,464<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,464<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742173065904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,880<span></span>
</td>
<td class="nump">$ 9,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,649<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,529<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,529)<span></span>
</td>
<td class="num">(13,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(17,468)<span></span>
</td>
<td class="num">(13,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,470)<span></span>
</td>
<td class="num">$ (13,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares used in computing net loss per share (in Shares)</a></td>
<td class="nump">22,377<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742178786624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares used in computing net loss per share</a></td>
<td class="nump">22,377<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176109376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 43,406<span></span>
</td>
<td class="num">$ (34,580)<span></span>
</td>
<td class="nump">$ 8,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">10,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet', window );">Issuance of common stock in registered direct offering, net of fees and issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,372<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet', window );">Issuance of common stock in registered direct offering, net of fees and issuance costs (in Shares)</a></td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services (in Shares)</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances under equity incentive plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under equity incentive plan (in Shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,879)<span></span>
</td>
<td class="num">(13,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">53,524<span></span>
</td>
<td class="num">(48,459)<span></span>
</td>
<td class="nump">$ 5,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">10,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts', window );">Issuance of common stock in public offerings, net of fees and issuance costs</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">20,045<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares', window );">Issuance of common stock in public offerings, net of fees and issuance costs (in Shares)</a></td>
<td class="nump">20,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AtthemarketSalesOfStockNet', window );">At-the-market sales of stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At-the-market sales of stock, net (in Shares)</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants (in Shares)</a></td>
<td class="nump">719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services (in Shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances under equity incentive plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under equity incentive plan (in Shares)</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,664<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,470)<span></span>
</td>
<td class="num">(17,470)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 77,432<span></span>
</td>
<td class="num">$ (65,929)<span></span>
</td>
<td class="nump">$ 11,535<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">32,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AtthemarketSalesOfStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>At-the-market sales of stock, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AtthemarketSalesOfStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share of issuance of common stock and warrants in equity offering net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of common stock in public offerings, net of fees and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of common stock in public offerings, net of fees and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of common stock and warrants in equity offering, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742173023760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,470)<span></span>
</td>
<td class="num">$ (13,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,701<span></span>
</td>
<td class="nump">2,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on asset disposal</a></td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_IncreaseDecreaseLeaseRightofuseAsset', window );">Lease right-of-use assets</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">458<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liabilities</a></td>
<td class="num">(355)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,952)<span></span>
</td>
<td class="num">(11,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="num">(1,638)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="num">(1,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market sales of common stock, net</a></td>
<td class="nump">278<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">742<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public and registered direct offerings, net</a></td>
<td class="nump">20,065<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,085<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">5,433<span></span>
</td>
<td class="num">(5,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of year</a></td>
<td class="nump">3,799<span></span>
</td>
<td class="nump">9,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of year</a></td>
<td class="nump">9,232<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RightofuseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ReceivableFromTransferAgentForWarrantExerciseProceeds', window );">Receivable from transfer agent for warrant exercise proceeds</a></td>
<td class="nump">142<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CashPaidForAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncreaseDecreaseLeaseRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncreaseDecreaseLeaseRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ReceivableFromTransferAgentForWarrantExerciseProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivable from transfer agent for warrant exercise proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ReceivableFromTransferAgentForWarrantExerciseProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RightofuseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of right-of-use asset obtained in exchange for lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RightofuseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742174513824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1
&#8211; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.05pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin
pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part
patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access
to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and
streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand
the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass
market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the
MODD1. In March 2024, the Company received comments from the FDA on its submission, and the Company is in the process of responding to
those comments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and
general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue
to achieve profitability. The Company&#8217;s expected operating losses and cash burn raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company&#8217;s
independent registered public accounting firm, in its report on these consolidated financial statements for the year ended March 31,
2024, expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to
continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital, through the sale of additional
equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form
of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions
acceptable to the Company. In, May 2023 and February 2024, the Company completed public offerings of its common stock and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2024 refers to the fiscal year ending March 31, 2024). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of
Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reportable
Segment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
operates in one business segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>General
and Administrative</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily of payroll and
benefit costs, rent, stock-based compensation, legal and accounting fees, and facility and other administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains its cash
at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
and Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Economic
Disruptions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may
be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly
detrimental to its existing stockholders and to its business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cash and
Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash held in
demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of
three months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Property
and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are recorded at historical
cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five
years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets
acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is
recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment
and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended
use and placed into service.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Fair Value
of Financial Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB)
ASC No. 842, <i>Leases</i>, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease
contracts. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liability
represents the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present
value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less
at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the
consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases
where the lease does not provide an implicit interest rate, the Company uses the Company&#8217;s incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. We account for such
awards based on Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 718, whereby the value of the award
is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually
the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance
criteria before recognizing compensation expense. The fair value of the Company&#8217;s stock options is estimated using the Black-Scholes-Merton
Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected
life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model.
The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Per-Share
Amounts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO)
during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding
for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options
and exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prior
to April 1, 2023, the Company excluded pre-funded warrants from the computation of WASO. The pre-funded warrants are now included in
the computation of WASO. Prior period amounts have been conformed to the current-period presentation. The impact of the change reduced
the previously reported loss per share by $0.13 and increased WASO by approximately 1,223,000 shares for the year ended March 31, 2023.
The reclassification had no impact on the Company&#8217;s net loss or cash flows for the year ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,481</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock purchase warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,173</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,217</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,698</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company&#8217;s historical
net operating loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the
year in which such tax attributes are utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Comprehensive
Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2024 and 2023, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective
application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU
will have on the presentation of its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S.
and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently
evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742174466352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Consolidated Balance Sheet Detail [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2 &#8211; CONSOLIDATED BALANCE SHEET DETAIL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Prepaid and other current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivable from transfer agent for warrant exercise proceeds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">465</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,209</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">283</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,654</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,977</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation
    and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(679</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(256</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left"></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,975</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">267</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">339</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742174510944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 3
&#8211; LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>W.
Bernardo Drive, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
39-month lease term expired on June 30, 2023, and, subsequent to expiration, the landlord refunded the Company&#8217;s security deposit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Thornmint
Road, San Diego, CA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases
of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of 8%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the
operating lease.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Future minimum
payments under the facility operating lease, as of March 31, 2024, are listed in the table below (in thousands).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal year
    ending March 31,</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">405</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,327</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:&#160;Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(137</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
paid for amounts included in the measurement of lease liabilities was approximately $476,000 and $230,000 for the years ended March 31,
2024 and 2023, respectively. Rent expense was approximately $449,000 and $237,000 for the years ended March 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170766592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
4 &#8211; STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Increase
in Authorized Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In
February 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Articles of Incorporation (the Amendment)
to increase the number of authorized shares of common stock from 50,000,000 shares, to 100,000,000 shares. The Amendment was filed with
the state of Nevada and became effective on February 15, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>February
2024 Public Offering </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, the Company entered into
an underwriting agreement (the 2024 Underwriting Agreement) with Titan Partners Group LLC, a division of American Capital Partners, LLC
(Titan), with respect to the issuance and sale 9,090,910 shares of its common stock at a price of $1.10 per share in a firm commitment
underwritten offering (the 2024 Offering) by the Company. Upon the closing of the 2024 Offering, the Company received aggregate proceeds
of approximately $10,000,000, before deducting underwiring discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2024 Underwriting Agreement,
the Company granted Titan a 30-day option to purchase up to an additional 1,321,989 shares of common stock to cover over allotments,
if any. On March 13, 2024, Titan exercised this option in full and purchased the additional securities for aggregate proceeds to the
Company of approximately $1,454,000 before deducting underwriting discounts and commissions and other offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Titan
was paid a cash fee of 7.0% of the aggregate gross proceeds of the 2024 Offering (including the over-allotment option) and reimbursed
certain out-of-pocket expenses of approximately $75,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>ATM Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
November 22, 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the
Company may offer and sell, from time to time at its sole discretion, shares of its common stock, for aggregate gross proceeds of up
to $6,500,000 through an &#8220;at the market offering&#8221; program under which Leerink will act as sales agent or principal. The ATM
Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any
shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at
any time, suspend solicitation and offers under the ATM Agreement. In January 2024, under the ATM Agreement, the Company sold 153,879
shares of common stock for net proceeds of approximately $278,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>May
2023 Public Offering </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 15, 2023, the Company entered into an underwriting
agreement (the Underwriting Agreement) with Newbridge Securities Corporation (the Underwriter), with respect to the issuance and sale
in a firm commitment underwritten offering (the 2023 Offering) by the Company of units of its securities. Upon the closing of the 2023
Offering, the Company sold 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock for aggregate
proceeds of approximately $9,390,000, before deducting underwriting discounts and commissions and other offering expenses. The securities
were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the 2023 Warrants) to purchase
one share of common stock, at a public offering price of $2.13 per unit. The 2023 Warrants were immediately separable and exercisable,
have a per share exercise price of $1.22 and expire five years from the date of issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares of
common stock and an additional 661,267 of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter exercised
this option in full and purchased the additional securities for aggregate gross proceeds to the Company of approximately $1,408,000,
before deducting underwriting discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Underwriter was paid a cash fee of 7.0% of the aggregate gross proceeds of the 2023 Offering (including the over-allotment option) and
reimbursed certain out-of-pocket expenses of approximately $125,000. In addition, pursuant to the Underwriting Agreement, the Company
initially issued to the Underwriter common stock purchase warrants (the UW Warrants) for a total of 709,760 shares. Subsequently, the
UW Warrants were reissued to the Underwriter and its agents for a total of 604,623 shares. The UW warrants were exercisable six months
from the respective issuance dates and have a four-year term and a per share exercise price of $1.32.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>May 2022
Placement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares)
of the Company&#8217;s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of approximately 1,348,000 shares of common stock at a purchase price per Pre-Funded Warrant
of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and
may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the
Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202
shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants were exercisable beginning on the six-month
anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Issuances
of Common Stock and Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the years ended March 31, 2024 and 2023, the Company issued 1,429 and 11,264 shares of common stock to service providers, respectively,
with fair values of approximately $1,400 and $22,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Prices</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration<br/> Dates</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2023</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,565</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">605</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2027</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,070</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2028</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(649</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2024</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,521</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised
prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2023, the Company had the following warrants outstanding (share amounts in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Exercise Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration <br/> Dates</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-42">&#8212;</span></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">January&#160;-&#160;February 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,438</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">November 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,565</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742271912432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5
&#8211; STOCK-BASED COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Amended
2017 Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Company&#8217;s stockholders approved increases
in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the
Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation
rights, restricted stock, performance-based awards and restricted stock units (RSUs). The Plan is administered by the Board or, in the
alternative, a committee designated by the Board.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock
options granted by the Company generally vest over 36 months and have a 10-year term. As of March 31, 2024, the unamortized compensation
cost related to stock options was approximately $2,035,000 and is expected to be recognized as expense over a weighted-average period
of approximately 1.3 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock
options for&#160;909,533&#160;shares, which are subject to vesting based upon the achievement of certain performance milestones by the
Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were
granted under part one of the Bonus Program, vested upon the Company&#8217;s submission to the FDA. As of March 31, 2024, the Company
had not commenced expense recognition of&#160;242,307 (net of forfeitures)&#160;of the options, which were granted under part two of
the Bonus Program, based on its assessment of the probability of achievement of the applicable performance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended March 31, 2024, the Company granted options to purchase 127,500 shares that vested immediately when granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
weighted-average grant date fair values of stock options granted during the years ended March 31, 2024 and 2023 was $0.99 and $2.85,
respectively. The following assumptions were used in the fair-value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended March 31,</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.51% - 4.72%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82% - 4.06%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 152%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 223%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 6.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 &#8211; 5.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options. The expected volatility is based on the historical volatility of the Company&#8217;s stock price.
The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury
as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has
never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the activity in the shares available for grant under the Plan during the year ended March 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>for
                                            Grant</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">989,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,650,705</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,006,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,006,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,789</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">175,689</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(175,689</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.48</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,132,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,481,090</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,448,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,448,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(240,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.84</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,648,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689,341</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">No
stock options were exercised during the years ended March 31, 2024 and 2023. During the years ended March 31, 2024 and 2023, the Company
issued 25,390 and 26,789 shares, respectively, to its non-employee directors under the Company&#8217;s outside director compensation
plan. For the years ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately
$37,000 and $86,000, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
summary of RSU activity under the Plan is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Grant-</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair Value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.91</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at March 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">187,499</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
total intrinsic value of RSUs outstanding as of March 31, 2024 was approximately $347,000. The unamortized compensation cost at March
31, 2024 was approximately $171,000&#160;related to RSUs and is expected to be recognized as expense over a period of approximately&#160;2.25&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the range of outstanding and exercisable options as of March 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Range of Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">$0.93 - $2.00</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,237,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.31</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,409,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,006</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">$3.95 - $7.51</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">943,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">771,478</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif">8.61 - $17.70</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">509,130</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">470,442</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">$0.93 - $17.70</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689,341</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.88</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,651,670</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.28</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,006</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at March 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742180291536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes - Open [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6
&#8211; INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The income
tax provision consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current portion:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,730</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,933</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,467</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,400</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2024, the Company had net operating
loss carryforwards (NOLs) of approximately $35,000,000 for federal income tax purposes and $50,400,000 for state income tax purposes.
These NOLs are available to reduce future taxable income and will expire at various times from 2037 through 2045, except federal NOLs
from fiscal 2018 and later, which will never expire.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also had federal research and development
tax credit carryforwards of approximately $2,100,000, which will begin expiring at various times from 2038 through 2044, and state research
and development credits of approximately $500,000, which do not have an expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
losses before income tax provision for the years ended March 31, 2024 and 2023 were solely attributable to US operations. Significant
components of the Company&#8217;s deferred tax assets and liabilities were (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,742</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,933</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,025</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(239</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Reserves, accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(92</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(288</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,209</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,822</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2024 and 2023, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742271965824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RoyaltyAgreementAbstract', window );"><strong>Royalty Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7
&#8211; ROYALTY AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of
a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176500256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 8
&#8211; COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Litigations,
Claims and Assessments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated
financial statements for the years ended March 31, 2024 and 2023 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Purchase
Obligations </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2024, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $1,100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In December 2023, the Company signed a device integration agreement
with a provider of connected-care and remote monitoring diabetes technology solutions. As of March 31, 2024, the Company had a remaining
obligation under the device integration agreement of approximately $400,000&#160;over three years for technology license fees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742174511200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 9
&#8211; RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Manchester
Management Company, LLC (MMC), as the general partner of Manchester Explorer, LP (Explorer), combined with the holdings of its affiliates,
JEB Partners LP, James Besser and Morgan Frank, owned approximately 11% of the Company&#8217;s outstanding shares of common stock as
of March 31, 2024. Mr. Besser is the Company&#8217;s chief executive officer and a managing member of MMC. Mr. Frank is one of our directors
and serves as the portfolio manager of Explorer and as a managing member of MMC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
February 2024, Explorer purchased 900,000 shares of common stock in the 2024 Offering at the public offering price per share of $1.10
for aggregate gross proceeds to the Company of $990,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; ">The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2024 and 2023, the Company paid her approximately
$137,000 and $201,000, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718,
of stock options granted to her during each year.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176388032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (17,470)<span></span>
</td>
<td class="num">$ (13,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170644096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742178765712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Going Concern</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and
general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue
to achieve profitability. The Company&#8217;s expected operating losses and cash burn raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company&#8217;s
independent registered public accounting firm, in its report on these consolidated financial statements for the year ended March 31,
2024, expressed substantial doubt about the Company&#8217;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from this uncertainty. Implementation of the Company&#8217;s plans and its ability to
continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital, through the sale of additional
equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form
of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions
acceptable to the Company. In, May 2023 and February 2024, the Company completed public offerings of its common stock and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2024 refers to the fiscal year ending March 31, 2024). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of
Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Reportable
Segment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
operates in one business segment and uses one measurement of profitability for its business.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and Development</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
expenses research and development expenditures as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>General
and Administrative</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily of payroll and
benefit costs, rent, stock-based compensation, legal and accounting fees, and facility and other administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration
of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains its cash
at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
and Uncertainties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Economic
Disruptions</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in- place&#8221; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#8220;shelter-in-place&#8221;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#8217;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may
be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly
detrimental to its existing stockholders and to its business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cash and
Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash held in
demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of
three months or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Property
and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are recorded at historical
cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five
years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets
acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is
recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment
and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended
use and placed into service.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Fair Value
of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB)
ASC No. 842, <i>Leases</i>, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease
contracts. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liability
represents the Company&#8217;s obligation to make lease payments arising from the lease, both of which are recognized based on the present
value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less
at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the
consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases
where the lease does not provide an implicit interest rate, the Company uses the Company&#8217;s incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. We account for such
awards based on Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 718, whereby the value of the award
is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually
the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance
criteria before recognizing compensation expense. The fair value of the Company&#8217;s stock options is estimated using the Black-Scholes-Merton
Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected
life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model.
The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per-Share Amounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Per-Share
Amounts</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO)
during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding
for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options
and exercise of warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prior
to April 1, 2023, the Company excluded pre-funded warrants from the computation of WASO. The pre-funded warrants are now included in
the computation of WASO. Prior period amounts have been conformed to the current-period presentation. The impact of the change reduced
the previously reported loss per share by $0.13 and increased WASO by approximately 1,223,000 shares for the year ended March 31, 2023.
The reclassification had no impact on the Company&#8217;s net loss or cash flows for the year ended March 31, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,481</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock purchase warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,173</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,217</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,698</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reclassifications</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, <i>Income Taxes</i>. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company&#8217;s historical
net operating loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the
year in which such tax attributes are utilized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Comprehensive
Loss</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2024 and 2023, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
November 2023, the FASB issued ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>,
which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective
application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU
will have on the presentation of its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
December 2023, the FASB issued ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S.
and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently
evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742271970752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options to purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,481</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested restricted stock units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock purchase warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,173</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,217</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,698</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742271929264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Consolidated Balance Sheet Detail [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Prepaid and other current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receivable from transfer agent for warrant exercise proceeds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">465</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">147</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,209</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment and software</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Construction-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">283</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,003</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,654</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,977</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation
    and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(679</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(256</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left"></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,975</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,721</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accrued Expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">267</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">72</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">339</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176379904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments Under the Facility Operating Lease</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Future minimum
payments under the facility operating lease, as of March 31, 2024, are listed in the table below (in thousands).</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal year
    ending March 31,</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">452</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">470</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">405</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,327</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:&#160;Imputed interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(137</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,190</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742174678528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Prices</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration<br/> Dates</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2023</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,565</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">605</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2027</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,070</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 2028</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock warrants exercised</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(649</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of March 31, 2024</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,521</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span style="font-family: Times New Roman, Times, Serif">As
of March 31, 2023, the Company had the following warrants outstanding (share amounts in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Type</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Exercise Prices</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration <br/> Dates</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-42">&#8212;</span></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">768</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">January&#160;-&#160;February 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,011</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 2027</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,438</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.60</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">November 2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,565</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: right; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742272004224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions were used in the Fair-Value Method</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
weighted-average grant date fair values of stock options granted during the years ended March 31, 2024 and 2023 was $0.99 and $2.85,
respectively. The following assumptions were used in the fair-value method calculations:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended March 31,</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rates</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.51% - 4.72%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82% - 4.06%</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 152%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83% - 223%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 - 6.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0 &#8211; 5.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Summarizes the Activity in the Shares</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the activity in the shares available for grant under the Plan during the year ended March 31, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>for
                                            Grant</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">989,466</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,650,705</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,006,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,006,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,789</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">175,689</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(175,689</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.48</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,132,292</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,481,090</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional shares authorized
    under the Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,448,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,448,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,390</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options cancelled and
    returned to the Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(240,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.84</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at March 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,648,651</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689,341</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU Activity under the Plan</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">A
summary of RSU activity under the Plan is presented below.</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Grant-</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair Value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-left: 9pt">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.91</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at March 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">187,499</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Outstanding and Exercisable Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the range of outstanding and exercisable options as of March 31, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Range of Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">$0.93 - $2.00</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,237,066</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.31</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,409,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.52</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,006</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">$3.95 - $7.51</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">943,145</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">771,478</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">$<span style="font-family: Times New Roman, Times, Serif">8.61 - $17.70</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">509,130</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">470,442</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">$0.93 - $17.70</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,689,341</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.88</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,651,670</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.28</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,006</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742279248720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes - Open [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The income
tax provision consisted of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current portion:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,730</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,933</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,467</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,400</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
losses before income tax provision for the years ended March 31, 2024 and 2023 were solely attributable to US operations. Significant
components of the Company&#8217;s deferred tax assets and liabilities were (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,742</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,933</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,658</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,025</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(239</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Reserves, accruals and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(92</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(288</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,209</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,822</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742179917152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation (in Dollars)</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average share outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>The Company and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170090352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive total</a></td>
<td class="nump">15,049<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive total</a></td>
<td class="nump">11,173<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive total</a></td>
<td class="nump">3,689<span></span>
</td>
<td class="nump">2,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive total</a></td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742274493648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PrepaidAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivable from transfer agent for warrant exercise proceeds</a></td>
<td class="nump">142<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total Prepaid and other current assets</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PrepaidAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PrepaidAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176144288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,654<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(679)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PropertyAndEquipmentNetAbstract', window );"><strong>Property and equipment, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PropertyAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PropertyAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170665472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued wages</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742179912256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OperatingLeaseExpiredTerm', window );">Operating lease expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PercentageOfAnnualRentIncreases', window );">Annual rent increases percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Obtained a right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476,000<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=modd_WBernardoDriveSanDiegoCAMember', window );">W. Bernardo Drive, San Diego, CA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=modd_ThornmintRoadSanDiegoCAMember', window );">Thornmint Road, San Diego, CA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeaseExpiredTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expired term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeaseExpiredTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PercentageOfAnnualRentIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of annual rent increases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PercentageOfAnnualRentIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=modd_WBernardoDriveSanDiegoCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=modd_WBernardoDriveSanDiegoCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=modd_ThornmintRoadSanDiegoCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=modd_ThornmintRoadSanDiegoCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170273456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742166666960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Nov. 22, 2023</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>May 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,910<span></span>
</td>
<td class="nump">153,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">common stock price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds (in Dollars)</a></td>
<td class="nump">$ 1,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,464,000<span></span>
</td>
<td class="nump">10,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CashFee', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Pocket expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_compensationServicesEqual', window );">Compensation services equal percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PaymentOfUnderwriterPercentage', window );">Paid cash fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_PreFundedWarrant', window );">Pre funded warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,701,000<span></span>
</td>
<td class="nump">$ 2,724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_WarrantsToPurchaseSharesOfCommonStock', window );">Underwriter common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=modd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">11,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AgreementAxis=modd_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,816,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase up additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwriterMember', window );">Underwriter [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockholdersEquityLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Underwriter agents shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PaymentOfUnderwriterPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Underwriter Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PaymentOfUnderwriterPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share of pre funded warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to purchase shares of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_compensationServicesEqual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation services equal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_compensationServicesEqual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=modd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=modd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AgreementAxis=modd_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AgreementAxis=modd_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=modd_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742165911008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Warrants Outstanding - Warrant [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">7,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Common stock</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices, Common stock (in Dollars per share)</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="nump">7,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsMember', window );">Issuance of Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfSharesIssuanceOfCommonStockWarrants', window );">Number of Shares, Issuance of common stock warrants</a></td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare', window );">Exercise Prices, Issuance of common stock warrants (in Dollars per share)</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationIssuanceOfCommonStockWarrants', window );">Expiration Dates, Issuance of common stock warrants</a></td>
<td class="text">May 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsOneMember', window );">Issuance of Common Stock Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfSharesIssuanceOfCommonStockWarrants', window );">Number of Shares, Issuance of common stock warrants</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare', window );">Exercise Prices, Issuance of common stock warrants (in Dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationIssuanceOfCommonStockWarrants', window );">Expiration Dates, Issuance of common stock warrants</a></td>
<td class="text">May 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercisedMember', window );">Common Stock Warrants Exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfSharesCommonStockWarrantsExercised', window );">Number of Shares, Common stock warrants exercised</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesCommonStockWarrantsExercised', window );">Exercise Prices, Common stock warrants exercised (in Dollars per share)</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercised1Member', window );">Common Stock Warrants Exercised 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_NumberOfSharesCommonStockWarrantsExercised', window );">Number of Shares, Common stock warrants exercised</a></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExercisePricesCommonStockWarrantsExercised', window );">Exercise Prices, Common stock warrants exercised (in Dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices, Common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationCommonStock', window );">Expiration Dates, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockOneMember', window );">Common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices, Common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationCommonStock', window );">Expiration Dates, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January&#160;-&#160;February 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockTwoMember', window );">Common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices, Common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationCommonStock', window );">Expiration Dates, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">February 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockThreeMember', window );">Common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Prices, Common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ExpirationCommonStock', window );">Expiration Dates, Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">November 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExercisePricesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Prices, Common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExercisePricesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercise prices, issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExpirationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExpirationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ExpirationIssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration, Issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ExpirationIssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NumberOfSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares, common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NumberOfSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NumberOfSharesIssuanceOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share issuance of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NumberOfSharesIssuanceOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_IssuanceOfCommonStockWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercised1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_CommonStockWarrantsExercised1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=modd_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=modd_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742172566736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableUnamortizedLoanFeeCost', window );">Unamortized compensation cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,326<span></span>
</td>
<td class="nump">909,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Expense recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock-Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Fair value of stock options granted price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableUnamortizedLoanFeeCost', window );">Unamortized compensation cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Fair value of stock options granted price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Total intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember', window );">Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,390<span></span>
</td>
<td class="nump">26,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=modd_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Shares approved under equity incentive plan</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableUnamortizedLoanFeeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481598/310-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableUnamortizedLoanFeeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=modd_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=modd_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742165886800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems', window );"><strong>Schedule of Assumptions were used in the Fair-Value Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems', window );"><strong>Schedule of Assumptions were used in the Fair-Value Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">3.51%<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems', window );"><strong>Schedule of Assumptions were used in the Fair-Value Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">4.72%<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">152.00%<span></span>
</td>
<td class="nump">223.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170808176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Summarizes the Activity in the Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Begining Balance</a></td>
<td class="nump">2,132,292<span></span>
</td>
<td class="nump">989,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Begining Balance</a></td>
<td class="nump">2,481,090<span></span>
</td>
<td class="nump">1,650,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Begining Balance (in Dollars per share)</a></td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 6.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Ending Balance</a></td>
<td class="nump">3,648,651<span></span>
</td>
<td class="nump">2,132,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Ending Balance</a></td>
<td class="nump">3,689,341<span></span>
</td>
<td class="nump">2,481,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance (in Dollars per share)</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Shares Available for Grant, Additional shares authorized under the Plan</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Number of Shares, Additional shares authorized under the Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Additional shares authorized under the Plan (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant', window );">Shares Available for Grant, Options granted</a></td>
<td class="num">(1,448,533)<span></span>
</td>
<td class="num">(1,006,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Options granted</a></td>
<td class="nump">1,448,533<span></span>
</td>
<td class="nump">1,006,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted (in Dollars per share)</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards', window );">Shares Available for Grant, Share awards</a></td>
<td class="num">(25,390)<span></span>
</td>
<td class="num">(26,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of Shares, Share awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Share awards (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant', window );">Shares Available for Grant, RSUs granted</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares', window );">Number of Shares, RSUs granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, RSUs granted (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant', window );">Shares Available for Grant, Options cancelled and returned to the Plan</a></td>
<td class="nump">240,282<span></span>
</td>
<td class="nump">175,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Options cancelled and returned to the Plan</a></td>
<td class="num">(240,282)<span></span>
</td>
<td class="num">(175,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share)</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 6.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares available for grant, options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options cancelled and returned to the plan, shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs granted, number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs granted, shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs granted, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share awards, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742179952864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Schedule of RSU Activity Under the Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Balance Beginning | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant- Date Fair Value, Balance Beginning | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Balance Ending | shares</a></td>
<td class="nump">187,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant- Date Fair Value, Balance Ending | $ / shares</a></td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant- Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(62,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant- Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742178728160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToTwoPointZeroZeroMember', window );">$0.93 - $2.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding (in Shares) | shares</a></td>
<td class="nump">2,237,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">8 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in Shares) | shares</a></td>
<td class="nump">1,409,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value (in Dollars) | $</a></td>
<td class="nump">$ 538,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ThreePointNineFiveToSeveenPointFiveOneMember', window );">$3.95 - $7.51 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding (in Shares) | shares</a></td>
<td class="nump">943,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in Shares) | shares</a></td>
<td class="nump">771,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightPointSixOneToSeventeenPointSevenZeroMember', window );">8.61 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding (in Shares) | shares</a></td>
<td class="nump">509,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in Shares) | shares</a></td>
<td class="nump">470,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember', window );">0.93 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding (in Shares) | shares</a></td>
<td class="nump">3,689,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable (in Shares) | shares</a></td>
<td class="nump">2,651,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value (in Dollars) | $</a></td>
<td class="nump">$ 538,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $0.93 - $2.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">$ 0.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | $3.95 - $7.51 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">3.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 8.61 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">8.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 0.93 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">0.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $0.93 - $2.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | $3.95 - $7.51 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">7.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 8.61 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">17.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 0.93 - $17.70 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems', window );"><strong>Schedule of Outstanding and Exercisable Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">$ 17.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ScheduleOfOutstandingAndExercisableOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ScheduleOfOutstandingAndExercisableOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToTwoPointZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToTwoPointZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ThreePointNineFiveToSeveenPointFiveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ThreePointNineFiveToSeveenPointFiveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightPointSixOneToSeventeenPointSevenZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightPointSixOneToSeventeenPointSevenZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176269040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeLineItems', window );"><strong>Income taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Net operating loss carryforwards federal income tax</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards state income tax</a></td>
<td class="nump">50,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet', window );">Federal research and development tax credit</a></td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">State research and development credits</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742274509952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - Schedule of Income Tax Provision - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_CurrentPortionAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax provision</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_DeferredPortionAbstract', window );"><strong>Deferred portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(3,730)<span></span>
</td>
<td class="num">(2,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(657)<span></span>
</td>
<td class="num">(1,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision</a></td>
<td class="num">(4,387)<span></span>
</td>
<td class="num">(4,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4,387<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CurrentPortionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CurrentPortionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DeferredPortionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DeferredPortionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742175722400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract', window );"><strong>Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170296064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes (Details) - Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,860<span></span>
</td>
<td class="nump">$ 8,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense', window );">Capitalized research and development expense</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,568<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">19,497<span></span>
</td>
<td class="nump">15,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets', window );">Section 179 assets</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves, accruals and other</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(19,209)<span></span>
</td>
<td class="num">(14,822)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesRegulatoryAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742176394896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligations</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=modd_DeviceIntegrationAgreementMember', window );">Device Integration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligations</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=modd_DeviceIntegrationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=modd_DeviceIntegrationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139742170624656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_OutstandingSharesOfCommonStock', window );">Company&#8217;s outstanding shares of common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price per share (in Dollars per share)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=modd_FounderMember', window );">Founder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Company paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_ManchesterManagementCompanyLLCMember', window );">Manchester Management Company LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_modd_AggregateGrossProceeds', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock (in Shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s outstanding shares of common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=modd_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=modd_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_ManchesterManagementCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_ManchesterManagementCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!L#[N91F/;&WE/I6&OX%4$L#!!0    ( #6*U5A_G([LS0,  +X-   8
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MV5GA-4D)UX D9I#O5(F]$&EJ<P7;7,$:QS^!\P7EJ$PQ0!S\A:H/P'/? ^A
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M_KK!2.P@TD#\OJ:4/S?D2T+M:V?+_P!02P,$%     @ -8K56+[LF;E%!@
M?QL  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RM65UOVS84_2N$5PPM
M$-<295MVYAA(W!4KL!9!LF[/M$3;7"11)6D[V:_?):5(ED0Q2>&76%(NK\[]
M/A071RX>Y(Y2A1[3))-7@YU2^>5H)*,=38G\R'.:P7\V7*1$P:W8CF0N*(G-
MHC098<^;CE+"LL%R89[=BN6"[U7",GHKD-RG*1%/-S3AQZN!/WA^<,>V.Z4?
MC):+G&SI/57?\UL!=Z-*2\Q2FDG&,R3HYFIP[5^N K/ 2/S-Z%&>7"-MRIKS
M!WWS);X:>!H136BDM H"/P>ZHDFB-0&.'Z720?5.O?#T^EG[9V,\&+,FDJYX
M\@^+U>YJ,!N@F&[(/E%W_/@'+0V::'T13Z3YBXZ%;#@=H&@O%4_+Q8 @95GQ
M2QY+1YPL\/L6X'(!;B\8]RP(R@6!,;1 9LSZ1!19+@0_(J&E09N^,+XQJ\$:
MENDPWBL!_V6P3BU7/),\83%1-$;W"GX@1DHBOD$K(G?H,\19HB'Z?O\)O7_W
M ;U#+$-_[?A>DBR6BY$"#%K3*"K?=U.\#_>\S\?H*\_43J+?LYC&304C %]9
M@)\MN,%.C5^)^(@"_P)A#X\M@%:O7QXXX 250P.C+^AS:.VUC> I@H(31+%L
M6V0L4XQ:W59H'=NUZF*^E#F)Z-4 JE52<:"#Y:^_^%/O-YO)9U+6<,"X<L#8
MI7WY#7I/PJ75R&+EQ*S4#>:P'/KA./06H\,I?)M8, OGE5@#V*0"-G%&YCK^
M%^JI2&_%H0=%/(M80E%6(M9/]76D0[B74!"0Z[;X7=ILFYPS@&=2UO#3M/+3
MU!G >\6CAZ'NC3&*> H#0Q+3<NFCOJ8VXPN-TY.(X=#S6V&U">F2M04UK,"&
M3K!_ZKCI<2 E1"YF,N>2)#:(8??M;8#.5]F]CAP.GU4VS)PV?**@+V*%DZ&M
M(I)RH=A_YH'-E%G'E#&>MFSIRO@3;/?UO,(Y=R?&CH#=B$FYA]0 "H&T$UAD
M;VCS+H!Y"V-7!'N!':/OU0/-<S?@'<FV&F:9%-*X-&%DS9+^ZBV5GJE\SZ6M
MZ8*3F>X[ W4K:$Y8_%RPA0>XVE%1NL3J ;\3C>%\W(J83<CO*6$?UWBQNX@I
M-!LD-.,:\LT06J\+)^Y ",:XC;,KU)]:]6CWG8-S>1U%?*_'1TZ>R!HFARG6
M*!*Z'IZ=;<4<="MV,FMC[@H-@8WW@*['L>^>QT4]Z')(C)M/*L$*==Q%$4PF
M;:P6J7ZL]83VG8/-<(<7IZ\5]<22E\%\TLD+FYSO^7X/\GIF^M.7:=^FIGTL
M.U#Y&N#.6?SFOG,F;4TGU+/8=P_CV[V(=D0W'-@^Y$('3SV9(J$_]BS7U,OJ
M@^YH!EKHM5FA56P:S'I"5T]?WSU^.TGWZMAU9ZP5MTVL'W<]C?WYFU)NPS("
MA/9EV,XI_^:4.Y.VYMZOGO;8.4IAU/&(TKAT 5%#F'+#E(@'""H0P2(5@<6F
M0*VD)K87FN+;W%*^J$E/VSW:C>;M%!'7,QV_---/#:6/5$0,NGG+.G0D0I#,
M/CEQ=WB'G<GIAO$3%M8L +M90-/"?+].6&2:AZ!;)A454)TQ Z:LP.H-%9#I
MLC^:-@+@3=MSS"(6!F$/3\8U4<!NHE"U%&B"!Q8#\/73J^L3=WD ]KU9!WI7
MS &]I@OXY>T[RR)AN,+[F!97'W1?-!;I@)@+W=(/4&%]R=9E")-Q$+2-L/"(
M"0[#'BMJ(H'=1&+5!_4">@1:0T)EF8X$E,\3)<)J0)<J!.&\O86Q2,V]<-J#
MOZ83V+T'=^.GFLX[D'<WVG,<= J]*]6PKXF\Y@ X=$ZE;SPSF$^&**"UY;YU
M'X9_8@_>/YS.I:WIBYI98#>SN.OL:!!?*P)2AF?0QZC@YGHKW23G3U;?.-_V
MJM9<NL7V<6#:PX%Q34BP^_O '8THY*G>&)D6KF 2R8W>=&XA=8V5Y7BJYU=>
M-GVKO99/"-UY]1/\PS6O@IIZ!"]\:# -7N^SP3)K,@=G_:AP+FU-<VL"$K@)
MR)<,B 9%BCSV?,#V.U]MV[%RBA2P1B='&2D56W/"(Y'9=Q=G M73ZA3IVIR=
MM)[?^)>KXBRH5E,<37TE MJ_A(K;@$KO8PAX1'':4]PHGIL#DS57BJ?F<D=)
M3(46@/]O.%?/-_H%U9G;\G]02P,$%     @ -8K56'#>6!%V&   4T$  !@
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M37+$4N\0L"!I*ZMZ !/Q5@Q>.$RD>CJ%%X$I9.PL^AB))1@R%F?(EFK=< ^
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MI^*"!F4'K)AT'F_6]-7UE2E^)Z+'E_@<WD0?&+)0+P8>YXSY.RH>F83_I4\
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MB=*%TIQJ^RE.OZ[7GW@@0%:JDJ2\S!9"XSK>:FV<UO R5ED&4D@SMM0J8Y/
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M <:72MGZ 3=H_@/#U7\ 4$L#!!0    ( #6*U5@)(]_YU0H  *,;   9
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M%A#8\96L^[./Q:IM.C.<7EVSF16J)O>:)KI_N/DF]XF#/194F5Q2,ZNY::@
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MBU:AUN3!R8Y*:]9(Q'B&/%C3+%=XF4QCR.>R]KL8V'449$OE<BQD23H/UBN
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MK5HT?CNN?]QNV06$?4BW:JE5J7*!IH?7VFCDPVTYO!N< ';VP?$QI>57QB:
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MC -TH-A'%_6@>SG&A_BP=1FQ2]GZ8)^:^UCG5<,(MAE <L+P:4.\(UB%)FB
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ML,%>' ?PD2N<M>A$P%56O2Q.WE>7ZEM-R1+E%5^FRJ9U 4E0"7A351KN>0P
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M-^#[TD#Z9L$.]C]F)O\"4$L#!!0    ( #6*U5CW)5R$*00  -0(   9
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M=W0Q>WTYYP7\Q)^YN7.=OQ4=95%57^G#I^S=T90X,H5):R*A\<^MN3)%093
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M_,$,'QS0/Y.#F_@+E=Y$\C"!23<9*': 8;CI7*A:8'[Q\9P7,.P0[R^@23(
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M.CX+P;0BUVZ<+AMA66E',M4L<_HNH/$&=)]I[;8;'Z#[TLS_ %!+ P04
M"  UBM58EHY+;9@#  "L"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6R=5FUOVS80_JY?<5"+(@'<2*8LV7%M [:;8@.6-4CV\F'8!UHZ640E426I
M.-VOWY%R%*]PM:V (/'E[KGG[G@\+0Y2?=(%HH&GJJSUTB^,:>9!H-,"*ZZO
M9(,U[>125=S05.T#W2CDF5.JRH"%81)47-3^:N'6[M1J(5M3BAKO%.BVJKCZ
MLL%2'I;^V']>N!?[PMB%8+5H^!X?T/S:W"F:!3U*)BJLM9 U*,R7_GH\WR16
MW@G\)O"@3\9@/=E)^<E.?LR6?F@)88FIL0B</H^XQ;*T0$3C\Q'3[TU:Q=/Q
M,_H'YSOYLN,:M[+\762F6/HS'S+,>5N:>WGX 8_^Q!8OE:5V;SATLI/8A[35
M1E9'96)0B;K[\J=C'$X49N$W%-A1@3G>G2''\CTW?+50\@#*2A.:'3A7G3:1
M$[5-RH-1M"M(SZRVLM:R%!DWF,&&E[Q.$1[<<7B/AHL2+G[ANQ+UY2(P9,]J
M!>D1>]-ALV]@CQG<RMH4&F[J#+-_ @1$M&?+GMENV"#B+5=7$(U'P$(V&<"+
M>N\CAQ=]M_=_K'?:*#H[?Y[SOT.?G$>W]337#4]QZ5/!:%2/Z*_>O!HGX;L!
M[I.>^V0(??5 ]9FU)8+,X4YAPT4&O,[@HRE0P;95"FL#:ZW1Z'/<!]'/<Z?P
MIX6-OV?C;Y,0>1>B!E/(5I-M?>F=,I&.27IDPAV3>2^!3W2Q:-3PFA!G]!Y/
MF'>/*8I'>^ @5[(""GVM<T*A"X(PZ!*" U>T:$@?52HT0J-DBIAI"P!O7LW8
MF+WSNBBH'DY##+'W&B9)[$Q-82 %<9^"^'^D@"Y*9;XXSV\^MZ*AJ\N,X&<T
MYZ(_"#P0?>]?HG]" E](U&CFWBU/"[*COMJU\1^Q\)J^,Q9Z6UDUK:'8O0A8
M<2US0Y%'2!)Z/%LX1K7N9GTKZK<N!UH#FT4P'H5AY/V$=%<6LLQ 5+3[B!9*
M0Q0!B[V/>2ZHTEY,)!$]7C1*X@GI7T^GI*_UG"[MM*W:TM5GAA2+5'!KT[.<
M>"65$7^Y!;A(IM=P"1<L3N"2$LT(Q:5Z-&7CH60G?;*3_YSL=9JJEBC=',_P
MN0P/HGUWAK^VW"\<J$)L+;%)9-_)]%@"T12FS,9C%MI,1]=G8Q&<=) *U=[U
M20VI;&O3-9-^M6_%ZZX#O8AW?9R<V(M:0XDYJ8974SKJJNN-W<3(QO6CG334
MW=RPH-\)5%: ]G,IS?/$&NA_4%9_ U!+ P04    "  UBM58P(?')KL"  #M
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q]E%UOVC 4AN_Y%4?9
M-+5214((I6,0J71#J]1JJ!_;Q;0+DYP0JXZ=V4XI_W['#F1,8MPD_CJ/W]?V
M.=.-TB^F1+3P5@EI9D%I;3T)0Y.56#'35S5*FBF4KIBEKEZ'IM;(<A]4B3".
MHLNP8EP&Z=2/+74Z58T57.)2@VFJBNGM'(7:S()!L!]XX.O2NH$PG=9LC8]H
MG^NEIE[847)>H31<2=!8S(+KP62>N/5^P7>.&W/0!N=DI=2+Z]SFLR!R@E!@
M9AV!T>\5;U (!R(9OW?,H-O2!1ZV]_2%]TY>5LS@C1(_>&[+67 50(X%:X1]
M4)NON/,S<KQ,">._L&G7CFG'K#%65;M@ZE=<MG_VMCN'@X"KZ#\!\2X@]KK;
MC;S*S\RR=*K5!K1;3337\%9]-(GCTEW*H]4TRRG.IG=(E@R</;&50',^#2U!
MW528[0#S%A#_!S"(X5Y)6QKX(G/,_P6$I*:3%.\ES>.3Q'NF^S <7$ <Q<D)
MWK"S./2\X6F+/Z]7QFIZ!;^.F6P1R7&$RXR)J5F&LX">OD']BD'ZX=W@,OIT
M0F#2"4Q.T=-'RK2\$0BJ@$5C&XUPSR6OF@J6;$L98 T\T^%JL"7"@F5<<+N%
M;S5J9KE<@W=XS-7)?8^[V@FH6@&]>B^@Z004>P&J$R"<@ M@QEF@^\O*[@)I
ME'""&XLY<.D)UCTV6+F* &=^3#6&R=R<]WL+;C(F8(M,]U#FCMX!>P0<03**
M7>,2DG'D&F-(HE'O25D**UKU7@]TV@<7PWC<NT-C)G!;U4TKQ2*9MG V&([A
MO+=T)R MO#+1^)MH&8*SE7/+Z06])]#@8P3'KCP\2,$*]=H7&@.9:J1ML[$;
M[6K9=9O"?Y>WA9#LKKDT)*"@T*@_'@6@V^+2=JRJ?4*OE*7RX)LEU6/4;@'-
M%TK9?<=MT%7X] ]02P,$%     @ -8K56+ENIX0> P  N@<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULS57;;MLX$'WO5PS419$ KG7U91/;0)RV
MV!9H&]3I]F&Q#[0TMHA0I$I2<?SW.Z1D)2E<=_=M7R0.><Z9,[S.=DK?F1+1
MPD,EI)D'I;7U11B:O,2*F:&J4=+(1NF*60KU-C2U1E9X4B7")(K&8<6X#!8S
MWW>C%S/56,$EWF@P354QO5^B4+MY$ >'CB]\6UK7$2YF-=OB"NW7^D93%/8J
M!:]0&JXD:-S,@ZOX8IDYO ?\R7%GGK3!5;)6ZLX%[XMY$#E#*#"W3H'1[QZO
M40@G1#:^=YI!G](1G[8/ZN]\[53+FAF\5N(;+VPY#Z8!%+AAC;!?U.X/[.H9
M.;U<">._L&NQ:1I WABKJHY,#BHNVS][Z.;A"6$:_820=(3$^VX3>9=OF&6+
MF58[T Y-:J[A2_5L,L>E6Y25U33*B6<7*ZORNU*) K5Y]7*:Q)-+>/N]X78/
M9[=L+="<ST)+B1P\S#O192N:_$0T3N"CDK8T\%866#P7",EA;S,YV%PF)Q4_
M,CV$-!Y $B79";VT+SOU>NE_+_NOJ[6QFG;+W\<*;V6SX[+N!%V8FN4X#^B(
M&-3W&"Q>O8S'T>4)TUEO.CNEOEC1B2P:@: V\(UIS:0U\+FQQC)9<+D]YO>D
MXG&_5^8%): 9S\M^R@=@2X1K5=5,[J%DA8\W2M"AILRP.]A1CW;@S)1,([!*
M-6Z(2R*IQM"H.;^ VWV-\*FIUJA=02N'I0WS@#KG!N%&\]S'-=?,'^ E$TSF
MI&?@1W\I3 :C\0C>&]-X# %R557$,FZE'_V-HQ'\!O$PI2W*]HX[^1>LT2":
M1)Z7]+RIFXXC6.PJ*.",..>';+\$C[/?.S3E.%%K!G$R&"4Q'%FG]/^P3L\J
MC0=I-J6JHF$4@S]IR>5SQ&3LQL?#*((/3#;T,L!K>(=K[9M^@9[ALT$4QYXQ
MCD[AXD&63@^X3^H>?04>=ZLL$]V6.78NPR?W:85ZZU\-0WN#YJ>]6OO>_F&Z
M:N_C1WC[JM'R;+DT('!#U&@X&06@VY>B#:RJ_>V\5I;N>M\LZ7%%[0 TOE'*
M'@*7H'^N%_\ 4$L#!!0    ( #6*U5C+9$Y=T04  "\/   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;*57VV[;.!!]UU<,W*1( $66J*O3Q(!S:;?
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MQ@>6&<[Q12LD;<#OT[+4[804=&_DX;]02P,$%     @ -8K56%D"MPO6!
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M;Q;H]QO.U>/ .*C_5['X%U!+ P04    "  UBM58BH<F>GL#  !@#@  &0
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M H(T&_#]6@B]GY@#FJ8R_ 502P,$%     @ -8K56$SBJ9.N @  ;0<  !D
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M-;J\(KAJBWL[,+)Q]7$E#55;URWI/41E ^A_(:5Y'=B2V[^PZ1]02P,$%
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M&U1?4S&U.ZLP:@GLGK"G..,H@;UL<FX"V<VJ5:7J0-"\7)AYI$+0M-P] (F
MJ0+Y_YY2\7R@UGJ:M;W-/U!+ P04    "  UBM58^4G>A&P"  !;!@  &0
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M!V4#\'PEI=DM;(-I_T_B?U!+ P04    "  UBM58 EBXQNT#  "/$P  &0
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MC?-NO,R9QBLI?O"4LHDW\B#%):L$/<C-5VS\Q#;>0@KMGK!I]@8>+"I-,F_
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MU:%I0C4?U02J250+4"U$M0C58E1+*$W-7%>JL,V7.O-NH[4*5/-13:":1+4
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M\E*V'0U[Q%^G@D=5<-:#*(C+_]Z/ZH/8"E ';P30*H#N!KR50:L"M$,S#*J
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M38?2C(KVWE1BOY5VINY-):!V,93F0&DNBM:6?&,9JW+/^$\NO) $<3:?B-/
MK]3_[A$?ZB%#:3J49E2TEI\VZ##4H%DM*,V&TAPHS471VO)OS&15[B8?<?6;
MG'2TYJ$.,I1FO/.9T>(*N+2^!*YS'H#LD 6EV5": Z6Y*%J['!HS6I6[T5]X
M?,JB5<A?&2-ZD#!?\.R;EJXH0<UH*$V'T@PHS832+"C-AM(<*,U%T=H_QVI,
M:?I!IC2%FM)0F@ZE&5":":594)H-I3E0FHNBM>ND,:6IW)2^+XQG$J3INO.7
ME%?R^*/K >H_0VD&W?>?Z5";[LX@NIJ-QI.=^;,%[9L-I3E0FHNBM17<^,I4
M[BOGO[@EQO=U(%Z)$_LLSG\93VY#3WYMGIQZM*ZAUC&49D!I)I1F06DVE.9
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M"[Q)^"/=_4'VA'R9;TZ37/T'NWVL8X'Y)N<TW3<6"-(X*W[QZUZ(@P8P.-(
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M3BCT .I?<:[V%9V@>HWY?P%02P,$%     @ -8K56%)NU6HV!@  72<  !D
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M'Y;T5P#C#&A_I37N)RY ]Y_)?@%02P,$%     @ -8K56%[_][,E P  -0L
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M:; \<,T,"SA0=@)^3Z4TVXY=H"X)HS]02P,$%     @ -8K56*98J/#2 P
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M$D7V/;CS/@I7[ZEP_=_+X6]02P,$%     @ -8K56)>*NQS     $P(   L
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MU)M_ E!+ 0(4 Q0    ( #6*U5@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -8K56)S]5Z_N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ -8K56)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  UBM58P>\W0K$'  "M,P  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ -8K56/+('NP] @  LP4  !@              ("!] \  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #6*U5B6_7;U3P4  *,5
M   8              " @6<2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  UBM58 I.Z0_\"  "A"@  &               @('L%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ -8K56'^<CNS-
M P  O@T  !@              ("!(1L  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( #6*U5A^@Z;#E0(  (P&   8              "
M@20?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  UBM58
MP@("008&  "")@  &               @('O(0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ -8K56+[LF;E%!@  ?QL  !@
M     ("!*R@  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M #6*U5APWE@1=A@  %-!   8              " @:8N  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  UBM58)PF+;((#  !R!P  &0
M            @(%21P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( #6*U5@:1NVU@00  ,8)   9              " @0M+  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ -8K56.'>M +V"@
MS"   !D              ("!PT\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  UBM58"2/?^=4*  "C&P  &0              @('P
M6@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #6*U5@<
M %'0G 8  %0/   9              " @?QE  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ -8K56*_I9JDM!   9 D  !D
M     ("!SVP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6*U5ATC(IO"A8  !%"   9              "
M@3^   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ -8K5
M6,\>>L,0 P  =08  !D              ("!@)8  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  UBM58EHY+;9@#  "L"   &0
M        @(''F0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( #6*U5C A\<FNP(  .T%   9              " @9:=  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ -8K56+ENIX0> P  N@<
M !D              ("!B*   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  UBM58RV1.7=$%   O#P  &0              @('=HP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #6*U5A9 K<+
MU@0  #0,   9              " @>6I  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ -8K56,8>ZT2L P  MQ   !D
M ("!\JX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  U
MBM58BH<F>GL#  !@#@  &0              @('5L@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #6*U5A,XJF3K@(  &T'   9
M          " @8>V  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ -8K56&5I!??K P  YQ,  !D              ("!;+D  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  UBM58^4G>A&P"  !;
M!@  &0              @(&.O0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    ( #6*U5@"6+C&[0,  (\3   9              " @3'
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ -8K56*'"
MZ^&E @  V@8  !D              ("!5<0  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    "  UBM58)):%$MX.   #X   &0
M    @($QQP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M #6*U5@B9ALBD@8  /LS   9              " @4;6  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ -8K56,>3?(AI!P  >$P  !D
M             ("!#]T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  UBM58BT@)DX0#  "L#@  &0              @(&OY   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #6*U5AEKQZ_#P4
M /$7   9              " @6KH  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ -8K56.YC'43\ @  F0D  !D              ("!
ML.T  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  UBM58
M4F[5:C8&  !=)P  &0              @('C\   >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( #6*U5B$"E.-@P(  ',&   9
M      " @5#W  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ -8K56%[_][,E P  -0L  !D              ("!"OH  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  UBM58!1B+?1X#   >"@
M&0              @(%F_0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( #6*U5BF6*CPT@,  *8,   9              " @;L  0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ -8K56"&Z&7,\
M @  $@8  !D              ("!Q 0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  UBM58E'?ZAA,$   N%P  &0
M@($W!P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #6*
MU5C(7@&J1@,  ,H4   -              "  8$+ 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ -8K56)>*NQS     $P(   L              ( !\@X!
M %]R96QS+RYR96QS4$L! A0#%     @ -8K56)=5HPS; P  SAX   \
M         ( !VP\! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #6*U5C]
M+-6EK@$  ,$;   :              "  >,3 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #6*U5@F^H>GM0$  -P;   3
M      "  <D5 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     V #8 L0X
' *\7 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Consolidated Balance Sheet Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail</Role>
      <ShortName>Consolidated Balance Sheet Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Royalty Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RoyaltyAgreement</Role>
      <ShortName>Royalty Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Consolidated Balance Sheet Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</Role>
      <ShortName>Consolidated Balance Sheet Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/Incometaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996008 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable</Role>
      <ShortName>Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable</Role>
      <ShortName>Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable</Role>
      <ShortName>Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Stockholders??? Equity (Details) - Schedule of Warrants Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Warrants Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/StockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncometaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income taxes (Details) - Schedule of Income Tax Provision</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable</Role>
      <ShortName>Income taxes (Details) - Schedule of Income Tax Provision</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncometaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable</Role>
      <ShortName>Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncometaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Income taxes (Details) - Schedule of Significant Components of the Company???s Deferred Tax Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income taxes (Details) - Schedule of Significant Components of the Company???s Deferred Tax Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/IncometaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0207206-10k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modularmedicalinc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea0207206-10k_modular.htm 10644, 10645, 10646, 10647</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0207206-10k_modular.htm">ea0207206-10k_modular.htm</File>
    <File>modd-20240331.xsd</File>
    <File>modd-20240331_cal.xml</File>
    <File>modd-20240331_def.xml</File>
    <File>modd-20240331_lab.xml</File>
    <File>modd-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="468">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0207206-10k_modular.htm": {
   "nsprefix": "modd",
   "nsuri": "http://www.modularmedicalinc.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "ea0207206-10k_modular.htm"
     ]
    },
    "schema": {
     "local": [
      "modd-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "modd-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "modd-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 245,
   "keyCustom": 37,
   "axisStandard": 17,
   "axisCustom": 1,
   "memberStandard": 17,
   "memberCustom": 21,
   "hidden": {
    "total": 65,
    "http://fasb.org/us-gaap/2024": 50,
    "http://www.modularmedicalinc.com/20240331": 12,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 128,
   "entityCount": 1,
   "segmentCount": 41,
   "elementCount": 648,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 468,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "i",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "i",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "995304 - Statement - Consolidated Statements of Operations (Parentheticals)",
     "shortName": "Consolidated Statements of Operations (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - The Company and Summary of Significant Accounting Policies",
     "shortName": "The Company and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail",
     "longName": "995308 - Disclosure - Consolidated Balance Sheet Detail",
     "shortName": "Consolidated Balance Sheet Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.modularmedicalinc.com/role/Leases",
     "longName": "995309 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquity",
     "longName": "995310 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensation",
     "longName": "995311 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.modularmedicalinc.com/role/Incometaxes",
     "longName": "995312 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.modularmedicalinc.com/role/RoyaltyAgreement",
     "longName": "995313 - Disclosure - Royalty Agreement",
     "shortName": "Royalty Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingencies",
     "longName": "995314 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactions",
     "longName": "995315 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "modd:LiquidityAndGoingConcernPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "modd:LiquidityAndGoingConcernPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)",
     "shortName": "The Company and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables",
     "longName": "996002 - Disclosure - Consolidated Balance Sheet Detail (Tables)",
     "shortName": "Consolidated Balance Sheet Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.modularmedicalinc.com/role/LeasesTables",
     "longName": "996003 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquityTables",
     "longName": "996004 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationTables",
     "longName": "996005 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.modularmedicalinc.com/role/IncometaxesTables",
     "longName": "996006 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)",
     "shortName": "The Company and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996008 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share",
     "shortName": "The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable",
     "longName": "996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets",
     "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996010 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net",
     "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable",
     "longName": "996011 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses",
     "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.modularmedicalinc.com/role/LeasesDetails",
     "longName": "996012 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "modd:OperatingLeaseExpiredTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "modd:OperatingLeaseExpiredTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable",
     "longName": "996013 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease",
     "shortName": "Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
     "longName": "996014 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c47",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
     "longName": "996015 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Warrants Outstanding",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Warrants Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c70",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c71",
      "name": "modd:NumberOfSharesIssuanceOfCommonStockWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails",
     "longName": "996016 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FinancingReceivableUnamortizedLoanFeeCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FinancingReceivableUnamortizedLoanFeeCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
     "longName": "996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable",
     "longName": "996018 - Disclosure - Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c104",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c102",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable",
     "longName": "996019 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan",
     "shortName": "Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
     "longName": "996020 - Disclosure - Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c107",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c107",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.modularmedicalinc.com/role/IncometaxesDetails",
     "longName": "996021 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable",
     "longName": "996022 - Disclosure - Income taxes (Details) - Schedule of Income Tax Provision",
     "shortName": "Income taxes (Details) - Schedule of Income Tax Provision",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable",
     "longName": "996023 - Disclosure - Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate",
     "shortName": "Income taxes (Details) - Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996024 - Disclosure - Income taxes (Details) - Schedule of Significant Components of the Company\u2019s Deferred Tax Assets and Liabilities",
     "shortName": "Income taxes (Details) - Schedule of Significant Components of the Company\u2019s Deferred Tax Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails",
     "longName": "996025 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
     "longName": "996026 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "modd:OutstandingSharesOfCommonStock",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "modd:OutstandingSharesOfCommonStock",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0207206-10k_modular.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r497"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued wages",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r475"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r100",
      "r348"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r497",
      "r736"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r652",
      "r653",
      "r654",
      "r656",
      "r712",
      "r737"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds",
        "documentation": "The amount of aggregate gross proceeds.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r544",
      "r560",
      "r595"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "modd_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement [Axis]",
        "label": "Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "modd_AgreementDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "AgreementDomainDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r587",
      "r596",
      "r600",
      "r608"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r244"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r78",
      "r101",
      "r119",
      "r149",
      "r153",
      "r162",
      "r163",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r285",
      "r287",
      "r303",
      "r339",
      "r415",
      "r481",
      "r482",
      "r497",
      "r509",
      "r674",
      "r675",
      "r724"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r119",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r285",
      "r287",
      "r303",
      "r497",
      "r674",
      "r675",
      "r724"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL NON-CURRENT ASSETS",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r285",
      "r287",
      "r303",
      "r674",
      "r675",
      "r724"
     ]
    },
    "modd_AtthemarketSalesOfStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "AtthemarketSalesOfStockNet",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market sales of stock, net",
        "documentation": "At-the-market sales of stock, net.",
        "label": "Atthemarket Sales Of Stock Net"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheet Detail [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r525",
      "r537"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r98",
      "r473"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, at beginning of year",
        "periodEndLabel": "Cash and cash equivalents, at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r51",
      "r117"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r51"
     ]
    },
    "modd_CashFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CashFee",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash fee",
        "documentation": "Percentage of cash fee.",
        "label": "Cash Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_CashPaidForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CashPaidForAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for:",
        "label": "Cash Paid For Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r102",
      "r103",
      "r104",
      "r119",
      "r140",
      "r141",
      "r143",
      "r145",
      "r151",
      "r152",
      "r168",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r193",
      "r194",
      "r196",
      "r199",
      "r205",
      "r303",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r403",
      "r424",
      "r447",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r632",
      "r648",
      "r657"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Prices, Common stock (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, balance",
        "periodEndLabel": "Number of Shares, balance",
        "terseLabel": "Number of Shares, Common stock",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RoyaltyAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROYALTY AGREEMENT",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r91"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r72",
      "r341",
      "r402"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r176",
      "r177",
      "r469",
      "r671",
      "r673"
     ]
    },
    "modd_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reserved",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common stock [Member]",
        "netLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r652",
      "r653",
      "r656",
      "r712",
      "r735",
      "r737"
     ]
    },
    "modd_CommonStockOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommonStockOneMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock [Member]",
        "label": "Common Stock One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r403"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock purchase",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r403",
      "r421",
      "r737",
      "r738"
     ]
    },
    "modd_CommonStockThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommonStockThreeMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock [Member]",
        "label": "Common Stock Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_CommonStockTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommonStockTwoMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock [Member]",
        "label": "Common Stock Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, $0.001 par value, 100,000 and 50,000 shares authorized as of March 31, 2024 and 2023, respectively; 32,464 and 10,949 shares issued and outstanding as of March 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r343",
      "r497"
     ]
    },
    "modd_CommonStockWarrantsExercised1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommonStockWarrantsExercised1Member",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants Exercised 1 [Member]",
        "label": "Common Stock Warrants Exercised1 Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_CommonStockWarrantsExercisedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CommonStockWarrantsExercisedMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants Exercised [Member]",
        "label": "Common Stock Warrants Exercised Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r66"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r84"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction-in-process [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r650",
      "r711"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r650"
     ]
    },
    "modd_CurrentPortionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "CurrentPortionAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion:",
        "label": "Current Portion Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r650",
      "r711"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r710",
      "r711"
     ]
    },
    "us-gaap_DeferredIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r89",
      "r650"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r71",
      "r261"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering cost (in Dollars)",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "modd_DeferredPortionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "DeferredPortionAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred portion:",
        "label": "Deferred Portion Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r710",
      "r711"
     ]
    },
    "modd_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development expense",
        "documentation": "Capitalized research and development expense.",
        "label": "Deferred Tax Assets Capitalized Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State research and development credits",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves, accruals and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesRegulatoryAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSignificantComponentsoftheCompanysDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Section 179 assets",
        "label": "Deferred Tax Liabilities, Regulatory Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r564"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r22"
     ]
    },
    "modd_DeviceIntegrationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "DeviceIntegrationAgreementMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Device Integration Agreement [Member]",
        "label": "Device Integration Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r241",
      "r242",
      "r243",
      "r489"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r564"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537",
      "r588"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537",
      "r588"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "verboseLabel": "Loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r133",
      "r138",
      "r140",
      "r143",
      "r144",
      "r145",
      "r148",
      "r281",
      "r284",
      "r298",
      "r299",
      "r336",
      "r353",
      "r476"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r143",
      "r144",
      "r145",
      "r148",
      "r281",
      "r284",
      "r298",
      "r299",
      "r336",
      "r353",
      "r476"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per-Share Amounts",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r147"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r490"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r490",
      "r651",
      "r704"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r651",
      "r704",
      "r706"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r651",
      "r704",
      "r705"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State tax rate, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r490",
      "r651",
      "r704"
     ]
    },
    "modd_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofReconciliationofIncomeTaxesProvidedattheFederalStatutoryRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "modd_EightPointSixOneToSeventeenPointSevenZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "EightPointSixOneToSeventeenPointSevenZeroMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "8.61 - $17.70 [Member]",
        "label": "Eight Point Six One To Seventeen Point Seven Zero Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r93",
      "r110",
      "r111",
      "r112",
      "r121",
      "r122",
      "r123",
      "r125",
      "r131",
      "r134",
      "r136",
      "r150",
      "r169",
      "r172",
      "r175",
      "r207",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r325",
      "r352",
      "r358",
      "r359",
      "r360",
      "r381",
      "r447"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r538",
      "r554",
      "r589"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of Fair Value Measurement [Member]",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r302",
      "r485",
      "r486"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "modd_ExercisePricesCommonStockWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ExercisePricesCommonStockWarrantsExercised",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Prices, Common stock warrants exercised (in Dollars per share)",
        "documentation": "Exercise Prices, Common stock warrants exercised.",
        "label": "Exercise Prices Common Stock Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Prices, Issuance of common stock warrants (in Dollars per share)",
        "documentation": "Number of exercise prices, issuance of common stock warrants.",
        "label": "Exercise Prices Issuance Of Common Stock Warrantsin Dollars Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "modd_ExpirationCommonStock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ExpirationCommonStock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Dates, Common stock",
        "documentation": "Expiration common stock.",
        "label": "Expiration Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ExpirationIssuanceOfCommonStockWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ExpirationIssuanceOfCommonStockWarrants",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Dates, Issuance of common stock warrants",
        "documentation": "Expiration, Issuance of common stock warrants.",
        "label": "Expiration Issuance Of Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r485",
      "r486"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation (in Dollars)",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards federal income tax",
        "label": "Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_FinancingReceivableUnamortizedLoanFeeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableUnamortizedLoanFeeCost",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized compensation cost (in Dollars)",
        "label": "Financing Receivable, Unamortized Loan Cost (Fee)",
        "documentation": "Amount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r631",
      "r666"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r524",
      "r548"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "modd_FounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "FounderMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder [Member]",
        "label": "Founder Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on asset disposal",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r427"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r525",
      "r537"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r75",
      "r77",
      "r337",
      "r350",
      "r478",
      "r481",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes - Open [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/Incometaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r248",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r265",
      "r273",
      "r275",
      "r276",
      "r277",
      "r377",
      "r490"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r135",
      "r136",
      "r149",
      "r154",
      "r163",
      "r251",
      "r252",
      "r274",
      "r355",
      "r490"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r249",
      "r250",
      "r259",
      "r260",
      "r264",
      "r269",
      "r371"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r490",
      "r704"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r116",
      "r266",
      "r267"
     ]
    },
    "modd_IncometaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IncometaxesDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r646"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "modd_IncreaseDecreaseLeaseRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IncreaseDecreaseLeaseRightofuseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease right-of-use assets",
        "documentation": "Lease right-of-use asset.",
        "label": "Increase Decrease Lease Rightofuse Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r587",
      "r596",
      "r600",
      "r608"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r612"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r612"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r612"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "modd_IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in registered direct offering, net of fees and issuance costs (in Shares)",
        "documentation": "Represent the share of issuance of common stock and warrants in equity offering net.",
        "label": "Issuance Of Common Stock And Warrants Shares In Equity Offering Net"
       }
      }
     },
     "auth_ref": []
    },
    "modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in public offerings, net of fees and issuance costs",
        "documentation": "Amount of issuance of common stock in public offerings, net of fees and issuance costs.",
        "label": "Issuance Of Common Stock In Public Offerings Net Of Fees And Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "modd_IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in public offerings, net of fees and issuance costs (in Shares)",
        "documentation": "Number of issuance of common stock in public offerings, net of fees and issuance costs.",
        "label": "Issuance Of Common Stock In Public Offerings Net Of Fees And Issuance Costsin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "modd_IssuanceOfCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IssuanceOfCommonStockWarrantsMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock Warrants [Member]",
        "label": "Issuance Of Common Stock Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_IssuanceOfCommonStockWarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "IssuanceOfCommonStockWarrantsOneMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock Warrants One [Member]",
        "label": "Issuance Of Common Stock Warrants One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for services",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r634"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r634"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r322"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments Under the Facility Operating Lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r38",
      "r119",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r286",
      "r287",
      "r288",
      "r303",
      "r401",
      "r477",
      "r509",
      "r674",
      "r724",
      "r725"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r73",
      "r345",
      "r497",
      "r649",
      "r667",
      "r717"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r97",
      "r119",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r286",
      "r287",
      "r288",
      "r303",
      "r497",
      "r674",
      "r724",
      "r725"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Disclosure of accounting policy for liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableDisclosureLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired term",
        "label": "Long-Term Debt, Term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r715",
      "r716"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "modd_ManchesterManagementCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ManchesterManagementCompanyLLCMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manchester Management Company LLC [Member]",
        "label": "Manchester Management Company LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r245",
      "r300",
      "r334",
      "r356",
      "r357",
      "r368",
      "r393",
      "r394",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r484",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r676",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r245",
      "r300",
      "r334",
      "r356",
      "r357",
      "r368",
      "r393",
      "r394",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r484",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r498",
      "r676",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r53",
      "r76",
      "r95",
      "r107",
      "r108",
      "r112",
      "r119",
      "r124",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r142",
      "r168",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r281",
      "r284",
      "r299",
      "r303",
      "r351",
      "r423",
      "r445",
      "r446",
      "r507",
      "r674"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r587",
      "r596"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "modd_NonemployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "NonemployeeDirectorsMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employee Directors [Member]",
        "label": "Nonemployee Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_NumberOfSharesCommonStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "NumberOfSharesCommonStockWarrantsExercised",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Common stock warrants exercised",
        "documentation": "Number of shares, common stock warrants exercised.",
        "label": "Number Of Shares Common Stock Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "modd_NumberOfSharesIssuanceOfCommonStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "NumberOfSharesIssuanceOfCommonStockWarrants",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Issuance of common stock warrants",
        "documentation": "Represent the share issuance of common stock warrants.",
        "label": "Number Of Shares Issuance Of Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r478",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ]
    },
    "modd_OperatingLeaseExpiredTerm": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "OperatingLeaseExpiredTerm",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expired term",
        "documentation": "Operating lease expired term.",
        "label": "Operating Lease Expired Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards state income tax",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r68"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pocket expenses (in Dollars)",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r425",
      "r460",
      "r461",
      "r462"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r532",
      "r543",
      "r559",
      "r594"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r546",
      "r562",
      "r597"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r546",
      "r562",
      "r597"
     ]
    },
    "modd_OutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "OutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s outstanding shares of common stock percentage",
        "documentation": "Company\u2019s outstanding shares of common stock percentage.",
        "label": "Outstanding Shares Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "modd_PaymentOfUnderwriterPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PaymentOfUnderwriterPercentage",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid cash fee percentage",
        "documentation": "Payment of Underwriter Percentage.",
        "label": "Payment Of Underwriter Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "modd_PercentageOfAnnualRentIncreases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PercentageOfAnnualRentIncreases",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rent increases percentage",
        "documentation": "Represent the percentage of annual rent increases.",
        "label": "Percentage Of Annual Rent Increases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "modd_PreFundedWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PreFundedWarrant",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant (in Dollars per share)",
        "documentation": "Per share of pre funded warrant.",
        "label": "Pre Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r403"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r193"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r403",
      "r421",
      "r737",
      "r738"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r342",
      "r497"
     ]
    },
    "modd_PrepaidAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PrepaidAndOtherCurrentAssetsAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets:",
        "label": "Prepaid And Other Current Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Prepaid and other current assets",
        "terseLabel": "Prepaid expenses and other",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r173",
      "r174",
      "r474"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "modd_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "label": "Private Placement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public and registered direct offerings, net",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from at-the-market sales of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of common stock warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "modd_PropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PropertyAndEquipmentNetAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net:",
        "label": "Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r322"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r99",
      "r349"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r322",
      "r338",
      "r349",
      "r497"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r85",
      "r88",
      "r347"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r322"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r72"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r72"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "modd_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "Purchase price per share.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r208",
      "r211",
      "r236",
      "r237",
      "r238",
      "r245",
      "r300",
      "r332",
      "r333",
      "r334",
      "r356",
      "r357",
      "r368",
      "r393",
      "r394",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r484",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r501",
      "r672",
      "r676",
      "r715",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails",
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r208",
      "r211",
      "r236",
      "r237",
      "r238",
      "r245",
      "r300",
      "r332",
      "r333",
      "r334",
      "r356",
      "r357",
      "r368",
      "r393",
      "r394",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r470",
      "r471",
      "r484",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r501",
      "r672",
      "r676",
      "r715",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ]
    },
    "modd_ReceivableFromTransferAgentForWarrantExerciseProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ReceivableFromTransferAgentForWarrantExerciseProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from transfer agent for warrant exercise proceeds",
        "documentation": "The amount of receivable from transfer agent for warrant exercise proceeds.",
        "label": "Receivable From Transfer Agent For Warrant Exercise Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from transfer agent for warrant exercise proceeds",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "modd_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy for recently issued accounting pronouncements.",
        "label": "Recently Issued Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r538",
      "r554",
      "r589"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r210",
      "r329",
      "r330",
      "r340",
      "r346",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r420",
      "r422",
      "r454"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r723"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r428",
      "r429",
      "r432"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r210",
      "r329",
      "r330",
      "r340",
      "r346",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r420",
      "r422",
      "r454",
      "r723"
     ]
    },
    "modd_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r378",
      "r379",
      "r380",
      "r430",
      "r431",
      "r432",
      "r451",
      "r453"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal research and development tax credit",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r472",
      "r481",
      "r732"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r148",
      "r170",
      "r171",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r296",
      "r297",
      "r298",
      "r299",
      "r310",
      "r312",
      "r324",
      "r325",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r664"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r539",
      "r555",
      "r590"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r540",
      "r556",
      "r591"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r547",
      "r563",
      "r598"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r148",
      "r170",
      "r171",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r296",
      "r297",
      "r298",
      "r299",
      "r310",
      "r312",
      "r324",
      "r325",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r664"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r61",
      "r344",
      "r362",
      "r367",
      "r376",
      "r404",
      "r497"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r121",
      "r122",
      "r123",
      "r125",
      "r131",
      "r134",
      "r136",
      "r169",
      "r172",
      "r175",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r291",
      "r292",
      "r294",
      "r297",
      "r311",
      "r314",
      "r358",
      "r360",
      "r381",
      "r737"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obtained a right-of-use asset",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r496"
     ]
    },
    "modd_RightofuseAssetObtainedInExchangeForLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "RightofuseAssetObtainedInExchangeForLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability",
        "documentation": "The amount of right-of-use asset obtained in exchange for lease liability.",
        "label": "Rightofuse Asset Obtained In Exchange For Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "modd_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for risks and uncertainties.",
        "label": "Risks And Uncertainties Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "modd_RoyaltyAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "RoyaltyAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company paid amount",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds (in Dollars)",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase up additional shares",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported [Member]",
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r136",
      "r148",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r296",
      "r297",
      "r298",
      "r310",
      "r312",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r633",
      "r636",
      "r637",
      "r638",
      "r655",
      "r664",
      "r668",
      "r669",
      "r713",
      "r720",
      "r721"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions were used in the Fair-Value Method",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assumptions Were Used In The Fair Value Method Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Components of the Company\u2019s Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "modd_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/IncometaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r490",
      "r704"
     ]
    },
    "modd_ScheduleOfIncomeTaxProvisionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfIncomeTaxProvisionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "modd_ScheduleOfOutstandingAndExercisableOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfOutstandingAndExercisableOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding And Exercisable Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ScheduleOfOutstandingAndExercisableOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfOutstandingAndExercisableOptionsLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding and Exercisable Options [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r322"
     ]
    },
    "modd_ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfReconciliationOfIncomeTaxesProvidedAtTheFederalStatutoryRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Taxes Provided at the Federal Statutory Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity under the Plan",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarizes the Activity in the Shares",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding and Exercisable Options",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "modd_ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfSignificantComponentsOfTheCompanySDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of the Company\u2019s Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "modd_ScheduleOfSummarizesTheActivityInTheSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfSummarizesTheActivityInTheSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Summarizes The Activity In The Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ScheduleOfWarrantsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ScheduleOfWarrantsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r479",
      "r480",
      "r483"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation (in Dollars)",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity Under the Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Options cancelled and returned to the Plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant- Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Begining Balance",
        "periodEndLabel": "Number of Shares, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant- Date Fair Value, Balance Beginning",
        "periodEndLabel": "Weighted Average Grant- Date Fair Value, Balance Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Additional shares authorized under the Plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)",
        "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant- Date Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rates",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Balance Beginning",
        "periodEndLabel": "Number of Shares, Balance Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Shares Available for Grant, Begining Balance",
        "periodEndLabel": "Shares Available for Grant, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant, Options granted",
        "documentation": "Shares available for grant, options granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant, Options cancelled and returned to the Plan",
        "documentation": "Options cancelled and returned to the plan, shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled And Returned To The Plan Shares Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted options to purchase shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number Outstanding (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Additional shares authorized under the Plan (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Begining Balance (in Dollars per share)",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance (in Dollars per share)",
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant, Additional shares authorized under the Plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs granted",
        "documentation": "RSUs granted, number of shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award RSUs Granted Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant, RSUs granted",
        "documentation": "RSUs granted, shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award RSUs Granted Shares Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant, Share awards",
        "documentation": "Represent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Grant In Share Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Share awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options granted (in Dollars per share)",
        "verboseLabel": "Fair value of stock options granted price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "modd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, RSUs granted (in Dollars per share)",
        "documentation": "RSUs granted, weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options RSUs Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summarizes the Activity in the Shares [Line Items]",
        "terseLabel": "Stock-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognition",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "modd_ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Share awards (in Dollars per share)",
        "documentation": "Share awards, weighted average exercise price.",
        "label": "Share Based Compensations Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Share Awards Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "common stock price per share (in Dollars per share)",
        "verboseLabel": "Public offering price per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining\tContractual Life (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r102",
      "r103",
      "r104",
      "r119",
      "r140",
      "r141",
      "r143",
      "r145",
      "r151",
      "r152",
      "r168",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r193",
      "r194",
      "r196",
      "r199",
      "r205",
      "r303",
      "r372",
      "r373",
      "r374",
      "r375",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r403",
      "r424",
      "r447",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r632",
      "r648",
      "r657"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r43",
      "r44",
      "r93",
      "r110",
      "r111",
      "r112",
      "r121",
      "r122",
      "r123",
      "r125",
      "r131",
      "r134",
      "r136",
      "r150",
      "r169",
      "r172",
      "r175",
      "r207",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r325",
      "r352",
      "r358",
      "r359",
      "r360",
      "r381",
      "r447"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r150",
      "r314",
      "r335",
      "r370",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r426",
      "r427",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r502"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r150",
      "r166",
      "r314",
      "r335",
      "r370",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r426",
      "r427",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r502"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r531",
      "r542",
      "r558",
      "r593"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions were used in the Fair-Value Method [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockBasedCompensationDetailsScheduleofSummarizestheActivityintheSharesTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofSummarizestheActivityintheSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of Summarizes the Activity in the Shares [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockBasedCompensationDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Member]",
        "verboseLabel": "Stock-Based Compensation [Member]",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares approved under equity incentive plan",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances under equity incentive plan (in Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r61"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for services (in Shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market sales of stock, net (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r61",
      "r372",
      "r447",
      "r464"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3",
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (in Shares)",
        "verboseLabel": "Stock options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r61",
      "r222"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter agents shares",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r61"
     ]
    },
    "modd_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in registered direct offering, net of fees and issuance costs",
        "documentation": "The amount of issuance of common stock and warrants in equity offering, net.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Warrants In Equity Offering Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances under equity incentive plan",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r40",
      "r61",
      "r381",
      "r447",
      "r464",
      "r508"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r43",
      "r44",
      "r61"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet",
      "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r57",
      "r405",
      "r421",
      "r448",
      "r449",
      "r497",
      "r509",
      "r649",
      "r667",
      "r717",
      "r737"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r118",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r295",
      "r450",
      "r452",
      "r468"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONSOLIDATED BALANCE SHEET DETAIL",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "TheCompanyAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ThornmintRoadSanDiegoCAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ThornmintRoadSanDiegoCAMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thornmint Road, San Diego, CA [Member]",
        "label": "Thornmint Road San Diego CAMember"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ThreePointNineFiveToSeveenPointFiveOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ThreePointNineFiveToSeveenPointFiveOneMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.95 - $7.51 [Member]",
        "label": "Three Point Nine Five To Seveen Point Five One Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r722"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "modd_TwoThousandAndSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "TwoThousandAndSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan [Member]",
        "label": "Two Thousand And Seventeen Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter [Member]",
        "label": "Underwriter Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Agreement [Member]",
        "label": "Underwriting Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r81",
      "r83",
      "r86",
      "r87"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "modd_WBernardoDriveSanDiegoCAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "WBernardoDriveSanDiegoCAMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "W. Bernardo Drive, San Diego, CA [Member]",
        "label": "WBernardo Drive San Diego CAMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506"
     ]
    },
    "modd_WarrantsToPurchaseSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "WarrantsToPurchaseSharesOfCommonStock",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter common stock purchase warrants",
        "documentation": "Number of warrants to purchase shares of common stock",
        "label": "Warrants To Purchase Shares Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares used in computing net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares used in computing net loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ZeroPointNineThreeToSeventeenPointSevenZeroMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.93 - $17.70 [Member]",
        "label": "Zero Point Nine Three To Seventeen Point Seven Zero Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_ZeroPointNineThreeToTwoPointZeroZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "ZeroPointNineThreeToTwoPointZeroZeroMember",
     "presentation": [
      "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$0.93 - $2.00 [Member]",
        "label": "Zero Point Nine Three To Two Point Zero Zero Member"
       }
      }
     },
     "auth_ref": []
    },
    "modd_compensationServicesEqual": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.modularmedicalinc.com/20240331",
     "localname": "compensationServicesEqual",
     "presentation": [
      "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation services equal percentage",
        "documentation": "Compensation services equal.",
        "label": "compensation Services Equal"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001213900-24-054877-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-054877-xbrl.zip
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MSR1EOE^Y\MNJ HZG)H@F$Q)S6%0SK@W0XAD5X9."K7_X-T@4Z9^Q5-Q47%)
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MV0S3_ 2%EU4H[7WQDDTN_R[3ZC.M=D-WX>B74,72!06G\<=2<BM#GD6+,([
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MHHHF?Z.B-4D6P9BL3NFT/B*]484;,P@TK6B8,,9JLX6RII4+;O (6&MA44?
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M]&#M ;<!J1#BH$T.S(X-G90MX$X@O@('MYV. 4E,:XW%@*A&SA/:FP/YF_&
M4C+'X&3YT'8NSA8D+G1)FD0U?\U9_K$VC#N-4.Y!\T.;5ROOE+=Y;>?DA5<
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MZ'!"5T&L=8)9-G2!D)3G**KK,ATU0IKG8_O.>&'E8I59;#^5/C'L&U9AQ.W
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M4Z&RK/2ETL=O7OVP*%U#2G)4>12-TGTO];KSVL,YNJ>>IK^7\%["5R2<XT)
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M-U($X$;GW<[\LQ$;PE83J2J8\TV@K-IK-0KEAM6KA%XE]"KA[(B1;VI7K4J
M(E I36P#&3_:H(W42DG(5/70U?(P97[-RF8EG=<&20HFP"^U9*XF#^S[$=1;
M/_[?3<#6I*WZ3KB^6XX,<M ^3M&?:%X-$6^KN# +>5\SAP5G:\KK,LJKL7(-
MH7^G&IQ+1T%[V1EG2= J?W9J8>W1>('B\WU99@/7/BR/<"53"XH_?4(S)6RY
MN0YFYD=DK+6YY5XL="]V6C09^\)YH.>BMM?S?U_,31FUY>P(_TGX-$LYDLJ3
MAC2_]L'!E3T8[B8C<K08P8'%7/01N9L</YU!@<@&R7E)/VTJQP$&48MPSL1L
MVGCBPVK&[\P"JAXZE$9@DIB@T139@>YHTPLTB5"Z- DZ>M+-D*(P"6T(\GG#
MPT.%W7!/5&@E&AW'H/X3YG#)S!>/.#5 CYNE-?(/D:7P("VH:=*\J%UFP5+^
MX#TQ<!Q^ECRD?04\)'C'+![N$4![TYF:J"KV^R#3S;[F.G.?B6I.9C*[\(6B
M7.Q]>OUSD_KG8+GU3W!4FWG5:Z(;U41%IR53QWAE89PUZ&/5,-V9X-WXD#<,
M]<L;L!H")89.CJ7P;QFH'0G;WX?N2]^A ]HS#?ZU(1U8L)[,6FL?IX+&JUZ<
M[_9=L93<.SJZ1\_F7[YEF^X^FG^YTL6_:(GVE0[&,S+5DB)+;)5YS6EK * =
M3B2*E2<R'9/-M; D] B3Z#T3SUP48@2$*%-K_DU*-(Q%6-,V#VVK\=91P#D[
MT;<07_:RTLO*=<A*?1Y8M L4':X#B@:N"?6WP40''8SH).(\O\8>&<J]Q'TH
M>+-OPI4&))J7CRF]7Z+6]UJXUEX+@-Z$%_B_56#GI8$Z+]9JX<\!0+\5_'FA
ML2P!17&G RZ"%'96"P;%V.2/-,%Z<'"'^V<>O#M:0I9*N[6++<W7,:C\(/MA
M%Y!Z+ACU0L.X0N#JA<;1-J>[7(#K!3N"K(!AK[ ?R/=(N?.HKY!>K9#>Z2ND
M;UW<\<ZZ)M;ZT6'K?J4/L0GLA]SGF&TH_U,82>[#VP:KN/7O<VX0[9:_P;'-
MJ>,([Z:J/225A!]LZXZ5G'[@RJLM?D-\KUM1<'?OPA!W1C9Z6;]=;_!+6AI'
M?2[6OH0827S%!K>ML24JPW@7B^/TNB0,6APF7VT#+=I02[M@1.0]TINL#4Y*
M35LSJN!8")J4/8LV!M0)#_5PKULS_OW*%MXL0N9#BS+%0( HW\SFM4((Q+F6
M1HU+65 D0?DF;?\W.3;8RP77M^>L,U=;VY5#=\2<+'XS""P!V1@=C_Q.;=.F
M3+@S>X&64PROJJ;22FD$ C).M[IF)7YV_1ZE8'LSMS_Z^J-/:CEM_R0>-])N
M*TDTKG=D.!8K+5 B+1];%ILEH=)OR+!=I;[0#U..TUT-2T&O1'HETBN1,Y1(
MV]2'U,G09?:CIIX6I4MVL)U3FDE4<D5U!R865:N  .DU+VO_MBB20?BZ;"8"
MWCPHJAF903$_?A]W*$JYDH9PL.^U8VM3%!VLP0UKK%XY]<KIUK[/#2FG=:%X
MB,^W[LD'K]YP2T0.V"UQ:P_"^711,8^A(XZ0A&+$B;\<N30EN8:V OD.](Q\
M+JT6.4T,NL.VI^Z\-!4]9F1LR^MH8D1!Q=CHX]0D+6+#W45;XD)_@5=1;FH)
M(.4JQF7054CQ,L$E0@[V1K9(G-4F?7'*M>@>>36S92L%I.%XY#\;FFXP3%@$
MR@JW3MN4TB<*-%^FZ2BM0VE"'NRW/2AQH]=V1 ?(W/Y[-)N_#-^X\1])>T^>
M?A$2&LC^ZX,W1P,\0S$Q(2@Y,)F:;NG5<:^.>W5\"]3QI;W!:S,K<F8?L_9B
M2\9K\3D=S2L*D8$84](>9$+&6F5O:$2?S9SWK$7$30W>T "MT3+>3KD_9<BD
M/IUJIV5XAM-_[E@P6AS?:*$]J:H3DS,)\/49C;U"ZA72K7V?NZZ0WBA@2W21
M!6TQ ;*SBY+"< T2XNGD77)=);2-P'I)/70!L;T[V:N+7EW<3W7Q@7997,Q:
MA=&:)6&!O&UL<\6ER4AW< A]14-(3U#XIAV+1,@<C/A7:>F<O%N!%^F52J]4
M;NG[W'6ELFJ#K!8EA-$$O<TX-7\"! 'R<*40-EBX2 B'QR/P<AQA\Y*!"*R5
MXJ8L!4*.-G-Z92-NCI?8$R8Q4"K<'\5SL\V!+O,U?BT*U#P$;XOR-"J3N_T^
M=QW[\_<"2S&6I>"ZD9:;J1,_/2DR;1DDS"5RZ/OE<_-HE&ILEJF^FCP6W!AH
M1D<%NDKFRDE2"664A'_;"L,@JKA&R(HSQ!T7@(.8N9?*(DIFT?S^DI?<>?OA
MMIW_-W]^7S57&Y+1[/8WS.G-TOG_R@GH<9>T!."5,9\90Y> 0+/(S5 *=9E5
MK9"Z]/VL-F4>,3CO0#[/Z-Q^DV-[)N&&]C7;/WBC_<PVY6?"VD97''H'\6N#
MMJ!E^ZO#U^Y73FMP[[ (/=%XJ!,A5-.RP6+.-8.JCXJF"B?DGX#.2/N059ST
M:7N>IMKCBW29+:/#%+4%PHH*8OIT)E4'3G[A@1?%UY&FM3DMQJQ(3,8]=CD=
M%<WP[(2')<U=!35;G YAFS"ZD::6VZ55LB8.I:L),E $S%#CAM]S3A_%/[99
M+1"VCD-Y&-:G!;KMHN4:T(VX#4 )]*VCF&*^>4R@#/'41*6P[TG\UQ)I.49H
M^@W-TT. ':!?9"]8@M78+?H],J%ZW=OKWLL%3A^^=FJS8^X(J[(E05:(O0*?
M+=<Z[3'ZY"2-()RD256/:$XZ=STC>@'L!; 7P#,$D,YL(=0A4?*DD<XMFQ35
M5O$V5IF(,0*.8MN=%5RSMBTKCGED;4VGBJ87P5X$>Q$\@^#M[_^7O7=K<AO+
MK@;?\2L0/?874@PR6U+=779'J"156Y\ME[I4[9YY^@(D0!(E$&#CDEGTP_SV
MV6M?S@4$4U*WI%2JX0>WBDD"!P=GW]=>^T7DL8L+Z@H,7B YXF^'TIK#\@*K
MP8RAO/;#E-"S!M]W7^:UY!'*W]#+TVM[4=YX@<_K;=O1A_M%/A?Y7.3S[?,#
MCUQJ@!=C'7>6&=BW@KW,>;+VQ:;,\<LBHW"U'JJ+]2X'U:D@1=O#4.WI=@5+
M[:ZBT)4^*"^JYJ++FVV92HL@;&S3[A&ZKVL$[G7;'J)TO3/,XU#5U?]4.G>(
MTWX:^0J(B71&7ESES9!O!04*0G>L15QM^-#2!8ABI$2^&[I* <G) (HZ6E!<
M=./6W5?:5]VX:/HQ<\!R>V%_J%2[H>30,9NEN Z,C5W+>/0&=^S-DY!+26*B
M;*XJ)J*FG=56RESN#A(F;#VG%S+FO/&%E&!<$AP9BAGP7;#Q5YQ,%96)5EQN
M6< %165BY-J!4SHU_;\=>H)]NI7.BLU<[]'S2^?--GOL'7_T/XY*?;_K%XZ9
M=R73^6HATSDETWFTD.F\[6&[F[+RP;C5I;&\;9;2XFVN_Y>VR(]9HG,)(I:\
M+&V;&BUL@ 4X3D(>8Q V[\^"C'YY^-1GQF6TO'R#T4=TBU\>3;X  '82,@EH
M]K_?T0T71H E5EAB!5G!B[*@8+VIUNE%/ K!Q_/%V/&Q>E$U%68$?O/-@S^R
MD%&XWI)[O %"D-Q.^*/Z59'<>U_3-[/TZR_H^^6POKS/,U4>/7CT@*</'],=
MV4V)[7^K4$0D_?#5PW\VD,^?7YV >_[AB&06@5X$^AU-,$DFQ;-OE.;A7_JZ
MVJ?_SR,1K'L<8%)@B?]MQ\%GVE"+_@$9NXOG?]+^=<[OT7^^C4 _^C80:"F2
MA50<BT O KT(]$TK8%P-N:[G);KJ#VW/Y^JG?5,=V@*^\'HG B8I]$@D'WX7
MVECUC"L1Y$42/WE)_.K+?WZO.0'Z8;7?DL(?_NUW],#=^M]^1R=E6_Z?!P^^
MO/SUL 5/_YOE\<NO/]JJOII9E3NJ[[BG'S:WXKUKED4)765"H22?R^%M-<O[
M7YQZ"F^ULL]:$WSRZ_]E5_9E(JF3R'OBX(M4E>11KCBK;]-XP>/8A.T5W-$%
M8L\KSIG(',E:"K$=SPM(=^V!&RNX;[P;M$BP3_/K_,BS5!)!?G>ESKFEJ[]X
M^EPPD]ZCY/$+8;18YF2.N"D^3_^_?_HJ>_#@00IR#>WTX-('3_F]8JHC0T0^
MM<A3&2J?&95Q<N_IBV?W)Y,$F)DDKW3"Y[C'3WMC4T+&J4-)V558R&4=5WA"
MX8D;>.-XH;S1%P4],C.0%,Q5@JWBYY2""?-<VLADJW?WKBS.V^EHYO:'S*8^
M\':N>7!@W^ZER64UUJ\Q7ZIN;=PR_^O>_]H.WY-1!EYU=]]6NRJ':W )V)49
M1"^3E)N&P:E]!484O!%S!RI!>'*7CCLSF)X:^ D")AT&VH"2DVY'5!!7;7'D
MC?GF$1V.4?E?QIZAK#W&/Z/@%D!PF'X/XT#XCB<0'#=W^7DPGT1G0^ VMF(M
M?BEN5C!S],IIJP9).^"#E[N\V^?K8_I#V92;:DCOO?SA/C]Y,N,(T2;L;?IX
MTP,@A/E%>,L,XP4I=KY>C_Q M!F-FS843YQ=K\FFNXK>"\S7@./TB 1]+(Z7
MZ6,ZNG2]+[[X9PR&/)3M@0XP/7UE[Q;)3,YZ2J=#?9QKK?Q>A;8O.;)*KW+(
M;OXK0K(C_UQ^!/RN?5-SJTXG\'C<(1^ ;UXG_'X!9F[: 07"!A-;@@PIK8,;
MM7"W&G?[ZO].CV7>+6-C3]?_AI%)'\<+^GKJ!2VOYV.3*-=UXH2/=8PC0%9"
M0%(V@RJ;H1/206E J(;*!C8-UZV,Y"%U*RK6])(#\A>F4YE9B_[_MF53D/<5
MHPV2J VB!O:8Q^FTAQT+?^XXN4K@(KA78<4S@E@C"6BK%PN:7[]&7UBC Z6'
MR.")IJ]("Y=&HDHFGZL\XV'(7Y>+LKC%TXC$W7:7\!0]MA$'\NMJ$'Q#W[,'
MI2U\KBDFP(AHIB#M]^C5I3,(U97+]+ZHOB:6A]L"R>4@KZ9(__OBCVU@:\GR
M))OJ-S2X,-2OL[.>PX /,AY3?0*]WZJMX57 >E>],]B,5BE5$& )V2W$R#XZ
MYM4PU&S$>1P@7(FB7 OH1L\F_:A+[I67V\N,S%YZ:/N^\JU'8@3YBWZ9<U_L
M2=W+ M.B[?$.9,T=B49WU59=%KA0TMDH-'9F9DM&&Z$T:G607\S*^E<1NRK.
M\UD=TR>D3.@>())".941/&M:&PR\+(M+J\[) D!+&ZF0R96'L[]>)C^40Y[^
M4"$LI4=YWJPO^=T\+5_GZ<_T2#R.7C[A)@9VKI^TW>'2!HS9@/IH<JE$!N2E
M6G>9G#6M!?/#/GR$[JUAUV<)'+F*G?ZA;<GM[FII!^M[GDXB_:4NWP7MR:T6
M=T6_G%<G;X,-^GK!!IUB@[Y8L$&W2;7V:<G73;FV!%&.##-!FH-[.3'C55,A
M%<^G\+&6!%@N7?$M2M9Y38>%(E^OG>G+'*\_&[OV4-*2UQ3FD2M4]AZD#HCJ
M.@2IBYHC@]*NKBH&PHK)0::%?*QK&0\I:;@*D=DU$]9S4D)L#)LC)/AK9"-@
M&]0*O&A7E9@1_(L#.S/=C_;_Z4T3IP>JWH?H;%&"V'TD7S2#H:V0.U##:5WX
M+HP6_T_"=A0C^'Z(P]T^#T&^X2L./?62WJXA.8#=MZO[3(0D@*0MM^?FN.=/
MY[#^=^Y0WG6A>AP6CI)O?.%($QL@NV0?<SQ(*A!_[/+#D8YZVPKG Q(.GLD<
M)V/7@K9NZ,$9+->K./;I2Y>N8V 7SO2A;3M)Z>GY3;9=.Y(O(IP4=+0% %X6
M?K I+P9G?+N7<V9AC"R: ZH6_IV@O??2DJG>9@08SP(DN9."CXTK?M\NR&>1
M_OA&TQ^W _7^U%[)1P3;/J<MJ$& .^9U\A+6L!N."^SV-M?_T]@E.IXKE9G/
M''<)KXX,8@LH-UJ>?P&[[."R%%Z1#Y)WKWL4*JJ&O\ ?DA(E72RIH=?DH%SL
MR$DA13B4'(^1LFQ(/Z(2).3$!W*)AIRB7:8I PT87:J'<=_ U#-#,D\.IV.3
MZP Q!*GZ=\EIBX7Q%TOU8C;^7*:*(UOP0[G.E0R,H\RRV0+&M.&.)/9])-V/
MCAZA?[>DEW;HXX9P$%V&BPLRMA0V#E:-P@VZ<CO6(,*W)F2A7<7.9\KH3,IJ
M)Z/0JZ:@=XVJ!\:<]0G*4AB-SL:DW!]VR-_Q"[*))/I2@@W6[)^\$EY2^%:"
M[R$$QX/0?^]D= !.C#U69JND#Q-[C_(F]B6]@6))\]^BD]4CC?R"\RY?/,Q0
M3OI2YKD#3L>)X3]?OKJ4-KE!ZE4-?)VN! N-"G*F%5WQR_FGCQZE4 8<3W@J
M&)>3B:?8,QG7"G1;$E>$^D&/9701X?6[RCN.;/(>%&)N1(,[A<?,3^*;ZHAT
M4X]5P;V'[*?Y'_'\BD!BM1^QGY#^^927'&+^+:^^*ZV$V'!226N-2E98NFV9
M>S!NC*2;C?5@G0P57<&H4=UV\\5LE_ -<4%)#NE:T#D<:HUZ07C!DA*LH:4P
M(K-+UU6W'O=7\"KXRS8AD<=U<$Y-UMN7B=W(N$0V7&:4/"-IH8JOUX\;]"9*
M69'?I4[SA9:8O!A\WP9WC"[[&\YH=#V7BVZX38?KCQ"TAF$//XOY6?J</@&'
M2SP8UA@P]OVX^M61*.X/7;G3PM]&9H%E7(O7"3MUBV),G5\;][*]5J>;?QV[
MJB^JM?M0XF)2[SJ'M]-,/:O*(LC4PS?")(JT(-V 6@WC+:3@,'._+9\NT\[V
M P6$4;!SP(1A^2H[6=S)/7,A4=GQ1FPZSM(:WN R_6GBB:H32&IH4P%8=A3U
M)CZL<V$YG ^<V$PY*'/'&OGFS>#5D7*L*VE&"^Y>-:F,EF4-;WA9V /X:7//
M>L-V=B7^U6P9"*.PI<BW% >1_4.DZ,A2](J]H7L>;;A<]![")SWS0#/$G;Q+
M&*V[I_//SFG'N>\,&]0.\:!=VD"Z^EJ0/\JP%_!8[<7&->1@;ZM>GM6Y_OAC
M-MD(SI>"Z2Y'@_QE\E@02&_85STG[/M@@^KJ=2E[LL]?,\P(I3ZL:]\6O'0G
M'M&F.5^7,6L2"PQM@O_EYGQ I=K!6;^)?Y#3DJXJT@6ZY>ZR;*#'#EY.%T4"
M,BMPD&2PVGIQ(%)V4DB,:-4J)]+GWX[HE"B0E\8CTILT"QWHE< #".\';H&N
M98O@[^=3RWD*M![_D!8Q=!7[9=&5/YQ!OZ6*V3=+Q>RT8O;E4C%;*F8W^Y;_
M6OWAQZ>/([^R^L/B6][F^I\WR4SSO/D29)#996#_@74[60^U#=&0V$NZ0J%X
M3ADKFT\N(K63#>/ \M[QV_#8L:$;V:PG9+%1)QQI"5P=$6._S]<[^EVF>#"N
M>\H7<OR9C-!5-71,J;/E'SC&&JL*L@65-2.7MT;=Q2<*<L^FF['+DX +B!.<
M,( V()>>:0^DM%QZV 'U^B_*>ZST1$@.JDM=5/FV:3GEMD%-58:EV<+H20IF
MD)#(6W^S'N$P[>D/6W%Z$J8<V-M#D7=\Y5'V>E'>@'T>\/3D3;7/:Z!Z.[\\
MP%W$[#._,&WYFNF:F/;HZ-A%+;?)4&SZ-UTXF5Y8<S^\+9C^)#4W>D< !3)9
M4D??8PI$O?EA[ [ ,KGLYGI7[OEP"-"&_6"E&FJF]W</ENC]@]M7<G-QX>&A
ML/<NK*A["B56;>VXH]@EE%5:H8[',6]N7O.E$2XQ5HR/,+^Y)*!99FP27@AY
MQ?) !IP_$0-.1]L$Z$"6G-LNCFPO;$N7Z7.M@$Z7)WGH))_Z_3S)69ZR.+O=
MM!NKX\PVJ4!C\S-+B]M%QWX46CTAEL(E*L[\KB\36B2]ADPQ5CJJD+\;/_V2
MVKFU]?^EE/Z1D"LX;N]QZ4UA%@LF@\]I_)0Q()/#/4Z-0._UN#0!)1K&Q<;C
M%[VFW4CBMR <I--8,G$ZK$$S@J]M%#!'G0..C'\=R&G.M_Q/S)SB <,P+G02
M-824$!C?2#@8&JI>?DEQ6RM?D?Y4_A3BS.AC_@,]1]O1.LK?Y'^E4B(T+V-W
M55)D9#G;B?5<#OWM^9S5'Y[R2TA>=J6^K9]]:/NSX.8YWR"NZ%U]T+O^HG[@
ML"\1BU0!?$-F)VQKXY*4O,%,^N8FJ@=Y)RLV.R$.0,/P<ZR&*GD:U3EAP?5@
MIR0A<^92/ND]^O%7#Q_<>WW_?EQ_I?-5H.ASU>+XT-TP*=W]S'U5G0]W=;<2
M_M/+%X\S_]VQJ163?$S@=EL^I[3RRQ/<)'WN?/.6<73L4ERCY9 'F&^DCX[>
M3OE;N1>$-C]UU,+E 8?(=+&GZM>H:2DNU$G*Z7_DL6[R^N<"!]L5>YUN"<S-
M53,(.[VPY\KL'\_Q9/;OY^E%(DY>4+,ORJVTH*5=U;\^J;G/G1(=)R2=,H,V
MGS*]/I#TI16P.%&'7&++ TE\S@ZETS[?E%H7+=FC)JLI:>\G\?N'@QE$/V)!
MD/]<*8Z ?7Y^0IY-#VL;_@ 78ZB9.P,6@R1A#")'L2EQ?JQ@.QREM5:,*K](
M;1*"IUG)F?%BHM86'MK)^<(KE$0\3I2LTF]-XM.9-VR-E4<-6A"XIGFQT_'V
MM"(;<JTOI3<71$>H3!/G<9(WT0%O;FX;/;R;5?VG4<9$O1("5I^"2._AJQJ.
M_NG5SS8YQK7AXG_CG#OVD7N?\[44%SKDJ0?)=B8Z@87=YKI2IZ4K>7$XNQM+
MQ+JSR4&=1E4!*7P&)MAAMQEKK<$W%_NJ)X7&,N#]GLB5T;N+.Y/7";"4=+5:
MJPC^Y?I1$%S!YVV4A+R]>/^ZI<>G$B2SU7P!HD$KS%!9AXT>4DD&3U]E(M4:
M]^LW")J]P[,G2O^NTB('FEQ$NDK5[U+@ ZKP(/G;)1I@Z8TR[O*55'Q7<C1)
MZK.\T GI_,HZ^Z@W7 Q]Q/J5PS#G)T,"@H&#)O!K3@I8\ X#MS_D5<<U5OK)
M;D20*Y6:H-A4");U@&H30 .>VQQ&(M@S5GZ(8NM:=@91_Z]C=UP<SUM;/\M9
M\OQF+7JB[="3+[6H2-#>0E3.BHGVZXOXGA=>+SFJ":<"%&1!X#F<R->:HTE1
MTV&3'(2AR+NBST@]]\/%7,C4!6YXYH;VJ5*U:7^P9-NQ*J3UKEV/4B4D1;:F
M($VKA[35%[PT>LR3-5ZF?]E59":8F6+.RHFKY+U#[PM%WF"PW"P-+^:O9@VY
M^;EKL U.I'KO6)9<+?,D(_M]NFNOT=>7.;?5)H59.9 +E_H$)^MYPR,EP2-I
M#+\FDP)76C!#/6LQVL''/1<L46P,(W'F9-R<V0SVS$DO[JOAS/U[[01)\&!R
M_U<*-!2WVUOT)X_3>X\><CCPY#*%FOCF^_2+K\4WYPQB(9,@-!3PKA&R9SX<
M<.Y/VH:M?VALM+!?+85%\>DO[J*Z*'>UZ5:$3ZSQ"V=,"MIFP0!XX2M*<NC$
M>6!'S"!CY 6T/?M^'+]6+F4>6!A:+5X<!1+TXDQ F2E"OTO;#1=C,#OIOJ,4
M*-9YI ZUTN.EC]/I#_G+25UN^:;R/;<X=SG8JP"0P8'-OLP;]DSN5?>]=\N_
MN$;GU/22SCM]D8/.+TL??O?-UVZT'ZWK(J=C6K#T)]%3R8A KUYS+,"69=XO
MUG&R$,C2"MG:K@R"%18:'X#0DL+(A/\?7:NZGYP^E<#ESKVI*.34L^2I2C;^
MO""\Z?V9\*_BW)43(X$Y>7U(CLMC:?BF?C.;@O-ZB@]QWW,&C']%-FNMN)EM
MAU]/90$O(!ETJ*'</8-%(%EPH8:_]T0#EE$D\O*,LIC@?M!WG6[*T@?/>6I&
M(/'AKWJXBU-T>[7&C7=% )0U=>A/:Q &AQJ5O0MF\>ZLP!1IQVQ.9;+*DGFA
MB++0U>5D.^'DM9=M.W'/%4>TSKGQW@EVM!C6[@,F>%%HQL,UA.^J@RN^;3L
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MK96%=K.YX+LYL+^,!04J8H]TJYKA+LQX.'I$'E[>AHV1S(1R)4*^"/@BX(N
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M(K\&Y7FBE.XZM2F\@^ $YR]?:1>%O_PIVXR?.&F?;:1U-$9"EUV9\/ZLQTZ
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ME<69SF33E0SZ #1DRQ4+U/JORQ7W4.1#>GU]?;DG-[;.NPN-2R_)Z;WD.[;
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M=OFV\'/Q.+(W' M#,H5FV)O<J(!-!BS'4!#\"T>&,[C[5M/4P7"M1"!4U>'
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MAT15AO"VAKRBW).F1BJP5!PEHUF42I!^LG;H (6M<.*<40=XEJL6J[ &O&N
M;I5](NCRPY-(IZ5143C6DS,T*9\?\O)#G^LGDQ/%D)%ZCZZ4O+X&ET$ N$O0
M4]]V]"<.X15:XJPY-ZQ@7N<$IF>_TK#%0^H0JXA<,*T">$P&>@*\V]Z+@1U^
MOBG0,4EPK%1&Z$I&DA#"<=&=:TP)M)#=2+MD2/8<$"L4\8L(Z6)BY*@8^7@/
M(P54W)S8=O)(] P#$([B=U3;7.G;=%T>^'A/U_7\Z3-=ROV3G=/S35_Q9_S0
M5:U21NWW&/Q*XB</,-$"/-J5?VN@3]UP>3*^(%V,54L^Y'XH;MY4^URX '5X
M+6!$)NJJ"C*0QUR+NT4O27IC(>ZL<^B[@9"#OI&7J-T;NUS^:I=$VV]+T11?
M@F6<7Q13+;5C4S '!!Z$*3SRD>Q</N@75N4:G<.>$NJ+!_0X=#[SS<#3E-9E
M1>=<7F7"KU+1E?9&BU)G]I;1_K=6T[9W;6_95A^]887?\?!U._.BN4C44D!'
MZO JB;8]]T)'P>5P;D#&N!!]_RLT[Y[>B._?T[][MS0> 'ST1(F !G8@0/Q%
M']%)(#_1,5J)>QXYS/0<#L.8,^P0K>V%-O7:CM'6[N'#N]WH!.<&R<$+7,O@
M;.NCU@4900B_2VUE$AD.$W2)&@A>CQ<\/,,!MQT"@R5'7?O(U^@LYN&,/IS
M.5;)<3A,T#5GP<;QI8VPTWT]X4B'EZK75&86YFO9]\S0C'Z<B:;DEO-TJFU,
M_L76;9EMDLTPWR#<]*!BAO$9>BR=J#[W4Z#IGC\+[OB'-N\*KU%^_L%KE"$M
M@5R>;%A?#:5[I8Y3 )J/CF+AE6;3-A<A1CE4G(8]C[03=_'8^B4H5 -NFE_H
M>O"5R9KTV\8^5Y:#FX@6 !@]-2T]9O!N?XK<$GD5#NPN?#V"B\_7:XHLV GB
MXRA*/>ZXVY3TPE4%HE4J;@;0X^P4;V)X24]?$/*8BE"#Z$=18,P,P\9&VZRJ
M*_*+2,E-=\3!,?N#Y+/#:JIP::7@B\';X5>:Z!>ZLBZO</1XCSR':43M@R8V
M1J?YI>9.M -=8W06#A OB^/>?I#],A74.%R7E38-K,J&U,#00X+<MT1)-C,O
M_C)]=N*(IN_1$4W^9D<T?4^.Z.4=FS_^89W9.QFHH:5(B<.4G:^?3+)GIKY)
MVZ"CR@N8MU&<JFM2$Z/D+LFFH=?4,Y^$';:ST4RB*3**Y=!Z4*YW35NWVZK\
M##O,/O2Q<&QHW(94F(KCWM67^6#J^I<N+[CU)_D)TE^F]_ M-9)_?O7REY^\
MQ:6OFXI%WH;N!^YROM)6/:,-D[4-1I.H;YD,0<E@LDT]5G1BR!U@F*1[PT=K
M377=;8ZA;U]2P%3PE\CM:^'1JX_#J^,"D-9\Z.ZCO[V"_Y6?3?:B"'VGVM5-
M<>JMG3M@]>L=+;AV0:D1DALK2>W<-K!_VKDFF*8-*,?9\A@C+4BU0<A7A$NS
M!U#/7NX&4-V9/7>11T!09]?@NQBCLOFL>SJ*_+*8B4CF6]#3L],P"G,2_TXY
M"1'X)-H.+O1#?'])[+@^^8P#+._/91Q_EO7!& YSF'LH"JEH!7-P\@(FG9[G
M\KTH^7_P_-O3D1R#-BV-')];*U,W R'2PNPD\^M4W9[1X:^KPDW)D":9W%,\
MV<'B+G]V%$_[ZCFN:Q0)-#$<>D4^/8X=PBZ:1_Q:P0*\4!LQ%XN-MM8W1R?!
M ?94I220\X2\+D<EH,*.72K-&?M--BL+8G41\UR,&N,\A('?::*&R1%ZS#]#
MZWY+=SNR4B(5UVU+YH>@?3?>?R2^BV$'#U*9\W+T$HD''Z,([:&A3;2-20G-
MV%GK2B_UD;C_35O37FM>"-3<='-RZ M1H=Z+M;L4K=SC[)+$%>:G<^6T:(G&
M?\6'C5L"[:#5[.KG*(=US!%1Y]>9J3$A5!L#/LXP&@T\#>,2\\K-XVAXA@6R
M+6!/!9*&[^88I9TR2G@<U.R\+HHOF1=5J-W:BH=W!$UO=).F=/.3'''FA!)B
MU@7JHY 9B"+FYHMC9^Q[2%CJZ(K?Z()YDC&_(<' **U"%J.<#$YU[WD5+@!P
M=(%SG=C\8I#=Z<B35"VS*X.^=)]KTVPIO>$HT. GM-CWLW'V/E%3(1& S$63
M9DXY<XCLH=Q9;<1,)?,GK,-D2 3<@Y-O$$/48D40H%] 28Y[)A3 9SERAYO\
MJA7F;CHSR'8F4;4]%.Z;"^Z?7WCPB9X81(N!-3^=8#=3W=.@\C2('#'O*:09
M9MU2HKED]DJF7/SI3+P#$V1EPXA#3J:8H8"X\3+]KY%6CE#&D4F9?ZT>>>B4
MF V=L9PI6T[)3X7,D.S<F)(LJGQ50C].+#P)76[!@N5H)DX1LOJO&P"G-:"A
M?93F9-Y-QV3)NW-:;?6[MU:*2]Z[<M&M'W[:9!X<B6-$E&RO3OC%Y(W@Q8(L
M_2V.LSA>_#Y)=)AN9=RO0.&],8)WS\><!'S,;OI%Y-:T?35)[4HJ&_X%<WNQ
M*[ATN"^0RKL*J309<X37+%F)S.^=<V@"8?4TR60PT"</?)]F=FYP<F14GV3V
M3Z?8&)^.S9$OD.SB.6XZ<-O5/)%X:3QQM @OF0M'9NQQA O._Y:%\_M4%ZV0
MN\M'7\$.VH>LO/%Q]"EF:.N''TNX;VV=?YMR^/L6^WZMRUR;:)/JM#--[8*?
M/2BA>'I\'UF5PE8>T$8Z\LOI+VH>R<E-<Z@]2CE/J+K(G)<\_BSG+9.<R13#
M$,WN0/@?E%4BYR-R5YS^L6SO>6_D<U [[V%E[P0J?KB BD]!Q=\NH.+%TBYN
M\ >T5&HB2(?OJI5P-H\]+X*=2^1>M%0@-8#)*-53^Q$@#J57Q8H'?5!;NC$S
M8QQM2&F(0\YXK0 '6\C\C*6C;Y&[.RIWOA]!I8.+/%=Y57/!R\E?KD+D* LY
M$:X3?T*/LFN/0JX&T6+T0[KNVKZ_\-+71CB &R3PX[46+AG!N09#;D'DTLF-
M\VI]F']N@AI_WI1 4U]YADV95XAF0AF'N"1^/W)1S8]:UCJLE,?;9E,5$NXI
MM&(*E@HP\P)XND+$8-^<8*><A99#Q)Q#2K6:R$$HBZ5*]K$DO4G"26FBA.''
MQ.\L^$]/N*PN4U"SKT GQ62S:!P:,F$3QU1BJ:B-S<P-Z,0 V9?T(.;4*A;*
M2!>[]IH17ML24Y.Y$Z4L7\?'L^JCAHW5<7I< 7MI+HJJQVQ;J]R!PF3;V&P/
MAP$*YJ@F;@1NRV!#L(J6^T/='ID<W$:[ HC@9Y_U9:>-3PS_T+\).[#6VO@_
M'"UQT?JZL#+>!Z-<0>F[$AS.>N=GA<M_3R8-,N=TU7M4FY*S<#]1))YN"NQQ
M!I4!A']AZ$A&K=#O$[EC.*<0"64%)P6]*^6A=P!&S,-M8E ?J9=QV+4=N1O*
MIX^^ BV6HTA:"D[K1&TLAN!#LZ^W70D,D6#@6!Q3$T<;6"\2I.3^(29?N[^D
M\DM_63%!NTU/YQ'6S)8NH*T PL/0- >Z&5P.,'F3R&7GY"WSWF-<XE:Q(\<U
MECH^AK-UE0!FANO9K)VJDTG9TG;  R8.(Y?+T=[583_<O!^+&RO%DPNCGH=6
MF9(S?)\"$06SI0)HC5CYJN59&=HN(L7SN7(0&HC<JQ("OP#J6@CP1:$KZJ\%
M. =3K$P6):M'W><]<$K88)Z/.CEY:9[P7EYP6I()&LH0>DV)2A^=8KCD1=%Q
MV0\*W(U7'G:8^N5BMG/0Z,5W^UBL,$4)?P'RY(EL';248:.JQ,XJ#%-2(>"8
M5'I^5C/:+U@I,.@B5P!UV'1K+D5]C)2*UQ%HOY!64D%5;D^Z=/(SYXM;:OU@
M@_*W'(AHZ8\G?V,T&M0%!K+DX>YJ'N[_9^]=EQI7LG71_WH*'7;WB:H(P33F
MWK.;""9%=;.ZJJ@-U)JG?ZT0=AK44Y;<D@SE]?0GQRTS)<O&@ URE7;$7ET3
MVU)>1HX<U^]CHX.-+W'+A]JHIB(,H5,4*I%<G\,XS"JXBE181[V^_$4XFPYI
M]E3]>[E_05M+V@[Z$=*F[1GZZ<[0 WJ8X,7B/C"*!B61AG"'60<8\1BQ*R+*
M\D*.FD%^2*3IO'1N*M6W>*'-+KYMSU-[GM;^/-4<&P8X=8[.((IK.[=L)Y[8
MF8;.4XY8>S+:D[&&)\.QUDJA+['5D"Q03#2XDX!B(4$GI5RD ,R=IJ/-:9(N
M?6FZN>11]ZX]5^VY6L-S104VHS3/(_2 )$",</%S;"U,.V!/B HQ8%TVU=K3
MT)Z&=3P-97^#'0KB>7M(3.2MKOF\-I!&03@.,6"3NS;$I,U]G#B-[@B8(=E&
MZ'1'H(;>71@#H7)+G-@>J+4\4&X* S+YY-TP4ATSR#'"$P2FV9 S/+S<S2KH
M M*<*]@UXZ3((HG1R:$,"9_S+LQN .4"2NGX BLU?G%(3FA:Q%]:8#@(;O,
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M(#>TI"48/2 3&N<$Q0Z2#F>Z7T9[5KF6BQZ%1$ )WE(TC.NJ4@/3#@UK,RA
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M%)/*E@O^*C9B%M1 ;W^2(=^0,WL*Q0(!%@78T 3.D/I.+&W<-B>NXCE  -'
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MC\PG-ZIX4.2EY*I.CU=VB,3)4=4>;RPPS=Q1D!Z):DQ[Q?1I"$08Z"/X%>:
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M2JP9UQCA&VT=M:F;91IMZ '5)IZ<*M<"D7(Y^+,)AT^-Q..H*%954PTZ1>?
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M<TX+S.QB?_U)M]/I^N_J/W]?,7CKQNHHG#IEYSD8,!RN)*2]W$+ P.B&0N:
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MJ-?K",37<08I,X1FQ(SD$% (^E(L6U#Y]JRZA9G).<D&8W;+-C:0BIO5"A'
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MC$G'-UH/W2!%,) 0$[.YPX&E?,2@NTV)'!?"*(R@SGCT<&=K70:]91 V5.3
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MD68?<+P+(+M6N7?AIG#Y=[%/%9LUZ&:P_1%ZACT#5AKE;F-SJZ)7IZ)_@_X
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MM8;\;GE.F&_1S X]O($_8W/ZJ2)++XR!@(P[J1_"B:NLQ/!9)/A&.&80B7H
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M)GV&K!QJQRCH[.XW0U;6W;3]F@$(FC9M$<3Q/^,(D0P#'$BBJI9N>RY>+8Q
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M@\.=A4OAUY[H+TKZ"HJ'-E<!CW^>YV-P:(B::0"=9MI&UD_2FP.=9YFZC7+
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MV#&,.7XA['S#HSI#0 VQ1SKNJ)Y=U!LYB>P4U+-S7W;+U%,[2O_U$/*S-QB
M2 =?=:*_44^<LF;UP<#%4*$R<PN..%"8<,X$42A[$!C#P+G U9<PU)".3>IG
M%XUFL2(OIR2U3[-V79I:7:+0QA*%2NHJ^\+ 71I5Q*"B1:9N))ZX3G_:_L<
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MNR[Y _H8C^>=LP?7A /ZCG@=/LHS"7A1N,#[2PS0#!88/!53\SZA-WYVNC<
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M"DL=_OQB K<;("+ 1?G=@0N#=S, ,4E.REMJ/XG*)E(^*^KNM.I;<'>VK<'
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M*DT076F7,'PT#%F&52'8KRAW4OWFP'_8AYO>XV\?M=[C);MSSEFG42NQ7\V
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M"2BQN2BX!Y;&9F)LWG&!$H J]&>!ESZW3(Z=.N%9M<2SXCB$H5S7*,8BX/
MK$%==5J<J?D6G+D4S!U2*!KID4YQ78S@#%"@!2@X0M611<;4T\J8/+;01&5,
M,'P/^2+80DO$0DNHQ("$A"E>O<??&([GDB,N&A4:T"7@P:3Z,2]PK2<7CW.Y
M/W5MT4DS-"V@-4U0=4C0&!B%;X<O%BMV@R)I#ZX.IU-2CO^ ^]H"?[+3#UY$
M4[6F_L@1[B8-8P"F(R83;_>F_?_(OK?@QK@TJ8^K=_$IJ!_]H+%.'4>>1@W
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M,*, . L2"AJFM^A>HB(+*W(X?/$%\'/.L$P(*RMQ.,8^\;=)"5:S!8AK= ^
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M*TLF"N$@=/S5%&D/6-ET# &L)Y?Z9]_H0]_DX5,#K0[:O](HM6H)P91H+P2
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MA4<-_'*CAF?LU*JU\)!;SQ+M1CWM([Z]2_+:GR3HYD#M5'&C0"NUTMDU$HZ
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MU.OU4KV>L+%IY9:I3H8=@[N[4I=JY19=2GQC9I?1#-W4Z>K1&'4CF56]2/-
M D%I60B* 4'!_Z)])O<S+\=%AAU7.\-%#>1Z;3%OKR:P# UCN[L4F#OU50)K
MEL"^ARM#+=0+'%2*B=TC7$I.^(;8H.T@*=D&M7]-+9\:=N2NTV=T?G'3*>N[
MCFXP^/%9+ ]^!8GFX4[N@36EMAXA)9T)G@G^(+=I H4"L,C.T\@!$.?TP2K%
MYZI%U-PE. -,RGV=5JO2\^E8LQ\G4'GLP[?'[]Y'N=(2J=>$CQMCTU;KP8&:
M0]F+.\8%;VBZ!7^W=813B?:NCL>F[W,.>,<I*J+Y+?+=:*=;KA8CSD728AY
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M>>>R>HO1SF6A#T<Z>&(Z7$>L20:A-3YGO83)-\*"G(*1XKB^^0]'#1]B4QL
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M>DKW//0:SWDXMQ95U";,>$\X\E:1(QF6#AEIM%YO./7<(0^3.WZ__+K>KH
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M/E4V>GMT ]8#GOI<DK6T4[BNN8(B#5S1^MT.'(_DMO5#4<T,L-)R4!*1X48
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MG'T5GBS2"_.'Z8^D"/@=VP=L_.6EX_D>" ',X1AWW$_'"+2OM[J #V)TU.<
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M7YGK@0\F)ZP!WC3U'H?7@9-7)D[\7A;Z_\Z$A<%N_M#S8R\; 4B $A(<S1+
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MK+HP.XM2K4_*.I+X2@20=TRLN"96O&UBQ:\CZ\/_;H("G:>LG\(E+Y"+V$+
M.CDY657)^#3175&P\P7ZRW9?>I:PU\=K7XK??*", ^S;]HX5<:OY 13Q)>C3
M\\LKQS[^K^/#/ZY/_CRVS[]\.3D\QL^X8>KEQ?EE]_K8_O7\S^-+K.<XSF&S
MSGA<09??"JGG0K6TWYD,BLKF9S(OH301I(<IPZI)(#C^H[J)"1BN%RG:V^D0
MQX1$=^MH"- @)X!"$,AQ4%3(B;_# Y[Z?>;=2T7LX32#<0)Z2/WTT;[S^^D0
MW]+\^=V3QJM-CDZKJ/G>Y*Q&N4@'UWAV&3)]-_'_1_"9N;4+D%>))VHF@ZD3
M/G_M";0]/G]L.A#V?IZK'JJ'2_=FW<"R^X*-U,/@0F:G5 'QHD&"_W%X>'S\
MY4O!!'/<L]Z?I@ZFB\338BER>W]9YYGCI@_IANXX5U3GK*BFD-($1*LT!=;^
M/$%ZX6:!?>1?8$3Z(<1.$^(+I*6:DR]:Y.WNK#@,7KAD'0&HX3".S92:7V'1
M7L[5?3+>;F+:-%\['PY='[L,J[O/SRJ=]DC99FLA*O^)N=7VE3<<^?VW)2IW
MM]=65)YS*1)>LS\H*A\CI850S%'FAL(^$E?8C]G>:&V^,;(Y6$.R43)G+43.
M54II;U]$D Q%O-'>W.B\,1K:JU6B;YN&%D(JLJ_DH6QP^+:H9*?]XU')<B7-
MQ= /_+%]-118JW7_%D5-O;W^MHEH(;1RZ,8CT$I_1L$W-T[!K %J>6.DTOGQ
M2&6Y\N8X"("$SF59]V$4AE$,%)6\,3I:QQC4@W3TGFX+YMN/?NVN-DHW_WXX
M>?./GY4N.1[@OXE(57X)9DU&SIN-]@Z^7/]^( ;I/(FVXJ=.89:77M75F;#4
M.9LH^JG_BP;4N%6$"=_;Y3GX)1XAZC6D^P.0;GNM2+>;]?W4T.P/3K.=M:+9
MLXA&9*N.%+]B/0(W<7@[=+R"22VQL%PN8^%G2FU6L$=?1 BYGTA[L:G[1S7Q
M91WS5%80*Y9LQX&UE)Z7<8VF;(&2]QVA:0<IR T<N<D5G?## -'!W>DG4,8M
M/":3E;BKI!?[/:PZ7-=\HU7#XR\^9T'0L*9V\^/OHD<_M3[F>1'^I]),&AQQ
MF>"0F#X/<IU>=9OX*!GU^25MU>P1IPK)FK/V3DX)%K9NB7W*]\4F+0&5?\F2
M]UN1\$1Y!\Z)%:HWOF>[_5L_B>)[[!\0CZDR6_WU7JZE/K[)A77#OJ*=M0X.
M#AP;AQK!07H"7'(7IR+1)!N+%00GON6#DDZG#5N2T"N^*H&($YA";?-ZYZ2!
M'X^JTWYP7*Q-,WO#-+BWW)POD$\N?83758JS>S[[$8Y0<WCX'7 #ST5,4LP_
MIG:B +U[N^='LGT4=Q>0,R)^XT%..+KG<Z/;0&"KL:DT0?=S'-V%]A\A+@B<
M?-^P_L(B^\"'I;C.K[SM?V= D-2_-(V8.) VBF% ]7VDU/16:E3X/04_!C'-
M0ULU2I#%V8B4HO0/P!C<)S[)#SDAAD^'79@V5%8C_)''*5 9I.Q1.@&O3;V,
MG)JL5=\H(S5Z&7(J7.P: =#%S27Z*]1G4Q=T9*,!-0 7./R;D,VJ>'WUAJ*[
M%LZK19AIO7ZX5-+BX;?? #O#*.+^::D_HI+X ;Z.FH=QTS-<Q@:'4:1%GR9:
M$#>2:@<M-I!P*PSX+Z+)<\=^BI67+L];QOY0M_1DA43\1/6=2.Q,3C:F=A!H
M)/N Z9MA*L=@EQL3*5APEZV<;_*B=IH2#%(OI3F,1 D*1/QU&F15[/J!'1OU
M,0_U@7E1ELR+:J"V(-D@/RA$*RL*SH5QIC=C&*LD&Z;C/)6&=<F=X,Y8V#'A
M/S/\DPM[.0F]1BZ"U<=* &,%^N]9@.JGM4>2CV3LTS08"</\:1O;D 7@N-X
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M%QFM?:<&L]8#F"4'GWQ&%7QGR.# 8')ZB4,H4"YK4[3LE8EK4'K3V7<L7-<
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MGJ(!4;9+;@VFC#BD_B9X#QC%YQOWN%35B/Y,Q?*::2_*1$/SR"<C969SS=[
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M[7B!GWOLV\;9S7<OKZ4] +@[3L J53]53'TP4!^P]ME%>">O7NMMY_PF?DX
M8BM]GJ_+=P\PP$__\:[][L&3+"A5X041MB]"5,)K]@KN\J%PY0+P:LBDBH!+
MT%-@)H&A]DLO?O]I)N_S"FVG-2"R+JGDY9!7Z45W M/@4"@&_;F*NX<(;V+E
M.0/TG S>@EH4=%\!##\$O+M!8)^CCU: O"PU#> 7 _CK"!SEUP$OQN*>9V<]
MEEPHXXYSVCKF!3X50A]M::X6"7WS[4K["+D\ S)S)JB-GZ;UA*Z%S'Q1-1L3
M&V0!LC9:FQM3Y[<8E*TDRMJ;&U.'(!B4K2K*IC;+-RA;192M%+*>:BM]M'L
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MS&Q:LB<K[=HITX,^XA"4W+SFP3DXOWG$UFW)4"X&1\^R"[F^#V8]&_.G(DG
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MYK;B\,YB17D/E.1S1S$:"3]D0:J&_1$W\A@V_.@_,S?)8C?Y:&_T-F?:1?O
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M*0]*'_X]%B/7#^G2X=;U U1Z_ <,ZP^R-)-Q#_#@Y1_8$F!APY]XNC$X!LM
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M[<H1*\UE]<CL>$5HHX1*G \*=9F2M'+T0MZ G3HUJ.6&@8+16"NBJZ2,.2]
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MR<7#OCDH?UO+?O4.-@]C]7[^!%!+ P04    "  UBM58YW^$#T,'  !V(P
M'0   &5A,#(P-S(P-C Q97@S,2TQ7VUO9'5L87(N:'1M[5I;;]LV%'XWX/]
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MX5-1]:(P)+&DV+'D_U72,>9Q7E7R46>-!;GP0\W)LQ&VA6OPJG.R8.']R5,
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MW,D[SV?TTED=G?[19LT^>E$@\R"[(!FBI#)14T9)TU3)JB%NJ$R39 51:FF
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M(-WY 1C/!]$N@H+N3;GFL17 C>S6II..:>$&$3F2'),A(O)].A7\9J!D9M,
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M4M\BH?TO1\W7267Z58SVVQU]JU/A<B5&.@Q93$5YB7R/7)BLL::8O!1@<[+
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M=.:#K^E,26<^^)K._-SI3(VBT[$[3JNJ1 O]!:>]$ FW4=$//Q&(QD"(SD5
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M=273TFCEW,O!H7I7P6ERRRB;%AK["8,$A8-L8E<NP(9B4#T5J0NN[:%V"@+
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M(!Y&B!(=*$"OD4M8T#I9?2S(A L5T>4PH_/5DQPLVW0?3O=6WGSH>HGWA3$
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M+@'/J/;L7U,QSD56-6U8D=CS\VW8GL03\>K!#9#=AZ<.+3S)"YS4@F2L9"P
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MH!#!DAV3Z_+_=7(]6.2GH- GS.)_\_35\W\^P7_\_>R7GY_\?U!+ P04
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M^SU4.\$C!H\YM^3'!*.+[#^V_"P'(8$?.(A5.\.XH'>%8Z#V$2CP0BUJLUR
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M6(R E,3>43M$&X[.5=00[002X^).O']B-C=(;[P\.73'^ZY8K&G-(R)2OI*
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MBIT(\$SJ&<Z:<6"I%92CG8>:P<A"(Z&%8I'NA+6A#R,JO<=E1OLBW)&I9R.
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MIENZ3/M95R$69H,.O&F_S@-;,V5#6CUJ/!V?8^2IT6P=;IK'"KH>[M_8]6@
M^:VKTA[CJY)?X"_TBN5_ U!+ P04    "  UBM58J<W6$(><  !:JP  #0
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M#4KC13UDM>0SR=P%M3\A\(_(Z.@S"#7(I]V?M1;I9=A.7Q&U@#!%[HV@3;;
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M_X6>>QL>95F]=3[U*&LK['^DT5?**A6P3^/,G>3WJ70%;,+<OY5[G32H@/W
M8]>QI@]P%;"YFU7+$/_V# W7QOI/]'ZP[#DYD__#B[F1_)XBZI/]-JG_P1\.
M[I.[-W-LEW2D@4KY-#U07R/=SIJ?K)07584I1S*!0^9F*6"+9^K^49I0M>T*
MV.VS4E4%[&EE)T46C+*C<[.DZ<H!UR>_WD524<#>^XBZY32JL?]4YY5[ZM*,
M'^0E@U/D>3/U/@ KO;7>5HD>:Y1Q':M68DKHB[GV_V)ZELD_*F#UY_FF4K3
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M0DFW0U2 VL8WF*.O&R-]0#\-O;;\:P8KFL6K[%X,BB+MD-%(>A N-%7J*%;
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M"=O_*N!YI(:[O_[^X]'L[%X+J;#=2 KEI5WZT*V#B+C;H;]+*KI^ZP;PS]M
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M$+W:@(1D(,32K0+W^>;)'.O2]6^/!2<P6_OG!8C^8F!Z*:F2_=A\V]72Z&A
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MRJ7ZP& 9O',4_Q>+F</>?-%&8"X>L!ANWG3??X ^N7]PM5I:W2NJ-OY9/VV
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M^E]^_Y^[,7QWCN+VME'EL)<!D\55$O8,4)[#:^0$)Y+=N1$0X9'600ZAG6(
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M#7OK)WO[R]=;\GP$EE:GZ"N'-#+E2_P70SW;+LV5#U9LS;$L[M21CX0++-1
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MRBJ&L4=+3L6:3(=EL!#X8]'<5]?(XS;RBB(91N+LK=.F >X=T@;"W/@E6;C
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M+FL/5J?J#>;S;HLMUWA&NU9'.SWJNTP>./)_O11.;WGL/P!02P,$%     @
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M:&BO!:;N#*XM0,5$*W/#_7TQZ5)? J__?48(RL':Z/=RWIQ4XH'9V?PY48[
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M$"Y],?)P\<ZB:BDTH9>3KQG1A$*T#('8;,1^_V3*<"ATME2+2\UQ@EPKBL'
MF%5_P]9DTV/][''-E56!P1V5SBA.[C&O!!I<C=2);4LACE6F\*8.+XUT>#%0
M.F5%2^I%8M>XU2BW2(W"3Y;[8RD?>-)8:R#7XE[ZY[-W+A%BR$2T(33L_EWV
MJ=<M/E4N<,I-A:;>YYW-9=W@1VNHTV)2Q2D(9175.HQAT.G?0/-4:OOWHRRL
MU#-"HQ0UVC&N@W4%"U$Y@L'=[P/N7@!R["Y7>RG^TNNDF?S[*M.Q"T WQ]FU
M"T"N@]&E563870!6+@_[>-*5"\#OFM)@C&[5!6 O,%CNW'P#>!DPV-WHP$>P
M70 &]>?;:PY E^,@49=4V#SL K!:+'\!H.[$.Y " RX;0A1I2#:&_Z[&_)(M
MW/+!,Y/"XOYQ.>#@"T#2/XQ#D4AUR3CZ"B\ 83(=%X"?!X'_9D+532[UCA,F
M8LYE#Z@=R=(C!S_'=5UE?:JO@\A3?3G])->_K? ,QO<'DP7_L4!VX(LNN?*Q
M<@+1H>-#QX&(BQW1^/*.SG(T)H-2<PZD\?X7  JWCK,"Y7^!^A>H_W^#,D><
M/2 .8;ABS?QZ_W[*0_&$/F]"P-M(4[4AP[\:ONA(V3[K](5R/'LV.\1P+P4@
MH\4)^?>8-U'*[&?\>(VN#!NCT4X%<%\6I,+::FX1UI<?6/+M+2)>,]<1M+'N
M'%)0>;//U"*SFO?F2255[D%H!.VKU?[&"\!M$+ZY,/;D4(RS"UOZMK8"/V[!
M')%E:1CRR2T@O@W=QOFF<C03V[Q .<K3JQ'ZWMI#(]+FA3@2YP2-9GRTJF7/
M37"!WS<R\H"Z.JH/:==#5,<%\Z+/&\\^_X=OT2O%^^QHE>CQI-'M!7$"_[>\
MYX/#M\S-;T+$O ^M=.ZV#K6DCC!0O [^6K;"!#BC)$20;E+F$5W9(I7N.P$+
MGYF.<_CT?I.M<^M)MPO;?@-JLMX;DS[X4D9=:VU%ULZ[5W.,LDE3<;*[4QSI
M0NC$8 ER33; TVBE\1 __\,L"MZ=%531[UPCM_7:,.DVRT23C7+([LA/!/HF
MI+ RZ#/.LB@C'ZT37&XWLY'Z,';8)]B#NA#N0'ZVK[?!BB]8JM<DCP]OUR8F
MG +/A/'6S,+??\K&0E[=[G"N2WRLV%T]T&0SL=F0^SJ5[Y5O=?B6SMZG5[%O
M]3OM8A?K?7H@G"ZRZHI_VYZ+U)],Q0CX3]\W ^R,708K?/4IK^_(22 .MMUX
MN.&$W.= Y4O<?4 ^%&^$%<$\Z@R,!3\-:/2TDG"KL%8OZ?R P._$N::;Q8!8
M%&UQ.$4VJ$]AB_6-5+G5XU_J_AGVR>TP[7#C9R.3;NQ?6ST2@M\4LC,QHO?.
MMU^\R,]S6_O=*"3F5JR>%> %5%27RE7PS"!MYRNI@?V>94FARLR0YVG$Q0O
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MU[/JZ^S >DN/H;_H8+[T\0X5T8ZEH@O '1)/0"#1'[]X]);(7'ZFB=_B%)G
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M\5NJQN=Y[2YYVA71N_Q/$1;YY")]TG,E-V!QF$P1)S.&S%SQ"BWU<>.5T,S
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MN5%_*6D*ZUQK0XZV>06\X]%'=3VY]9%Q[=PW1H_F535)UO9^IW;B2E=NW-X
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M?F'BY>_CM35):>$<"%ZIB/'A(Z*M%X*EPWQ:+OR>CWO;.E<*2S][/_QWUS#
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MIB-.:Z$RUH1O&U0'UQ6K$_@.H[+Q#)"EJO?_#!T+GENB-A).S00$SP!D\3/
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M?'ZP-B4GBD]H_?')]Z8%RX]ZPQZO,U4WRKRXI_3^FAPESBWWYD$N/EB%PI5
M&6F%W$JZJO;2R],C$S,"ROX3V!+I],G>?EU1LG&3*!B^]88<9]UYT;MBH^%D
M7J-/+-$UH\(HMDQ+T%:\V^E1;]V,@BC*!&/. O%=-OL0\_O+4F9,T7&/68J(
M;N@OW]+2W)?IK_(3_B-Y31I8MIEWDBAT?$0.5RQ5+E_E;0ITO,S"\ MT3QKE
M)X=^,)"MW/8<#58DK20$!U!&K,=\=ZZ+-B[RNW;<-"A FK=E%OSAKG7@SK0=
M1U8$/PDHM-,E]H\J/'F%&T(8+(=HZ*:%&.NS\W0P6LDHHFOW&>!Z,JB*^CKF
M;R9__.-%LDE.>WO#<RQZ?23\$92WZ?<7XJMYT,6WA,0Y'69#/2+<@4S^/?\S
MN84.IWAV0PJC*L3^D_FDR1$,?UET/@=(3?@8S$26N>4^HEIQ^#5MY>D(%J/V
M^,5ZH9:SM%/]P]^VQU&7GP=G+YZR*YT\/4+%(@Y/./R+>J3 "ZN\BX;4:V"A
M"W(-L_@EMHW+>P^^J09(X2;A[3=YLI>@?"LBNA)5I6N0V)E\5^X [ZXAFOOX
M'Y?R%// 6HL]><[MD2ZCX51N"X+VO:L2:9 BF4 +JT>QYD:EGCF*RX:97G8#
M!T(DQZW*8TU[M\QW]'K*,4FLO63[37YRVSPG+@CHTSG<CWJ=F*VGR^B8$*&J
M5!3)IO'UJZSSJ\PIL3-G6;UYA O5HR;3J'0=<I R+B'"@8\Z'^LI@_$ >O@>
M T6"54D\TN_=S'9T0@PZ=Z$3Q5S4-R+#$+CR+,82]F^B *&6)+-9LMC"UNI$
MYCK]HA:P.'##")#6_9Q:44U>)=<;*(%FA72KZH97,OR6/XG^-GU$"LYXQ,;X
M&,QQ&G<B2^9#RDL6XV;O2T:Y[,F!69 :NT1&EWXATA57GVQMK?'S9:J X+S4
MKHOQ;O\7J,W"AJ2%KQ#GCWKH2/!.HOR.[H?&;%RZ7+I"E@T1"K[]=#O6RZ)(
M3#3;,"9)K=^P%[&9PM$B$1LR.2NZ[[G;]RQB$=4EB=T\3JFG*(9[W(\>7S&@
MY/>?UA<3219 O'K@/PD>R3=$;_*K!W0GWVV;V#@#;.8?7]B0S(?FVPUN!3,O
M9* __!X 17?99GLZU*]/G &<Z\_OV+?\FUAM.C[DF\4^O0F4=H0*%@J>/P.X
M.%ZG^\$<Z;HG0N[I-7D0>YB#-9ZY3&I7U*ZKP2^3KIH(QS!&=<\[[VKJJ0F2
M@*KMY8E0:G,EMJ&TO\2XD9#D?6TZO'=:^_'NE\.*RP:FNW'B9+?!B.HVTJ%M
M4Y'24^EM8E>*!WYD#BO>Q.$[BR.7?>AT$MN2G<3.=DWDZR+N!%AL\?X;A5=(
M)=*0B"O'_4'6LWL!":W8=W.\=,^O1(A"(E/$?C%1//SS)W %S-_P<M\\^SK@
M=F$*==EF*?+]+CEZZF'J$0NEH=TT>AF?%:59N5_W1EIJ 7=-*.!>W;L.[8SC
M:%*-E"'ZW^_24[WQ8NW-'-4XWS'Y*9:Q<:UN;DI'-PXV515Z[,VDY=!8I-Y5
M0*,(2UY*D4ZZ:.)]?M^_^W;7TR1%+J4+@,QY5MWRE:V-_IJL3*/:'91<+C&M
M=^L0R!XM\2N.%\8:CK[$IYN3&.O)A_6[*OE4TL9&<D?,;V:^8/+._8_OWRGQ
M+/+\DMT_8&0<.2W(Q.#YP)RM)%JF3?G!OQX%O[52ZT;D-F)P'$S71<-M05#@
M\\]BM?_:$#C0."L%?]1C8K['<YW7?B[:<;=P\<LUI?>+I7YN[7XR,1 &/()M
M"'[DO9%,4O<>/^X88:6#$*K*$SJ4I7] B$*W+0Z#$EA@=)[H=:*>U(/RAY6'
ME6(9<M@E*>V%DE^/QGJ!.J@@[<R6U]M$XIRK+K^FIU'A6$$!L:6MUA+2B %B
M=EZ'_'OE!<^=<,#']2L_U/9&QM.^XLW2QE>USG_6+E#0.E]9W'[>@*5;67A%
M67CT8#%7FW, &Z,&%,EFY M&R5V5DJO/KQG=,;<9R1PPKDM=C)<,VDBM>T@T
M$NIGU^-L[Q8B5):62'_=YR3S%H7CF4,ND#[:.-(3VE7 G_;=,-+P8+$\-V):
M2<%L#^G82 ;4:"1H19F/0BL0$57K@1=K,G5C1(L\Y)?J$K=P64 S'<!^P(DC
M2?_-&[S-"9BT*M>O;7":7=R'@59..AX^LW2L=%#OG9X-@*<F_T@R^L0V*9\5
ML&@OVF<U)+54/Q(>4TX'=X1*"XB$F!&!TLPLEX];:8E*&>]QF2.F,9TE"($\
MVF1>M*K\M71F/^%:DEQK 5W/8@@!RR!XD4U+IY#D901<K[56D7<N5P-=2N>2
MW-+09*';MJGHHO.A1,Q<QFFEC[ &3^WWIE&S#9NQG<P]T^J</2Y8"&3 FN*'
M<265-<(N#X4"[57GZ/Y6$_<')SH$V0F7R)JL]HZKO,ZPTFRS;693E.O7KC<'
MZBIDR2CI2RDJ FC@OTQU3\@LES>,Z\:V$$WW5PQPT.&-YQ_-JK*,:X+,8U+K
MFN)?UX1A!CC*DTH^4>^:FQ9%$11%,S3P@I%R>D.8UPI_5*K<:U@*;6>D>MX,
M@D-K+X^+IY&M%V0-).HRM2,K_EAH2.;UD&.B3DPQ]/A?QX[#)*KK1T3DBY$3
M%K(C4]S3KG;C\%\ANGUMF0QL!<PJO9E_;&OSH/%=LW%^<2?I6!^'$=UV&;8U
M&Z%>*J7'6 Z=V'X#+^ZPK(V;S;"\.@914%,'40@#W[5RWVR+8)E%QVOK1^C6
M$=_#G7V^C2W)-I1G72U5]$O1\W0#"J.,*^W<V@ARH)5&&^>N_8ORHUR!!8J*
MO"XSQ.UTSII\3U<I-ON!EZJS4E:?B0,(.,O/FIW[3X =-WM[]W1Y89Z<2 <:
M R@]T)%Y::Y(S11\.1M>#AV9[[].$R]IE;/TLE/O2#0J[!'(NQ7%)YSV2(3(
M<4$JHI>@3'J T;B+!'7(]I,]V?(H19U%<%2G"F=S<@#: 1G1H7DEKBN#,S4W
MG" #S2NLE0G?/D!5L8C^"G'?YK>R]6M."LHJ=*F)*K$YT03Q&=T_&E_7C/?G
MQ?GYC7.T>@DD^A\;#)3;NT,];X'NKTUH\-?7CTG+<%["$8$=?X;UQQ_U2 ("
MZ=0;[Q ^7UE\]%0H9BO:O-F)8VU7V%?K1_X25,TEKF&]M[8]_[T?-@NNL53B
M;>G 1A"YDK&P3&R<VF,8FNYD0)A0>X(XK7;2I%DFORCVP'HLU&3"PJ(?"YL"
MON.2!N2X* 7) ]<]5S1X*.A]CM5,A?I%F2A@*91WJ>$G#43RO&&+=-^S#&?L
M/2>,OJ!:IE.H#O-@ZM/^@+](]I<@HM<GN'AGYR/D&S-DMO&2MZ61^6W<5KE7
M]K%75S--:QL$6,;V@U0O?0 A-SUVFF\C\W4_J!8\![YA.=BW',;U-&YQO",5
M(2Y>F,3-FC\;+X<?J N:5H[AIO&NN%&YZ<:@#;X"*[>,K>TMY[0Y%YN;BZ_C
M=<\-??[<^T_3<[DFPWFK[[6C<*&6Z+DE53V!$K1[ILA1Y#+2=HO7 >]:M.[W
MB?#&U*.<!'TEKO:2E*8L</J_D-[Z?S7$U"?P(:M!%.Z/:O:+F+=V-3$++==A
M#*FQ\5X.+R31,4*NK,G)A"N-E#+@#9?ZS?;T]K.JS7_:_6"4>$VZ=+Y[P[I;
M,]=ITD%_: C(3$& [WL"^8>&\'CPE +DWJ!O0EC#>F?QS%M;\/=1/")&B3LI
M[%6+37LP:^<=>Q"_8\1N;5S[<D5F%UDLYK\7Q2:I$)^R*X8UFMQAA;]71[*A
MNL!=LY@2Y:>\N>HY7@Y/VI/;AG_);C#;\OVBX)PB.LEEEG'*75_0O-;/U .*
M2Y/#Y,6%T6:&-\V2*T_/#3D*!LN<%C3?I7]LQ9!;8E&7?;$?TA]+^1"1[N!H
M4_J(-;XZT=^#*M2ZX'D#>B3]=<I1Q@#7.(X])ZJ*QF4_DV]'%M%V!O<EUS!R
M\P"[#7&!BV8@LLN(:$9C(^0,T*89/#Z^Y,-G9\#?\>XC3><BQ][D#.>;R_=K
M^&Y*J98\]2Y2?EF)?./"I-1H8-9!<K?(LQ?-7,DW*^ STO4!91S]:]?.$EMD
MC.&V32N_M<@[^497H#2V9B7?X8O$,-QF=S16--FH2['J>#WZ9#&&<0TP? ;H
MO^<BT$+)<=T_ WQZ*+CW2]*[C[;4T/(V;?[*DD_7[[]7%P*\/LX9:)+8B,W_
MG71_5Y>,R9'$_D8$Z0.7$@:O29(=Z6_LBPO!$2+.$LRZ.3(WSNW?"'[T*<$[
M9K\ /,U3WW:BZ'0&\'E[<DCY<1)00OO+DUD4U)*()<O4WS*U%%*K$VQZ!F#Y
M=+)(:KP3B,0)GHZ[.Y]BA=_*4DB[0:@V:R7-OV&J,IYP[)5IW"1":+F*2K0;
M"@'CW+ )>:=ETL):4BTW& /7*GZG.7*%F1"6]DC?62?NA5A;<9>'SM3P!OU;
M'LH/*E5)$DY4LP1NI=]AJQ9D>3;\&7DZ\RP"ERK)H=,HKG!$Y*@Z"*XYT4/,
MAJP>CT>?K"333GT'3B"B2F> DLT+AZ@VWB!J=)[BR2T@F4F0*>.TA:3!? 9H
M,%W\KKY&T.$DY#(N:#*T"[*F]T![F@:KV)_,"73QBY\O"RV4:<S-4RH5<L%'
M-Q,.!] O9E"MQL3KBPLPY3N+#"X3NS/ \H?)K?&\Q8<;@;F'PF> 0_8QB02W
M^17!/4TK-^P/YERZQ,@T.]\"<XV2)M7W:>)$[8ED]01_8-#XWX5MM;4X=P:(
M 1@P742UC5X8892T'NR?NCNH7JLM_0M]]F"&-CZ\G!9V!MA:/0/LZFVF<M*'
MQ$XX._38?V@ A&I.D]I:N,A[+T28[R7)4I9^<-*^7W>Z$/M!)VA@DW0<.A\Z
MF'.?*IW(W1I.J<@@Q0D,F!+&4:07<?X_FT=WC"JRT'I_8?>*<?S%=%FM$+^]
MD,I862*<:S<@+]E0*5-^A=>W<$59X5N]*-;%O_Q;DH'D+"X28^@KWHMYGF=\
M51F4*3WA+JE?,PTO2#(Z%,P?M5K4[$#1)1$#GQBB]$92[H<S@"L?-HK[B#7*
M,U@RSPZ:>TNTLI'ZNN25Y9QU.2X&'*ZR3UO&WU1/*K?B?<=\KOZU]52:9DOS
MK6 $%1NK)DGB^XOBCM?*F[GHBQV)?1KY"R#'R(?T&;K'0^=L(#;X"6N8FC(\
MJ,066EP;V(E/_3@%3;_QQFD4FW%]!<(1+XJ&/%<N-8[](H&^_:#+%"X_(/QU
MOE%LNV>-6R;,;@5CF7WM;9FEUR<)'4.6QEJN9+,EJTQ+]ZU.8:)MHZ"1J6/&
M&0"'.KGU:I[F2K5JVZ?FMF[,ZI$\.ZR:JQKH"07TD9"5L(,X%?V<];:]-O#"
M;CKU[WSMIM?3_G Q1*)A6=HM-Z<":E3%CN;;-04(ZHO\' 94F?"OU>,$S0J;
MSF(H;U=6>;>_$\I%)3S>303$=G6IH/*AS8M4A]N)(KI/ME_1_97_6[;Q"(C\
M[Y>RKL=&^[E_S4MTFWDQ;^0-1K#A)2J<$B%6W,8F*3G<MXJM4N761\(,_5."
M9T2#4IV\)G]6L\9^JKY^'JUFR?ZV3)<@/A'K:HB[!V&CT0-*=#7F;ZP/QQ*+
ME,VS#!WV= (Z6SJ4/&3C9-,U]^E%@H=2>"Q3S+>LVU6^%W>UUR?Y?YP.?]Q\
M]"CH#_9V)V9HW:>[9>%76W1WA%UE5DF:M-(CO<\A$2G.:D'O)R:4!N/7B?;-
M=E19CQ@"DSJU\OO"8J4)E$6.YE:I<\ODX?_6=GDA<E21-7*.P_M'I>!E)...
MG&O0KZ.)]JA7^K^[QC2><4L/N@;WAEN8U0QSDH,UJ9*D^0Z9FVM6#9[Q)QPE
MUM")6D=*V"24(3$D(R_(YKX[-0\UIR<-\ZD_66D8X0,11C>#-6\9R%>4N83X
MD%G2'QI\M;<]:L9\(\*8C))(A>$K>J/DL?V^OM<Z=55-\7/K70;W'W7+2=4&
MPAEYA?;"WW]4V3C.WM],S$]39X[,@060XLDP Y%PZ_S&6EN_.GS S43IN[9U
MTAB(FW74?=LL6(SW^C<WT5C<FW-]='?]3P(B]=]KLC?!4?C?E7B]. =8EC+[
M@*WM\[HZ?0QC@IQEY&TBEC8N7B&:1(U].Q-E^ZM"ODFRPT&2LCR7OC@Q*HUN
M"']-=T7<")=/8+9W<*NVUJAX4XZC!VOEN3<+?+"WW'A>25V$9:K,@WP*,?&Y
MY=UY3;E5T$R7^+B7\$+H=V:8JK;XK5#G:OV?V\/]ZIV=[7T^_OX^JCT^ 4$(
MN0G_6N]^?W^UB<<@R?FOK%S4R^FD?C&306"S*#V2GM4^ "4;++;0$YD^;)TH
MWJB9<&!+T*].!?K*L+J)V<<3U=T];\BEF6U<'E[LO,]7A+>,9I6@T(H6'@0+
M%D'7\I$7+(99XT,5>TA+] 2R$VG@"LYI$14-9/231L?D9-@AZT:><K+\')N\
MIE7#.-V1O$'I%T-_/>GWT5$TX#"YC?$@5X?R.IDJ8"\]J<?51+WPGS]1(2H@
M1*0@,UB37<TT[T1A&/?$'PVM#2SYV,%%E/EP(@(]C7EY"8.-W:[ W*T:>8ET
M/@"="IH-AMZ>6WMKYV[5@%.1'R4V,<)EK""C".8UX1:J0U%>MUL_ZD9UB9W=
M^@11ISG'$A:B2R:RJ"C%^E&+P&7T4'7W/_IUC:-XD<IAC\51/JV(8W5?C!EC
MV*T"U]AD5#"R/,:_'[/Z<E3J7O7H)L9H\V%_D&? TM.201.F@<S4OY% 75W:
MF8(N^K@CY1J%(>CF"(SN\W/_E_B3<6]PKA<<2:R(X6R#&-%^[#@-F9O5-,28
MAH-OK<G O&6V[R;WQ_W*P(I%$V3AW^B"AI0"2,MF9[%6T8G"Q(X\F'G>#J;)
MZPD\X,NMG4)ZMO'ZS#K8K 9:Q.=S?N(.7P'C\=6CVP6UNV_(QX^B 93)8#'*
M2KLFCQQ?G=KCA5S6]0F':X01@BSB1EP>5"6NL[_B6Q>C^TDV$+/].F<>1/ )
M@!55&["$C03\J-G+GLE]IZ:<YZ;!>OKO\K!<HRI?MK$GRXQ[>F4'G^E8!<>"
M3$*;W3HQI=F%4>+]0>]Y74M=7<;-:,DP<G/.MW<:YB-G !(D@>WDO(HK[0']
M0_!++\$H%NQD=[QQ12C3B5&(E\:];"&&J.C^3+?0!HR<N^]$MMZ$O#RMRS2]
MO:DAF&V^X$;96(52S1GL]N!C\(^D?K4W<T*:YYH?Q)D$Z]L+GS9 QT^BY%=/
M[*JL63E$LX%_":DSO^HTP"ZN]M.2T2L6RS- Q]S]\:_?&W+^Z [AA;X69GV;
M!;L&%$9A/.3ZF8PFY"]'/!N5*1?B9527EW7[3OA+>I5HP4, 3 ,,MHCV(Y;Q
M1'( 0R18>.@;)2VCA%Y$_D> 38"3'A:0-XVTLOH(045!MO[>8\OL#&"<"QI;
MJ:(JQE:<F*+=F8Z=VH=1;IB*;R4EDZB_<81BR4J7%B@KR'9<0&V.2F-X]XQ]
MQ_%1]^H_6J0;C7X3[5UQK.U0;+!H+BOJXRIR6D#<='^\IA@8S%"OPQEIF=(#
M-8;. !\_G@%@&]CWN>?4;E/ [<0L&]@9X#:*](!ZHY(?,^-E/X.T)>U#G&E$
MG0[5<:V7%<@(BVJ"]SK<D[OMCPJ<:&<]ZP#I/V&WFUF?NT_5C)0'!?6#K<8)
M+J7SL^L<[HI5[A &7J1_)C,&A-SU3++ATN$&+TO)7DU_V/7\^C'/=3FA*V3W
MKD<>NVC>F#^FT<D)N.RM7X?Y8E<V!+WJU_(/WRSR0_"!&:$"!<7#13SE%A#O
M98R9SX>2 W<S*]]O);TW\+9=1L^7"G<"=!C2U(@H-2^LNX88-;0250%3*?@=
MU'?ZU#4':B=1X+Z57=EYW?T[<6KZ4PV^-EX5*11_93$LP,#Y1JA%UV7F.]LO
MU,$ZW0")BD%E8=H:0H9EX_[A8A5E(.H%_LD=O\$Y:&W2K&;Z1=,^M;EG+!<]
M$2I]WJ^BYI0LM:,$=(Q65#;T>0TQW=$(H&*;I5-:R&L$8PC!(Y66R5)F5#[W
M\Y\.-^"]L"_O17Y*IO$?2(H[SIO]'A_R2EDN[-'I00_IRA+[=+[MEIC&\73)
M?BCBD11NFM3=L=_JESPQ2T[VAM>*JQ(:0:"LC6(IWV/HCJ=T =LT!-*V-P,6
MRA$*YQG+GHROLSN7]/9KYL<.#37*3EO0^UO>.N0S0&2''-<<_S!6)+W]Z.+6
M;@KU1EZ1$1^,&*UL<G0YPSOSS2-6&8M1YWOE69FC:B$5]%+;G<O!O",5.'L!
MD%]"1X[2F("D_2M&:Q0HHF4TD=%'ZF<YO* _LJUE1^4_I>7+'C^@Y4ZA:&!Z
M##6_*Y'.1PNBA'4GJ+GR_1,,IBI:QY6K"2T$P<*G:(=XVSIAW"!FPB<DGFQ=
MH:97XN0:L>_\NG7%&*OB.Y.GA']0ZI.JK!5DB'8S9D=7#!:9/O>OSFQ\/Y@_
M4)"\E%1->(Y6W^$Q_^*27U-=<L,6QJ,J+I-=05"N0&99)G2V\.)90#;C!UPU
M,3H4_BA-HM5YJ^<COE-P^'WQ/&CYSAT_B'3VZ]KJY?O5E6&Y6ZS'(\<\J%9!
M0@CU]71["P<*IJIN1;)J@[WT]"<EO)\39-*EMD1*V2?I,T4YQ_Q,)M%B O\]
MUFF>SN5W]TI7-,KCXE!<U]N$GP$N_J K'PL?.LA3GP\%/Z,?7[SIV$<%=V3Z
M>I(&KLW\LBBJI:.^S>-'>9^\[;^>(S+ZNIX*7U".ADN(!5TZ[NL4D#]6Q_E
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M;W@"U;8#$.Z_*M*7/P3JJK=(3E<T6\YD_3,D+=/F8+]\\]?2;(_+PFMY->]
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M^PBO6XZW:X4V[YR'U;KC]T\7-XH50NH#_WKU!WM>O%?.#D!>2[(*#4-/MW\
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M_9V^[;UI7.7\-6LE9:4Q^:L$J'MZ[5#6N%LO=T6KG:=84,\3=>3^NL+@:,6
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M5,QL'L[?;Y@P/M5X,;T?!^%9T&Q&JVJ4+VSHGV?><.4(/DE/\ZHVP.9D<+3
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M&Z8$T0K6.1/]OI$Q3O;3BP-..K31"Z#E/.<W. 3,E*LSZ*&)&K+DWW5DF_1
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MEP!C5$L'"M7>G'YJ,>T#;N99W0X0:DH!9F^>HF)XP*B*W+KM/2N]._(GW)>
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MO*_BA]1K:^I06+)DP6^,%*3Q1E*T68A=BG&"0;.ZS\4?P/]<]P!W 0!W  =
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MM^OK-GS9SXBA.<(2X4XC,K:W%UR8H8'!],].4A3$"]ZPC1HFGE<A=\6P>-,
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M@_M=)N3]C4?A_ED32<^Q&;E+)GSC&^.@^F[@G.\GCQ)V'>G*VP=Z*)>=<JO
MC(W:65Z^C=[:'<.,I/2H&M.D @I!5B@$6$^L[(J+R.9HUJS>8@OYW>3+$;:M
M8)V;KG\7[B]T5ZE)A$\,YG+U?&-AARWF%WMAEMWHU 4KXN:9QAQR]Q]OG\@?
MB./@,I =EKL>_@J&N>/1B+>KO_+%SC:Y90EG^[,I0 1L4E<-DM)_*?5N&!_P
MJ7OISJ.%!\'XK&=,<?SY2F;3-O<(H=EY8%%3V?Y['7\3%';KTZ^5Q]-2K-TS
MN?/^"@KR1#.[B;% +-[RF2H>6AG?M+O[O!2R>U95=VZ;>]'J] T.Q#%EYK]$
M'=/&%"!ASW(!M^;\.E($S^:U7_I=58^'KH,H,<<^M.6RR57J]ZZMQ !$W1];
M+7G%K/_N7/N#KRT_)#2]R^/@TK*BF[Q6J*Q=48J=>WD%/8H>3=B:/?588!+)
M<MUWG9QR3HF/V]PE__85G_%U,RM !;:N+#,GWW^U,_U(_O"$W*+HSY&V*2:6
MY/-AX\+?WXZLB&>'C_EP7B&KD?TVAHJ>(,-IKVT-70(J*W$DQUK=:5[6_EQQ
M=2[)'K3\UL9,L=+9Y).E!6Z2(,[LLW<P%UF3*)Z"X[Z][N'7F(PN ZUTE/_\
MRRSK?C\@$VC<XK'\!V*)D&,YJ:'C;*8)%3EHVU$]<T#PG"=)*\^+M;K1(9ZV
MU4+CJ!$2PQ6O_X%TG/'=V^BV"4</42YFPI;\C:- D%)_DAE(H,<P_6';P.0.
M]YDAPO*\&&':RD=**.]ACBOH=;]@(LC&'EB2%-LGJJETSK.=1*,GT]([KVYR
M\8RS!1H21&ZF30_S9P17P6&+NP$])LZK]]J@">Y]:9X#F]@ZP4?1#I"17L*1
M<6"33R)_7!G3A^][_:(.SL(B!_,2Q&NBN&_&'2_=!SQ36'H_?KX$>(?  E!2
M=WZX3?%[\X=\@I>63L9RT1_';6;/R%W<D5H*GN;;#*918:,VPNVU\_(EGYAV
MNU63,'C1AYUB/5&N,(??J=]G.:O5<)2L:8*&139-;8F!R0O[ZMT+=-)QMYZ_
MS:7;9%O25!DJZ, 9CFM??>+-2GL)R%/_*>3ZW4JO_D]53ZI6)D*=- HMZ/(K
M(MGL H9%8M0[XZL#(WM9PJR?Y)_/C@KUG:-JKL/B:O*'PFSCO09]K8BM==)#
M=R GIZC5 O<1\)R"CG)WCB^O(S"F C&I5M]P8'V%N[4Y;9J6J:WQL=*GT'H:
M_J(/_83$Q[--U'HF*\!IHUA>%@6OR;J>5?CT_N?\V5=K$=WXS8Y,!4A'6HXN
M(V'MX"8TPXG#*+4/Y7_D\:=O-.;A[T<9Z\-&224X=W,778A(KV8LUV=^H<$B
M0<OR(N,],FCIGP0R .^XKEH##1L5Q<I?_;W3P?T-]MIZY,]4SE^J^NE['U^<
M7!>Y!&C:$E[$O;>1(;A]+B"B8V'I6A,(*&?9'Y*/8$,H2**#>&\-NW,4Y>2@
M_0\FTI7%QI?1<@PN_J$RT%YFFAC5-[9_7#'/QP_;N$BG?=P,\!_-+,E$:TWQ
MPY:[WMV]O#J\^Y5'0 1>)#GF[38[K]X'SJ"QA9$BC"U53^$?< \C^^VI^B]
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M!^[&X%K>X#N"&>!N76B/61 ,YE?@8A"89^PL=A2@; ;2'.4^15P"0LFDL$N
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M.]%=!4LJ[XFW&JY,-\U?8HN0+M*2R)VX1K4#QY?US/2<YGULENN3?Q8M*?,
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M>T[RSNBZ&&VK3SJZ(H_/#*G=\ T.8]Y"6?B+B\U@3GA60']_P[(?7W) >H-
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MN9%+"O\GP9Y&F.CT>8DHT:E_8PC>RA<%&B6S$.F%W YI:.%Y&$E,8& %0C)
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MF?9IVGB!ZE#(Z^P2P.@BU_CBV SMCXYZ';N[^QOL5S2:3VHCVEI4:]NG24M
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M<Q=B#"0D!#[W%NFKE-UJ,WC*%4"H54[!7 *N.)M5Z3N5;ZC2(&AEE!_OS@=
M^V\E/(\=T/"]3NPFZ*$M'8Z:ZW:O$X P'A"'D^O>LV+#^=NK:;C[(>+BS'Q9
M7C',$"PU_D;:RYQE\^?QMY.F/@?9;5_S='3Y?]42Q0?Q]W*HWE6Y#WI,P1/5
MKB(2;_ZGF%XSC?I,@?YG\=WO):)WWOM=-]N?P0\Q@J5M^&UI;56B*M)976MG
M;BM%I:I+?75@E-4C%!;DTT9!GXSN/6C5SI>;J+)-]RL7N$@+=@8]=[X$ %KE
M7;HZU8$D-:*$P6/)!W;,-I03%< JP!>&OEGMZ^\?7Y$AJVZU,3K]P]#^P#?
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M:'GPHKV]>\8<,5@QCX1TQ#9FIIX*%13,U:'.Z<_J%YQ)T=-J ,AZ%!U9]W#
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MLZKM#Q2Y!S-??!OSJIYO9V$=_CW*E8W%>:!RO8M.Q\BK]0MDBS7TP"&K#WN
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M%)AO7L.E )^T&-DQ";[_F[$J*"&+\J<*O2;T.1U-G:N7$H728-O^TQ:<)IV
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M34IQ+[,I/V.W/?GY.3?H0+C8LY-T5E&*L0<+=SI]Q@JNJP?8G7\)]XH0+D5
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MC_ F?Z0,S/")1VC_O0"L1C*%&7KO/N@U/U_^]7=V]A"Y^Y><<*I:GU\I"6-
MJ"TIQ^6K.ANBI[R5M6X$0"P,WI2,8FBH'$QP5ND4*Q=T:FT]I>("@%)M(U
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MF9V3HVX _SYRM'"VC4YRBE00G[-:"'8^MAZ&$T%7D6+$ I:* SL^(Z%?A+H
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M:VI\FN+3@ "0_B@L=(ONR E9RK-J\-S7[M+0\)G:BO[D:N2+QI?M*5ME>5?
M+18B_BF]:4UZ2-S9X.BD=%FPIBK*E37A]S*37S%-FCV5\]["XYNM(BBQA4.
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M,,Z_B]A6=P)$X?-$YIGNQ;8T*75Q40Y!TWN]*>9 VV?:[\GBV3'"V4U]G,Y
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MT+GMY.:T/E0;T(SA!1'30DP=4,T>4S35A'U*":T3S]]3KE)3&Z+HGU/=A:O
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M>NX,D8EQIGZ:.%,H!\+-Q#82'Y-FY'<2U6O"0:8=*LI#+1\'S?H0GTTP\:T
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M"B[+<1);"(>\/#S2>I4#']AI4 O+E#G)TS]%DQCS <"U"V;*'WI'#"CIW6R
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M=/5(,A??.[/4)BVLRD2/1_W215MDZX&ZGW7SLJ0_UL;H7??UH@U)G]10^^)
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MK'(3Q)I@\6-\3L/0X[42C6.3FSSMD,VL EV'^@H+ 3#\4?1&H>6DKLQYRIV
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M]95GL I.O>Z"GSS?N&HA +#$B1HE2+]NY'JIY$T%%I3:K!,![7'\\Y24RG*
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M(H^3CI52@<R 9"57'^#ZY)73@%%^*L0I18'XD.09O<3E*GF+R@1-A=FH0/+
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M9%#R<K\O <'IZ!@9&#F8F#CD!'D$Y?[/.?\ L,*!!. E&(0 :%A!8%;0>1O
M#P @6M"_ _Q'0#1@""T4!J>C9_@U4,L"T(# 8!H(F)86 OG5#?W5!R"LM!<%
MD1K02Z8., 2.32XR*0\NI%G5RF[V>5L8Y>@;14=_^0H')Y?(55$Q<0EYA>N*
M2LHJ6G]H8W1T]?3-;UM86EG;8)V<7>Z[NKE[^/D'/ H,"GX<_?3/9\]C8N,(
MR2FI:2_3,S+S"PI)1<7DDM+J-S6U=?5O&QH_?FIK[^CLZNX9&AX9I8Q1QR>^
MSLTO+"XMKZRN[>SN?=\_.#PZ/OGM @%@T'_F?W2Q_G+10"!@".RW"T03^'N
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MCXXNBL4;,*?J@O_\TB':!Y__ E!+ P04    "  UBM58B@!/I(1'   >50
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M!^3%QAK@GJ0-E]=I7H>>&B! LRR,MZ6H)5;0QRAD%/#.D&NMAXCF\%JUY'+
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M?-:U2/R9PLQ:IM0]L !7"+BB750[I\(YC'#V?QLQ)W]EH?9)F0S1HUP3C"W
M;[XT3]EF*"D3&JRK>".%VVUD^A:%]2KI%.:P^@4YD2SFU46J0<3)7NA-2PT7
MGS$9@W$[.7;)$=WHS+'4^%9Y\/+Q[,.N)S-$S[6K+5AE^;UL\3:YT<(SOWZ<
M#I:6#X"3/UF N#":*G'F9EU.< .S?;[F)F'U3/M81>BW<#'</CW[<'\?HF(G
M(=0QU4Y0^W"/ &$Q.)Y-_+L$2Z?0VR[!YL=JU<)([UEM/3@VK?>64JH'3*WM
M>E!3'<D:<^'\CT"!RXU'D[Z9DXR$>TEQ-8^2"(4;';7LGI_O:1NW4VG*$KO@
M:-I6O6QD?29<(P*O*K8B''C-'6Q00@@VK8YI<=+LLZ23$%L-@^"')2D/!7E2
MSF@U-AQM"9&&=:#%PJ)WM!!1&>?"-1?""N*$T*;IB^')P?S_IP1F0\\SE-S!
MS)0!=["=5CCO"&YMY&7[9<= IP5>A['T&;@6&P/4C_F]3XBPLKS*>PK)Z$B;
M-7+<M;;H&!(KC]#R\%K7!;HCW%B6B+E@+A6>K]B3-3;/8$GN8YR+ WXGAI&M
MJ67Q>FKY'H.I'*J"7H7:7=D:.L^ML-?C[$G>MZ?#GQ_X*#<OTS@V)N^J,\T:
MS"(LU?+VT(R%2'],&K9K;WW6OYU;I.*%\YJM@[J!&4]ZS<BXT[ZD:LY3ZT?N
M>U$=4.SNSW8_T^@LU'C R+!:@XR.VD8MR7)FX[F$6>L89_QX)6Q(_1-L'+GC
M%P$4)UN:E3AOGO5/X"JJ:J**X2EPH-#3O1^B:\C(>/4^NU/<XTC=QJP:6\-U
MLH^$T!B%J9.U(LJ^YD8.<0 _(NFNXH.E[ZHY;P07/1!=A@@2NCN2!V.WH'%C
M.N+EZAL_@_55?H'%QCYH.\L!4R]F6%05^72BO.Z5!6,_(0KILM15/<0@QE)\
MF_C94P;DR@!];#C^JR[>K?'3-/0D!A0/CR?5O2\/'LLI 2Q=P!+:QE>W:Z6!
M8HW,"FN\'4:7$TIZ[J=O$%TWH$<V=#<&; $QH#)"?26.J+.,+Q>]A,MV^.?I
M7E*R69.EG]8+5+]&>?@/>I\HX.)HPE(+ 3-Y==F\ 8,L,^P\WMX&L$-D.F]N
M5Q"3M-5Q$6QR26\Q/0:WXU9J5P@PG9&4Q19 AODD100!3T5L/>.\KIVU5O[=
M"-FN!/TT#^_I4F0>'DRQF+U3W5U+Q+NDD>3.CBGQ'#IBP^K2GN\]6XID*A<W
MHO!<FR6]>*O]/2UH]F/%L%$DXRKP;J>%)E8:;694IHP)"3CI >(\/U>+SS)O
MW&2?@9+&V\?@C<2BN):V;9"[0$\22$Y5+#M^?/=E70O*=IV@#$#WEI6_5%%R
MFY\UC<*<OZOIS="-]R%?/H'91[J5K00<3E5@S6,%Z[LM$PT5UX*=?3NJ0(-S
MAN!P50^[/8[:D[6[4FJ]'&MR.:J#KIM,L);;,$A6S+#K6Q]C26<5&YPP*SL.
M7AAN3Q<(+H=C[]&^>U#O7'+SIYB-82Z76Y3406_.W'\>/K\AG=5[IPJ6Q,FC
MQ4B2/D,\EP/V/77E59@<W]7$&<0L]CI169ZPJ?JZPL-B@N_<@,F,$J;*Z7<G
M7!I2K"!;U%OZ-\"2_4+%Z6RPU>F.>W"<BA06*XH=;QKJ1WDQ .]_6>3YE&.M
M!BJ,G7:/)IT7;K=RQ,=ZHCZK-;NQW#H6HDB_']TWWEV>&H2TCP4]/Y<L"63H
M>F-_>Y6VF:1/\5FRAHC4PZM]PA_O*GM.\"/_DWJU6:+T\ R%J"A#+8]11$1Z
MN,PIO&-('\% NFV$-ZG/==)P1CR[MOA6QW[8^4C%A<V>.;$>UP99:>3:"Y,9
M=W[6BJ!/VCD1BS]1FL6$3)T)RP(-LHL^FYJL+55+3H6]E;#8N/K12V>F:6WW
M44DY2EX,#P\_]6F<-95)8AP7",B,LME@9-? DT,T&=EMQWZ)W]K>$17(J[B3
MVAIE,M$;0^'Z_2-+U%4.<XS4T+H7WUB&-UV*T%S\E>P@)2AUG[20];3 ]:DK
M6?;C17>)AEVF+IY;!-T,;S9=D7('Y#I'$2F8MQ2PXNQG>1FC:0$OZ 5:57B=
M3S",3N=W0H8SO-E71PM7Y"A-H^"1C[O%E8R!.S:32*DJR:?A8>$;6(.[BUP2
M+U+E=QZT4S3Y5+S.WF<S]&3/^>3-NJYL#CZ;Z:<C1E%*>E>17/J?..S)8!VS
M.SP "A!0-@]E,"_ILT61)!,MT1^'B[[^D40+FS>V%]9D'%-_DNP3=N=AQC&Z
MF^G19^%3P[L19@SN_[%-"QMJZO3&D,DBT,!??I"%#Y9_=2%YQC$SOT#D SV\
M?$0(#.#YM4@U\KW(977^I6K[0=;4U#2?>/<CS4"*][V8/%L3WH(*KX5P+4HZ
M!1K+D/$B;+YO")UZ&:L'+)Z;7%BH]70=YG6#15R+*%M2<0LY"_G4*VN_G>[X
MUQPKL+5;$>T,-9G7^LF5U45U6;I:<W@;?;,KP!+R'@8X;IX3A^YNE53MU:SR
MS*;VA<CN[@C.0@;(]P($5B^E>L"O3E1ITU!TIS\E4'9KX=;G+=VX.7)4?6*9
ML3[^#E."!].:2X0B6 =Y5R0/C3-_%/S^[07!PX5 SW/NZQ@).V]"D>RJC4G8
MW-20!70R1_U[P//S+2U<_@U"KKCL8ZZZ/?V(3*K5$YJ37/%H S:A08PW=E(T
M-3NI]E>3G/< JF&+85%)\\5><VN=)8-*R23'Y4'%[,>:REA^HS?)-F* ($<?
MS[E%]<OI"Z>?!CD!1'NKV.T^6 YPE3+_^T7XJRC@ #U;ZO$:"0H*4U96^VZ8
M1VFH8UH25O59>H(@>_58,T5I6ZSCR<G:_"R!,NNX4-9],UM,O"+E -#'Y(H(
MV8F<B'V3(0PU-VY.C#E2Q5))=")K^<,BKM+;_ 6&Y)H4_; 8<V/9A#G30VE7
MQK0Q49-*,3Q%K >*00O,BA#7Y5B>B0Y]W<AI(3W=Z"Q,2D\?^2W,:.T]<*F[
M0$OFP&![-@_![W<9A;SF7ADLM<7SY<807SW]%MJ,I:W5^3;ATZ*OTA?!/&YC
M/?G86<,FZ$[9^^CY5MILZLW.+:TP^%8.@T2T6O&@QDOZ9$<6=V[:"KO=7U;Y
M'4^.3/'<=G6^U7.J\+3C#I%=D)N>\SUPV-P@)[R.8'T/1'KYO_0RB<2"\\N:
MAMNJ;6ZMW:-?.3\G)G[W$O6F>8%K#B;U\,[<#ZIG9&U-UZ!+@9D@4FB\DMNM
M;L6;FG*ZSY(5)BU7OK6#@C7%:166TH*&XA7C!@JE<^U4<N[OFH@$T3UREIBO
ML$YEKT\CKY0JU$=&Q/"\__G T'<M1*-_:3F.*+*W2;AI/+M^G-Q#?)__<^*;
M<^<$KA5;B'"VAP]497+[>V"2"Z)\9!TP^J-2RG^87X(7("#]DIK-TY4XE<@O
MOG2=4KBK*+&6SY=.K[;*L\M0>"GKRK' /_Q$ 8L@>BZW<Y](;W4*9>E6A"E>
M(]%2U8(BO)9(.++1&8S43<Y]N ,SE$@?>_GH47G)6-VKZ]80VBR6C!!:X(\"
MMS%$</E"_0@4=M97R#4^0.I,@H'4P__\F^ZERL(SW?IL::%ZK\[&^K9UW;U(
M'")?JT>1*O= D?EHQ8&CR_+;:MY/RS:C5#8"]1)-(UVK&N(:&NT<-ZF"U:U#
M^#$PI13)R:2>'N:30AC3\Z9-F+4EC=K57),G$D^NL<2<D&VJC[ILC:F8B1%D
M^&(\NJJ')X1] YX>T1"!9Q57CS448CP8.5+MOV6DU43'FHC""%7"N+:LB]UN
MHS#+J^_9<IA']4INP)\5]+9\9-D4-X$9_U\MH5?1YR\'-ME%2-?6B\\_USX6
M;V<M51!ND-!0Z\7N<-W>+G_NS&-QQ.#%-U,Z.7*(BC;^T?&[8J>'F7_VL33H
M25$B'MJZ3\1*@98V%:T4I\Z!O)H/<*)NV^58H'4E5R2K(#LOOVV"U5>09_T,
M!RDZY:=E;NCBXI2JLR%,9:DO(D7",!WE1/Y6DEA3(KD2*"6 7(%76/:YAM(H
ME09M1L*?L0I,>;GSYK/B94YA"XS<\@790K(*^%PKIMOBY4APK%^R3]>R-G/(
MLGMJV*-VU@&J5_LBK*LT/ET"RO[#!P;155ISP1(+'GDUGIPX7#E4L:_6 OT/
M-+-*P%]7[^A(1.K*%&W9Q0UUTA W3HN23MZ,[ZWB"&6Z4$*>K$FL153D96D-
MEHG9YBYT?[!)*Q;6D=A2B74GYOJTQHRA*7#MV"/J[ZF''!VO/[1 ) #A],F9
M49N;7PQM_1SSZNE&5Y%YQ2'$)S][I+2\-@+I*U5YSU#?Z5EAD"?25 ^[E/,W
MZ9N$&$J1YE65N&"!+K6RL;W3%NI269X2D/E&9+:'^9+PKP5V$GFEFC![2W88
M7@>Y>_9,J)R%YOA)(Z94\VORUH56I.81IF'QD*ZHS,5&FEPR1WQ2!<81QB"[
M;VSTTM'^>'\'?"P=KZZXKCM[ZS5=XGO@7=MY>ZW/>G 0,=+SO4&>XG)FX=5>
MK^OUQ=XF]<.+P&(!S6+U+:Z+(_7JJ$%JAEC_31:^L]M<N-BD%OW2FG=A#6'(
M;+4]3^M2_::L24R(]QB;KY&_%:Q](G$OX!WE^D1'_C1.DR*.A^=Z(KX5KKJ+
M#^E@ WIF3DL"K@>AYSW8?Q0,F3;A8Y(C[KL/7N=)HZ;'?7C<6(Q;"$LI_<OC
M5E2ECZ^VN?:Z1C\OYP&3 M(LJ%Q9(B2EHYR%.X5\@X?(S_8,#(F6:D"1Q=D*
M3G.?Y$>37^<N#B$C@FA1F>==@:N@6Q:AC (73DDOK!@72X.E2*NX:I/AA&A#
MR5$!?64B/7<8M07,FYE[X,Y_7S@A:WYJI-S-RYU,)2[(VJT\M[@[QDEQ0)D*
M&08-<U72B(GF0 [+HVM9D\4K-_)N1)TMDDN)$J%\V%.Y+!]?-,+;X//#$J3X
M'[^[%65C,35)P\!LAV#4N0<[DA&)'M=%4U>TK5G;N#\Z?LV^1_"%KJEZ/-V#
MR[3WRE0@08+"[H5#<?8.@^KA>5S1;((C"6V.XMW:NK= 4R]D9<:0V&)IM=#R
M:PY'J+>M;.RR8&/!IY$SF<\OA8\[(D[!(F[*H<R!SHCZ=SG?!@1K=M"D*='/
M*),^8ZQIDF@6OOO99?)<6;@AI?;E.7G.3/T-"9'#C;(O]O?MK@*PXIOR\NJ2
M2AESM1A:.7UY<:  ;Y<B(X3.^X]T^"LEGJ1&-I%<%MXZ>N1O85&5S&%M+Y=(
MY';HR2PU!RO4"T3QEW9*V=A?J_YPD$\#TPK[>#[ALW07[=O4\O(7;, _>MS-
M9-:>[P]F6<*89]CNI<NQ]-FI/8GT$V!?96)N9[#_IMYM^=)"2#?!KY,'?S.<
MLRZ&?%UR*#.FYG9G-)^.(D0_F%*%?"65VU;MY,947T[9ZF7R!N/WE9SH%EB>
M>\"5X3"H(<;\FP=(.I;_&P7OSO'X>9UE7/33F1F>X*4X/&TT;2%0U=B2/^2:
M K2CDIN1]4^J(EGYF*O'B:ME H)O&'YJ?J@9.U"FX>;B9HGUZ^4C__+C','8
M[-'3Q (T,P*"24&?3Q3MGAPPQ[S83)E/?H;A)F]0G7'F'1:2,P?5 <I.\I3Q
M%$:T,ZY"<0?.B\@")"XRZ(S?NU+GI/L@G)59+G9]HI4$,Y8?"(Y@_-9\/EW0
MY EK '/L+_/5NM,PLI)L]+ZS13W?%#.N2EGO'*EM+>'M&9 U-*J2_ZA.UB+<
M[N9!"SO_C[5/:NV/_\QQ"!\1=.&6#OA%7KV+$PZIO$F!U\QN+/DH720C*04R
M6>8[X[T'SB9]+W<Z%V@.4]N]L*:W^)*K6/KLGM(^$9^3?H;9CRD?LM&\;.6R
M=1G;SH[%2^Q+.71W\H:)QCF/[74A9N'ND^ ]O=0>D^E5E:GVE$3BKF5U<LR;
MZS_65W&"Z@ITOR&UT1[K<P]H&=P#*^:+GJ@Z"V:>B!XOY.*^UM4V)JE3OX5S
MI;+O(JN7D]^,>=+M3Y+^+6=DZ'.C9O-%@4&(B')5!19.%_QY@=(_]K)_%D1H
M0H_[<2N5NW7M-SN[>3PGGH;]9 ,D["]_#WSH4X5&(/A[H/A259NIE1*?7HK\
MXV)EUUUGX:I"DHIM;9N H*E4I7R6G==AHMD]< JDGMT#*,++;#_N@4W=7Q]V
M/*<)+S#7)&:?0)9O\VXTO+IE?YC? T.3%Z3QMT\UFN\ FCNOULC+5Y5>UX L
M%+>_8[-%Z$W@<>9>M)<-1.FN4/@G9O[D/9!:O,_+?/G*T?J:</UWCS^;=8M5
M8G=M5_+GW<TU7O2"_V\[0!4AW/CO=?CVL_DW5ACA'0A>ZI]&@&[1?B&?_ =R
M=RARSH#B>T"8.!0<9/V%VC"[.RLL>@B<S0_!03VX1H2.@%]V(1] 4>"IY%'&
MO)_:VW U^MDR3^W,4 &%CF>N$[+8"/6&(:1Y6>+\[N .#OQ@WJD;(Z\YX6RP
M1>1-X&G>N3*4,J:R5VA>EY+,7IM$#YZ#^A$9X4_QZ0=Q#H\RX?U'GKTY)Y@S
MBI 7)-#Y%W_-C^?5^MS]'A#I@D*N\IP&7Z _C!L0^5;QRN^7Y(WG!<0G\L%)
MX-F+YE,TK\E;!N,]VWO !O+Q85#N-8FRO-O6\X_W0-1_0]_,:26(_HVT5[>1
ME_7"/3#,>@_H'J8[[HQ^)^.\XCG0!%M&_D$$A^&\<8B!MJ077:_,RIWR4X='
M:.T,6)@")Y/9W!!<,EV(-RYT'FU[[<YOSQ4[N/=LH=11WLR/DED6R-/?X7:4
M3T[]=[+]\O&_.M9S(O48]TSC'C@YN^NBAMKM$]1?(L@/6F5"<)G^G,7ZET=S
M;[2@2.+(H7U _V T7_4=ZLD#YC^:GO_H8*3[?^B@\8>4Q-\*_M;J-W%RSRN@
MQA0JT(5X-M?\"]V\6M\60(T&^^"$PM]C@W^OG)DQB,AUH=?5]:#,WVJ_">VX
M+N@/FH%?8@=D!>PGLQUU'YR;7&U;#N"7>>3Q156W*MF<Q=;G]K^;/'B!Q='%
MPW/P;YZ;Y_"H$M[G=!U,D5T75%8 ]QK^PW&9?[/#XH$,X-'XO>A?U'"G3^U7
MK<BY#>"^I2+\31M::'3Q_4O\#BJ>)#0)OM#\Q0F]\ZC_BI:A-SG'OT5_<>V?
MHX$/HW3^U*DPM4H":LF95<B.YR\U'JQ/M/@G>6G_YJCF'Y3\0^7&.-EUP@>5
MA:$J+YZB0X7IREP"KIZ\>Z05)M)->G*M,@D==?F.3F&;S0:_SDU9]./8Z]Z?
MO5FD&O*EW?? G\ZY=;^E\_K;:_@3'D7,^^#>2&@4;;M23=\SO0<>KPEP>EU=
M#LK^<I;_U=]\^]TNJOX="A^B K@WM3+GUO>7=R&K_G43.M?ZG!M^&36Q1/,<
M,+-@A4K0K/X]D$XP=@_ $-X#P<7/?_,4;/YK+<TJ0EZ"E1_"D.Z<Z\6L)50M
M,2C!OHM!,XO9+3G]N&6:FN4M-Y4\16N6F;+(.:#Z]AR*IL;D5^!X"&)_]K;3
M_3_$_-\0[\K^ABC_@)#"0Z7Y]L[+ML>KU?#!+,W_5_YF_UN7O\3HSV-7M%_(
MC>/,>)"K8?L\%1]$%$99N-%ZZ,K'\"':U_NY4$6VPF<5^5*YMHFP6$<2L7S:
MC!)^WW_L2-#JCY77],<?4^Z$G) Q=/&=FL/JFH;;C75[$\K2IM$C=\* >*_L
M(P(Y=W!FKLH(YL/..]AW*6]6C].,DZ&[J:XO//&BAB>]9-4E8(IN%*>E+_8*
M/:N%HO#M,T3A[;;=@V^MZ51$4-:J-FZ^'[60GVWJZH,7P!<#-%//B198(7N
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MRS7[ZS.CW5C24)7^_=F;HGI5G@6N3S),K%I7NY.IWJ0E?E>?#5.8#/G&"3*
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MQY!N*\+355M97NU1&59YIC XA0#+G,*HF]<61V\F)Z,*8,EPUYF)M+,<5@\
M61V1_++I2U':>>KZ.E]^.S:U**960FN&'"+JH>)&QZ3.H+J*D40P-E$2G>H/
M*16B6]6S?$((RMB!E<[+C@8KGU>VXIE$0R\VG4DC3KW[/<!MJ-1CZ-++\X]E
M0C_@[#/A1BF1\^'XD5UFO\9L'9OE_.8LBQS]B1U7$CZHE\4.DY("[?Q =;<!
M/6=J=J$U=G#'&<N_+TI2F5?^% [U%)]ST:^BK\HC7T]B.LY?]&YXU>^@ 2*:
M@%Y?/6*]5[CW] <[Z2M8[AD\5^]3K8NML AQOE$OHTNW[8N^3V+U=:87R&@^
MTV0L3C%\I,PO>H Q*P%<<V?&T3EMR6,9Y*"X<"6T,". AQ,C=%FF45B1?4X6
M)H#WMOL31YLE2F]ZI/U)C&Q)&CKUX6 *) I?"S5\700)^-1%&<$CA\C_+J/F
MT"G%EO9C8[M=) M(BA=6G'$UQZ-=54(,L(]<&J!;P8X4Q*,4A^VY952#'@DC
MDZ;*2@):GJHY&ZAKO)NS/^'6J/X=[?1E;9VJ1[_)LO,DP!$L?A3S&;3=^7*F
M>F,MSRBO+_44N>;E8SVCJQ(;^^]P7]PF9:5\DI>,)[QYC_*W897)-;K]-3%*
M6.;#EDMD8=.U992C7JD\-:9A(/SX7 Z/=(.'(CG,?5(6.LFLKL[GR]4X@^.?
M)*%BJ(X7-,=IC9,S3]7>UC"6B<OV'>\M^M901@CRVVM^E$-$:$_RYH8=ENY&
MHDY8*D+N!B!P$:Q#&E$#^3$ZS$SRA]^EL U@F+K@'0!/1R@*>S^%'T86U'7,
MO;O+&=91Q6([/5:U>XK3LOF<T^S+Z6P6#&M1(E<1SX?*((ZU?R=C^\[M,ZJH
M]E')WJ%URO29!.%G/*>GN2L3Q3_MTK'B](IO GKIM*Y27(&CB,K1,1L8*I@A
M#>"[MJ(\#HO)<Y+G"B75=Z=V+D/9+S R\ROT@JIY#/H+<3$9";Z#QBTW(J6W
M-M/0S$GZ:ID?(4]0I!D1K>AA>N9,%DM'$-8S<DD)^!BW!9#R4/RT8ZOAV>JP
M&A$AG:[Y\<3N)"NM@'"J89\89+;JYQ,]H'92Z4 2^/&[41QKC"8*";!12^6P
MB@]%85^ZS5<12(>C1_L.D:";RENQ6/GL0(4CKY+FHT<Q.HFO_5H<O8BNYX?8
MV4K+/\+28V*B[ QOMN92?=9=TZ\&/"I4[S._L(8Y"YKQ<%!]"+A1NAE):)\F
M#F/=J.:]*$RBA4M.E1W3BUYVM0)FGBMM%D2XNSGOR, _4D^:%QIA3G[#U.]M
MY(VT&H;M[3;A9UK:YS;:CS]FZZC WB.7(QQU9U9Z> K_\U5W&S\*+1'OH$=W
M&D*5.>V+ 83V,JKEP&X>N1SX,(SVLZR(21F>Y#>1M+RXP8A2&U]YSE8*7V1I
MM)9\G=]"TLMOHURGO*7'3F\-(>!%B61L]Y3S5!PB#USPQJ1Y@UWCGMLII/I4
MF0AZKHCPHZD4V)K@/K?(PL7SS@.6[N[:O1:5%2Y$%HENV'.C@K'BY<1)?R8[
M<Q88PFEJ(LWYSB9&\-E)I:%TB5<[1$F.\DL^=Z:"E3SH4*\N"YGN2S=HUXOQ
MZ($8_<C_M_S[N\ VQ#.0Q-%+?;VK%*[[H7(9=1RW5D4*LQ/!T,]X)DO>RO1H
MO7=%+  QPN#0ZH2H#/NQ\L\X%?T*1WH3XAUA2]G]2O!#Y9JY(\11$\'B$ M*
M^.ZY_10M@:Z'ZI3_<Z29C+9SYUN]:CY-]NA' F,:?'N#\Z.D6)C4 2-C5N[#
MH*\>T&G''ZH?:X7%+@-GU(ZC^RI$/UU:2<11:?EMWF#V128$# I5IB_/#A'H
M"%3Q):.;$Y6U.[-1N@8H(!)5<6U0_32F)*.%&VZ:29TW$WJHCM=^-!BCES;&
MRM:[ZM"(56/M(W4;BG1(7$"<#EH*9?KF7?>_41\SKRR:Q# 2E 2(U]!L2$G=
M%(0Y4C:[ 0>>?XUS0H+^HM.YKBB1>J]BXI!824L"[54NH1=_-<QL6 12!Z7$
MJDEVTC'=OD"YVW:4=*=V-W%O2@()+HD$_(:?"'GJ^3AD1_ZA4DVZ!UI?K/(Z
MPP]//*6D$JR/!O>^84_]3&48D8)N<6FM,'FP?Q!0GI.=3%?=(Q*&*;R''7"+
MB0<S=?>7<41#@*;)H$+?0HE9Q9M"I;5[0,,+<^U5&NH]\)<3Y#*\F?^E1_/?
M&C 5%A6?UPOO3A.)/39*$;E)%U]ZOBM%(KRDG/JVX#+XC$R(H0"+(G'J51^<
MKQ^I4130,B3\I@)F[C\93QF%%O8>>%#EMSYT$O(BA$E'^$'T<[_O\PI/<$\D
MBA!"_C)FNAB@>V/FY9C[4.7[X\%X[>7=360^5$5>BNZ;LQYI3LK^/6+$<^Z&
M<XYX.ZBA>5G15MC>J%\4K<9B6# ]6>P/1$@6_PNT<M5!_8#*>J[BZCV@UJP!
MU/ZM,N[XJ!S"/5"5<Z$1^5#ERO^GZA6DU%N*,@0>LQTN\=W6\M+ N_M,'N5,
M:>G(V/-I?<47H7WY5F+=+0E8_$\ Y>/].5.<-78$;/6K"0\AY@;/ .]G'O\]
M>]+^BV/M"<?,;+3>3!PUE!*&B:=['H"YQ\F]P(4FZE*,53_[8EY@?>LI*=FU
MG?'F_*_LG2-A5\8CA_2T/-]=]O)2-ST-G9XVP^>?6S[\GY52I+5,J6;64X:0
M$T]'CMF&^.F+JF3#B88QR?%;;8+$MZ#I_7>UR35U22LT]E:BX5E6W]=JOG>3
MN2O C7BV@2^2(DLE[M9O=WS'*A=)7PLV-LR8T;-4BR>9JX!2ZN>\IR 7I(9P
MA5RK[5\X9$SB;_"33(GM1C23Z<O"?&6,\*E.!FU'$\CN@:E,R,G(.>T]T'#6
M]=IYA=9HU ]=Y!Y(?SE+X:\F8QO=^!8:^,E7:[=9E3./0.%%V*);,D0\" /E
ML#)82$ U"9NKH*T(V>3#,)X.'B'"!X(VGQ8HCC+4-0623#[&DAH[%C#46RA,
MPY34&K0)(BZZY1@6N!S_R%#49VKMH5B89/TT QOY42_,./7S%XE&P$WX823Y
M7PK]:-VQ=VG59,)9F::)6$XWM9J8LE";*EO"YYVOP#V^:,F?]&0Z"O=O&)O?
MDNO F6-#9&']WHV2L[YIGW+'TPF-59".!S.5=-VM%Z&_?[[*$+KI:\J$$Z"6
MT .' )_0QDK\$ZT)PUW9/,6^*YZ@E68LO)QS8O10$Z<7KK@O90HH6FU.?24'
MRK@+$#[@!.M'W@RHY*:A#!B3<,EPTCRX33F?%K;XH2%_3O2@KUD(4/"K->[Q
MT$4CPYO^+N3/OE<3LL%4$P9<F)EY3E+JZY%6+X.P(UK=C59!D_@2;4E?&^UM
M+:WS-/B8I\>[C8(*Z*:R6"V68CH"AGEF1<AH_HM9'AK,OU1*HH4M5Q?OEWJW
M'KO+>@^XYO_ @U']U<J]0?-:,*L4 Y1_-80>.%0(92*43 6_#7X/I"C\T+DB
MZ:_ Z(VJ9Z,%V>Y%VHXKGNX4U*['/</RE[]KK7\CV2FKPV(G:(+ZJ:GM3_,6
M*,DAZ#XT,O]MSCR57DZ]%]SX[T* PM\ZI_YIQ^:'AL1_;4;N#25.FG&#6N=*
MU9C'C\)#0 M,XUZZ9JFO:FMKP@=ZEWQ9G/#VNEM.!8P; ;7_@.S?%<S6Y!G_
MR>[0H?ZGU<#_4WTXC?N>YJ"W?7!@9?R,/X_<&YV<[$;*I#ZZ;U6$8UU)BQ;I
M+8H/#G ;AK\'_ALC;NXIT*"AX@B:=?SU$XF_?BJA(Y,5WAOU\!:Z6@(:[2Z\
M=F:WY/8H<SG0&L\W[P%HA*L3_B-"/S3 5I'0F.94Q5ZQ.HF7\!#:'KZ0F,W\
M*_!!6XH:^T^)C*C<L)5R_Q,)^5]C_TZ%)M^>JV3NC=P#COG)S3NRR[=Y'_^9
M4-S;"50???)S-#:G[.)HP=<&&](N9$6YD\*I)5FEKH1J2PF-V:^+6LF44_D9
MTHBJR_)2H,$,KWOS#SW@^3UNP=#&L"/OURCZ/CSHR9"-<UL;RTC[2HXP6<]V
M[&2 T:F)*68)N2A,_@-"R"N,=23;3CZ"V2A:N.8;!R]H!)X'VXBY%OI>ED&F
M?P:L;U,AQ F-BGC,BDNMQC'5D\=E>V2:X7;&(+CN8_L6I[!0Y,K!V"[2V':W
MD!IX\T<^*)%UX^ 9T+#B;HT[I5ZQ?FSXJ!03#P>1GQON& V<>F"OL#DA1+N(
MT%]>83M$\4GLXUJ]Q]$^(@O?(^!4^!\8_)JKC@PE5V;>S903*,3D!RI<P7T1
M@8,KWM"X)N6KT#7EJV@5-R:!3<[=B1&$68TT [8\Y\'0_/C+K7B94$\,N(2T
MXUO1_D*50W/=>3WV']W1_$^G=SQDFH?)<W_U27\.[_AOWSPDIC^,]$<6?FCX
M-XCKP59SBJ:"KSNNAQ'^X8G\X&W3_^&D82-_C/H'DH=T_(\!_?\4SU,Y(EIB
M<!@P'ENYZ=HT@=WXO\SQKVRFL_&@A;WXOXC#<?RGDX[,4X7AP<6J_Q#,N7W/
M/#R,& ?-N__Z=FRI4PJ6E%>+[I1GI6%!$+.#)?O;A*E@XT^D3M5/9T::B3:U
MECF/E99N;E!."YK/]DYS:8F_=PLXDSJ7]W%'PWL:18<?=;>_3P!?$Y/QOTLK
MOP<^7,CY\N<6?:$U"KTPD%S!$';]4>9BV1 &RS!B0B-H C?DB(GI$K"J4S9.
M(05>7]B=A!$HHR;J'G(9-P:.);^F,'=>B#VM<_=_:QBT4A_VOLF FXJ4'"[R
ML/AEAC</0607U\2D*K=;P(\/LBS(I$:L1*QI0(S2,1\L0^FHT.Q=Y+N94,1&
M$[\!'V^B8XGE9$]\!])_?=*$&7]G>BL<QY;*?#UVZ47_%GJV?7Z30V8K@JKU
M<@8<W'"U_Z36ECU=>V5CW; 3Y1YP,!2P/</38 Y-JPR!CUC^*$GX_JM@KW!H
M-<,DJ+A1!EZ(P2=.Q71>[>MZ0B;^]Y:],8J-;=XTI/3R(XM1:1WW."6/,MI:
MU'6?R+.7=PM7@EL'.9?=J,DZ(*>74]#E3@_GTR/'ZO,E;?6H@$!5Z''$RCY#
M7G\!0J@6.]$D SM<E1  CV9UMH%8,-NS,EUX>WPA2I:6GY"!RT)M9QMF!>8"
MY6@ _@Z8.%EI;?9KWQ1DGKC&[I,DU/:N[H>Q$)VMU]UQ,20X3%$V1&?5H)Z4
MD\8.%7LR)#H<Q5:\;2B>W[-1->EAK7H.Y4I5I)U)=62'32(LL4"&]G!?26V/
MH,MWJX2]/1$R?_S4##%[C&@<'>+W=_VR2<\M"*B,28W)X])%$&BWZ6C)Q  A
MV;/PLZ^*6;]>F%D"^ @K I^*2GW;5^DQ4-&.V??IW6CA\#1TNQCZ+,K$2-X7
M("=@$8)2#9.5V*OR$*H3.6*1B<\SQ/M2Z[L@@A-U*.PA0%]9H,+)"QWIV?=?
ME+#]:#:2W95=&"OY73)?VC33SBEM1*5AY$SRGA7VTL)AP!40)+&5E:VSWG3I
MQH?5#MFX*\8LJJG%LK-Z,1*0!*)_D=!]95 %S7 3V'WX1=/5!VS\[W>)EDHI
MJ=RANX4TV%^A8(QNY->;,. Q- H(OL8#E"U%Z6C&-D)(K\)JM$B=SPHXY!!Q
M9[:]B3(P2@FHL&E!).4[+3EWGU7F-F,E@W37^%OX96)<:6YJNDA5H.D_JG1A
M04/RV_>]&E1BB^5H648WW-0M^2!.M72&NM?YK%5<Q%VE-,6GA76T<*A6Y;;F
M&-P,>I_L>C$96;L,"#FN"BM5PX<;(I"_SRPY+_W\DK"GJ?3[O^-D0P_ Z5\5
M?\41F#B=;;JWQP(Y=%5R_>(\1,(I:AG>K#BS*BJ^9/NEUK!2<$5.&U217JV)
M'(_:+-[WK=-'24O64$:P?FDZ:Q0#WFH^SR.I>5OC/)-]0:L?(='K=A*9+6)A
MC2SN3QV@!%]_U8;3A,ES.G2ILH8'$[13P/R9JNBH/41SS3;&9>OR76:UMH8:
M0JOD3HN1.E*? YSS<M)BAC?+DDS]C85O?P&[)3<H=TH0J7L^B2I2)60^XBI(
M?I1+>PZ#=VAC1S-Q  \FA/+'A@G;*S,LD$=?C,S/Z*WC8<LS"20J4R)K!9MM
M5E_V+ZY$0_C0_1JH4-84TN@9AR!K>@^ 44\Y8++_[;T5+'<(%W7B<\&>_//1
MJ04&SHJ25_DVG31H,*<KWZ0#)+5!*@H,@XRWF"O\#.A<@XN*OG,:?7424F '
MOX@$ ,9;'$E8 SBU+N^X!P0ZR%]2&3U)6G$0A@:J+JVQB0N%)$T>O>B-]C#Y
M15OL8AJJY80OB_2CFSHX$P[AHAT1&<T&56AHII3)8;6=8RWSM5(TT=6PWOQB
M 8A:^7F@FNP; =V3?E6D)IPC.(TMKDS%D!DFH7<6SQDB.0CFB%9)(\0QGO?D
M%K['77GRC=EQ@M*&/FJ /K<OS^IJ[05&XR;<\/N@YHV$S.Y0B&M(9H;ZW-3F
M1%5U/-BD)IBK(2NV_DC@M,-4#M[S)702^9]B#P"DQ ")WRWRAV^5/OZ'V^)Z
M0<D?\5RQO898%>1%L*\>&A+1A+<G^-1X,."'QJ^;G'FT:2B[GWJB6CF[:)[^
M/YO_K0+HD#6YQ0[_KN_=N".R9C%COD'_8XE33=8-#Z/9+VUZL\=Z[>TLJYQ/
M6=:7V).M9L:TL20WON_Y?%FMP>J]DO[/9UL(V@B6G*&DKLJ6\4GI/\.\I"6+
M&I0AK'Z0"5I>&DSV((8&7%K1T(&/:\5CDWTN]I_/A-6M7K;W]4REB<E3$TMZ
M^Y-J:U>6W+:>'?DT<^F=)<GOI]TI\BNH>R\A(3>%<2'^((*&(!-'XPG'69.Z
M&/K!$6 #B@M@J'#\040*IJ1/ '/3*H[E8 ]%5O5-U;UZ.L91Z[AB;S)+3Y-Y
MRO.?_56S?;;.NZH2>6>2AT*>[FV6)[_F ;O5^I7X@@4<9@Y-BA=9X<Z[ABM0
MT,.,7XMGXM8B/LU_($^&F7Z;:/-=^&RNU9%/>U)W?1+AOW[_PK6VN?FZ6_>=
M]/\HM'K/OHLO=WS*8#J/Q0%HKM,Q7)T:P/PZ"'-.1V3YCDF67NL,ORR;O7+Z
M"N976MH/(I^&_C[*(1\3/B-SG\3':9-S9<*F!SKN\KB5KSJUD=' D^]N>7KA
M^;/'6)EM_=].^J4KGS/]8O:Y?P<?WSCV?GOE['V_\CL$#(PW/&X[YZ#>I;[A
M1\.W-:M7N*S=9&0F<L_SV-?GS,J2YQRL^Y<R5*G?>G;00D+VHU?>,@:AQ>RW
M=D2_-3Z2^UA6/*A5:=ZM>W>3=J9-4>/\_7:[S7P'BS^M:3$5Z4?#?JU;6;O,
M5\2_6*7-S)/M;^N5!^\LU#.LJW*? QLNE^UNZB\"K<J*=UUO,=OKX]JK/X3/
M_6=(<7/BBEDDKB#@Q^ZW4_GV7C-9^^.%6BYK7N=-<.NSNRGM\23W[M:.GQ%_
M[LQB^#)_F_>+_5.!OOH[_]1.>=[,6^_FK[@[UZGH6W'^Q, EX=J*DY4EF%=]
M?3OK)3#L;ZO^9TC_M/CMI/\,FW^&9FG 1);\SMG7_3.T2H/IRO0B[0EFCR9#
ME(08_6=8:]_^:5D *]">?^>?ND/4K[J"36#KF6K^4_U@X9AGVY?&WH^]>3K3
MVF7!ICN\-\(#S!64_W[8:WDLV^[4[:.&KZRJ8\Y]BF9/+EJZF(')ME-]SH/J
M;T<9RNK!'H$8$@ILP]MCY3=6ZE7I/PU=Z1[H(!;W+K2([1[_4G6(2U9 5]@P
M1/Y.V?\&'+C?ZK76NF+C[^OV_':S5OS3FNK7WBO5A:(]0D1/:]J(R9?_G']I
M=KKHK_AG91,7?#KQ<T:"S,<#ZO;QSQVDB7/?5+VGZ0QOG_P*C:JI?RW^VD%8
M^F3QQ7HM8'3_MI\:;NNK2ISK?@9^.UE_\\]JOG?G/MS9,^W2A'8>\7*W<]+R
M'^1?^U]^O+?O6?U6XRTIO*TSZAKJK1AN$C83Q%]9JBP\=R]_UFIPM;^ <Q_8
M59 4M!H8H'6$^8M@ICY?O]94N-!F6_Z126Y.FQ\P+"BR#^Q?FA&I<SK/Y?;!
M.V7M"6?$M_D7.TAA#R=T_GS6TR<UPH[Q+P6M+;F^_E*#R8I%72S(ZS?"IUU-
M+7K:H3;[FPAL!" 8-!X0#!MO\ >-/OA#1W!:[?=<J042D+$!$=!0 6%MVJ:S
MC%,V!Y&LCWCKSJ;T')F6EVEW:#YTZ(BKOG(%B(",\6B"AGPT8>,KRT&C+<NA
M8R\@'7BT+8U6"6,Q+@S+H$Y(8-$6M':6YHFTEUV;J>EL5&US95<=>WA8R#5B
M$!SQ2 2V_W\3 %!+ P04    "  UBM58]HONPB,2  !&O0  $0   &UO9&0M
M,C R-# S,S$N>'-D[5U[<]LXDO]_/@7.5W65K:RCAU^Q+\F68D<^99Q(:\EQ
M,EM;4Q )25Q3H 8 92F?_@"0E$B1 $%)=I@95DUE9!)H_!K]0*/QX)M_+*8N
MF"-"'0^_/6B\JA\ A"W/=O#X[<%=_[#5O^QT#O[Q#H!?WOS7X2&X1A@1R) -
MADMPZ4UG?<L! P(Q'7ED"EZPZ=_ (9@P-KNHU1X?'U]9O RU'(*HYQ,+4?$
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MW>=GRF/!1BB%+LN/O03?1Y"*\/]02P,$%     @ -8K56!@@((QF"P  OG\
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M#'?WC#X"> AO@0V;7']==?FP9^6S'BYEP]7&0E?D2C[DA,\O ,/*R) ])[\
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M4Q8(Y/:8(N1BK+/GOQ\O8NS_ %!+ P04    "  UBM587P*SSST[  "=IP,
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MB\NT?6/JPC!O,&M;<FVS,N3S> 2K\O=7B)!&R>(\C'*R$CZA[#I)TQN$V9F
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M4WP6>:'U^C$]VE_%&M<4!\QCEV1.F#X#>8Z*_Y)9T+98^ZDPBT-XJSV,0J"
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MOMKK=16U;N,\1;@[-\Y[?C(&9 $8O17S_%+,\TLQ'> <U$LQ%B[W3K?'UWL
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M78<+VV)7H>@N(&Q;T$KX6G]48)<Q[&':13>]0;CJL1;ZEN793L-16;AM\7$
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MXBQL\OJT=!"7=_4=C-UN$Y>C!%2R6S$_O8O")437N!8";H\12IZ5"!Z5BCG
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MYZF479&\TJ[MM9U<GIK5Q]XD6HU.FK7/<:52U! C,>:0$Y*CU?BO?]$ /X<
M"( D0/E2=3FO) )H=#<:C?[\T_][WH3H"2=I$$?_^=GIER>?(1RM8C^('O[S
MLX]WQ[.[L_G\L__W9X3^XT__Y_@8O<<13KP,^^A^C\[BS?9N%:!EXD7I.DXV
MZ/-L\P4Z1H]9MOW^U:M/GSY]N2+?I*L@P6F\2U8XA5^@XV,R83'E68)APN_1
M91*@O^PB]/H4O3[Y_I3\WVOT<7E&?GC]%1OR'W\*@^B7>R_%B, =I?_Y66VE
MY_LD_#).'EZ]/CEY\ZKX\#/VY??/\(O&]Y_>T*]/O_ONNU?TK^6G:<#[D$Q[
M^NI_/ES=K1[QQCL.HC3SHA4LD ;?I_275_'*RR@F.^%"PB_@I^/BLV/XU?'I
MZ^,WIU\^I_YG#&\(_2F)0WR+UXA"_GVVW^+__"P--ML0 **_>TSPF@](F"2O
M8/RK"&>PP'>PP.DWL,#OR*^NO'L<?H;@BX^W<^%>OBOG8 ->_7E0R!Z *=K0
MT5\OX\P+=<$\'/EJ:%S*(#8"]A#.$'Z^(O#D4,&W$E:C4^6,7=L9?LYPY..*
MEV#F>-7X)@1&CI-B(%WX/S_;I<</GK?]QRQ-<9:>[9($1UD;12F!AD*R]M)[
M"DX^\!6<Y%<XS-+B-\?P&XHG_MQL[P60 $4#S$*J?*:!D*S&.]V[^T=X'U*Y
M0+X"D8BCXX]WG_UYN5C.KM#9Q]O;B^LEFMW=72SO_O2*3O3G)KRSI(E9+UD5
MZY)_=@"<?_%J%1-!L\V.PSK8ZR3>=- DBV7;>O7G7O2_)D"-R *UZ0F@#CB@
M D#*!->+ZV,A(SADA39YVMQPL,57/27"*'S@B/I2FD_GP(MIVY.B5X%W'X1!
M%N"1!#UG 1?2O@V&DLB_FL_>S:_FR_F%8S80TZG.$H)=&M\ M?G&8POK)[^V
MMI0)IDC\#JKWE 9W6;SZY3$.??)2O/C7+LCV Y.=LX +:= &0\H(=\O%V5__
M:W%U?G%[]_O???OZ].T?T<5_?YPO?W*M X@)5F<0P79?_7E@O&]Q$L3^7>8E
MF3[V3SCH?^>%\/:NL/S"4'S2/(L#(ODB\O51?*J"XI?'R*?#Z#^SR!]=_G4N
M-_B9U+D-N2"I7I%H=GT^84FI2FC!Q2I&3:6]:#'>8@L&UB!ZN'C>XB@=7,%J
MSV^?M5HPB'@))D)Q\37"^><ESSC@%R%]Z@S"WV!?CIA'JWB#K^)T-)ZHK?#J
MSZZ8H@)"P!;P)P14*5@CCM*Z&'')%6T:<?GB8(]-75>+.ZJ9+@E$9W%$IM^1
M%18E:M[A=9Q@]MW2>\;IQ7.6>''B!Y&7[.<9WE!#$!E)=AM2X#),2#STBW],
M2&T_%4?<BXSI[^FD**"SH@RF=7U_6N"_^@D:&_'F&N,USD83T,VY7;R,&Q (
M6)1\@T+R9Y?7,Y<*=09J;V1P_><))_=QBK70R7OEMO#IYH3KH_2DQS$ZBS>;
M.*(Z]=VC1]"_V&7@:8>0A(%/E72I$0Z9HAE$!I;@Y.6/=?1Y$"$VY@NWEDD5
M*M99J'//(]FD.LPE76!);%-\6OP&2#&&[8I<P')YV044SX+%QJ 4!AVAE Y#
M<37.Y34U-%'ZF+J(0")*$8XR9KR J*XX(C^FL^=@:$5&OM;0;\Y0PE%22 1B
MEGV*JF_1S_#UW]W*6B7Z-:VE75OO\1XERL"9ES[>)/%3X&/_W?YCBOUY5+Y\
M9ZLL>!K#<ZBQL'V+ESIP$MUZ169 .S*0/ !K5C&O'.M>4=0D_8$6J8,B0V.:
M8)5Y]$1>@ [8D[?P9-B3 YPJ>P;%T,FSIX3T"NPI0M&P['D91$2G=,">O(4G
MPYX<X+K8<YM/ >'KZV(XGT6GPZ$2ZBMPJ A+AAP*2\#_0'=X\D)0&V[)"4B"
M589]^,,L\IN_J'UY0Q]=\VB58"_%YYC]]^)Y%>Y\ZBU9/1*RX5NBGURLUW@U
MM G:,O C/)2ZCHK='4J.6Y#/@C[W\WF^@'N!GD+R;F'_P-7:;M_(3IBZ\<"S
M3[?::\N>!)C2@1[::Z1JW^L#L^#$G8F.U1'R,G2/'X(H@ILN7J,]]A+'FM@@
M'#38Z6G[?2P:&/L"SK- RID!DS^TV.#?3%"S;)I%:20/7A3\2GV09W&4QF'@
MTQ_(JC>$?\@B],?%.E?(O+"TPZ2S>P*6-[BZ,PQ,-JUR@T LBB9ZQ-1TYT5[
M>CKN=IN-E^SA,-P%#U&P#E9>E*'9:A7O(OITO2'+KXB^C'XNIG9LZAN4R1J!
M*8/AO<<1FA&L^T&X(\\4?(=7NX0^5I@:@WWF[]]L=P4D%UX"=QIH/]0F_F[/
MGV $,_:8D ZLE,A.VXC;$)S!^@!4C3BTH[O(IQJ?^1I)6B.COH<#/O32=+'^
MT4L2(@X7R6WP\)B-<(;$ZPROB\D.@1 .D:H-W\.ED8] <8+HF)8SR(52U46\
MAL(DW;GI\S#W?]\]8IS=XA 2V<^#=!7&Z8Z0;B1-1W'1$8(Z9*RE!I6(S\IK
M&/NH""J@4Z%SG'E!R-5*'/"<'L'K#*B!'^-41:*];+W SP.QB3JSR!YQTLB&
M'XDG=5:VS)@:H FX$ZJ@^+L0@R#,9Z-*-9T(Y7,@-N-DU&<#7JBSJR[6QN19
M^[SJPIJM )8T=:3.F3'ES+S> ?+H')-G1T,V/+S [01I*0+&,UD5A"HR?"J*
M.;W:QJ7021\) ?$?V?Z&8#$C"X E:PN/\7?[)1D^@KJNLJ)=Q5T!(F$N1?1P
M?$4>3CY:DM\']^0>H]29@@JO0=HFSZEAPU2M%\Y_C8>_C"1+N4A^D $DO7^V
M^4 JSG QZ@A%.'-IZU"AI1)O%?L?/B2D^ZZ1@\2_9/Y74*-/]L5LM4IVV&_7
MBQGIC=2]GN6742= "N^A? Y4)/].Y:&N3-R&H5()(>:UY$33VV(T%\\:(3#2
MR\3+V:J5!3\I7M+B(3?O%"DXO(MC]MO$?(_WQQ4$&(UES#V8W*;_N;FTZ/E
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MI*6;>P3057P6C66:S$WD8K$4-.6AI3S8:JA<#L%ZKN7FB(S&.2:#4497@3Z
MH]80IFJ/O%B3E?,.,G?G>(V3!/L$-E;8=1;5RRP9'JKAUG5SL@:#7^%XU9OV
MU%IRD[]D5:>?O A!BHIUZ<V2UR6'.I"UM07I9^X.V^!<R#EQPU+,]-W:6N-]
M$J=#/ST%B]CO9\L'1%I QR_8-R/L>UB\W($:+2=878.6;-:P2%,Q8WDYU+AQ
M));A+C6DB/V.L4Z$'Z +QE*5@WAPJ?-16 UR;4Y0H2F/JX0(,'[@M_BU-O/P
MM:Z[5AOX]:8OFIKP"'CKO"V=FF65'7-5!RVEXHJ# /V0-'KIWL9[+\SVLX<$
M4VNREHXH'&RC/*84 @%/Y)^C\ON)J%==5"AU).E^>_17BS>;(&.!6)%_%M-6
MDSB"/I.CFQ3UUK;<ATT'-F'/K'(.JMPW9IE0=0DC'FB4P-%&EJEFGO?ENO&2
M;+],O"@E$X)':R0.[5S.JN6["QJ1Z&/#$!V'Z@/=RT!=NM:Y3@D=ADI]_K0<
MJ<U <W+[%<<;ZXMZH][=72SO7(LF/AT:-<7;F^G3]-=")SYASST'3*#63N+L
MX^WMQ?4238DG5)I%R'OAF>E+K'/[0;_V67;F)<F>W'ICQ/2IK6F_ZXT27"*6
M(H.H4K2"?^!JN-ORC#K4;6A RJ@PMC)MXS0@4X[8=I&_AFW!Q(5"9(!GK:;W
MR&>#'!LA)21J/NI%.S272\WRWZP&Y?ICBND: _.)?"WKZHP4')%.3%MDQVNT
M2S$S$1U8B)SW)A"04-R)@+=Q TV(&AL^1O0G[&L9A=JC[-U)?  $U'=I\!&B
MMK3T\'?10ZFMN\<BWUHE?^5E'21SJ\(FZKDSG[V;7\V7\XL[-+L^1RJ%YEUT
ME= D?*.KA Z&C.(;6GQ^8B9E#BO@NQ T)PJ2QKVH.>F6-2>]S'/6.C7*6S2Z
M$B5ZK^F:$'']I-9KPJC2?=&T_6*\(^^F&V\/Y0Y'Z[W(6\3^\YD/B,@<EW\,
M[8K@:[>U!>2$.FCY)]JDX4M8T.AH'&;I6,R!YB*'2%CW-TZR8S+W)F]ZQ8^U
M</[H$5%3_.KA(L#T^A),?4VV89.[:NO9U&R4H9+UL>_DL2EQ69NP"HQV@ >S
M6/F6WG5JION>3D#W/7T1NN]IG<2RC9@*#XD3W%[<A LO@!@:H[B(SZ_C#*-O
MOW M,Q3HJ1@#89R:U>+0UV92XO4$I,3K%R$E7G=+B=>]I,1-DD?T48O*&-Y"
MW@K6;?(<( 3T+[]D'9R.T/\]^?+DY)2\<Q+TQ&H%?'UT<G+"RFL2@5&FV1ZA
M*(XP"M(4NJ&#((FK^C NJV9(:%R7&"(<];#T-J>\\9)%0@NM^73V&YS05.51
M&4ZXJ M55@VT3LY,&6>6+-E9^M4YTW617LR'4B09A[$WUSA,F!^5(5N+.7BT
MRR%2Y;^6!'0<M*=&5#&K<?$PS,7*II[3J\$"=^4+V38]BT'19"EVAT[GSN21
MKXN/:ALWMT#S)AZO'W+7:E/@I^XNR"*FFJ0V)B1I%WMQ>B$;\AAK=SN:_M^:
MWC87'0(@L0+$D5CK/STYH7H_*/9?G_"? ,BC&=8?"#L\HC>G1PBP04>0?[PY
M0N3K+88ZS3C<_Q&]>7WTU3?LSZ<G1]]]]5U3_!T^(70F=\G@(GXZM$ZT:#((
M"UMZ9*BLZ$"Q4P!+SOZZ3PNW_*7SK%!%S="VB2><W,>#4(U7X+!.-HT'X6^/
M;CW*[M96&/DE*%O)C:5< (V2D)"]_]SRE\K;KVOW ZLI>F* !Y&DSRF/!"^>
M N9U/EL3C_+P%JWBPK H@$7G&!^\N1UZN22DD[+/X8O;]?&MX.F^N0D\CU[J
MMI?D,+COTPAXYOL!Y,QZX8T7^//HS-L&F1<.?'!%J[@XN )81%%WY==$UPO\
M8Z+EK=@ QZ;7#L(U(O D.S96X6YQY@41]B^\!&K4I[/5:K?9T7SL<[P.5L'P
MF?B="UIW<G;#) [F+#Z$$DCPI5M53IV<S01\I?WW\&>6(5@7SU!M653(<+A
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M7[^(0IA?MVY3P49,WQ\"E\D\>L*I2T><#(#I..(D4,H<<>O*$1<4,TS;$:?
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MU:0<1IUPOIRR<5U;$1S0V<-#@A_ >5-^SCPX];C++UYFB0%5+ASI(<O!?X_
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M_P WI?$Z(^(=3T3Q[Z#B0="Q</L](N%IB  UZ,PAR.V!D"X=B94D2[GA)S%
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MP<59R&$ISL+")$?6/1F<0#=)$">(51)!/\,@-Z&=$D(4*CIO<^91G33B 2I
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MID(#\$2Z<CX3JKXO2O9"N >MVDB=[=7?)^&SZ,$B#<W;$)&&-L=J+NA!"7$
M9"$<&<7IJ<YE34]7!$A4H:H:39_^C?&3TM@UB5C>K3KX,4^T6F2/.*DM-=9]
M*U[';N$J(1Q&?#:9,(!.,M:EF!P'IGH;M4U!SGNB8[G48"'. I:UM38$PO!S
M^B'EF.LX2O(?82!EFRG8F<3TJO.*8,O&NEI]OK%#0.1KV;1#2B'IX"$Z"-5&
M3:3DAA(E1:PT;/"'8&9])4EI(ENA(2K Z/*.5#6RK1GID*U4BY2Q,K2(&DLS
MZES.:I>*+FCT&6XJ!:I5R:H@LEH*TY#4\>/5#M0R:H_ER879PT."'PA<[Y,X
M36^2>(6Q+[1Z0\Z&1X-@((K0*\:B!QB,MOGH+UW&D/&VTSKWLEU;IT!&-.B-
ME_R",PAK+"I37^-,1(59=DR&'+,Q*(5!0(X4AAVA"&=?.HN8$6^F38..?0__
ME.LDQ9F7/EYB+,+[#28+DN$/-(9V13Y&:XS=(3L'M_W8KV_#-CL71MFE]TQ;
MK*1GWC;(O! <0+<XQ61SC[/(/\=/.(RWS.H%'B,AUFOC49)/0-]"?C4%PFR.
M+QV:9HPWWJ)?3Q3:IOC%>HVA A)F=G@"]2V1K+<8$!:$ 8LQF667V,>)%T)I
MYAW1E_:-K]6.G$\&0%5G<NSH7"@M)@,W!DK@*O*VVS!8T6S_+"97$CB44,!\
M'9^'1-I_\:7+W)TAD-5BF.$H,+AZV,T]=?]O"H:D.*(705'4O?C %_%(LQY0
M>H38).P^1)^*VO"XF,>A>J*^V3:--?%D70HTX)NGZ<XCN%BL.9!"U'X8>DG9
M(DU$V>L=U$*'DU\0CQQH1N,@7X#>Q#QZ3X;*>JCHH+L)7H>V32FPPC9(Z%]K
M0(I/;_%Q@X[NM"HN]!RR"/?H0'&MH)$R2#<-CM!<_6"YHXQTEQ):*6!G!"]
M)_G(19Q SN0Y9O^E"92TXT>\WJ68*H$BVK'\] 0^/H[7Q^1SY,'W#N6?RG9X
MT3^*.'!POKA\0U3P@G58I-L\8H']"Z*.)4'T('G"W^(MO&7(RP4*AJ:TFRHY
M<,);#=X[I2831 BS/(@X7ZGYZ+=/<%/TM+F@'Z)M*SU<<.?1S>Z>O$$*Z%("
MWF)-'N20&UV,.(M3L3R>E28V(4,0'MC254H>2*GI!SY<DZ4HQY2C5[":.\'=
M$TUJ7**+=OM/G9Y@!WE ;;>V/ [7.'@M#X2QH1FH20D']]%50.2?3R0@@>Q]
M3& ] T0F$:T,M%_BY^Q=*-&YJZQ6:L:O*BQMZ7BTCA,4%DM0GGB 1="*K>*4
M)12WWB*Y%LI<*('L^"[6C+5,#"&5 * *!3G:7 6>:PFQ3D?U[;9(J8LIVUI!
M$SZC%QE//]0Q>3@FI][[3!M?]J_NQ1;#"S)ZH,\2^J#$/L0FBPA8#D A?:!A
M-@1!5.^73M,QA%MIT:5CT];M2K4"MXQ5&BPB]!^QJGIY!GF*XEI]8"8G6P=J
M6WH=7!XI^7;;U%+ CG62Y4V+%FN:^_4I"0C_5SX=H=>'C0*ZU,:A&RY9[!-&
MOJD6851P8)\P)0"+]2R*=EYX2WXLC#"*]]*VX9WSZ#0H@;\&Q40.K1(=6VS3
M204E#I3]FP1?[@CK%$80B:^TLB01,J$U'56H!TZU]L,]M)'/W:0+;.=9.=3?
MTN6@*C.8J%L*S@.C@$NNY\'?1K=XEPYP7I4*O"0;H;%QY D^>R!C+N,DYXC*
M$:83HY:44R- $LKRR9$'L].7;GX^ZC[&5AR;BWA6 YRTZ-P#L_:5;  VRL(]
MO "P7ZMWG,01^>>*]40<T,:1Y O2IQ5D6-2^:JSI\#P;(87+!X:H=< '3:_/
MXC[S@@C2?"^>B="*'C!A7?HDN0J\^R ,LKVB+&@YR5"<STU]*OGLS/Q%7VUA
ML8!;A5,?(6T&,,2I=<7T-DA_ 8/K1[#. 9"0Y#3DF8?YJ4US5U_!Y0E7V#&'
MGJIH<G"?=S:V%?6U;5J"WL/E1*35DQ>$] J+D_<R!3CON^@5WU-Z/\"((Q3G
MG7\>V)QNS_/(^&DQBQ5Z6)<4QKO*^R&=@94Q#,F&(O\69[N$R,-E3*X,J$N3
MUZY19;VBL=2JF)-*F"2?%2)1Z7N9C#DJC$X<-G5I;7*!S>$8M3=)7Y*4O+W[
M6)S%Y@$56FW(@$+R':'HP$WD])DS/!*&8ZH./-MV*PVQ#TVQUF2<WYC@ZD;+
M**STFQ%#]+?T7ZE@3_.H]HV.JQ,8B_WKGE;86]4K['D5:.A^W_ANFSL./%@Q
M_PO]=RIA7GC[U3]U%R=EBQ3#\;41#[B(KNC<8=JA6M1.\(\8'M.@"./$>\"-
M"'TU2?HIGX&P(YWB(+]APAPX$)KT.7!0^DR' U.-+18;2><1:T JVVCMU)GP
MZUU-(&KPZT08UC56%=G;-9@N'^[WW;?-/1\5M4"'@\W=8JC^PF+[ZEWN7HNX
M_,=#ODZ*&2#6L>SX!T$[5%]@5J1"I:A%DAR!$O%[;QNG?[R)?HH^1.?+Z+_(
M?^[8[V#PQLN.Z"3XV=ML0WQ4?'_ZT]<?3M^<YU\FA3J44GV(_!@G .&:P )O
MMCC":(^]A,P5/&&T(6 ^DA,*YH;L,2"?X@CYWCZ=@(7+*HGY1\X!ESFY6VC\
M,O7MG.\@=IF)"-K"IBNE0B-KI>E.,4U6<5RB8F!<M?EN#%JX8*H"J&5<1 MH
M1-U5L<@E)T Z?A$OP0^\<\832EMM45H#0;9M1?4'\QU.GB!WF+"6%\JB),L7
M=IJ/@)/KA4[M@\*-M*C1L66;%?I:!3P*IVJ 4XEX+88A,@ZQ@4>(?.^RT%7'
M5NI4T-J]Y6*;#)#9?4HO;&'>'?T*_5Q\Y[:F9A-F'J9YN[)54/#'=SB)B+84
MGR=$#[WSHO, /\1GLP\8!+]0X2Y&(3H,D7&(#D3%2'=/2?F.VM)? 0$VA<Z%
MEX!26A9_. _"72:IFI)_#E'5B XX0OD0E_)&L L>]TLW;-J8<?6(_1UM+KO;
M;#QH6Y(2K7<&U76(7C:/R ^YH?/@7,I;&NE/:[.!HS9THJ9'^41HL4;55 B>
M#<5D:![1G_-8C6)"MX]58Z)72K\9"BVV;:B2>>(T/2.:ZWX=)U+'3)7"!$-0
M8XPK>G7OAB<INO9NO?(W"[XK!)C\RBR^1J7$_ID-<-U>BK\-'OYE&[;:-]W4
MS57V R8:UVZ3.QR"])?+!.-YE&$":"8K8T=GY74+FS5]F?7OBB0H"L 1JK59
MK@%QA  ,!'"@ A $D#C57$?',X_)+!'7*K]6MPIW<[<$LB1805 !F!H^1@%Y
M#<"6BGN'%K#N#)OE<EV%-\)CY3J(+H1@I:/J3F?%OQ$LA.A*CJO)#XPW+K>-
M01J+ZL"!3;L9WU2S?9.-!:M.]TD^"ZJL?KE^MZB[2.A<;CE#:]L\NAO@S5Z/
M;>-LGU.NWE%F3L%LJ)@.T?D0F1#E,Z):!4XVIS-#KN.LJ5.+Q);629"KE&6-
M/_).RXNE,KE>#$>'MIAI5/YI[JY%-F6,V+S#\Z*[YW@+_<3G4;I+6!VA9!NS
MHH0W"=X$NTU'&>Q\'I1/A,J94&TJE,^%\LF<:H&Z.^>)6S/L6;2=%,;NFSBA
MZF:'A;DT\>??MPT@KLJ6'VR@=;BD&[7:5:3E7R 2F#SPLST$^6>SR <?*BV+
MKN5H*68A_X)YJ!>[G&D:/5&[=ZSDC^G E]47#M]9SM2I:_R)_DG>A!NQX8B-
M1VR"HUP!!?_9)_:%<YN5VEZYCPT-+-GM@,@8ZIIL?I<DDA-7>C/++UU3XQ!R
ML7_M<'>6K87&<4PLE(3<F5E"@P52VJIQ^>A%>4AAV05G'I&W:D0>+-0,4GO%
MC&C/8M"A&GB(PH<R B!:%.:M$D94 LFL8$?UMZ5C2ZA+$@E-84Y9QI87NE92
M2?[DJ=>1<OZX:4'=TK8$^[)H()KY?@ D]\(;+_#G4=Z#1BC@R\\1? ]A?_D(
MYX*>OQ&NO)?MV7)KX<)EE3]L.F-7*F]=,8(;Q^+877>X&ZFWCK]U>Q:6O^$D
MOHF#*+L.(KQ\3#!>QLM/[%?P-_B?7.K %XA^CV .1"=!RQB1:?+?TT_H_SL0
M2[:%DOIN6])*%U&V;@=I 4N>S;/F\J;U7_(A",8X(\Q !3M/[3[L=MMM2'4-
M+Z3]Z,+XTSQB:1 *=I+Z< 3C$4R :C-,2+HI[I6KJ>F@R=:QT:NOS#M'N1]H
M4?J!^%;F<I[)%"X>L0[UJ4WM[1IGP$XW2?P4^-A_M_^80K&G4D#D7LB@6Z\@
M,[$#6,P%[[K/83JBXWV!*HE93<D_F@X.ICX6>&?4%)=6C:)7<?0 DOX<WV>R
MNM3PW3%\@.#+H^;-YH)&AX#S*,#?G&4[S$V2VU'I$6=GGMGDA-5!BQ%,[A4V
MR=Q@Z13KXLWP\-^U=4N4H$*7JI>ELGD9/!%=\PX_81S17\(O%A&6J^5,#:_I
MY3 *U'(V4?X7^DLR5]M>8/^6TMEUZY[21YE-@HZ0+\=32<2^@CRJ3N@4)^M5
M*LL\*BR7Q9J-#!T7O/$"$QI/;0OOLYC:-%>T"6!$KO('LD)'E$1]#-BSBE&<
M^%L'$ERV(YX,[\: 70,7N5.V7N#G-IXSN?LH_[@P;1VALP,GDILKM+T!P>TI
MVJGE4]#R!+]/XE3H7>5ZR>D(Q^X6_C:47-^U#=NTAER1HX9QTSQ3%MK]X&5$
MK*H&Z[*ICM"!J>H(E?,=0:;U/:9V^"-4S"X-TG6A]^NCA/LT,,6LI:.7)MD_
M/@11L-EMY+=-_E'[<K%(FQ:P=8P+=F+1J%&+N08UXS$.?9RD3,&XCC-<*!V+
MA%:[3KL#WXM\-0A8KDV9EV+)%3V8^JC2 .,$L>GE8>^.X][U$,0U3?;#MDWQ
M6M,]6X'8 ,UKKG97J?A5M! WIL")=B?>$5^[Z\* 7>WN#H?DUP_O<03AF^1!
M,/,W1': >2PCS\W"LZ=8USV?C6@?;#X:F]><L?1Z'B$V*?HY_^]4+CPSE'!/
M9@_D6A37AUE_L]5JM]F%7D;>D7@=K ))=^S#E,?/:X-1/OJ+B>4_MO?'(YXJ
M5FPY>P;HI<PSMPBM*7/RD&8MB,O)P8("W\'\U-I2#J9+_+MM=1W55KT**E;N
MXNJ<@%6[RX[-MUQ/XA&81^&EYSO\$_82:K(=Z@D($[+0$[?N.&T$:#_XQ%AT
M[WN=1T\X;?H+#7VNY4PUGZOCNU!]SQH>5B'&;)Q:*K%I" V-Q.CL2LR[!*OA
M8N]",8>S6TYQCZW;3 LWMGVUN1Q8QK,5>; F6#M%J)@!!&D^QV&&T-&44H34
M=\PU46OBR^(!K)4K-@I%JN4FTY*&RI%(]L^AZE8Y1U$/2Q8O0U[HP&R7/<90
M(DD[<J(:Z3KF3[XOU2"*0TRXS:,D_RA^E]L0;C&4 J5/$?).379>J.<M@G^7
M?RB==\6LS(R3SSLUGY(2,I1\3AIHM?7H'[F/#3?^@C84Z$@9>Y>GC"%.RABB
M+33RQ4N!4+9S@7H4](\OO9O51'H1G=J/!VB)1X5,1-%-,15#?L>V5"\*7H*=
MNV@-(K=H8B"3;[6(!M[!/XC=H$*?97H6M\1A,(?[: [N!KMC.R1XL7JS"[5W
M27R<M/S!T4&0FQ,"B??$ITP7#BQ[Q$S%=9YY6Y, S=S;$7.TRRSL1AFO@T1L
MUS[OL? J-""/1T0+ZA^-XO">%>)1V$?NXU'JP+;B4=H[L?BVG4>K>(.)>J_H
MQF;?PZ-(S4GMXCB)]L0[#?+]6R1$*_JA^:[F77>\\ ^!>6$*X1]RTT+G_FVZ
MN6@TT&+],<54#5K<,W_W/+IX7CV"G"2O#('[1A@/ %,>Q^MC,BG3&E$Q+01F
M%Q/3[EJ'*;SEY*ZC!<S1P@TCZ(ME)Z7'&W!T5PV2.3AYE82<%B(7[(U'/$6$
M6*XX05\N8(["?JUC2T=D?OZ28\-0;1SG6>?FX,GWQ26/ B;LAV&8J)W-#&4]
M6UV_IT.K$O"LT7CYP%+WDMX-'3@=]-F@1#_+[UC0,NK;@ =VI8!WL1.GOCBO
MGX&K\GS\C7%IVH4'NP'09'M1QMSQ4+O^+,%^D,&_)-EMU1#:18!(;#HJ_V&B
M8;22K?)5XP[,N*GGW[Y=%$OUUS(6.)?NA"OQ=^V8>\8T\663EK.0MI'*?2@M
MX=Y1S;FSY4*K@+.;VFE*F^213@<]=B\P0;#991!YT6K(TBCEC"^H-(H$"SPJ
MF^+2JO8LJ.HG-W\>U#,\KNH9<MLO3:BPH5AE44"$S0*33*3?>:&7=+\SB\NN
M^)SWO'1! ^XFN,B7;->J#I(#0(LT/$AJ:\-W>^H&A.^HP66Q7@<KG,#MM IW
MX,6@&1J@C+R/8Y]^G+?>17=QZ#Q(ZW"O7!V#BP_+[G5J<6#F=+FAA7WC6"NH
M02LTG]0W\U(*9O,:@8&B EV<H.S4J8/V;L7Z!X6Z'/I:1\&LT&HR(AVM*B'J
M*0X]M4Y><LC4M4X)%C2TSDY<VJL<?!7\:Q<096M/;I7W,0&)FB&2B.,HY1G,
MRN$T&Y).@/(94,L<XRYB77&7=1+J8\=VH2C"6/ _"!=Z\D)(BJA:^<$?",S-
M7]2^9(6QR-67@%_G'+/_ELI2X9J#9I(7ZS46GW&8]XB=\MKTC4:,[!/0N Y^
MV1R1ES@K8$*?%U!]4=?B2@\J@(88;&XEA5TZ<"V'#CC!<OS_-L&K@-VJD3_;
M0&>G7^F/XB#_:L@1M"(+,=5S:"!_;3Q]+6R3V&?UQEQW3Q+NDT?W3K182W[Z
M&-&?L%]<8V_$W2WR+\M^8F^<EB1L0]ZZ!$2;LW=)MR!XK8[>U]-"[^MN]+YV
MCMZOU='[];30^W4W>K]V(, AC8CL"2ZB<_R$PYC&-]<>2#\&V6/>0?%]_$0T
M+/@EK24Q9Y$F?AX,S2_"PF:GPKTV?^-1^XFL@(K6E-4:1ZQR!RJ6.8@?=U*L
M90A<<2.Q!J2"P]/YE?KI_&I:I_.K[M/YE8/3*>T4S6J0]&RNS2:9?E_MVF9Y
M!T@/478#K_ #'-9;O 4E,'I@+U3EJF5T,"I'3S?J6VF?7!N=.H+<J<U"NVU;
MM)U.2[2==HLVF\9,/@0GZN@]F19Z3[K1>^) Z@A3USZF>+T+KX*UT$O4D<7'
M)D PPT2S^:HM\L2-,F:LTNO0S#./J NL:A!#TT$)N+7P):+R=1GZ.38[R'9@
MCL!:WQTZ.Z5T(_P:_ 0<N[^;G*(^^.$QPB HM]@FOEFA15HP*8C.XS#T$K A
M4AU(M;)-9XDIPCSYU& 69EKD5.K=Z*&D);?[X]>=>O)6_?Y\.ZW[\VWW_?G6
MN7KRC3IZOYD6>K_I1N\W+EJ-Z51@_!0/6\7R4^PX^$5S][S+RPB!CNJIYS&"
M[#&>URWR+^/D<I?MDK+]CSC)H)YE6P10YN:+8C::$,3F*^^PJ11?5]L^UWUH
MAD-[C=,/),FWZF+RVVF)R6^[Q>2W+FQ'5?)"%88$D2IJF1Y0#!SRF]_AB/PK
MH^^YHWILV-0:NBCNEVM%TD&5K1,R>WA(\(.78=HSB+P\5QC[PE*OY=>L0Q(J
MOG=9C8R_@]9ID6W4:KL 6@3_QB/O^R71U%./Q@ZDYT&Z"N.42,K.,Y-/@>@<
MJ#X)JF8AYV8R#5LT]LQW/6FBS.*+EQ8HB-<[68&"=ET"WM&J9CJL_3"OU7Z
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M=A^L+[PD(H"7B;>S#8 NK/A>F[RN=Q73(\ HJBT )[M8HDIP/D)L&=>=-(9
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M63_6W!XL'QN$B8W*>E@?)*N8W*TV>\ 'M]@\]1$>38DPOPZ?Q6H ?1/@>R/
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M)O.N_5#K*G[0:)=3ZF2BM"K&GJ;[:H12#Q"UDH?*"(<$4G;''C]()QLC]TN
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M@T643HS-[& D&'<(E%+9Q918RW7)*POJ;@D+G@L"GD\;<:"_U$<^EUJ919D
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M>9!_@H]?*0'%TMT61$"7W-@U# UXRA)M^;=L''HV(!W\Q5$?/DH$9GA):>,
M9EI7JV C2DP; DC)(%CJI5UJ^IL-.F+3)MVU].%4^.(PY@1Q=!&DCFQ.*E5#
M QKF.&*^M38E.'GAFG'T=C0*J&:]" SEP7SUD<2)U=T)-9I!->: -CC27Y^'
M[)JP-76',D<;8(^EYTYWV$^=G&!M/,!-!R3>-P$?;QC!E)J@73Y C_W WN<>
MS#'K>$WJ92S^*V8SYR:)/%O=^^&&I"[-5<+<.R<B8DKMH >]!8M#5O?=),Y$
MXP/.J#WOWTF43E29APTY"7D%#/'$0RD)(DG\HBLS(]R2B6A,,IV6;GU&W' 9
MR!7!$T&&P7K<+Q>#\S"/B/6.E+X4EO;G>D,]J$&X<DW8;0AC1I1>N7][.TP&
MP,@954^8G%\&D<+TS?@L\(#;,!:>M,%9UYD",'(F=A$K9Z=!"*^>G4.5>)TX
MT=VY'SXTUBV8FYS;A/(<AJV6=ZV@>KS <!4KUKMBX9IR8AQO;B)1$[?M$#-Q
M8[I.9T78V9@! F.QE5NXOG>+:9,8M07@\S%#S*6_VTPQX%W52NGO\ CK-G"I
M3TI8SD/<4V\%Q7'<L8I:P0Z3,$?>U?M?T/=@/1#<,)K- U<RLQLHC)W=\]&A
M@=CD-#BET7W6$7JZF$01B:-WP!+0 0S9.!A*%+I(;J (/J0B$9"E,)I["\4I
MX7!=FA(_\":KD,7T#QLZH0W2\U ,K;3&KM/9/17O/Q(77HBF[,1W*'@5LA[L
M9Z([-!D"E_!KV#.%$7[EG9+T__EN15O2W9:EQN-[*(PUY"2SUUNE%S;8#L]@
M(M:7:U"90# B=\7(O4/%@%2)1]:.DJ,O=Y5NQKJD*2&!W340XJRV"Y(:+PQ,
MXD;[1RN7; _?2_$_,]$D)EPD'$V!GEK:F,I"R/V H9BM1C3L9/7JAB>N&R9<
ME5XY&U&]*BPOUV4)*6[9NEI00N+IJP4U7F#FKM>0(:> %/@<4>BB8G6X3T2=
M&! <U\95#T.C/;Z,)5$-_,T%;C (+/,O@C6),%_@VA!X&B]PK21&J5?)$>:7
M6)[KY/Z>4$8XZEQTXXW(IXNY$A1)%O?%R7-0 W_5 >,J!/-34YH%K$%G+(]"
M?\=H^N%I7!*U%.T1C[!X261C./$NB38$GL8ET4IBU!G#'%.7$$^.YJ@MQX*^
M&SKA84<WS4])>4!\)UU1TW.*^&6!^[S.%EKUMX)Z>MRN4A.U1V&=(%Z(1'7'
M+U=Q#W#0Z^%B!@SL'?8&&F._HZIO&.WN?QH&8"U%>]2N0AB  D_Q7^&0K!U?
M."TS;J4RZF8)SMQ9*?^B\,FTSF4_'';VZ/J))R=TNG=.L"0S3KTS+N[@QN/
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M+\VLC&/Q7QS&G"">,IF(9\%,;89S, \I+:0RZ#T,^)!2QLCFBTHM)-P0?Z<
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M#-C(4HU%VQHQV8! YGV1_1S;!AW7\-7#.2I->P=.;],_+H[O,$I$ULX7[OF
MAZ#WEQ^A<]A^;BKT@>I=VOM54$*(B/OM,ER_\0A-@7BA*TO*WIR(]-J&M[^4
M"Q!0)HE'XXM@$;)5Z5FY"O#H3S^]$7\2M:7B7_\'4$L! A0#%     @ -8K5
M6.^1"\LR8P( O/(6 !D              ( !     &5A,#(P-S(P-BTQ,&M?
M;6]D=6QA<BYH=&U02P$"% ,4    "  UBM58XR;NG]<!   $!@  '0
M        @ %I8P( 96$P,C W,C V,#%E>#(Q+3%?;6]D=6QA<BYH=&U02P$"
M% ,4    "  UBM58H7"-ITT"  !&!P  '0              @ %[90( 96$P
M,C W,C V,#%E>#(S+3%?;6]D=6QA<BYH=&U02P$"% ,4    "  UBM58YW^$
M#T,'  !V(P  '0              @ $#: ( 96$P,C W,C V,#%E>#,Q+3%?
M;6]D=6QA<BYH=&U02P$"% ,4    "  UBM58B6*%(%@'  "C(P  '0
M        @ &!;P( 96$P,C W,C V,#%E>#,Q+3)?;6]D=6QA<BYH=&U02P$"
M% ,4    "  UBM58%].W7^X$   I&   '0              @ $4=P( 96$P
M,C W,C V,#%E>#,R+3%?;6]D=6QA<BYH=&U02P$"% ,4    "  UBM58]ULJ
MB"DS  !2)@$ '               @ $]? ( 96$P,C W,C V,#%E>#0M,5]M
M;V1U;&%R+FAT;5!+ 0(4 Q0    ( #6*U5@1E ;2:Q<  &EY   =
M      "  :"O @!E83 R,#<R,#8P,65X.3<M,5]M;V1U;&%R+FAT;5!+ 0(4
M Q0    ( #6*U5BIS=80AYP  %JK   -              "  4;' @!I;6%G
M95\P,#$N:G!G4$L! A0#%     @ -8K56%[*9_(6YP$ E_4!  T
M     ( !^&,# &EM86=E7S P,BYJ<&=02P$"% ,4    "  UBM585_^:Y\=9
M  ">8@  #0              @ $Y2P4 :6UA9V5?,# S+FIP9U!+ 0(4 Q0
M   ( #6*U5AJE-?BIP\  #,0   -              "  2NE!0!I;6%G95\P
M,#0N:G!G4$L! A0#%     @ -8K56&$,+6@V#P  NP\   T
M ( !_;0% &EM86=E7S P-2YJ<&=02P$"% ,4    "  UBM58>\L._>$+  "=
M#   #0              @ %>Q 4 :6UA9V5?,# V+FIP9U!+ 0(4 Q0    (
M #6*U5B* $^DA$<  !Y5   -              "  6K0!0!I;6%G95\P,#<N
M:G!G4$L! A0#%     @ -8K56/:+[L(C$@  1KT  !$              ( !
M&1@& &UO9&0M,C R-# S,S$N>'-D4$L! A0#%     @ -8K56!@@((QF"P
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I9&0M,C R-# S,S%?<')E+GAM;%!+!08     %  4 #L%  #8+P<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>ea0207206-10k_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:modd="http://www.modularmedicalinc.com/20240331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="modd-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">modd:WBernardoDriveSanDiegoCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">modd:ThornmintRoadSanDiegoCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-11-22</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="modd:AgreementAxis">modd:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">modd:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-02</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">modd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-02</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:IssuanceOfCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:IssuanceOfCommonStockWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercised1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockWarrantsExercised1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">modd:CommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-31</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">modd:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-28</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">modd:NonemployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToTwoPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ThreePointNineFiveToSeveenPointFiveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:EightPointSixOneToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">modd:DeviceIntegrationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:ManchesterManagementCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">modd:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-17620">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-17621">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-17622">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-17623">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-17624">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-17625">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-88">001-41277</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-97">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-110">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-116">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-17626">10470 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-17627">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-17628">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-140">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-17629">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-17630">800-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-186">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-191">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-17631">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-17632">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-17633">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-17634">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-17635">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-280">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-287">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-293">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-311">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-17636">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-17637">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-17638" unitRef="usd">17971555</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-17639"
      unitRef="shares">32536700</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0" id="ixv-17640">Farber Hass Hurley LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-17641">223</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-5949">Chatsworth, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-17642" unitRef="usd">9232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-17643" unitRef="usd">3799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-17644" unitRef="usd">465000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-17645" unitRef="usd">147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c4" decimals="-3" id="ixv-17646" unitRef="usd">100000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-17647" unitRef="usd">9697000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-17648" unitRef="usd">4046000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-17649" unitRef="usd">2975000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-17650" unitRef="usd">1721000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-17651" unitRef="usd">1135000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-17652" unitRef="usd">1478000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-17653" unitRef="usd">4110000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-17654" unitRef="usd">3199000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-17655" unitRef="usd">13807000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-17656" unitRef="usd">7245000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-17657" unitRef="usd">802000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="-3" id="ixv-17658" unitRef="usd">285000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-17659" unitRef="usd">280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-17660" unitRef="usd">339000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-17661" unitRef="usd">373000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-17662" unitRef="usd">355000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-17663" unitRef="usd">1455000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-17664" unitRef="usd">979000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-17665" unitRef="usd">817000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-17666" unitRef="usd">1190000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-17667" unitRef="usd">2272000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" id="ixv-17668" unitRef="usd">2169000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-17669"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-17670"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="-3"
      id="ixv-17671"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="-3"
      id="ixv-17672"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-17673"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-17674"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="-3"
      id="ixv-17675"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="-3"
      id="ixv-17676"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="-3"
      id="ixv-17677"
      unitRef="shares">32464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="-3"
      id="ixv-17678"
      unitRef="shares">32464000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="-3"
      id="ixv-17679"
      unitRef="shares">10949000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="-3"
      id="ixv-17680"
      unitRef="shares">10949000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-17681" unitRef="usd">32000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" id="ixv-17682" unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-17683" unitRef="usd">77432000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-17684" unitRef="usd">53524000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-17685" unitRef="usd">-65929000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" id="ixv-17686" unitRef="usd">-48459000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-17687" unitRef="usd">11535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-17688" unitRef="usd">5076000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-17689" unitRef="usd">13807000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-17690" unitRef="usd">7245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-17691" unitRef="usd">12880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-17692" unitRef="usd">9062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-17693" unitRef="usd">4649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-17694" unitRef="usd">4816000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-17695" unitRef="usd">17529000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="-3" id="ixv-17696" unitRef="usd">13878000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-17697" unitRef="usd">-17529000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" id="ixv-17698" unitRef="usd">-13878000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome contextRef="c0" decimals="-3" id="ixv-17699" unitRef="usd">61000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c5" decimals="-3" id="ixv-17700" unitRef="usd">1000</us-gaap:OtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-17701" unitRef="usd">-17468000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-17702" unitRef="usd">-13877000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-17703" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-17704" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-17705" unitRef="usd">-17470000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-17706" unitRef="usd">-13879000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-17707"
      unitRef="usdPershares">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-17708"
      unitRef="usdPershares">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="-3"
      id="ixv-17709"
      unitRef="shares">22377000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="-3"
      id="ixv-17710"
      unitRef="shares">12103000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c6"
      decimals="-3"
      id="ixv-17711"
      unitRef="shares">10462000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" id="ixv-17712" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" id="ixv-17713" unitRef="usd">43406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" id="ixv-17714" unitRef="usd">-34580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-17715" unitRef="usd">8837000</us-gaap:StockholdersEquity>
    <modd:IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet
      contextRef="c10"
      decimals="-3"
      id="ixv-17716"
      unitRef="shares">449000</modd:IssuanceOfCommonStockAndWarrantsSharesInEquityOfferingNet>
    <modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet contextRef="c11" decimals="-3" id="ixv-17717" unitRef="usd">7372000</modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet>
    <modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet contextRef="c5" decimals="-3" id="ixv-17718" unitRef="usd">7372000</modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c10"
      decimals="-3"
      id="ixv-17719"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c11" decimals="-3" id="ixv-17720" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="-3" id="ixv-17721" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c10"
      decimals="-3"
      id="ixv-17722"
      unitRef="shares">27000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="-3" id="ixv-17723" unitRef="usd">86000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" id="ixv-17724" unitRef="usd">86000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c11" decimals="-3" id="ixv-17725" unitRef="usd">2638000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="-3" id="ixv-17726" unitRef="usd">2638000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-17727" unitRef="usd">-13879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-17728" unitRef="usd">-13879000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c13"
      decimals="-3"
      id="ixv-17729"
      unitRef="shares">10949000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-17730" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-17731" unitRef="usd">53524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-17732" unitRef="usd">-48459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-17733" unitRef="usd">5076000</us-gaap:StockholdersEquity>
    <modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares
      contextRef="c16"
      decimals="-3"
      id="ixv-17734"
      unitRef="shares">20552000</modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCostsinShares>
    <modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts contextRef="c16" decimals="-3" id="ixv-17735" unitRef="usd">20000</modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts>
    <modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts contextRef="c17" decimals="-3" id="ixv-17736" unitRef="usd">20045000</modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts>
    <modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts contextRef="c0" decimals="-3" id="ixv-17737" unitRef="usd">20065000</modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c16"
      decimals="-3"
      id="ixv-17738"
      unitRef="shares">154000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <modd:AtthemarketSalesOfStockNet contextRef="c17" decimals="-3" id="ixv-17739" unitRef="usd">278000</modd:AtthemarketSalesOfStockNet>
    <modd:AtthemarketSalesOfStockNet contextRef="c0" decimals="-3" id="ixv-17740" unitRef="usd">278000</modd:AtthemarketSalesOfStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c16"
      decimals="-3"
      id="ixv-17741"
      unitRef="shares">719000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c16" decimals="-3" id="ixv-17742" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c17" decimals="-3" id="ixv-17743" unitRef="usd">883000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-17744" unitRef="usd">884000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c16"
      decimals="-3"
      id="ixv-17745"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c17" decimals="-3" id="ixv-17746" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="-3" id="ixv-17747" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c16"
      decimals="-3"
      id="ixv-17748"
      unitRef="shares">88000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c17" decimals="-3" id="ixv-17749" unitRef="usd">37000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-17750" unitRef="usd">37000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c17" decimals="-3" id="ixv-17751" unitRef="usd">2664000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-17752" unitRef="usd">2664000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="-3" id="ixv-17753" unitRef="usd">-17470000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-17754" unitRef="usd">-17470000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c19"
      decimals="-3"
      id="ixv-17755"
      unitRef="shares">32464000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-17756" unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-17757" unitRef="usd">77432000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-17758" unitRef="usd">-65929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-17759" unitRef="usd">11535000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-17760" unitRef="usd">-17470000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-17761" unitRef="usd">-13879000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-17762" unitRef="usd">2701000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" id="ixv-17763" unitRef="usd">2724000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c0" decimals="-3" id="ixv-17764" unitRef="usd">-21000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-17765" unitRef="usd">426000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="-3" id="ixv-17766" unitRef="usd">152000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="-3" id="ixv-17767" unitRef="usd">19000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c5" decimals="-3" id="ixv-17768" unitRef="usd">203000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-17769" unitRef="usd">94000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" id="ixv-17770" unitRef="usd">14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <modd:IncreaseDecreaseLeaseRightofuseAsset contextRef="c0" decimals="-3" id="ixv-17771" unitRef="usd">342000</modd:IncreaseDecreaseLeaseRightofuseAsset>
    <modd:IncreaseDecreaseLeaseRightofuseAsset contextRef="c5" decimals="-3" id="ixv-17772" unitRef="usd">203000</modd:IncreaseDecreaseLeaseRightofuseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-17773" unitRef="usd">458000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="-3" id="ixv-17774" unitRef="usd">-200000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-17775" unitRef="usd">-355000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-17776" unitRef="usd">-200000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-17777" unitRef="usd">-13952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-17778" unitRef="usd">-11011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-17779" unitRef="usd">1700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-17780" unitRef="usd">1638000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-17781" unitRef="usd">-1700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-17782" unitRef="usd">-1638000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-17783" unitRef="usd">278000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" id="ixv-17784" unitRef="usd">742000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c0" decimals="-3" id="ixv-17785" unitRef="usd">20065000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c5" decimals="-3" id="ixv-17786" unitRef="usd">7372000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-17787" unitRef="usd">21085000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-17788" unitRef="usd">7372000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-17789" unitRef="usd">5433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="-3" id="ixv-17790" unitRef="usd">-5277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-17791" unitRef="usd">3799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="-3" id="ixv-17792" unitRef="usd">9076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-17793" unitRef="usd">9232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-17794" unitRef="usd">3799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <modd:RightofuseAssetObtainedInExchangeForLeaseLiability contextRef="c5" decimals="-3" id="ixv-17795" unitRef="usd">1561000</modd:RightofuseAssetObtainedInExchangeForLeaseLiability>
    <modd:ReceivableFromTransferAgentForWarrantExerciseProceeds contextRef="c0" decimals="-3" id="ixv-17796" unitRef="usd">142000</modd:ReceivableFromTransferAgentForWarrantExerciseProceeds>
    <us-gaap:IncomeTaxesPaidNet contextRef="c0" decimals="-3" id="ixv-17797" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c5" decimals="-3" id="ixv-17798" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0" id="ixv-8448">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 1
&#x2013; THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a
Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange
was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger,
at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company,
as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed
its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin
pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part
patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access
to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and
streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand
the wearable insulin delivery device market beyond the highly motivated &#x201c;super users&#x201d; and expand the category into the mass
market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the
MODD1. In March 2024, the Company received comments from the FDA on its submission, and the Company is in the process of responding to
those comments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Liquidity
and Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and
general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue
to achieve profitability. The Company&#x2019;s expected operating losses and cash burn raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company&#x2019;s
independent registered public accounting firm, in its report on these consolidated financial statements for the year ended March 31,
2024, expressed substantial doubt about the Company&#x2019;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from this uncertainty. Implementation of the Company&#x2019;s plans and its ability to
continue as a going concern will depend upon the Company&#x2019;s ability to raise additional capital, through the sale of additional
equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form
of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions
acceptable to the Company. In, May 2023 and February 2024, the Company completed public offerings of its common stock and warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2024 refers to the fiscal year ending March 31, 2024). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Use of
Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reportable
Segment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company
operates in one business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;General
and Administrative&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;General and administrative expenses consist primarily of payroll and
benefit costs, rent, stock-based compensation, legal and accounting fees, and facility and other administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentration
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains its cash
at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Risks
and Uncertainties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Economic
Disruptions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in- place&#x201d; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#x201c;shelter-in-place&#x201d;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#x2019;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may
be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly
detrimental to its existing stockholders and to its business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash and
Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash held in
demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of
three months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Property
and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are recorded at historical
cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five
years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets
acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is
recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment
and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended
use and placed into service.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value
of Financial Instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB)
ASC No. 842, &lt;i&gt;Leases&lt;/i&gt;, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease
contracts. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liability
represents the Company&#x2019;s obligation to make lease payments arising from the lease, both of which are recognized based on the present
value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less
at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the
consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases
where the lease does not provide an implicit interest rate, the Company uses the Company&#x2019;s incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. We account for such
awards based on Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 718, whereby the value of the award
is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually
the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance
criteria before recognizing compensation expense. The fair value of the Company&#x2019;s stock options is estimated using the Black-Scholes-Merton
Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected
life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model.
The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Per-Share
Amounts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO)
during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding
for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options
and exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prior
to April 1, 2023, the Company excluded pre-funded warrants from the computation of WASO. The pre-funded warrants are now included in
the computation of WASO. Prior period amounts have been conformed to the current-period presentation. The impact of the change reduced
the previously reported loss per share by $0.13 and increased WASO by approximately 1,223,000 shares for the year ended March 31, 2023.
The reclassification had no impact on the Company&#x2019;s net loss or cash flows for the year ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,481&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,173&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,217&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company&#x2019;s historical
net operating loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the
year in which such tax attributes are utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Comprehensive
Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2024 and 2023, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;,
which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective
application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU
will have on the presentation of its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S.
and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently
evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <modd:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-8463">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Liquidity
and Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development and
general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue
to achieve profitability. The Company&#x2019;s expected operating losses and cash burn raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company&#x2019;s
independent registered public accounting firm, in its report on these consolidated financial statements for the year ended March 31,
2024, expressed substantial doubt about the Company&#x2019;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from this uncertainty. Implementation of the Company&#x2019;s plans and its ability to
continue as a going concern will depend upon the Company&#x2019;s ability to raise additional capital, through the sale of additional
equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form
of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions
acceptable to the Company. In, May 2023 and February 2024, the Company completed public offerings of its common stock and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;</modd:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-8479">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in
these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example,
fiscal 2024 refers to the fiscal year ending March 31, 2024). The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-8507">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Use of
Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the
reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could
differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-8519">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reportable
Segment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company
operates in one business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-8531">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0" id="ixv-8543">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;General
and Administrative&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;General and administrative expenses consist primarily of payroll and
benefit costs, rent, stock-based compensation, legal and accounting fees, and facility and other administrative expenses.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-8554">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentration
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains its cash
at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation
(FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial
institution failure.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c0" decimals="0" id="ixv-17799" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="c0" id="ixv-8565">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Risks
and Uncertainties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Economic
Disruptions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in- place&#x201d; and created significant
disruption of the financial markets. While the U.S. national emergency expired in May 2023 and substantially all closures and &#x201c;shelter-in-place&#x201d;
orders have ended, there can be no assurance that the COVID-19 pandemic will not impact the Company&#x2019;s operational and financial
performance in the future, as the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies
to prevent disease spread are uncertain, out of our control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Wars
and acts of terrorism have led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively
impacted the global economy. Since mid-2022, at times, the U.S. Federal Reserve has addressed elevated inflation by increasing interest
rates, as inflation remains elevated. While the Company was recently able to access the capital markets, in the future, the Company may
be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly
detrimental to its existing stockholders and to its business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-8609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash and
Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash held in
demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of
three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-8620">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Property
and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are recorded at historical
cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five
years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets
acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is
recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment
and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended
use and placed into service.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c22" id="ixv-17800">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c23" id="ixv-17801">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-8631">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value
of Financial Instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due
to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-8678">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB)
ASC No. 842, &lt;i&gt;Leases&lt;/i&gt;, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease
contracts. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liability
represents the Company&#x2019;s obligation to make lease payments arising from the lease, both of which are recognized based on the present
value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less
at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the
consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases
where the lease does not provide an implicit interest rate, the Company uses the Company&#x2019;s incremental borrowing rate based on
the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0" id="ixv-8691">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. We account for such
awards based on Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 718, whereby the value of the award
is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually
the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance
criteria before recognizing compensation expense. The fair value of the Company&#x2019;s stock options is estimated using the Black-Scholes-Merton
Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected
life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model.
The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-8719">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Per-Share
Amounts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO)
during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding
for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options
and exercise of warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prior
to April 1, 2023, the Company excluded pre-funded warrants from the computation of WASO. The pre-funded warrants are now included in
the computation of WASO. Prior period amounts have been conformed to the current-period presentation. The impact of the change reduced
the previously reported loss per share by $0.13 and increased WASO by approximately 1,223,000 shares for the year ended March 31, 2023.
The reclassification had no impact on the Company&#x2019;s net loss or cash flows for the year ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,481&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,173&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,217&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="c24"
      decimals="2"
      id="ixv-17803"
      unitRef="usdPershares">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="c24"
      decimals="0"
      id="ixv-17804"
      unitRef="shares">1223000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-8738">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,481&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,173&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,217&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,049&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,698&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c25"
      decimals="-3"
      id="ixv-17805"
      unitRef="shares">3689000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c26"
      decimals="-3"
      id="ixv-17806"
      unitRef="shares">2481000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c27"
      decimals="-3"
      id="ixv-17807"
      unitRef="shares">187000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c29"
      decimals="-3"
      id="ixv-17808"
      unitRef="shares">11173000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c30"
      decimals="-3"
      id="ixv-17809"
      unitRef="shares">6217000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-17810"
      unitRef="shares">15049000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="-3"
      id="ixv-17811"
      unitRef="shares">8698000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0" id="ixv-8848">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-8859">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect
taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion
of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more
likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation
allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertain tax positions in accordance with FASB ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. When tax returns are filed,
it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as
described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with
any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized
tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. The Company&#x2019;s historical
net operating loss and credit carryforwards may be adjusted by the federal and state tax authorities until the statute closes on the
year in which such tax attributes are utilized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0" id="ixv-8882">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Comprehensive
Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2024 and 2023, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <modd:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-8910">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;,
which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective
application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU
will have on the presentation of its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S.
and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently
evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</modd:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c0" id="ixv-8930">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2 &#x2013; CONSOLIDATED BALANCE SHEET DETAIL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Prepaid and other current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receivable from transfer agent for warrant exercise proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;465&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,209&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;820&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,654&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,977&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: accumulated depreciation
    and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(256&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,975&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,721&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued wages&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;280&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-8938">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Prepaid and other current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receivable from transfer agent for warrant exercise proceeds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;465&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="-3" id="ixv-17812" unitRef="usd">318000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-17813" unitRef="usd">142000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c3" decimals="-3" id="ixv-17814" unitRef="usd">142000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="-3" id="ixv-17815" unitRef="usd">5000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="-3" id="ixv-17816" unitRef="usd">5000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-17817" unitRef="usd">465000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-17818" unitRef="usd">147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-9012">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,209&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;820&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,003&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,654&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,977&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: accumulated depreciation
    and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(679&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(256&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,975&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,721&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c31" decimals="-3" id="ixv-17819" unitRef="usd">3209000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c32" decimals="-3" id="ixv-17820" unitRef="usd">820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c33" decimals="-3" id="ixv-17821" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c34" decimals="-3" id="ixv-17822" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c35" decimals="-3" id="ixv-17823" unitRef="usd">283000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c36" decimals="-3" id="ixv-17824" unitRef="usd">1003000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c37" decimals="-3" id="ixv-17825" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c38" decimals="-3" id="ixv-17826" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c39" decimals="-3" id="ixv-17827" unitRef="usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="-3" id="ixv-17828" unitRef="usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" id="ixv-17829" unitRef="usd">3654000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-17830" unitRef="usd">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-17831" unitRef="usd">679000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-17832" unitRef="usd">256000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-17833" unitRef="usd">2975000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-17834" unitRef="usd">1721000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-9209">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued wages&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;280&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;339&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c3" decimals="-3" id="ixv-17835" unitRef="usd">243000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c4" decimals="-3" id="ixv-17836" unitRef="usd">267000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-17837" unitRef="usd">37000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-17838" unitRef="usd">72000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-17839" unitRef="usd">280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-17840" unitRef="usd">339000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-9321">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 3
&#x2013; LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;W.
Bernardo Drive, San Diego, CA&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
39-month lease term expired on June 30, 2023, and, subsequent to expiration, the landlord refunded the Company&#x2019;s security deposit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Thornmint
Road, San Diego, CA&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases
of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and other certain
operating costs. A discount rate of 8%, which approximated the Company&#x2019;s incremental borrowing rate, was used to measure the lease
asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the
operating lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Future minimum
payments under the facility operating lease, as of March 31, 2024, are listed in the table below (in thousands).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal year
    ending March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:&#160;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(137&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
paid for amounts included in the measurement of lease liabilities was approximately $476,000 and $230,000 for the years ended March 31,
2024 and 2023, respectively. Rent expense was approximately $449,000 and $237,000 for the years ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c41" id="ixv-17841">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <modd:OperatingLeaseExpiredTerm contextRef="c0" id="ixv-17842">2023-06-30</modd:OperatingLeaseExpiredTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c42" id="ixv-17843">P48M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent contextRef="c43" decimals="0" id="ixv-17844" unitRef="usd">36000</us-gaap:PaymentsForRent>
    <modd:PercentageOfAnnualRentIncreases contextRef="c44" decimals="2" id="ixv-17845" unitRef="pure">0.04</modd:PercentageOfAnnualRentIncreases>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c3" decimals="2" id="ixv-17846" unitRef="pure">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-17847" unitRef="usd">1560000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-9365">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Future minimum
payments under the facility operating lease, as of March 31, 2024, are listed in the table below (in thousands).&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal year
    ending March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;405&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:&#160;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(137&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-17848" unitRef="usd">452000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-17849" unitRef="usd">470000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-17850" unitRef="usd">405000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-17851" unitRef="usd">1327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-17852" unitRef="usd">137000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-17853" unitRef="usd">1190000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-17854" unitRef="usd">476000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="0" id="ixv-17855" unitRef="usd">230000</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" id="ixv-17856" unitRef="usd">449000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c5" decimals="0" id="ixv-17857" unitRef="usd">237000</us-gaap:PaymentsForRent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-9454">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Increase
in Authorized Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2024, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Articles of Incorporation (the Amendment)
to increase the number of authorized shares of common stock from 50,000,000 shares, to 100,000,000 shares. The Amendment was filed with
the state of Nevada and became effective on February 15, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;February
2024 Public Offering &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 15, 2024, the Company entered into
an underwriting agreement (the 2024 Underwriting Agreement) with Titan Partners Group LLC, a division of American Capital Partners, LLC
(Titan), with respect to the issuance and sale 9,090,910 shares of its common stock at a price of $1.10 per share in a firm commitment
underwritten offering (the 2024 Offering) by the Company. Upon the closing of the 2024 Offering, the Company received aggregate proceeds
of approximately $10,000,000, before deducting underwiring discounts and commissions and other offering expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the 2024 Underwriting Agreement,
the Company granted Titan a 30-day option to purchase up to an additional 1,321,989 shares of common stock to cover over allotments,
if any. On March 13, 2024, Titan exercised this option in full and purchased the additional securities for aggregate proceeds to the
Company of approximately $1,454,000 before deducting underwriting discounts and commissions and other offering expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Titan
was paid a cash fee of 7.0% of the aggregate gross proceeds of the 2024 Offering (including the over-allotment option) and reimbursed
certain out-of-pocket expenses of approximately $75,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;ATM Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
November 22, 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the
Company may offer and sell, from time to time at its sole discretion, shares of its common stock, for aggregate gross proceeds of up
to $6,500,000 through an &#x201c;at the market offering&#x201d; program under which Leerink will act as sales agent or principal. The ATM
Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any
shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at
any time, suspend solicitation and offers under the ATM Agreement. In January 2024, under the ATM Agreement, the Company sold 153,879
shares of common stock for net proceeds of approximately $278,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;May
2023 Public Offering &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 15, 2023, the Company entered into an underwriting
agreement (the Underwriting Agreement) with Newbridge Securities Corporation (the Underwriter), with respect to the issuance and sale
in a firm commitment underwritten offering (the 2023 Offering) by the Company of units of its securities. Upon the closing of the 2023
Offering, the Company sold 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock for aggregate
proceeds of approximately $9,390,000, before deducting underwriting discounts and commissions and other offering expenses. The securities
were sold as a unit, with each unit consisting of two shares of common stock of the Company and one warrant (the 2023 Warrants) to purchase
one share of common stock, at a public offering price of $2.13 per unit. The 2023 Warrants were immediately separable and exercisable,
have a per share exercise price of $1.22 and expire five years from the date of issuance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares of
common stock and an additional 661,267 of the 2023 Warrants to cover over-allotments, if any. On May 25, 2023, the Underwriter exercised
this option in full and purchased the additional securities for aggregate gross proceeds to the Company of approximately $1,408,000,
before deducting underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Underwriter was paid a cash fee of 7.0% of the aggregate gross proceeds of the 2023 Offering (including the over-allotment option) and
reimbursed certain out-of-pocket expenses of approximately $125,000. In addition, pursuant to the Underwriting Agreement, the Company
initially issued to the Underwriter common stock purchase warrants (the UW Warrants) for a total of 709,760 shares. Subsequently, the
UW Warrants were reissued to the Underwriter and its agents for a total of 604,623 shares. The UW warrants were exercisable six months
from the respective issuance dates and have a four-year term and a per share exercise price of $1.32.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;May 2022
Placement &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
May 2, 2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant
to which the Company sold, in a registered direct offering, which closed on May 5, 2022, an aggregate of 449,438 shares (the Shares)
of the Company&#x2019;s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of approximately 1,348,000 shares of common stock at a purchase price per Pre-Funded Warrant
of $4.44. The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and
may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In a concurrent private placement under the
Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase an aggregate of 1,438,202
shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants were exercisable beginning on the six-month
anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary of the Initial Exercise
Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuances
of Common Stock and Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the years ended March 31, 2024 and 2023, the Company issued 1,429 and 11,264 shares of common stock to service providers, respectively,
with fair values of approximately $1,400 and $22,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;br/&gt; Dates&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,565&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of common stock warrants&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;605&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2027&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of common stock warrants&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,070&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2028&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock warrants exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock warrants exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(649&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,521&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised
prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of March 31, 2023, the Company had the following warrants outstanding (share amounts in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration &lt;br/&gt; Dates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January&#160;-&#160;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;November 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c45"
      decimals="0"
      id="ixv-17858"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c46"
      decimals="0"
      id="ixv-17859"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c47"
      decimals="0"
      id="ixv-17860"
      unitRef="shares">9090910</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="c48"
      decimals="2"
      id="ixv-17861"
      unitRef="usdPershares">1.1</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c0" decimals="0" id="ixv-17862" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="c49"
      decimals="0"
      id="ixv-17863"
      unitRef="shares">1321989</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c50" decimals="0" id="ixv-17864" unitRef="usd">1454000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <modd:CashFee contextRef="c0" decimals="3" id="ixv-17865" unitRef="pure">0.07</modd:CashFee>
    <us-gaap:OtherExpenses contextRef="c0" decimals="0" id="ixv-17866" unitRef="usd">75000</us-gaap:OtherExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c51" decimals="0" id="ixv-17867" unitRef="usd">6500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <modd:compensationServicesEqual contextRef="c51" decimals="3" id="ixv-17868" unitRef="pure">0.03</modd:compensationServicesEqual>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c52"
      decimals="0"
      id="ixv-17869"
      unitRef="shares">153879</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c52" decimals="0" id="ixv-17870" unitRef="usd">278000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c53"
      decimals="0"
      id="ixv-17871"
      unitRef="shares">8816900</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c54"
      decimals="0"
      id="ixv-17872"
      unitRef="shares">4408450</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c55" decimals="0" id="ixv-17873" unitRef="usd">9390000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c56"
      decimals="2"
      id="ixv-17874"
      unitRef="usdPershares">2.13</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c57"
      decimals="2"
      id="ixv-17875"
      unitRef="usdPershares">1.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LongTermDebtTerm contextRef="c57" id="ixv-17876">P5Y</us-gaap:LongTermDebtTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c58"
      decimals="0"
      id="ixv-17877"
      unitRef="shares">1322534</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c59"
      decimals="0"
      id="ixv-17878"
      unitRef="shares">661267</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c60" decimals="0" id="ixv-17879" unitRef="usd">1408000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <modd:PaymentOfUnderwriterPercentage contextRef="c3" decimals="3" id="ixv-17880" unitRef="pure">0.07</modd:PaymentOfUnderwriterPercentage>
    <us-gaap:DeferredOfferingCosts contextRef="c61" decimals="0" id="ixv-17881" unitRef="usd">125000</us-gaap:DeferredOfferingCosts>
    <modd:WarrantsToPurchaseSharesOfCommonStock
      contextRef="c29"
      decimals="0"
      id="ixv-17882"
      unitRef="shares">709760</modd:WarrantsToPurchaseSharesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="c62"
      decimals="0"
      id="ixv-17883"
      unitRef="shares">604623</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c63"
      decimals="2"
      id="ixv-17884"
      unitRef="usdPershares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c64"
      decimals="0"
      id="ixv-17885"
      unitRef="shares">449438</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c65"
      decimals="3"
      id="ixv-17886"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <modd:PurchasePricePerShare
      contextRef="c64"
      decimals="2"
      id="ixv-17887"
      unitRef="usdPershares">4.45</modd:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c65"
      decimals="0"
      id="ixv-17888"
      unitRef="shares">1348000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <modd:PreFundedWarrant
      contextRef="c65"
      decimals="2"
      id="ixv-17889"
      unitRef="usdPershares">4.44</modd:PreFundedWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c66"
      decimals="2"
      id="ixv-17890"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c67"
      decimals="0"
      id="ixv-17891"
      unitRef="shares">1438202</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c65"
      decimals="2"
      id="ixv-17892"
      unitRef="usdPershares">6.6</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensation contextRef="c16" decimals="0" id="ixv-17893" unitRef="usd">1429</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="0" id="ixv-17894" unitRef="usd">11264</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c68" decimals="0" id="ixv-17895" unitRef="usd">1400</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c69" decimals="0" id="ixv-17896" unitRef="usd">22000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-9549">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;br/&gt; Dates&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,565&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of common stock warrants&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;605&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2027&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of common stock warrants&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,070&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2028&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock warrants exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(70&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.32&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock warrants exercised&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(649&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,521&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of March 31, 2023, the Company had the following warrants outstanding (share amounts in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration &lt;br/&gt; Dates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;768&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January&#160;-&#160;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,011&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,438&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;November 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c70"
      decimals="-3"
      id="ixv-17897"
      unitRef="shares">7565000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <modd:NumberOfSharesIssuanceOfCommonStockWarrants
      contextRef="c71"
      decimals="-3"
      id="ixv-17898"
      unitRef="shares">605000</modd:NumberOfSharesIssuanceOfCommonStockWarrants>
    <modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare
      contextRef="c71"
      decimals="2"
      id="ixv-17899"
      unitRef="usdPershares">1.32</modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare>
    <modd:ExpirationIssuanceOfCommonStockWarrants contextRef="c71" id="ixv-9632">May 2027</modd:ExpirationIssuanceOfCommonStockWarrants>
    <modd:NumberOfSharesIssuanceOfCommonStockWarrants
      contextRef="c72"
      decimals="-3"
      id="ixv-17900"
      unitRef="shares">5070000</modd:NumberOfSharesIssuanceOfCommonStockWarrants>
    <modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare
      contextRef="c72"
      decimals="2"
      id="ixv-17901"
      unitRef="usdPershares">1.22</modd:ExercisePricesIssuanceOfCommonStockWarrantsinDollarsPerShare>
    <modd:ExpirationIssuanceOfCommonStockWarrants contextRef="c72" id="ixv-9660">May 2028</modd:ExpirationIssuanceOfCommonStockWarrants>
    <modd:NumberOfSharesCommonStockWarrantsExercised
      contextRef="c73"
      decimals="-3"
      id="ixv-17902"
      unitRef="shares">-70000</modd:NumberOfSharesCommonStockWarrantsExercised>
    <modd:ExercisePricesCommonStockWarrantsExercised
      contextRef="c74"
      decimals="2"
      id="ixv-17903"
      unitRef="usdPershares">1.32</modd:ExercisePricesCommonStockWarrantsExercised>
    <modd:NumberOfSharesCommonStockWarrantsExercised
      contextRef="c75"
      decimals="-3"
      id="ixv-17904"
      unitRef="shares">-649000</modd:NumberOfSharesCommonStockWarrantsExercised>
    <modd:ExercisePricesCommonStockWarrantsExercised
      contextRef="c76"
      decimals="2"
      id="ixv-17905"
      unitRef="usdPershares">1.22</modd:ExercisePricesCommonStockWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c63"
      decimals="-3"
      id="ixv-17906"
      unitRef="shares">12521000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c29" decimals="0" id="ixv-17907" unitRef="usd">142000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c77"
      decimals="-3"
      id="ixv-17908"
      unitRef="shares">1348000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c77"
      decimals="2"
      id="ixv-17909"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c79"
      decimals="-3"
      id="ixv-17910"
      unitRef="shares">768000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c79"
      decimals="2"
      id="ixv-17911"
      unitRef="usdPershares">6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <modd:ExpirationCommonStock contextRef="c80" id="ixv-9824">January&#160;-&#160;February 2027</modd:ExpirationCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c81"
      decimals="-3"
      id="ixv-17912"
      unitRef="shares">4011000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c81"
      decimals="2"
      id="ixv-17913"
      unitRef="usdPershares">6.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <modd:ExpirationCommonStock contextRef="c82" id="ixv-9848">February 2027</modd:ExpirationCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c83"
      decimals="-3"
      id="ixv-17914"
      unitRef="shares">1438000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c83"
      decimals="2"
      id="ixv-17915"
      unitRef="usdPershares">6.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <modd:ExpirationCommonStock contextRef="c84" id="ixv-9872">November 2027</modd:ExpirationCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c70"
      decimals="-3"
      id="ixv-17916"
      unitRef="shares">7565000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-9901">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 5
&#x2013; STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amended
2017 Equity Incentive Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
October 2017, the Company&#x2019;s Board approved the 2017 Equity Incentive Plan (the Plan) with 1,000,000 shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Company&#x2019;s stockholders approved increases
in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the
Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation
rights, restricted stock, performance-based awards and restricted stock units (RSUs). The Plan is administered by the Board or, in the
alternative, a committee designated by the Board.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based
Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
options granted by the Company generally vest over 36 months and have a 10-year term. As of March 31, 2024, the unamortized compensation
cost related to stock options was approximately $2,035,000 and is expected to be recognized as expense over a weighted-average period
of approximately 1.3 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock
options for&#160;909,533&#160;shares, which are subject to vesting based upon the achievement of certain performance milestones by the
Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were
granted under part one of the Bonus Program, vested upon the Company&#x2019;s submission to the FDA. As of March 31, 2024, the Company
had not commenced expense recognition of&#160;242,307 (net of forfeitures)&#160;of the options, which were granted under part two of
the Bonus Program, based on its assessment of the probability of achievement of the applicable performance requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended March 31, 2024, the Company granted options to purchase 127,500 shares that vested immediately when granted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted-average grant date fair values of stock options granted during the years ended March 31, 2024 and 2023 was $0.99 and $2.85,
respectively. The following assumptions were used in the fair-value method calculations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    Ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.51% - 4.72%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.82% - 4.06%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 152%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 223%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 - 6.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 &#x2013; 5.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options. The expected volatility is based on the historical volatility of the Company&#x2019;s stock price.
The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury
as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has
never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the shares available for grant under the Plan during the year ended March 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;for
                                            Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;989,466&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,650,705&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional shares authorized
    under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,006,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,006,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,789&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled and
    returned to the Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;175,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(175,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,132,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,481,090&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional shares authorized
    under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,448,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,448,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled and
    returned to the Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(240,282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,648,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689,341&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;No
stock options were exercised during the years ended March 31, 2024 and 2023. During the years ended March 31, 2024 and 2023, the Company
issued 25,390 and 26,789 shares, respectively, to its non-employee directors under the Company&#x2019;s outside director compensation
plan. For the years ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately
$37,000 and $86,000, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
summary of RSU activity under the Plan is presented below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Grant-&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;187,499&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
total intrinsic value of RSUs outstanding as of March 31, 2024 was approximately $347,000. The unamortized compensation cost at March
31, 2024 was approximately $171,000&#160;related to RSUs and is expected to be recognized as expense over a period of approximately&#160;2.25&#160;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the range of outstanding and exercisable options as of March 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range of Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$0.93 - $2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,237,066&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,409,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,006&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$3.95 - $7.51&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;943,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.29&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;771,478&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.61 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;509,130&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470,442&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$0.93 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689,341&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,651,670&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,006&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading
market over the exercise price of the option at March 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="c85"
      decimals="0"
      id="ixv-17917"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c86"
      decimals="0"
      id="ixv-17918"
      unitRef="shares">333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c87"
      decimals="0"
      id="ixv-17919"
      unitRef="shares">1333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c88"
      decimals="0"
      id="ixv-17920"
      unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c89"
      decimals="0"
      id="ixv-17921"
      unitRef="shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:FinancingReceivableUnamortizedLoanFeeCost contextRef="c3" decimals="0" id="ixv-17922" unitRef="usd">2035000</us-gaap:FinancingReceivableUnamortizedLoanFeeCost>
    <modd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-17923">P1Y3M18D</modd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c90"
      decimals="0"
      id="ixv-17924"
      unitRef="shares">909533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c91"
      decimals="0"
      id="ixv-17925"
      unitRef="shares">625326</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c3"
      decimals="0"
      id="ixv-17926"
      unitRef="shares">242307</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c92"
      decimals="0"
      id="ixv-17927"
      unitRef="shares">127500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c0" id="ixv-9953">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted-average grant date fair values of stock options granted during the years ended March 31, 2024 and 2023 was $0.99 and $2.85,
respectively. The following assumptions were used in the fair-value method calculations:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    Ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.51% - 4.72%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.82% - 4.06%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 152%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83% - 223%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 - 6.2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.0 &#x2013; 5.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c92"
      decimals="2"
      id="ixv-17928"
      unitRef="usdPershares">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c93"
      decimals="2"
      id="ixv-17929"
      unitRef="usdPershares">2.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c98" decimals="4" id="ixv-17930" unitRef="pure">0.0351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c99" decimals="4" id="ixv-17931" unitRef="pure">0.0472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c100"
      decimals="4"
      id="ixv-17932"
      unitRef="pure">0.0282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c101"
      decimals="4"
      id="ixv-17933"
      unitRef="pure">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c98" decimals="2" id="ixv-17934" unitRef="pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c99" decimals="2" id="ixv-17935" unitRef="pure">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c100"
      decimals="2"
      id="ixv-17936"
      unitRef="pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c101"
      decimals="2"
      id="ixv-17937"
      unitRef="pure">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c98" id="ixv-17938">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c99" id="ixv-17939">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c100" id="ixv-17940">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c101" id="ixv-17941">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-10076">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the shares available for grant under the Plan during the year ended March 31, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;for
                                            Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;989,466&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,650,705&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional shares authorized
    under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,006,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,006,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,789&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled and
    returned to the Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;175,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(175,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,132,292&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,481,090&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additional shares authorized
    under the Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,448,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,448,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(25,390&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled and
    returned to the Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240,282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(240,282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,648,651&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689,341&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c102"
      decimals="0"
      id="ixv-17942"
      unitRef="shares">989466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c102"
      decimals="0"
      id="ixv-17943"
      unitRef="shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-17944"
      unitRef="usdPershares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c103"
      decimals="0"
      id="ixv-17945"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="c103"
      decimals="0"
      id="ixv-17946"
      unitRef="shares">-1006074</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c103"
      decimals="0"
      id="ixv-17947"
      unitRef="shares">1006074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c103"
      decimals="2"
      id="ixv-17948"
      unitRef="usdPershares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards
      contextRef="c103"
      decimals="0"
      id="ixv-17949"
      unitRef="shares">-26789</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant
      contextRef="c103"
      decimals="0"
      id="ixv-17950"
      unitRef="shares">175689</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c103"
      decimals="0"
      id="ixv-17951"
      unitRef="shares">175689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c103"
      decimals="2"
      id="ixv-17952"
      unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c104"
      decimals="0"
      id="ixv-17953"
      unitRef="shares">2132292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c104"
      decimals="0"
      id="ixv-17954"
      unitRef="shares">2481090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c104"
      decimals="2"
      id="ixv-17955"
      unitRef="usdPershares">5.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c97"
      decimals="0"
      id="ixv-17956"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="c97"
      decimals="0"
      id="ixv-17957"
      unitRef="shares">-1448533</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c97"
      decimals="0"
      id="ixv-17958"
      unitRef="shares">1448533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-17959"
      unitRef="usdPershares">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards
      contextRef="c97"
      decimals="0"
      id="ixv-17960"
      unitRef="shares">-25390</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant
      contextRef="c97"
      decimals="0"
      id="ixv-17961"
      unitRef="shares">-250000</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedSharesAvailableForGrant>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant
      contextRef="c97"
      decimals="0"
      id="ixv-17962"
      unitRef="shares">240282</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c97"
      decimals="0"
      id="ixv-17963"
      unitRef="shares">240282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-17964"
      unitRef="usdPershares">3.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c96"
      decimals="0"
      id="ixv-17965"
      unitRef="shares">3648651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c96"
      decimals="0"
      id="ixv-17966"
      unitRef="shares">3689341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c96"
      decimals="2"
      id="ixv-17967"
      unitRef="usdPershares">3.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c94"
      decimals="0"
      id="ixv-17968"
      unitRef="shares">25390</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c95"
      decimals="0"
      id="ixv-17969"
      unitRef="shares">26789</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-17970" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" id="ixv-17971" unitRef="usd">86000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-10475">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
summary of RSU activity under the Plan is presented below.&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Grant-&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(62,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;187,499&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c0"
      decimals="0"
      id="ixv-17972"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-17973"
      unitRef="usdPershares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      decimals="0"
      id="ixv-17974"
      unitRef="shares">62501</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-17975"
      unitRef="usdPershares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c3"
      decimals="0"
      id="ixv-17976"
      unitRef="shares">187499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c3"
      decimals="2"
      id="ixv-17977"
      unitRef="usdPershares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c96" decimals="0" id="ixv-17978" unitRef="usd">347000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:FinancingReceivableUnamortizedLoanFeeCost contextRef="c96" decimals="0" id="ixv-17979" unitRef="usd">171000</us-gaap:FinancingReceivableUnamortizedLoanFeeCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c97" id="ixv-17980">P2Y3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="c0" id="ixv-10554">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the range of outstanding and exercisable options as of March 31, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range of Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$0.93 - $2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,237,066&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,409,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,006&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$3.95 - $7.51&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;943,145&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.29&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;771,478&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.61 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;509,130&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;470,442&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$0.93 - $17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,689,341&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,651,670&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;538,006&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c105"
      decimals="2"
      id="ixv-17981"
      unitRef="usdPershares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c106"
      decimals="2"
      id="ixv-17982"
      unitRef="usdPershares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c107"
      decimals="INF"
      id="ixv-17983"
      unitRef="shares">2237066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c108" id="ixv-10825">P8Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c107"
      decimals="2"
      id="ixv-17984"
      unitRef="usdPershares">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c107"
      decimals="INF"
      id="ixv-17985"
      unitRef="shares">1409750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c107"
      decimals="2"
      id="ixv-17986"
      unitRef="usdPershares">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c107"
      decimals="-3"
      id="ixv-17987"
      unitRef="usd">538006000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c109"
      decimals="2"
      id="ixv-17988"
      unitRef="usdPershares">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c110"
      decimals="2"
      id="ixv-17989"
      unitRef="usdPershares">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c111"
      decimals="INF"
      id="ixv-17990"
      unitRef="shares">943145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c112" id="ixv-10877">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c111"
      decimals="2"
      id="ixv-17991"
      unitRef="usdPershares">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c111"
      decimals="INF"
      id="ixv-17992"
      unitRef="shares">771478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c111"
      decimals="2"
      id="ixv-17993"
      unitRef="usdPershares">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c113"
      decimals="2"
      id="ixv-17994"
      unitRef="usdPershares">8.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c114"
      decimals="2"
      id="ixv-17995"
      unitRef="usdPershares">17.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c115"
      decimals="INF"
      id="ixv-17996"
      unitRef="shares">509130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c116" id="ixv-10929">P7Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c115"
      decimals="2"
      id="ixv-17997"
      unitRef="usdPershares">10.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c115"
      decimals="INF"
      id="ixv-17998"
      unitRef="shares">470442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c115"
      decimals="2"
      id="ixv-17999"
      unitRef="usdPershares">10.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c117"
      decimals="2"
      id="ixv-18000"
      unitRef="usdPershares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c118"
      decimals="2"
      id="ixv-18001"
      unitRef="usdPershares">17.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c119"
      decimals="INF"
      id="ixv-18002"
      unitRef="shares">3689341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c120" id="ixv-10981">P7Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c119"
      decimals="2"
      id="ixv-18003"
      unitRef="usdPershares">3.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c119"
      decimals="INF"
      id="ixv-18004"
      unitRef="shares">2651670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c119"
      decimals="2"
      id="ixv-18005"
      unitRef="usdPershares">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c119"
      decimals="-3"
      id="ixv-18006"
      unitRef="usd">538006000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-11038">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 6
&#x2013; INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The income
tax provision consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,933&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2024, the Company had net operating
loss carryforwards (NOLs) of approximately $35,000,000 for federal income tax purposes and $50,400,000 for state income tax purposes.
These NOLs are available to reduce future taxable income and will expire at various times from 2037 through 2045, except federal NOLs
from fiscal 2018 and later, which will never expire.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also had federal research and development
tax credit carryforwards of approximately $2,100,000, which will begin expiring at various times from 2038 through 2044, and state research
and development credits of approximately $500,000, which do not have an expiration date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
losses before income tax provision for the years ended March 31, 2024 and 2023 were solely attributable to US operations. Significant
components of the Company&#x2019;s deferred tax assets and liabilities were (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,058&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(239&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Reserves, accruals and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(288&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,822&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Based
on the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2024 and 2023, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated
financial statements at March 31, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-11046">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The income
tax provision consisted of the following:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,933&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,387&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18007" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18008" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18009" unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18010" unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18011" unitRef="usd">-3730000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18012" unitRef="usd">-2933000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18013" unitRef="usd">-657000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18014" unitRef="usd">-1467000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18015" unitRef="usd">-4387000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18016" unitRef="usd">-4400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" id="ixv-18017" unitRef="usd">4387000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-18018" unitRef="usd">4400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-18019" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-18020" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="c0" decimals="0" id="ixv-18021" unitRef="usd">35000000</us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-18022" unitRef="usd">50400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet contextRef="c0" decimals="0" id="ixv-18023" unitRef="usd">2100000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="0" id="ixv-18024" unitRef="usd">500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-11179">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
reconciliation of income taxes provided at the federal statutory rate to the actual income tax provision is as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-18025" unitRef="pure">0.21</modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate>
    <modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" id="ixv-18026" unitRef="pure">0.21</modd:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="2" id="ixv-18027" unitRef="pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="2" id="ixv-18028" unitRef="pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c0" decimals="2" id="ixv-18029" unitRef="pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c5" decimals="2" id="ixv-18030" unitRef="pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="2" id="ixv-18031" unitRef="pure">0.32</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="2" id="ixv-18032" unitRef="pure">0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="2" id="ixv-18033" unitRef="pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c5" decimals="2" id="ixv-18034" unitRef="pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-11262">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
losses before income tax provision for the years ended March 31, 2024 and 2023 were solely attributable to US operations. Significant
components of the Company&#x2019;s deferred tax assets and liabilities were (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Capitalized research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,058&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(239&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Reserves, accruals and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(288&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,822&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-18035" unitRef="usd">10860000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-18036" unitRef="usd">8742000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense contextRef="c3" decimals="-3" id="ixv-18037" unitRef="usd">3058000</modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense>
    <modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-18038" unitRef="usd">1933000</modd:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="-3" id="ixv-18039" unitRef="usd">2818000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="-3" id="ixv-18040" unitRef="usd">2587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="-3" id="ixv-18041" unitRef="usd">2568000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="-3" id="ixv-18042" unitRef="usd">1658000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-18043" unitRef="usd">193000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-18044" unitRef="usd">105000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" id="ixv-18045" unitRef="usd">19497000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-18046" unitRef="usd">15025000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="c3" decimals="-3" id="ixv-18047" unitRef="usd">239000</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="c4" decimals="-3" id="ixv-18048" unitRef="usd">111000</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c3" decimals="-3" id="ixv-18049" unitRef="usd">-49000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c4" decimals="-3" id="ixv-18050" unitRef="usd">-92000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c3" decimals="-3" id="ixv-18051" unitRef="usd">288000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c4" decimals="-3" id="ixv-18052" unitRef="usd">203000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-18053" unitRef="usd">19209000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-18054" unitRef="usd">14822000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0" id="ixv-11421">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 7
&#x2013; ROYALTY AGREEMENT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
July 2017, the Company entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder
(the Founder). Pursuant to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras
in return for future royalty payments on the Company&#x2019;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of
a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the
agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement,
reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference
between total royalty payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the
preceding quarter, will be made by the Company to the Founder within 30 days after the end of each calendar quarter.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-11434">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 8
&#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Litigations,
Claims and Assessments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses
arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation
or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also
entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company&#x2019;s consolidated
financial statements for the years ended March 31, 2024 and 2023 related to these indemnifications. The Company has not estimated the
maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique
facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Purchase
Obligations &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s primary purchase obligations include purchase orders for machinery and equipment. At March 31, 2024, the Company had
outstanding purchase orders for machinery and equipment and related expenditures of approximately $1,100,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;In December 2023, the Company signed a device integration agreement
with a provider of connected-care and remote monitoring diabetes technology solutions. As of March 31, 2024, the Company had a remaining
obligation under the device integration agreement of approximately $400,000&#160;over three years for technology license fees.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation contextRef="c3" decimals="0" id="ixv-18055" unitRef="usd">1100000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation contextRef="c121" decimals="0" id="ixv-18056" unitRef="usd">400000</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-11475">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 9
&#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Manchester
Management Company, LLC (MMC), as the general partner of Manchester Explorer, LP (Explorer), combined with the holdings of its affiliates,
JEB Partners LP, James Besser and Morgan Frank, owned approximately 11% of the Company&#x2019;s outstanding shares of common stock as
of March 31, 2024. Mr. Besser is the Company&#x2019;s chief executive officer and a managing member of MMC. Mr. Frank is one of our directors
and serves as the portfolio manager of Explorer and as a managing member of MMC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2024, Explorer purchased 900,000 shares of common stock in the 2024 Offering at the public offering price per share of $1.10
for aggregate gross proceeds to the Company of $990,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
daughter of the Founder is an employee of the Company. During the years ended March 31, 2024 and 2023, the Company paid her approximately
$137,000 and $201,000, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718,
of stock options granted to her during each year.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <modd:OutstandingSharesOfCommonStock contextRef="c0" decimals="2" id="ixv-18057" unitRef="pure">0.11</modd:OutstandingSharesOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="c122"
      decimals="0"
      id="ixv-18058"
      unitRef="shares">900000</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c123"
      decimals="2"
      id="ixv-18059"
      unitRef="usdPershares">1.1</us-gaap:SharePrice>
    <modd:AggregateGrossProceeds contextRef="c124" decimals="0" id="ixv-18060" unitRef="usd">990000</modd:AggregateGrossProceeds>
    <us-gaap:SalariesAndWages contextRef="c125" decimals="0" id="ixv-18061" unitRef="usd">137000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages contextRef="c126" decimals="0" id="ixv-18062" unitRef="usd">201000</us-gaap:SalariesAndWages>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c127" id="ixv-18063">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c127" id="ixv-18064">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c127" id="ixv-18065">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c127" id="ixv-18066">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-9"
      unitRef="usdPershares">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="-3"
      id="hidden-fact-11"
      unitRef="shares">12103000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="-3"
      id="hidden-fact-12"
      unitRef="shares">22377000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet
      contextRef="c10"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInEquityOfferingNet
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c10"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c12"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c10"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c12"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c10"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:IssuanceOfCommonStockInPublicOfferingsNetOfFeesAndIssuanceCosts
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:AtthemarketSalesOfStockNet
      contextRef="c16"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:AtthemarketSalesOfStockNet
      contextRef="c18"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c18"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c16"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c18"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c16"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c18"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c5"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c5"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c5"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:RightofuseAssetObtainedInExchangeForLeaseLiability
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:ReceivableFromTransferAgentForWarrantExerciseProceeds
      contextRef="c5"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c28"
      id="hidden-fact-40"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c4"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <modd:ExpirationCommonStock contextRef="c78" id="hidden-fact-42" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c5"
      id="hidden-fact-43"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="c103"
      id="hidden-fact-44"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="c103"
      id="hidden-fact-45"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c103"
      id="hidden-fact-46"
      unitRef="shares"
      xsi:nil="true"/>
    <modd:ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice
      contextRef="c103"
      id="hidden-fact-47"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="c97"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="c97"
      id="hidden-fact-49"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c97"
      id="hidden-fact-50"
      unitRef="shares"
      xsi:nil="true"/>
    <modd:ShareBasedCompensationsArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceShareAwardsWeightedAverageExercisePrice
      contextRef="c97"
      id="hidden-fact-51"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantedNumberOfShares
      contextRef="c97"
      id="hidden-fact-52"
      unitRef="shares"
      xsi:nil="true"/>
    <modd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRSUsGrantedWeightedAverageExercisePrice
      contextRef="c97"
      id="hidden-fact-53"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c4"
      id="hidden-fact-54"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c4"
      id="hidden-fact-55"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c5"
      id="hidden-fact-59"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-18131">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-18132">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-18133">0001074871</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
